Compounds and uses thereof

ABSTRACT

The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

BACKGROUND

Disorders can be affected by the BAF complex. BRD9 is a component of the BAF complex. The present invention relates to useful compositions and methods for the treatment of BAF complex-related disorders, such as cancer and infection.

SUMMARY

Bromodomain-containing protein 9 (BRD9) is a protein encoded by the BRD9 gene on chromosome 5. BRD9 is a component of the BAF (BRG1- or BRM-associated factors) complex, a SWI/SNF ATPase chromatin remodeling complex, and belongs to family IV of the bromodomain-containing proteins. BRD9 is present in several SWI/SNF ATPase chromatin remodeling complexes and is upregulated in multiple cancer cell lines. Accordingly, agents that reduce the levels and/or activity of BRD9 may provide new methods for the treatment of disease and disorders, such as cancer and infection. The inventors have found that depleting BRD9 in cells results in the depletion of the SS18-SSX fusion protein in those cells. The SS18-SSX fusion protein has been detected in more than 95% of synovial sarcoma tumors and is often the only cytogenetic abnormality in synovial sarcoma. Additionally, evidence suggests that the BAF complex is involved in cellular antiviral activities. Thus, agents that degrade BRD9 (e.g., compounds) are useful in the treatment of disorders (e.g., cancers or infections) related to BAF, BRD9, and/or SS18-SSX.

The present disclosure features compounds and methods useful for treating BAF-related disorders (e.g., cancer or infection).

In an aspect, the disclosure features a compound having the structure of Formula I:

where

R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl;

Z¹ is CR² or N;

R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N;

X² is O or S;

R^(X1) is H or optionally substituted C₁-C₆ alkyl;

R³ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl; and

G is optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl, or a pharmaceutically acceptable salt thereof.

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments, the compound of Formula I has the structure of Formula IA:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula I has the structure of Formula IB:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula I has the structure of Formula IC:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula I has the structure of Formula ID:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula I has the structure of Formula IE:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula I has the structure of Formula IF:

or a pharmaceutically acceptable salt thereof.

In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, or optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, R¹ is H. In some embodiments, R¹ is optionally substituted C₁-C₆ alkyl. In some embodiments, R¹ is optionally substituted C₂-C₆ alkenyl. In some embodiments, R¹ is optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, optionally substituted C₁-C₆ alkyl is C₁-C₆ perfluoroalkyl.

In some embodiments, R¹ is

In some embodiments, R¹ is

In some embodiments, R¹ is

In some embodiments, R¹ is H,

In some embodiments, R¹ is

In some embodiments, R¹ is H,

In some embodiments, R¹ is H,

In some embodiments, R¹ is H,

In some embodiments, R¹ is H or

In some embodiments, R¹ is H. In some embodiments, R¹ is

In some embodiments, Z¹ is CR². In some embodiments, Z¹ is N.

In some embodiments, R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₆-C₁₀ aryl.

In some embodiments, R² is H, halogen, or optionally substituted C₁-C₆ alkyl.

In some embodiments, R² is H, F, or

In some embodiments, R² is H. In some embodiments, R² is F. In some embodiments, R² is

In some embodiments, R^(X1) is H. In some embodiments, R^(X1) is

In some embodiments, X¹ is CH or N. In some embodiments, X¹ is CH. In some embodiments, X¹ is N.

In some embodiments, X² is O. In some embodiments, X² is S.

In some embodiments, R³ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, R³ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl. In some embodiments, R³ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ heterocyclyl. In some embodiments, R³ is cyano, optionally substituted C₁-C₆ alkoxy, or optionally substituted amino.

In some embodiments, R³ is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl. In some embodiments, R³ is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R³ is H. In some embodiments, R³ is optionally substituted C₁-C₆ alkyl.

In some embodiments, R³ is optionally substituted C₂-C₉ heteroaryl or optionally substituted C₁-C₆ heteroalkyl. In some embodiments, R³ is optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, R³ is

where

W¹ is NR⁴ or O;

W² is NH, O, or S;

W³ is NR⁷ or O;

R⁴ is H or optionally substituted C₁-C₆ alkyl;

R⁵ is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

R⁶ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

R⁷ is H or optionally substituted C₁-C₆ alkyl; and

R⁸ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R³ is optionally substituted C₂-C₉ heteroaryl,

In some embodiments, R³ is optionally substituted C₂-C₉ heteroaryl. In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, W¹ is NR⁴. In some embodiments, W¹ is O.

In some embodiments, W² is NH. In some embodiments, W² is O. In some embodiments, W² is S.

In some embodiments, W³ is NR⁷. In some embodiments, W³ is O.

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R⁴ is H,

In some embodiments, R⁵ is

In some embodiments, R⁵ is

In some embodiments, R⁶ is

In some embodiments, R⁶ is

In some embodiments, R⁶ is H,

In some embodiments, R⁶ is H,

In some embodiments, R⁷ is H,

In some embodiments, R³ is H. In some embodiments, R³ is cyano. In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, R³ is

In some embodiments, G is optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl. In some embodiments, G is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G is optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, G is optionally substituted C₆-C₁₀ aryl. In some embodiments, G is optionally substituted C₂-C₉ heterocyclyl. In some embodiments, G is optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G is

where

each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G6) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G6), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl,

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F,

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl,

In some embodiments, R^(G1) is H; R^(G2) is

and R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is

In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is Cl or F; R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is

and R^(G5) is H.

In some embodiments, R^(G1) and R^(G2); R^(G2) and R^(G3); R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R^(G1) and R^(G2); R^(G2) and R^(G3); R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heterocyclyl. In some embodiments, R^(G1) and R^(G2); R^(G2) and R^(G3); R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, G is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G6), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heterocyclyl or optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(G6) is H,

In some embodiments, R^(G6) is H or

In some embodiments, R^(G6) is H.

In some embodiments, R^(G1) is H, F,

In some embodiments, R^(G1) is H.

In some embodiments, R^(G2) is H, F,

In some embodiments, R^(G2) is H.

In some embodiments, R^(G3) is H, F,

In some embodiments, R^(G3) is H.

In some embodiments, R^(G4) is H, F,

In some embodiments, R^(G4) is H.

In some embodiments, R^(G5) is H, F,

In some embodiments, R^(G5) is H.

In some embodiments, one or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, two or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, three or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H.

In some embodiments, G is

where

each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, F, Cl,

In some embodiments, R^(G8) is

In some embodiments, G is

In some embodiments, R^(G7) is H; R^(G8) is

R^(G9) is H; and R^(G11) is H.

In some embodiments, G is

where

each of R^(G12), R^(G13), and R^(G14) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12) and R^(G14), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G12), R^(G13), and R^(G14) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12) and R^(G14), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, the compound of Formula IA has the structure of Formula IAa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAc:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAd:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAe:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAf:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAg:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IA has the structure of Formula IAh:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBc:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBd:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBe:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBf:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBg:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IB has the structure of Formula IBh:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IC has the structure of Formula ICa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IC has the structure of Formula ICb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula ID has the structure of Formula IDa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula ID has the structure of Formula IDb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IE has the structure of Formula IEa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IF has the structure of Formula IF:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound has the structure of any one of compounds B1-B11 in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds B1-B10 in Table 1, or a pharmaceutically acceptable salt thereof.

In an aspect, the disclosure features a compound having the structure of any one of compounds B1-B11 in Table 1, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure features a compound having the structure of any one of compounds B1-B10 in Table 1, or a pharmaceutically acceptable salt thereof.

TABLE 1 Compounds B1-B11 of the Disclosure Comp- ound No. Structure B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

In an aspect, the disclosure features a compound having the structure of Formula II:

A-L-B   Formula II,

where

L is a linker;

B is a degradation moiety; and

A has the structure of Formula III:

where

R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl;

Z¹ is CR² or N;

R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N;

X² is O or S;

R^(X1) is H or optionally substituted C₁-C₆ alkyl;

R³″ is H,

cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl;

R³′ is absent, optionally substituted C₁-C₆ alkylene, optionally substituted C₂-C₉ heteroarylene, or optionally substituted C₁-C₆ heteroalkylene;

G″ is

optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

G′ is optionally substituted C₃-C₁₀ carbocyclylene, C₂-C₉ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene; and

A¹ is a bond between A and the linker,

where G″ is

or R³″ is

or a pharmaceutically acceptable salt thereof.

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments, the compound of Formula III has the structure of Formula IIIA:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula III has the structure of Formula IIIB:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula III has the structure of Formula IIIC:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula III has the structure of Formula IIIC:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula III has the structure of Formula IIIE:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula III has the structure of Formula IIIF:

or a pharmaceutically acceptable salt thereof.

In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, or optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, R¹ is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, R¹ is H. In some embodiments, R¹ is optionally substituted C₁-C₆ alkyl. In some embodiments, R¹ is optionally substituted C₂-C₆ alkenyl. In some embodiments, R¹ is optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, optionally substituted C₁-C₆ alkyl is C₁-C₆ perfluoroalkyl.

In some embodiments, R¹ is

In some embodiments, R¹ is

In some embodiments, R¹ is

In some embodiments, R¹ is H,

In some embodiments, R¹ is

In some embodiments, R¹ is H,

In some embodiments, R¹ is H,

In some embodiments, R¹ is H,

In some embodiments, R¹ is H or

In some embodiments, R¹ is H. In some embodiments, R¹ is

In some embodiments, Z¹ is CR². In some embodiments, Z¹ is N.

In some embodiments, R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₆-C₁₀ aryl.

In some embodiments, R² is H, halogen, or optionally substituted C₁-C₆ alkyl.

In some embodiments, R² is H, F, or

In some embodiments, R² is H. In some embodiments, R² is F. In some embodiments, R² is

In some embodiments, R^(X1) is H. In some embodiments, R^(X1) is

In some embodiments, X¹ is CH or N. In some embodiments, X¹ is CH. In some embodiments, X¹ is N.

In some embodiments, X² is O. In some embodiments, X² is S.

In some embodiments, X¹ is CH and X² is S.

In some embodiments, R³″ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl. In some embodiments, R³″ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ heterocyclyl. In some embodiments, R³″ is cyano, optionally substituted C₁-C₆ alkoxy, or optionally substituted amino.

In some embodiments, R³″ is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl. In some embodiments, R³″ is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R³″ is H. In some embodiments, R³″ is optionally substituted C₁-C₆ alkyl.

In some embodiments, R³″ is optionally substituted C₂-C₉ heteroaryl or optionally substituted C₁-C₆ heteroalkyl. In some embodiments, R³″ is optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, R³″ is

where

W¹ is NR⁴ or O;

W² is NH, O, or S;

W³ is NR′ or O;

R⁴ is H or optionally substituted C₁-C₆ alkyl;

R⁵ is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

R⁶ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

R⁷ is H or optionally substituted C₁-C₆ alkyl; and

R⁸ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R³″ is optionally substituted C₂-C₉ heteroaryl,

In some embodiments, R³″ is optionally substituted C₂-C₉ heteroaryl. In some embodiments, R³″

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, W¹ is NR⁴. In some embodiments, W¹ is O.

In some embodiments, W² is NH. In some embodiments, W² is O. In some embodiments, W² is S.

In some embodiments, W³ is NR⁷. In some embodiments, W³ is O.

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R⁴ is H,

In some embodiments, R⁵ is

In some embodiments, R⁵ is

In some embodiments, R⁶ is

In some embodiments, R⁶ is

In some embodiments, R⁶ is H,

In some embodiments, R⁶ is H,

In some embodiments, R⁷ is H,

In some embodiments, R³″ is H. In some embodiments, R³″ is cyano. In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, R³″ is

In some embodiments, G″ is

In some embodiments, G′ is optionally substituted C₃-C₁₀ carbocyclylene or optionally substituted C₂-C₉ heterocyclylene. In some embodiments, G′ is optionally substituted C₆-C₁₀ arylene or optionally substituted C₂-C₉ heteroarylene.

In some embodiments, G′ is optionally substituted C₃-C₁₀ carbocyclylene. In some embodiments, G′ is optionally substituted C₆-C₁₀ arylene. In some embodiments, G′ is optionally substituted C₂-C₉ heterocyclylene. In some embodiments, G′ is optionally substituted C₂-C₉ heteroarylene.

In some embodiments, G′ is

where

each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G6)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F, Cl,

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F,

In some embodiments, each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F, Cl,

In some embodiments, R^(G3)′ is A¹.

In some embodiments, R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is

and R^(G5)′ is H. In some embodiments, R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is H; and R^(G5)′ is

In some embodiments, R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is H; and R^(G5)′ is H. In some embodiments, R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is H; and R^(G5)′ is H. In some embodiments, R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is

and R^(G5)′ is H.

In some embodiments, R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹. In some embodiments, R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heteroaryl, which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.

In some embodiments, G′ is

where R^(G6)′ is H, A¹, or optionally substituted C₁-C₆ alkyl. In some embodiments, G′ is

where R^(G6)′ is H, A¹, or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl or optionally substituted C₂-C₉ heteroaryl, any of which is optionally substituted with A¹, where one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.

In some embodiments, G′ is

where R^(G6)′ is H, A¹, or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(G6)′ is H, A¹,

In some embodiments, R^(G6)′ is H, A¹, or

In some embodiments, R^(G6)′ is H or A¹.

In some embodiments, R^(G6)′ is H. In some embodiments, R^(G6)′ is A¹.

In some embodiments, R^(G1)′ is H, A¹, F,

In some embodiments, RG″ is H.

In some embodiments, R^(G2)′ is H, A¹, F,

In some embodiments, R^(G2)′ is H.

In some embodiments, R^(G3)′ is H, A¹, F,

In some embodiments, R^(G3)′ is H.

In some embodiments, R^(G4)′ is H, A¹, F,

In some embodiments, R^(G4)′ is H.

In some embodiments, R^(G5)′ is H, A¹, F,

In some embodiments, R^(G5)′ is H.

In some embodiments, one or more of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is H. In some embodiments, two or more of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is H. In some embodiments, three or more of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is H.

In some embodiments, R^(G1)′ is A¹. In some embodiments, R^(G2)′ is A¹. In some embodiments, R^(G3)′ is A¹. In some embodiments, R^(G4)′ is A¹. In some embodiments, R^(G5)′ is A¹. In some embodiments,

is substituted with A¹.

In some embodiments, G′ is

where

each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7)′ and R^(G8)′, R^(G8)′ and R^(G9)′, R^(G9)′ and R^(G10)′, and/or R^(G10)′ and R^(G11)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is A¹; or

is substituted with A¹.

In some embodiments, each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7)′ and R^(G8)′, R^(G8)′ and R^(G9)′, R^(G9)′ and R^(G10)′, and/or R^(G10)′ and R^(G11)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is A¹; or

is substituted with A¹.

In some embodiments, each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G7)′ and R^(G8)′, R^(G8)′ and R^(G9)′, R^(G9)′ and R^(G10)′, and/or R^(G10)′ and R^(G11)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is A¹; or

is substituted with A¹.

In some embodiments, each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, F, Cl,

In some embodiments, R^(G8)′ is

In some embodiments, G′ is

In some embodiments, R^(G7)′ is H; R^(G8)′ is

R^(G9)′ is A¹; and R^(G11)′ is H.

In some embodiments, G′ is

where

each of R^(G12)′, R^(G13)′, and R^(G14)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12)′ and R^(G14)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G12)′, R^(G13)′, and R^(G14)′ is A¹; or

is substituted with A¹.

In some embodiments, each of R^(G12)′, R^(G13)′, and R^(G14)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12)′ and R^(G14)′, together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, where one of R^(G12)′, R^(G13)′, and R^(G14)′ is A¹; or

is substituted with A¹.

In some embodiments, R³″ is

In some embodiments, R³′ is absent.

In some embodiments, R³″ is

and R³′ is absent.

In some embodiments, R³′ is optionally substituted C₁-C₆ alkylene, optionally substituted C₂-C₉ heteroarylene, or optionally substituted C₁-C₆ heteroalkylene. In some embodiments, optionally substituted C₂-C₉ heteroarylene or optionally substituted C₁-C₆ heteroalkylene.

In some embodiments, R³′ is

where

W¹ is NR⁴′ or O;

W² is NH, O, or S;

W³ is NR⁷′ or O;

R⁴′ is H or optionally substituted C₁-C₆ alkyl;

R⁵′ is absent, optionally substituted C₁-C₆ alkylene, optionally substituted C₃-C₁₀ carbocyclylene, or optionally substituted C₂-C₉ heterocyclylene;

R⁶′ is absent, optionally substituted C₁-C₆ alkylene, optionally substituted C₃-C₁₀ carbocyclylene, or optionally substituted C₂-C₉ heterocyclylene,

R⁷′ is H or optionally substituted C₁-C₆ alkyl; and

R⁸′ is absent, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R³′ is optionally substituted C₂-C₉ heteroarylene,

In some embodiments, R³′ is optionally substituted C₂-C₉ heteroarylene. In some embodiments, R³′ is

In some embodiments, R³′ is

In some embodiments, W¹ is NR^(4′). In some embodiments, W¹ is O.

In some embodiments, W² is NH. In some embodiments, W² is O. In some embodiments, W² is S.

In some embodiments, W³ is NR″. In some embodiments, W³ is O.

In some embodiments, R³′ is

In some embodiments, R³′ is

In some embodiments, R³′ is

In some embodiments, R⁴′ is H,

In some embodiments, R⁷′ is H,

In some embodiments, G″ is optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl. In some embodiments, G″ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G″ is optionally substituted C₃-C₁₀ carbocyclyl. In some embodiments, G is optionally substituted C₆-C₁₀ aryl. In some embodiments, G is optionally substituted C₂-C₉ heterocyclyl. In some embodiments, G″ is optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G″ is

where

each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl,

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F,

In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl

In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is

and R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is

In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is Cl or F; and R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is H. In some embodiments, R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is

and R^(G5) is H.

In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heterocyclyl. In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G6), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl.

In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G6), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heterocyclyl. In some embodiments, R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G6), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl.

In some embodiments, G″ is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, G″ is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, G″ is

where R^(G6) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(G6) is H,

In some embodiments, R^(G6) is H or

In some embodiments, R^(G6) is H.

In some embodiments, R^(G1) is H, F,

In some embodiments, R^(G1) is H.

In some embodiments, R^(G2) is H, F,

In some embodiments, R^(G2) is H.

In some embodiments, R^(G3) is H, F,

In some embodiments, R^(G3) is H.

In some embodiments, R^(G4) is H, F,

In some embodiments, R^(G4) is H.

In some embodiments, R^(G5) is H, F,

In some embodiments, R^(G5) is H.

In some embodiments, one or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, two or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, three or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H. In some embodiments, each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H.

In some embodiments, G″ is

where

each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.

In some embodiments, each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, F, Cl,

In some embodiments, R^(G8) is

In some embodiments, G″ is

In some embodiments, R^(G7) is H; R^(G8) is

R^(G9) is H; and R^(G11) is H.

In some embodiments, G″ is

where

each of R^(G12), R^(G13), and R^(G14) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12) and R^(G14), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each of R^(G12), R^(G13), and R^(G14) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12) and R^(G14), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, A has the structure of Formula IIIAa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAc:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAd:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAe:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAf:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIAg:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula lllAh:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBc:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBd:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBe:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBf:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBg:

or a pharmaceutically acceptable salt thereof.

In some embodiments, A has the structure of Formula IIIBh:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIIC has the structure of Formula IIICa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIIC has the structure of Formula IIICb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIID has the structure of Formula IIIDa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIID has the structure of Formula IIIDb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIIE has the structure of Formula IIIEa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula IIIF has the structure of Formula IIIF:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the degradation moiety is a ubiquitin ligase binding moiety.

In some embodiments, the ubiquitin ligase binding moiety comprises Cereblon ligands, IAP (Inhibitors of Apoptosis) ligands, mouse double minute 2 homolog (MDM2), or von Hippel-Lindau (VHL) ligands, or derivatives or analogs thereof.

In some embodiments, the degradation moiety is a ubiquitin ligase binding moiety.

In some embodiments, the ubiquitin ligase binding moiety comprises Cereblon ligands, IAP (Inhibitors of Apoptosis) ligands, mouse double minute 2 homolog (MDM2), or von Hippel-Lindau (VHL) ligands, or derivatives or analogs thereof.

In some embodiments, the degradation moiety includes the structure of Formula Y:

where

A² is a bond between the degradation moiety and the linker;

v1 is 0, 1, 2, 3, 4, or 5;

u1 is 1, 2, or 3;

T¹ is a bond or

T² is

R^(5A) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

each R^(J1) is, independently, halogen, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

J^(A) is absent, O, optionally substituted amino, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; and

J is absent, optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₆-C₁₀ arylene, optionally substituted C₂-C₉ heterocyclylene, or optionally substituted C₂-C₉ heteroarylene, or a pharmaceutically acceptable salt thereof.

In some embodiments, T² is

In some embodiments, T² is

In some embodiments, T² is

In some embodiments, T² is

In some embodiments, the structure of Formula Y has the structure of Formula Y1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, T¹ is a bond. In some embodiments, T¹ is

In some embodiments, the structure of Formula Y has the structure of Formula Y2:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula Y has the structure of Formula Z:

or a pharmaceutically acceptable salt thereof.

In some embodiments, u1 is 1. In some embodiments, u1 is 2. In some embodiments u1 is 3.

In some embodiments, the structure of Formula Z has the structure of Formula AA0:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula Z has the structure of Formula AB:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula Z has the structure of Formula AC:

or a pharmaceutically acceptable salt thereof.

In some embodiments, J^(A) is absent. In some embodiments, J^(A) is optionally substituted C₁-C₆ alkyl. In some embodiments, J^(A) is optionally substituted C₁-C₆ heteroalkyl. In some embodiments, J^(A) is O or optionally substituted amino.

In some embodiments, J^(A) is

In some embodiments, the structure of Formula AA0 has the structure of Formula AA0:

or a pharmaceutically acceptable salt thereof.

In some embodiments, v1 is 0, 1, 2, or 3. In some embodiments, v1 is 0. In some embodiments, v1 is 1. In some embodiments, v1 is 2. In some embodiments, v1 is 3.

In some embodiments, the structure of Formula AA has the structure of Formula AA1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula AB has the structure of Formula AB1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula AC has the structure of Formula AC1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, J is absent. In some embodiments, J is optionally substituted C₃-C₁₀ carbocyclylene or optionally substituted C₆-C₁₀ arylene. In some embodiments, J is optionally substituted C₂-C₉ heterocyclylene or optionally substituted C₂-C₉ heteroarylene.

In some embodiments, J is optionally substituted heterocyclylene. In some embodiments, J is optionally substituted C₆-C₁₀ arylene.

In some embodiments, J is

In some embodiments, the structure of Formula AA has the structure of Formula AA2:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula AA has the structure of Formula AA3:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula AA has the structure of Formula AA4:

or a pharmaceutically acceptable salt thereof.

In some embodiments, R^(A5) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(A5) is optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, R^(A5) is H or methyl. In some embodiments, R^(A5) is H. In some embodiments, R^(A5) is methyl. In some embodiments, R^(A5) is

In some embodiments, the structure of Formula AA has the structure of Formula A:

where

Y¹ is

R^(A5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

R^(A6) is H or optionally substituted C₁-C₆ alkyl; and R^(A7) is H or optionally substituted C₁-C₆ alkyl; or R^(A6) and R^(A7), together with the carbon atom to which each is bound, combine to form optionally substituted C₃-C₆ carbocyclyl or optionally substituted C₂-C₅ heterocyclyl; or R^(A6) and R^(A7), together with the carbon atom to which each is bound, combine to form optionally substituted C₃-C₆ carbocyclyl or optionally substituted C₂-C₅ heterocyclyl;

R^(A8) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.

In some embodiments, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.

In some embodiments, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².

In some embodiments, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², F,

or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².

In some embodiments, R^(A1) is A². In some embodiments, R^(A2) is A². In some embodiments, R^(A3) is A². In some embodiments, R^(A4) is A². In some embodiments, R^(A5) is A².

In some embodiments, R^(A5) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(A5) is H or

In some embodiments, R^(A5) is H. In some embodiments, R^(A5) is

In some embodiments, Y¹ is

In some embodiments, Y¹ is

In some embodiments, Y¹ is

In some embodiments, each of R^(A6) and R^(A7) is, independently, H, F,

or R^(A6) and R^(A7), together with the carbon atom to which each is bound, combine to form

In some embodiments, R^(A6) is H and R^(A7) is H.

In some embodiments, Y¹ is

In some embodiments, Y¹ is

In some embodiments, Y¹ is

In some embodiments, the structure of Formula A has the structure of Formula A1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A2:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A3:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A4:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A5:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A6:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A7:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A8:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A9:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula A has the structure of Formula A10:

or a pharmaceutically acceptable salt thereof.

In some embodiments, wherein the structure of Formula A is

or derivative or analog thereof.

In some embodiments, the structure of Formula A is

In some embodiments, the structure of Formula A is

or derivative or analog thereof.

In some embodiments,

where R^(A9) is H, A², optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, the structure of Formula A is

In some embodiments, R^(A9) is H, A², or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(A9) is H, A², or methyl. In some embodiments, R^(9A) is H. In some embodiments, R^(9A) is methyl. In some embodiments, R^(A9) is A².

In some embodiments, the structure of Formula A is

In some embodiments, the structure of Formula AA has the structure of Formula B:

where

R^(A5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.

In some embodiments, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².

In some embodiments, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², F,

or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², where one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².

In some embodiments, R^(A1) is A². In some embodiments, R^(A2) is A². In some embodiments, R^(A3) is A². In some embodiments, R^(A4) is A2. In some embodiments, R^(A5) is A².

In some embodiments, R^(A5) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(A5) is H or

In some embodiments, R^(A5) is H. In some embodiments, R^(A5) is

In some embodiments, the structure of Formula B has the structure of Formula B1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula B has the structure of Formula B2:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula B has the structure of Formula B3:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula B has the structure of Formula B4:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula B is

In some embodiments, the structure of Formula B is

In some embodiments, the structure of Formula B is

In some embodiments, the ubiquitin ligase binding moiety comprises a von Hippel-Lindau ligand.

In some embodiments, the von Hippel-Lindau ligand has the structure of

or derivative or analog thereof.

In some embodiments, the degradation moiety includes the structure of Formula C:

where

R^(B1) is H, A², optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

R^(B2) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

R^(B3) is A², optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl;

R^(B4) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl;

R^(B5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

v2 is 0, 1, 2, 3, or 4;

each R^(B6) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino; and

each of R^(B7) and R^(B8) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, or optionally substituted C₆-C₁₀ aryl,

where one of R^(B1) and R^(B3) is A², or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula C is

or derivative or analog thereof.

In some embodiments, the structure of Formula C is

In some embodiments, the degrader moiety includes the structure of Formula D:

where

A² is a bond between B and the linker;

each of R^(C1), R^(C2), and R^(C7) is, independently, H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl;

R^(C3) is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl;

R^(C5) is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl;

v3 is 0, 1, 2, 3, or 4;

each R^(C8) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino;

v4 is 0, 1, 2, 3, or 4; and

each R^(C9) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula D is

or derivative or analog thereof.

In some embodiments, the degrader moiety includes the structure of Formula E:

where

A² is a bond between B and the linker;

each of R^(C10) and R^(C11) is, independently, H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl;

v5 is 0, 1, 2, 3, or 4;

each R^(C12) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino;

v6 is 0, 1, 2, 3, or 4; and

each R²¹ is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.

In some embodiments, the structure of Formula E is

or derivative or analog thereof.

In some embodiments, the degradation moiety includes the structure of Formula FA:

where

or a bicyclic moiety which is substituted with A² and substituted with one or more groups independently selected from H, R^(FF1), and oxo;

is a single bond or a double bond;

u2 is 0, 1, 2, or 3;

A² is a bond between the degrader and the linker;

Y^(Fa) is CR^(Fb)R^(Fc), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂;

Y^(Fb) is NH, NR^(FF1), CH₂, CHR^(FF1), C(R^(FF1))₂, O, or S;

Y^(Fc) is CR^(Fd)R^(Fe), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂;

each of R^(Fb), R^(Fc), R^(Fd), and R^(Fe) is, independently, H, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclyl, hydroxyl, alkoxy, amino, —NHalkyl, or —Nalkyl₂;

or R^(Fb) and R^(Fc), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O;

or R^(Fd) and R^(Fe), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; and

or R^(Fd) and R^(Fb), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring;

each of Y^(Fd) and Y^(Ff) is, independently, CH₂, CHR^(FF2), C(R^(FF2))₂, C(O), N, NH, NR^(FF3), O, S, or S(O);

Y^(Fe) is a bond or a divalent moiety attached to Y^(Fd) and Y^(Ff) that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring,

-   -   wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen,         oxygen, or sulfur atom;     -   wherein one of the ring atoms is substituted with A² and the         others are substituted with one or more groups independently         selected from H and R^(FF1); and     -   wherein the contiguous atoms of Y^(Fe) can be attached through a         single or double bond;

each R^(FF1) is, independently, H, alkyl, alkenyl, alkynyl, aliphatic, heteroaliphatic, carbocyclyl, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocyclyl, alkylamino, alkylhydroxyl, or haloalkyl;

each R^(FF2) is, independently, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(aliphatic, including alkyl), —C(O)O(aliphatic, including alkyl), —NH(aliphatic, including alkyl), —N(aliphatic including alkyl)(aliphatic including alkyl), —NHSO₂alkyl, —N(alkyl)SO₂alkyl, —NHSO₂aryl, —N(alkyl)SO₂aryl, —NHSO₂alkenyl, —N(alkyl)SO₂alkenyl, —NHSO₂alkynyl, —N(alkyl)SO₂alkynyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heterocyclic, carbocyclic, cyano, nitro, nitroso, —SH, —Salkyl, or haloalkyl; and

R^(FF3) is alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)alkyl, or —C(O)Oalkyl,

wherein if Y^(Fd) or Y^(Ff) is substituted with A², then Y^(Fe) is a bond, or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula FA has the structure of Formula FA1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the degradation moiety includes the structure of Formula FB:

where

or a bicyclic moiety which is substituted with A² and substituted with one or more groups independently selected from H, R^(FF1), and oxo;

A² is a bond between the degrader and the linker;

Y^(Fa) is CR^(Fb)R^(Fc), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH2;

each of Y^(Fb) and Y^(Fg) is, independently, NH, NR^(FF1), CH₂, CHR^(FF1), C(R^(FF1))₂, O, or S;

Y^(Fc) is CR^(Fd)R^(Fe), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂;

each of R^(Fb), R^(Fc), R^(Fd), R^(Fe), R^(Ff), and R^(Fg) is independently, H, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclyl, hydroxyl, alkoxy, amino, —NHalkyl, or —Nalkyl₂;

or R^(Fb) and R^(Fc), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O;

or R^(Fd) and R^(Fe), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O;

or R^(Ff) and R^(Fg), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O;

or R^(Fd) and R^(Fb), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring;

or R^(Fd) and R^(Ff), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring;

or R^(Fb) and R^(Fg), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring;

each of Y^(Fd) and Y^(Ff) is, independently, CH₂, CHR^(FF2), C(R^(FF2))₂, C(O), N, NH, NR^(FF3), O, S, or S(O);

Y^(Fe) is a bond or a divalent moiety attached to Y^(Fd) and Y^(Ff) that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring,

-   -   wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen,         oxygen, or sulfur atom;     -   wherein one of the ring atoms is substituted with A² and the         others are substituted with one or more groups independently         selected from H and R^(FF1); and     -   wherein the contiguous atoms of Y^(Fe) can be attached through a         single or double bond;

each R^(FF1) is, independently, H, alkyl, alkenyl, alkynyl, aliphatic, heteroaliphatic, carbocyclyl, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocyclyl, alkylamino, alkylhydroxyl, or haloalkyl;

each R^(FF2) is, independently, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(aliphatic, including alkyl), —C(O)O(aliphatic, including alkyl), —NH(aliphatic, including alkyl), ⇒N(aliphatic including alkyl)(aliphatic including alkyl), —NHSO₂alkyl,

—N(alkyl)SO₂alkyl, —NHSO₂aryl, —N(alkyl)SO₂aryl, —NHSO₂alkenyl, —N(alkyl)SO₂alkenyl, —NHSO₂alkynyl, —N(alkyl)SO₂alkynyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heterocyclic, carbocyclic, cyano, nitro, nitroso, —SH, —Salkyl, or haloalkyl; and

R^(FF3) is alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)alkyl, or —C(O)Oalkyl,

wherein if Y^(Fd) or Y^(Ff) is substituted with A², then Y^(Fe) is a bond, or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula FB has the structure of Formula FB1:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the degradation moiety includes the structure of Formula F1:

where A² is a bond between the degrader and the linker; and R^(F1) is absent or O, or a pharmaceutically acceptable salt thereof.

In some embodiments, R^(F1) is absent. In some embodiments, R^(F1) is O.

In some embodiments, the structure of Formula F1 is

In some embodiments, the degradation moiety includes the structure Formula F2:

where A² is a bond between the degrader and the linker; and Y² is CH₂ or NH, or a pharmaceutically acceptable salt thereof.

In some embodiments, Y² is NH. In some embodiments, Y² is CH₂.

In some embodiments, structure of Formula F2 is

In some embodiments, the degradation moiety includes the structure Formula G:

where A² is a bond between the degrader and the linker; and Y³ is CH₂ or NH, or a pharmaceutically acceptable salt thereof.

In some embodiments, Y³ is NH. In some embodiments, Y³ is CH₂.

In some embodiments, structure of Formula G is

The degradation moiety may also include structures found in, e.g., WO2017/197036; WO2019/204354, WO2019/236483, WO2020/010177; and WO2020/010227, the structures of which are herein incorporated by reference.

In some embodiments, the linker has the structure of Formula IV:

A¹-(B¹)_(f)—(C¹)_(g)—(B²)_(h)-(D)-(B³)_(i)—(C²)_(j)—(B⁴)_(k)-A²   Formula IV

where

A¹ is a bond between the linker and A;

A² is a bond between B and the linker;

each of B¹, B², B³, and B⁴ is, independently, optionally substituted C₁-C₂ alkylene, optionally substituted C₁-C₃ heteroalkylene, O, S, S(O)₂, or NR^(N);

each R^(N) is, independently, H, optionally substituted C₁₋₄ alkyl, optionally substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl, optionally substituted C₂₋₆ heterocyclyl, optionally substituted C₆₋₁₂ aryl, or optionally substituted C₁₋₇ heteroalkyl;

each of C¹ and C² is, independently, carbonyl, thiocarbonyl, sulphonyl, or phosphoryl;

each of f, g, h, i, j, and k is, independently, 0 or 1; and

D is optionally substituted C₁₋₁₀ alkylene, optionally substituted C₂₋₁₀ alkenylene, optionally substituted C₂₋₁₀ alkynylene, optionally substituted C₂₋₆ heterocyclylene, optionally substituted C₆₋₁₂ arylene, optionally substituted C₂-C₁₀ polyethylene glycol, or optionally substituted C₁₋₁₀ heteroalkylene, or a chemical bond linking A¹-(B¹)_(f)—(C¹)_(g)—(B²)_(h)— to —(B³)_(i)—(C²)_(k)—(B⁴)_(k)-A².

In some embodiments, each of B¹, B², B³, and B⁴ is, independently, optionally substituted C₁-C₄ alkylene, optionally substituted C₁-C₄ heteroalkylene, or NR^(N).

In some embodiments, each R^(N) is, independently, H or optionally substituted C₁-C₄ alkylene.

In some embodiments, each R^(N) is, independently, H or methyl.

In some embodiments, each of B¹ and B⁴ is, independently,

In some embodiments, B¹ is

In some embodiments, each of C¹ and C² is, independently,

In some embodiments, C¹ is

In some embodiments, B² is NR^(N). In some embodiments, B² is optionally substituted C₁-C₄ alkylene.

In some embodiments, f is 0. In some embodiments, f is 1. In some embodiments, g is 1. In some embodiments, h is 0. In some embodiments, h is 1. In some embodiments, i is 0. In some embodiments, j is 0. In some embodiments, k is 0.

In some embodiments, the linker has the structure of

wherein

x is 1, 2, 3, 4, 5, 6, 7, or 8;

y is 1, 2, 3, or 4;

R^(x) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(y) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and

W is O or NR^(w), wherein R^(w) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl.

In some embodiments, the linker has the structure of

In some embodiments, R^(x) is H or me optionally substituted C₁-C₆ alkyl. In some embodiments, R^(y) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(w) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(x) is H or methyl. In some embodiments, R^(y) is H or methyl. In some embodiments, R^(w) is H or methyl.

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of Formula V:

A¹(E¹)-(F¹)—(C³)_(m)-(E³)_(n)-(F²)_(o1)—(F³)_(o2)-(E²)_(p)-A²,   Formula V

where

A¹ is a bond between the linker and A;

A² is a bond between B and the linker;

each of m, n, o1, o2, and p is, independently, 0 or 1;

each of E¹ and E² is, independently, O, S, NR^(N), optionally substituted C₁₋₁₀ alkylene, optionally substituted C₂₋₁₀ alkenylene, optionally substituted C₂₋₁₀ alkynylene, optionally substituted C₂-C₁₀ polyethylene glycol, or optionally substituted C₁₋₁₀ heteroalkylene;

E³ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, O, S, or NR^(N);

each R^(N) is, independently, H, optionally substituted C₁₋₄ alkyl, optionally substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl, optionally substituted C₂₋₆ heterocyclyl, optionally substituted C₆₋₁₂ aryl, or optionally substituted C₁₋₇ heteroalkyl;

C³ is carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; and

each of F¹, F², and F³ is, independently, optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₂₋₁₀ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene.

In some embodiments, the linker has the structure of Formula Va:

A¹-(E¹)-(F¹)—(C³)_(m)-(E²)_(p)-A².   Formula Va

In some embodiments, the linker has the structure of Formula Vb:

A¹-(E¹)-(F¹)-(E²)_(p)-A².   Formula Vb

In some embodiments, the linker has the structure of Formula Vc:

A¹-(E¹)-(F¹)-A².   Formula Vc

In some embodiments, the linker has the structure of Formula Vd:

A¹-(E¹)-(F¹)—(C³)_(m)—(F²)_(o1)-A².   Formula Vd

In some embodiments, the linker has the structure of Formula Ve:

A¹-(E¹)-(F¹)-(E³)_(n)-(F²)_(o1)-(E²)_(p)-A².   Formula Ve

In some embodiments, the linker has the structure of Formula Vf:

A¹-(E¹)-(F¹)—(C³)_(m)-(E³)_(n)-(F₂)_(o1)-(E²)_(p)-A².   Formula Vf

In some embodiments, the linker has the structure of Formula Vg:

A¹-(E¹)-(F¹)-(E³)_(n)-(F²)_(o1)-A²,   Formula Vg

In some embodiments, each of E and E² is, independently, NR^(N), optionally substituted C₁₋₁₀ alkylene, optionally substituted C₂-C₁₀ polyethylene glycolene, or optionally substituted C₁₋₁₀ heteroalkylene.

In some embodiments, E³ is optionally substituted C₁-C₆ alkylene, O, S, or NR^(N);

In some embodiments, E³ is optionally substituted C₁-C₆ alkylene. In some embodiments, E³ is optionally substituted C₁-C₃ alkylene. In some embodiments, E³ is O, S, or NR^(N).

In some embodiments, E³ is C₁-C₆ alkylene. In some embodiments, E³ is C₁-C₃ alkylene. In some embodiments, E³ is O.

In some embodiments, E³ is

where a is 0, 1, 2, 3, 4, or 5.

In some embodiments, E³ is

In some embodiments, each R_(N) is, independently, H or optionally substituted C₁₋₄ alkyl.

In some embodiments, each R_(N) is, independently, H or methyl.

In some embodiments, E is

where a is 0, 1, 2, 3, 4, or 5.

In some embodiments, E¹ is

where a is 0, 1, 2, 3, 4, or 5.

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

where

b is 0, 1, 2, 3, 4, 5, or 6;

R^(a) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and

R^(c) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl.

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, R^(a) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(b) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(c) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(a) is H or methyl. In some embodiments, R^(b) is H or methyl. In some embodiments, R^(c) is H or methyl.

In some embodiments, b is 0, 1, 2, or 3. In some embodiments, b is 0. In some embodiments, b is 1. In some embodiments, b is 2. In some embodiments, b is 3.

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E¹ is

In some embodiments, E² is O, NR^(w),

wherein

c is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

d is 0, 1, 2, or 3;

e is 0, 1, 2, 3, 4, 5, or 6;

f is 0, 1, 2, 3, or 4;

R^(d) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(e) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(f) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(g) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and

W is O or NR^(w), wherein R^(w) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, E² is O, NR^(w),

In some embodiments, R^(d) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, Re is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(f) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(g) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(w) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^(d) is H or methyl. In some embodiments, R^(e) is H or methyl. In some embodiments, R^(f) is H or methyl. In some embodiments, R^(g) is H or methyl. In some embodiments, R^(w) is H or methyl.

In some embodiments, E² is

In some embodiments, E² is O,

In some embodiments, each of F¹, F², or F³ is, independently, optionally substituted C₃-C₁₀ carbocyclylene.

In some embodiments, the C₃-C₁₀ carbocyclylene is monocyclic. In some embodiments, the C₃-C₁₀ carbocyclylene is polycyclic.

In some embodiments, the C₃-C₁₀ carbocyclylene is bicyclic.

In some embodiments, the C₃-C₁₀ carbocyclylene is bridged. In some embodiments, the C₃-C₁₀ carbocyclylene is fused. In some embodiments, the C₃-C₁₀ carbocyclylene is spirocyclic.

In some embodiments, the C₃-C₁₀ carbocyclylene is

In some embodiments, F² is

In some embodiments, the C₃-C₁₀ carbocyclylene is

In some embodiments, F¹ is

In some embodiments, each of F¹, F², or F³ is, independently, optionally substituted C₂-C₉ heterocyclylene.

In some embodiments, the C₂-C₉ heterocyclylene is monocyclic. In some embodiments, the C₂-C₉ heterocyclylene is polycyclic.

In some embodiments, the C₂-C₉ heterocyclylene is bicyclic.

In some embodiments, the C₂-C₉ heterocyclylene is bridged. In some embodiments, the C₂-C₉ heterocyclylene is fused. In some embodiments, the C₂-C₉ heterocyclylene is spirocyclic.

In some embodiments, the C₂-C₉ heterocyclylene includes a quaternary amine.

In some embodiments, the C₂-C₉ heterocyclylene is

where

q1 is 0, 1, 2, 3, or 4;

q2 is 0, 1, 2, 3, 4, 5, or 6;

q3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

each R^(h) is, independently, ²H, halogen, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4); or two R^(h) groups, together with the carbon atom to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl; or two R^(h) groups, together with the carbon atoms to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl;

R^(i1) is H or optionally substituted C₁-C₆ alkyl;

R^(i2) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;

R^(i3) is H or optionally substituted C₁-C₆ alkyl; and

R^(i4) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, each R^(h) is, independently, halogen, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4). In some embodiments, R^(i1) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(i2) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(i3) is H or optionally substituted C₁-C₆ alkyl. In some embodiments, R^(i4) is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, each R^(h) is, independently, halogen, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4). In some embodiments, each R^(h) is, independently, halogen, optionally substituted C₁-C₆ alkyl, or NR^(i3)R^(i4).

In some embodiments, each R^(h) is, independently, ²H, halogen, cyano, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4). In some embodiments, two R^(h) groups, together with the carbon atom to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl. In some embodiments, two R^(h) groups, together with the carbon atoms to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, each R^(h) is, independently, ²H, F, methyl,

In some embodiments, each R^(h) is, independently, F, methyl, or NR^(i3)R^(i4).

In some embodiments, q1 is 0, 1, or 2. In some embodiments, q1 is 0. In some embodiments, q1 is 1. In some embodiments, q1 is 2.

In some embodiments, q2 is 0, 1, or 2. In some embodiments, q2 is 0. In some embodiments, q2 is 1. In some embodiments, q2 is 2.

In some embodiments, q3 is 0, 1, or 2. In some embodiments, q3 is 0. In some embodiments, q3 is 1. In some embodiments, q3 is 2.

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F² is

In some embodiments, F² is

In some embodiments, F³ is

In some embodiments, F³ is

In some embodiments, R^(i1) is H or methyl. In some embodiments, R^(i2) is H or methyl. In some embodiments, R^(i3) is H or methyl. In some embodiments, R^(i4) is H or methyl.

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, the C₂-C₉ heterocyclylene is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F² is

In some embodiments, the C₂-C₉ heterocyclyl is

In some embodiments, the C₂-C₉ heterocyclyl is

In some embodiments, the C₂-C₉ heterocyclyl is

In some embodiments, the C₂-C₉ heterocyclyl is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F¹ is

In some embodiments, F² is

In some embodiments, F² is

In some embodiments, F² is

In some embodiments, F² is

In some embodiments, F³ is

In some embodiments, each of F¹, F², or F³ is, independently, optionally substituted C₆-C₁₀ arylene.

In some embodiments, the C₆-C₁₀ arylene is

In some embodiments, each of F¹, F², or F³ is, independently, optionally substituted C₂-C₉ heteroarylene.

In some embodiments, the C₂-C₉ heteroarylene is

In some embodiments, F² is

In some embodiments, F² is

In some embodiments, C³ is

In some embodiments, C³ is

In some embodiments, m is 1. In some embodiments, p is 1.

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of:

In some embodiments, the linker is absent.

In some embodiments, the linker is optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₂₋₁₀ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene.

In some embodiments, the linker is optionally substituted C₃-C₁₀ carbocyclylene or optionally substituted C₂₋₁₀ heterocyclylene. In some embodiments, the linker is optionally substituted C₆-C₁₀ arylene or optionally substituted C₂-C₉ heteroarylene.

In some embodiments, the linker is optionally substituted C₂₋₁₀ heterocyclylene.

In some embodiments, the C₂-C₉ heterocyclylene is monocyclic. In some embodiments, the C₂-C₉ heterocyclylene is polycyclic.

In some embodiments, the C₂-C₉ heterocyclylene is bicyclic.

In some embodiments, the C₂-C₉ heterocyclylene is bridged. In some embodiments, the C₂-C₉ heterocyclylene is fused. In some embodiments, the C₂-C₉ heterocyclylene is spirocyclic.

In some embodiments, the linker has the structure of

In some embodiments, the linker has the structure of

In some embodiments, the compound has the structure of any one of compounds D1-D15 in Table 2A, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D16-D90 in Table 2B, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D91-D220 in Table 2C, or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound has the structure of any one of compounds D3, D10, D12, D13, and D15 in Table 2A, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D16-D29, D33, D35-D43, D46, D49, D50, D57, D60, D65, D66, D70, D72-D75, D77-D79, D83-D87, D89, and D90 in Table 2B, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D96-D101-D123-D136, D138-D141, D144, D146, D147, D149-D170, and D173-D219 in Table 2C, or a pharmaceutically acceptable salt thereof.

In an aspect, the disclosure features a compound having the structure of any one of compounds D1-D15 in Table 2A, or a pharmaceutically acceptable salt thereof.

In an aspect, the disclosure features a compound having the structure of any one of compounds D16-D90 in Table 2B, or a pharmaceutically acceptable salt thereof.

In an aspect, the disclosure features a compound having the structure of any one of compounds D91-D220 in Table 2C, or a pharmaceutically acceptable salt thereof.

TABLE 2A Compounds D1-D15 of the Disclosure Compound No. Structure D1

D2

D3

D4

D5

D6

D7

D8

D9

D10

D11

D12

D13

D14

D15

TABLE 2B Compounds D16-D90 of the Disclosure Comp- ound No. Structure D16

D17

D18

D19

D20

D21

D22

D23

D24

D25

D26

D27

D28

D29

D30

D31

D32

D33

D34

D35

D36

D37

D38

D39

D40

D41

D42

D43

D44

D45

D46

D47

D48

D49

D50

D51

D52

D53

D54

D55

D56

D57

D58

D59

D60

D61

D62

D63

D64

D65

D66

D67

D68

D69

D70

D71

D72

D73

D74

D75

D76

D77

D78

D79

D80

D81

D82

D83

D84

D85

D86

D87

D88

D89

D90

TABLE 2C Compounds D91-D220 of the Disclosure Compound No. Structure D91

D92

D93

D94

D95

D96

D97

D98

D99

D100

D101

D102

D103

D104

D105

D106

D107

D108

D109

D110

D111

D112

D113

D114

D115

D116

D117

D118

D119

D120

D121

D122

D123

D124

D125

D126

D127

D128

D129

D130

D131

D132

D133

D134

D135

D136

D137

D138

D139

D140

D141

D142

D143

D144

D145

D146

D147

D148

D149

D150

D151

D152

D153

D154

D155

D156

D157

D158

D159

D160

D161

D162

D163

D164

D165

D166

D167

D168

D169

D170

D171

D172

D173

D174

D175

D176

D177

D178

D179

D180

D181

D182

D183

D184

D185

D186

D187

D188

D189

D190

D191

D192

D193

D194

D195

D196

D197

D198

D199

D200

D201

D202

D203

D204

D205

D206

D207

D208

D209

D210

D211

D212

D213

D214

D215

D216

D217

D218

D219

D220

In an aspect, the disclosure features a compound having the structure of any one of DD1 and DD2, or a pharmaceutically acceptable salt thereof.

In another aspect, the disclosure features a pharmaceutical composition including any of the foregoing compounds, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable excipient.

In an aspect, the disclosure features a method of inhibiting the level and/or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

In another aspect, the disclosure features a method of reducing the level and/or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

In some embodiments, the cell is a cancer cell.

In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma (e.g., a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, low-grade rhabdomyosarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, or colorectal cancer. In some embodiments, the cancer is a sarcoma (e.g., synovial sarcoma or Ewing's sarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is sarcoma (e.g., synovial sarcoma or Ewing's sarcoma). In some embodiments, the sarcoma is synovial sarcoma.

In an aspect, the disclosure features a method of treating a BAF complex-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof. In some embodiments, the BAF complex-related disorder is cancer. In some embodiments, the BAF complex-related disorder is infection.

In another aspect, the disclosure features a method of treating an SS18-SSX fusion protein-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof. In some embodiments, the SS18-SSX fusion protein-related disorder is cancer. In some embodiments, the SS18-SSX fusion protein-related disorder is infection. In some embodiments of any of the foregoing methods, the SS18-SSX fusion protein is a SS18-SSX1 fusion protein, a SS18-SSX2 fusion protein, or a SS18-SSX4 fusion protein.

In yet another aspect, the disclosure features a method of treating a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof. In some embodiments, the BRD9-related disorder is cancer. In some embodiments, the BRD9-related disorder is infection.

In some embodiments, the cancer is squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using the disclosed compounds according to the present invention include, for example, acute granulocytic leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), adenocarcinoma, adenosarcoma, adrenal cancer, adrenocortical carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, appendix cancer, astrocytoma, Basal cell carcinoma, B-Cell lymphoma, bile duct cancer, bladder cancer, bone cancer, bone marrow cancer, bowel cancer, brain cancer, brain stem glioma, breast cancer, triple (estrogen, progesterone and HER-2) negative breast cancer, double negative breast cancer (two of estrogen, progesterone and HER-2 are negative), single negative (one of estrogen, progesterone and HER-2 is negative), estrogen-receptor positive, HER2-negative breast cancer, estrogen receptor-negative breast cancer, estrogen receptor positive breast cancer, metastatic breast cancer, luminal A breast cancer, luminal B breast cancer, Her2-negative breast cancer, HER2-positive or negative breast cancer, progesterone receptor-negative breast cancer, progesterone receptor-positive breast cancer, recurrent breast cancer, carcinoid tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), colon cancer, colorectal cancer, craniopharyngioma, cutaneous lymphoma, cutaneous melanoma, diffuse astrocytoma, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, epithelioid sarcoma, esophageal cancer, ewing sarcoma, extrahepatic bile duct cancer, eye cancer, fallopian tube cancer, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal tumors (GIST), germ cell tumor glioblastoma multiforme (GBM), glioma, hairy cell leukemia, head and neck cancer, hemangioendothelioma, Hodgkin lymphoma, hypopharyngeal cancer, infiltrating ductal carcinoma (IDC), infiltrating lobular carcinoma (ILC), inflammatory breast cancer (IBC), intestinal Cancer, intrahepatic bile duct cancer, invasive/infiltrating breast cancer, Islet cell cancer, jaw cancer, Kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, leptomeningeal metastases, leukemia, lip cancer, liposarcoma, liver cancer, lobular carcinoma in situ, low-grade astrocytoma, lung cancer, lymph node cancer, lymphoma, male breast cancer, medullary carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesenchymal chondrosarcoma, mesenchymous, mesothelioma metastatic breast cancer, metastatic melanoma metastatic squamous neck cancer, mixed gliomas, monodermal teratoma, mouth cancer mucinous carcinoma, mucosal melanoma, multiple myeloma, Mycosis Fungoides, myelodysplastic syndrome, nasal cavity cancer, nasopharyngeal cancer, neck cancer, neuroblastoma, neuroendocrine tumors (NETs), non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oat cell cancer, ocular cancer, ocular melanoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial cancer ovarian germ cell tumor, ovarian primary peritoneal carcinoma, ovarian sex cord stromal tumor, Paget's disease, pancreatic cancer, papillary carcinoma, paranasal sinus cancer, parathyroid cancer, pelvic cancer, penile cancer, peripheral nerve cancer, peritoneal cancer, pharyngeal cancer, pheochromocytoma, pilocytic astrocytoma, pineal region tumor, pineoblastoma, pituitary gland cancer, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis cancer, rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, bone sarcoma, sarcoma, sinus cancer, skin cancer, small cell lung cancer (SCLC), small intestine cancer, spinal cancer, spinal column cancer, spinal cord cancer, squamous cell carcinoma, stomach cancer, synovial sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma/thymic carcinoma, thyroid cancer, tongue cancer, tonsil cancer, transitional cell cancer, tubal cancer, tubular carcinoma, undiagnosed cancer, ureteral cancer, urethral cancer, uterine adenocarcinoma, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, T-cell lineage acute lymphoblastic leukemia (T-ALL), T-cell lineage lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, Adult T-cell leukemia, Pre-B ALL, Pre-B lymphomas, large B-cell lymphoma, Burkitts lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, Philadelphia chromosome positive CML, juvenile myelomonocytic leukemia (JMML), acute promyelocytic leukemia (a subtype of AML), large granular lymphocytic leukemia, Adult T-cell chronic leukemia, diffuse large B cell lymphoma, follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT), small cell lymphocytic lymphoma, mediastinal large B cell lymphoma, nodal marginal zone B cell lymphoma (NMZL); splenic marginal zone lymphoma (SMZL); intravascular large B-cell lymphoma; primary effusion lymphoma; or lymphomatoid granulomatosis; B-cell prolymphocytic leukemia; splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B-cell lymphoma; lymphoplasmacytic lymphoma; heavy chain diseases, for example, Alpha heavy chain disease, Gamma heavy chain disease, Mu heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone; extraosseous plasmacytoma; primary cutaneous follicle center lymphoma, T cell/histocyte rich large B-cell lymphoma, DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV)+ DLBCL of the elderly; primary mediastinal (thymic) large B-cell lymphoma, primary cutaneous DLBCL, leg type, ALK+ large B-cell lymphoma, plasmablastic lymphoma; large B-cell lymphoma arising in HHV8-associated multicentric, Castleman disease; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, or B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma (e.g., a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, low-grade rhabdomyosarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, or colorectal cancer. In some embodiments, the cancer is a sarcoma (e.g., synovial sarcoma or Ewing's sarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is sarcoma (e.g., synovial sarcoma or Ewing's sarcoma). In some embodiments, the sarcoma is synovial sarcoma.

In some embodiments, the infection is viral infection (e.g., an infection with a virus of the Retroviridae family such as the lentiviruses (e.g. Human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T cell leukemia virus I (HTLV-I), human T cell leukemia virus II (HTLV-II)); Hepadnaviridae family (e.g. hepatitis B virus (HBV)); Flaviviridae family (e.g. hepatitis C virus (HCV)); Adenoviridae family (e.g. Human Adenovirus); Herpesviridae family (e.g. Human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human herpesvirus 6 (HHV-6), Herpesvirus K*, CMV, varicella-zoster virus); Papillomaviridae family (e.g. Human Papillomavirus (HPV, HPV E1)); Parvoviridae family (e.g. Parvovirus B19); Polyomaviridae family (e.g. JC virus and BK virus); Paramyxoviridae family (e.g. Measles virus); or Togaviridae family (e.g. Rubella virus)). In some embodiments, the disorder is Coffin Siris, Neurofibromatosis (e.g., NF-1, NF-2, or Schwannomatosis), or Multiple Meningioma. In an aspect, the disclosure features a method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or any of the foregoing pharmaceutical compositions.

In some embodiments, the cancer is squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using the disclosed compounds according to the present invention include, for example, acute granulocytic leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), adenocarcinoma, adenosarcoma, adrenal cancer, adrenocortical carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, appendix cancer, astrocytoma, Basal cell carcinoma, B-Cell lymphoma, bile duct cancer, bladder cancer, bone cancer, bone marrow cancer, bowel cancer, brain cancer, brain stem glioma, breast cancer, triple (estrogen, progesterone and HER-2) negative breast cancer, double negative breast cancer (two of estrogen, progesterone and HER-2 are negative), single negative (one of estrogen, progesterone and HER-2 is negative), estrogen-receptor positive, HER2-negative breast cancer, estrogen receptor-negative breast cancer, estrogen receptor positive breast cancer, metastatic breast cancer, luminal A breast cancer, luminal B breast cancer, Her2-negative breast cancer, HER2-positive or negative breast cancer, progesterone receptor-negative breast cancer, progesterone receptor-positive breast cancer, recurrent breast cancer, carcinoid tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), colon cancer, colorectal cancer, craniopharyngioma, cutaneous lymphoma, cutaneous melanoma, diffuse astrocytoma, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, epithelioid sarcoma, esophageal cancer, ewing sarcoma, extrahepatic bile duct cancer, eye cancer, fallopian tube cancer, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal tumors (GIST), germ cell tumor glioblastoma multiforme (GBM), glioma, hairy cell leukemia, head and neck cancer, hemangioendothelioma, Hodgkin lymphoma, hypopharyngeal cancer, infiltrating ductal carcinoma (IDC), infiltrating lobular carcinoma (ILC), inflammatory breast cancer (IBC), intestinal Cancer, intrahepatic bile duct cancer, invasive/infiltrating breast cancer, Islet cell cancer, jaw cancer, Kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, leptomeningeal metastases, leukemia, lip cancer, liposarcoma, liver cancer, lobular carcinoma in situ, low-grade astrocytoma, lung cancer, lymph node cancer, lymphoma, male breast cancer, medullary carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesenchymal chondrosarcoma, mesenchymous, mesothelioma metastatic breast cancer, metastatic melanoma metastatic squamous neck cancer, mixed gliomas, monodermal teratoma, mouth cancer mucinous carcinoma, mucosal melanoma, multiple myeloma, Mycosis Fungoides, myelodysplastic syndrome, nasal cavity cancer, nasopharyngeal cancer, neck cancer, neuroblastoma, neuroendocrine tumors (NETs), non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oat cell cancer, ocular cancer, ocular melanoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial cancer ovarian germ cell tumor, ovarian primary peritoneal carcinoma, ovarian sex cord stromal tumor, Paget's disease, pancreatic cancer, papillary carcinoma, paranasal sinus cancer, parathyroid cancer, pelvic cancer, penile cancer, peripheral nerve cancer, peritoneal cancer, pharyngeal cancer, pheochromocytoma, pilocytic astrocytoma, pineal region tumor, pineoblastoma, pituitary gland cancer, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis cancer, rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, bone sarcoma, sarcoma, sinus cancer, skin cancer, small cell lung cancer (SCLC), small intestine cancer, spinal cancer, spinal column cancer, spinal cord cancer, squamous cell carcinoma, stomach cancer, synovial sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma/thymic carcinoma, thyroid cancer, tongue cancer, tonsil cancer, transitional cell cancer, tubal cancer, tubular carcinoma, undiagnosed cancer, ureteral cancer, urethral cancer, uterine adenocarcinoma, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, T-cell lineage acute lymphoblastic leukemia (T-ALL), T-cell lineage lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, Adult T-cell leukemia, Pre-B ALL, Pre-B lymphomas, large B-cell lymphoma, Burkitts lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, Philadelphia chromosome positive CML, juvenile myelomonocytic leukemia (JMML), acute promyelocytic leukemia (a subtype of AML), large granular lymphocytic leukemia, Adult T-cell chronic leukemia, diffuse large B cell lymphoma, follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT), small cell lymphocytic lymphoma, mediastinal large B cell lymphoma, nodal marginal zone B cell lymphoma (NMZL); splenic marginal zone lymphoma (SMZL); intravascular large B-cell lymphoma; primary effusion lymphoma; or lymphomatoid granulomatosis; B-cell prolymphocytic leukemia; splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B-cell lymphoma; lymphoplasmacytic lymphoma; heavy chain diseases, for example, Alpha heavy chain disease, Gamma heavy chain disease, Mu heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone; extraosseous plasmacytoma; primary cutaneous follicle center lymphoma, T cell/histocyte rich large B-cell lymphoma, DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV)+ DLBCL of the elderly; primary mediastinal (thymic) large B-cell lymphoma, primary cutaneous DLBCL, leg type, ALK+ large B-cell lymphoma, plasmablastic lymphoma; large B-cell lymphoma arising in HHV8-associated multicentric, Castleman disease; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, or B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma (e.g., a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, low-grade rhabdomyosarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, or colorectal cancer. In some embodiments, the cancer is a sarcoma (e.g., synovial sarcoma or Ewing's sarcoma), non-small cell lung cancer (e.g., squamous or adenocarcinoma), stomach cancer, or breast cancer. In some embodiments, the cancer is sarcoma (e.g., synovial sarcoma or Ewing's sarcoma). In some embodiments, the sarcoma is synovial sarcoma.

In another aspect, the disclosure features a method for treating a viral infection in a subject in need thereof. This method includes administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or any of the foregoing pharmaceutical compositions. In some embodiments, the viral infection is an infection with a virus of the Retroviridae family such as the lentiviruses (e.g. Human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T cell leukemia virus I (HTLV-I), human T cell leukemia virus II (HTLV-II)); Hepadnaviridae family (e.g. hepatitis B virus (HBV)), Flaviviridae family (e.g. hepatitis C virus (HCV)), Adenoviridae family (e.g. Human Adenovirus), Herpesviridae family (e.g. Human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human herpesvirus 6 (HHV-6), Herpesvirus K*, CMV, varicella-zoster virus), Papillomaviridae family (e.g. Human Papillomavirus (HPV, HPV E1)), Parvoviridae family (e.g. Parvovirus B19), Polyomaviridae family (e.g. JC virus and BK virus), Paramyxoviridae family (e.g. Measles virus), Togaviridae family (e.g. Rubella virus).

In another embodiment of any of the foregoing methods, the method further includes administering to the subject an additional anticancer therapy (e.g., chemotherapeutic or cytotoxic agent or radiotherapy).

In particular embodiments, the additional anticancer therapy is: a chemotherapeutic or cytotoxic agent (e.g., doxorubicin or ifosfamide), a differentiation-inducing agent (e.g., retinoic acid, vitamin D, cytokines), a hormonal agent, an immunological agent, or an anti-angiogenic agent. Chemotherapeutic and cytotoxic agents include, but are not limited to, alkylating agents, cytotoxic antibiotics, antimetabolites, vinca alkaloids, etoposides, and others (e.g., paclitaxel, taxol, docetaxel, taxotere, cis-platinum). A list of additional compounds having anticancer activity can be found in L. Brunton, B. Chabner and B. Knollman (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition, 2011, McGraw Hill Companies, New York, N.Y.

In particular embodiments, the compound of the invention and the additional anticancer therapy and any of the foregoing compounds or pharmaceutical compositions are administered within 28 days of each other (e.g., within 21, 14, 10, 7, 5, 4, 3, 2, or 1 days) or within 24 hours (e.g., 12, 6, 3, 2, or 1 hours; or concomitantly) each in an amount that together are effective to treat the subject.

Chemical Terms

The terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting.

For any of the following chemical definitions, a number following an atomic symbol indicates that total number of atoms of that element that are present in a particular chemical moiety. As will be understood, other atoms, such as hydrogen atoms, or substituent groups, as described herein, may be present, as necessary, to satisfy the valences of the atoms. For example, an unsubstituted C₂ alkyl group has the formula —CH₂CH₃. When used with the groups defined herein, a reference to the number of carbon atoms includes the divalent carbon in acetal and ketal groups but does not include the carbonyl carbon in acyl, ester, carbonate, or carbamate groups. A reference to the number of oxygen, nitrogen, or sulfur atoms in a heteroaryl group only includes those atoms that form a part of a heterocyclic ring.

Herein a phrase of the form “optionally substituted X” (e.g., optionally substituted alkyl) is intended to be equivalent to “X, wherein X is optionally substituted” (e.g., “alkyl, wherein said alkyl is optionally substituted”). It is not intended to mean that the feature “X” (e.g., alkyl) per se is optional. As described herein, certain compounds of interest may contain one or more “optionally substituted” moieties. In general, the term “substituted”, whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent, e.g., any of the substituents or groups described herein. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

The term “aliphatic,” as used herein, refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon. “Aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions. In one embodiment, “aliphatic” is used to indicate those aliphatic groups having 1-20 carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, di-unsaturated, tri-unsaturated, or polyunsaturated, or alkynyl. Unsaturated aliphatic groups can be in a cis or trans configuration. In one embodiment, the aliphatic group contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the aliphatic group contains from 1 to about 8 carbon atoms. In certain embodiments, the aliphatic group is C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅, or C₁-C₆. The specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species. For example, the term C₁-C₆ aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C₁-C₄ aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. In one embodiment, the aliphatic group is substituted with one or more functional groups that results in the formation of a stable moiety.

The term “heteroaliphatic,” as used herein, refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur. “Heteroaliphatic” is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties. In one embodiment, “heteroaliphatic” is used to indicate a heteroaliphatic group (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-20 carbon atoms. In one embodiment, the heteroaliphatic group is optionally substituted in a manner that results in the formation of a stable moiety. Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, —O-alkyl-O-alkyl, and alkyl-O-haloalkyl.

The term “acyl,” as used herein, represents a hydrogen or an alkyl group that is attached to a parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups include from 1 to 6, from 1 to 11, or from 1 to 21 carbons.

The term “alkyl,” as used herein, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 3 carbon atoms). An “alkylene” is a divalent alkyl group.

The term “alkenyl,” as used herein, alone or in combination with other groups, refers to a straight chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms). An “alkenylene” is a divalent alkenyl group.

The term “alkynyl,” as used herein, alone or in combination with other groups, refers to a straight chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms). An “alkynylene” is a divalent alkynyl group.

The term “amino,” as used herein, represents —N(R^(N1))₂, wherein each R^(N1) is, independently, H, OH, NO₂, N(R^(N2))₂, SO₂OR^(N2), SO₂R^(N2), SOR^(N2), an N-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), wherein each of these recited R^(N1) groups can be optionally substituted; or two R^(N1) combine to form an alkylene or heteroalkylene, and wherein each R^(N2) is, independently, H, alkyl, or aryl. The amino groups of the compounds described herein can be an unsubstituted amino (i.e., —NH₂) or a substituted amino (i.e., —N(R^(N1))₂).

The term “aryl,” as used herein, refers to an aromatic mono- or polycarbocyclic radical of, e.g., 6 to 12, carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.

The term “arylalkyl,” as used herein, represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁-C₆ alkyl C₆-C₁₀ aryl, C₁-C₁₀ alkyl C₆-C₁₀ aryl, or C₁-C₂₀ alkyl C₆-C₁₀ aryl), such as, benzyl and phenethyl. In some embodiments, the alkyl and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term “azido,” as used herein, represents a —N₃ group.

The term “bridged cyclyl,” as used herein, refers to a bridged polycyclic group of 5 to 20 atoms, containing from 1 to 3 bridges. Bridged cyclyl includes bridged carbocyclyl (e.g., norbornyl) and bridged heterocyclyl (e.g., 1,4-diazabicyclo[2.2.2]octane).

The term “cyano,” as used herein, represents a —CN group.

The term “carbocyclyl,” as used herein, refers to a non-aromatic C₃-C₁₂, monocyclic or polycyclic (e.g., bicyclic or tricyclic) structure in which the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl groups (e.g., cyclohexyl) and unsaturated carbocyclyl radicals (e.g., cyclohexenyl). Polycyclic carbocyclyl includes spirocyclic carbocyclyl, bridged carbocyclyl, and fused carbocyclyl. A “carbocyclylene” is a divalent carbocyclyl group.

The term “cycloalkyl,” as used herein, refers to a saturated, non-aromatic, monovalent mono- or polycarbocyclic radical of 3 to 10, preferably 3 to 6 carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.

The terms “halo” or “halogen,” as used herein, mean a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical.

The term “heteroalkyl,” as used herein, refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. Examples of heteroalkyl groups are an “alkoxy” which, as used herein, refers to alkyl-O— (e.g., methoxy and ethoxy), and an “alkylamino” which, as used herein, refers to N(alkyl)R^(Na), where R^(Na) is H or alkyl (e.g., methylamino). A “heteroalkylene” is a divalent heteroalkyl group.

The term “heteroalkenyl,” as used herein, refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkenyl groups. Examples of heteroalkenyl groups are an “alkenoxy” which, as used herein, refers to alkenyl-O—. A “heteroalkenylene” is a divalent heteroalkenyl group.

The term “heteroalkynyl,” as used herein, refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkynyl groups. Examples of heteroalkynyl groups are an “alkynoxy” which, as used herein, refers to alkynyl-O—. A “heteroalkynylene” is a divalent heteroalkynyl group.

The term “heteroaryl,” as used herein, refers to an aromatic monocyclic or polycyclic structure of 5 to 12 atoms having at least one aromatic ring containing 1, 2, or 3 ring atoms selected from nitrogen, oxygen, and sulfur, with the remaining ring atoms being carbon. One or two ring carbon atoms of the heteroaryl group may be replaced with a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, imidazolyl, oxazolyl, and thiazolyl. A “heteroarylene” is a divalent heteroaryl group.

The term “heteroarylalkyl,” as used herein, represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁-C₆ alkyl C₂-C₉ heteroaryl, C₁-C₁₀ alkyl C₂-C₉ heteroaryl, or C₁-C₂₀ alkyl C₂-C₉ heteroaryl). In some embodiments, the alkyl and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term “heterocyclyl,” as used herein, refers a monocyclic or polycyclic radical (e.g., bicyclic or tricyclic) having 3 to 12 atoms having at least one non-aromatic ring containing 1, 2, 3, or 4 ring atoms selected from N, O, or S, and no aromatic ring containing any N, O, or S atoms. Polycyclic heterocyclyl includes spirocyclic heterocyclyl, bridged heterocyclyl, and fused heterocyclyl. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl. A “heterocyclylene” is a divalent heterocyclyl group.

The term “heterocyclylalkyl,” as used herein, represents an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁-C₆ alkyl C₂-C₉ heterocyclyl, C₁-C₁₀ alkyl C₂-C₉ heterocyclyl, or C₁-C₂₀ alkyl C₂-C₉ heterocyclyl). In some embodiments, the alkyl and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term “hydroxyalkyl,” as used herein, represents alkyl group substituted with an —OH group.

The term “hydroxyl,” as used herein, represents an —OH group.

The term “imine,” as used herein, represents ═NR^(N) group, where R^(N) is, e.g., H or alkyl.

The term “N-protecting group,” as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, “Protective Groups in Organic Synthesis,” 3rd Edition (John Wiley & Sons, New York, 1999). N-protecting groups include, but are not limited to, acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L, or D, L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-20 dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups, such as trimethylsilyl. Preferred N-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term “nitro,” as used herein, represents an —NO₂ group.

The term “oxo,” as used herein, represents an ═O group.

The term “thiol,” as used herein, represents an —SH group.

The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups may be substituted or unsubstituted. When substituted, there will generally be 1 to 4 substituents present, unless otherwise specified. Substituents include, for example: alkyl (e.g., unsubstituted and substituted, where the substituents include any group described herein, e.g., aryl, halo, hydroxy), aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halogen (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH₂ or mono- or dialkyl amino), azido, cyano, nitro, oxo, sulfonyl, or thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and heterocyclyl groups may also be substituted with alkyl (unsubstituted and substituted such as arylalkyl (e.g., substituted and unsubstituted benzyl)).

Compounds described herein (e.g., compounds of the invention) can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbent or eluant). That is, certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. “Enantiomer” means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and/or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art. “Racemate” or “racemic mixture” means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. “R,” “S,” “S*,” “R*,” “E,” “Z,” “cis,” and “trans,” indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds described herein (e.g., the compounds of the invention) may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight optically pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight pure. Percent optical purity is the ratio of the weight of the enantiomer or over the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer or over the weight of all the diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure. Percent purity by mole fraction is the ratio of the moles of the enantiomer or over the moles of the enantiomer plus the moles of its optical isomer. Similarly, percent purity by moles fraction is the ratio of the moles of the diastereomer or over the moles of the diastereomer plus the moles of its isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound, or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s), or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms.

Compounds of the present disclosure also include all of the isotopes of the atoms occurring in the intermediate or final compounds. “Isotopes” refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium.

Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁸S, ¹⁸F, ³⁶Cl, ¹²³I and ¹²⁵I. Isotopically-labeled compounds (e.g., those labeled with ³H and ¹⁴C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, one or more hydrogen atoms are replaced by ²H or ³H, or one or more carbon atoms are replaced by ¹³C- or ¹⁴C-enriched carbon. Positron emitting isotopes such as ¹⁵O, ¹³N, ¹¹C, and ¹⁸F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Preparations of isotopically labelled compounds are known to those of skill in the art. For example, isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed for compounds of the present invention described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

As is known in the art, many chemical entities can adopt a variety of different solid forms such as, for example, amorphous forms or crystalline forms (e.g., polymorphs, hydrates, solvate). In some embodiments, compounds of the present invention may be utilized in any such form, including in any solid form. In some embodiments, compounds described or depicted herein may be provided or utilized in hydrate or solvate form.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Definitions

In this application, unless otherwise clear from context, (i) the term “a” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and/or”; and (iii) the terms “including” and “including” may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps.

As used herein, the terms “about” and “approximately” refer to a value that is within 10% above or below the value being described. For example, the term “about 5 nM” indicates a range of from 4.5 to 5.5 nM.

As used herein, the term “administration” refers to the administration of a composition (e.g., a compound or a preparation that includes a compound as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intratumoral, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, and vitreal.

As used herein, the term “adult soft tissue sarcoma” refers to a sarcoma that develops in the soft tissues of the body, typically in adolescent and adult subjects (e.g., subjects who are at least 10 years old, 11 years old, 12 years old, 13 years old, 14 years old, 15 years old, 16 years old, 17 years old, 18 years old, or 19 years old). Non-limiting examples of adult soft tissue sarcoma include, but are not limited to, synovial sarcoma, fibrosarcoma, malignant fibrous histiocytoma, dermatofibrosarcoma, liposarcoma, leiomyosarcoma, hemangiosarcoma, Kaposi's sarcoma, lymphangiosarcoma, malignant peripheral nerve sheath tumor/neurofibrosarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, extraskeletal myxoid chondrosarcoma, and extraskeletal mesenchymal.

The term “antisense,” as used herein, refers to a nucleic acid comprising a polynucleotide that is sufficiently complementary to all or a portion of a gene, primary transcript, or processed mRNA, so as to interfere with expression of the endogenous gene (e.g., BRD9). “Complementary” polynucleotides are those that are capable of base pairing according to the standard Watson-Crick complementarity rules. Specifically, purines will base pair with pyrimidines to form a combination of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. It is understood that two polynucleotides may hybridize to each other even if they are not completely complementary to each other, provided that each has at least one region that is substantially complementary to the other.

The term “antisense nucleic acid” includes single-stranded RNA as well as double-stranded DNA expression cassettes that can be transcribed to produce an antisense RNA. “Active” antisense nucleic acids are antisense RNA molecules that are capable of selectively hybridizing with a primary transcript or mRNA encoding a polypeptide having at least 80% sequence identity (e.g., 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% identity, or more) with the targeted polypeptide sequence (e.g., a BRD9 polypeptide sequence). The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. In some embodiments, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence. The term “coding region” refers to the region of the nucleotide sequence comprising codons that are translated into amino acid residues. In some embodiments, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence. The term “noncoding region” refers to 5′ and 3′ sequences that flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions). The antisense nucleic acid molecule can be complementary to the entire coding region of mRNA, or can be antisense to only a portion of the coding or noncoding region of an mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length.

As used herein, the term “BAF complex” refers to the BRG1- or HRBM-associated factors complex in a human cell.

As used herein, the term “BAF complex-related disorder” refers to a disorder that is caused or affected by the level and/or activity of a BAF complex.

As used herein, the terms “GBAF complex” and “GBAF” refer to a SWI/SNF ATPase chromatin remodeling complex in a human cell. GBAF complex subunits may include, but are not limited to, ACTB, ACTL6A, ACTL6B, BICRA, BICRAL, BRD9, SMARCA2, SMARCA4, SMARCC1, SMARCD1, SMARCD2, SMARCD3, and SS18. The term “cancer” refers to a condition caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.

As used herein, the term “BRD9” refers to bromodomain-containing protein 9, a component of the BAF (BRG1- or BRM-associated factors) complex, a SWI/SNF ATPase chromatin remodeling complex, and belongs to family IV of the bromodomain-containing proteins. BRD9 is encoded by the BRD9 gene, the nucleic acid sequence of which is set forth in SEQ ID NO: 1. The term “BRD9” also refers to natural variants of the wild-type BRD9 protein, such as proteins having at least 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% identity, or more) to the amino acid sequence of wild-type BRD9, which is set forth in SEQ ID NO: 2.

As used herein, the term “BRD9-related disorder” refers to a disorder that is caused or affected by the level and/or activity of BRD9. The term “cancer” refers to a condition caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.

As used herein, a “combination therapy” or “administered in combination” means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent and the agents may be co-formulated. In some embodiments, the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. In some embodiments, administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be administered orally.

A “compound of the present invention” and similar terms as used herein, whether explicitly noted or not, refers to compounds useful for treating BAF-related disorders (e.g., cancer or infection) described herein, including, e.g., compounds of Formula I or Formula II (e.g., compounds of Table 2A, Table 2B, and Table 2C), as well as salts (e.g., pharmaceutically acceptable salts), solvates, hydrates, stereoisomers (including atropisomers), and tautomers thereof. Those skilled in the art will appreciate that certain compounds described herein can exist in one or more different isomeric (e.g., stereoisomers, geometric isomers, atropisomers, and tautomers) or isotopic (e.g., in which one or more atoms has been substituted with a different isotope of the atom, such as hydrogen substituted for deuterium) forms. Unless otherwise indicated or clear from context, a depicted structure can be understood to represent any such isomeric or isotopic form, individually or in combination. Compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms. In some embodiments, one or more compounds depicted herein may exist in different tautomeric forms. As will be clear from context, unless explicitly excluded, references to such compounds encompass all such tautomeric forms. In some embodiments, tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. In certain embodiments, a tautomeric form may be a prototropic tautomer, which is an isomeric protonation states having the same empirical formula and total charge as a reference form. Examples of moieties with prototropic tautomeric forms are ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. In some embodiments, tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. In certain embodiments, tautomeric forms result from acetal interconversion.

As used herein, the term “degrader” refers to a small molecule compound including a degradation moiety, wherein the compound interacts with a protein (e.g., BRD9) in a way which results in degradation of the protein, e.g., binding of the compound results in at least 5% reduction of the level of the protein, e.g., in a cell or subject.

As used herein, the term “degradation moiety” refers to a moiety whose binding results in degradation of a protein, e.g., BRD9. In one example, the moiety binds to a protease or a ubiquitin ligase that metabolizes the protein, e.g., BRD9.

By “determining the level of a protein” is meant the detection of a protein, or an mRNA encoding the protein, by methods known in the art either directly or indirectly. “Directly determining” means performing a process (e.g., performing an assay or test on a sample or “analyzing a sample” as that term is defined herein) to obtain the physical entity or value. “Indirectly determining” refers to receiving the physical entity or value from another party or source (e.g., a third-party laboratory that directly acquired the physical entity or value). Methods to measure protein level generally include, but are not limited to, western blotting, immunoblotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, liquid chromatography (LC)-mass spectrometry, microcytometry, microscopy, fluorescence activated cell sorting (FACS), and flow cytometry, as well as assays based on a property of a protein including, but not limited to, enzymatic activity or interaction with other protein partners. Methods to measure mRNA levels are known in the art.

As used herein, the terms “effective amount,” “therapeutically effective amount,” and “a “sufficient amount” of an agent that reduces the level and/or activity of BRD9 (e.g., in a cell or a subject) described herein refer to a quantity sufficient to, when administered to the subject, including a human, effect beneficial or desired results, including clinical results, and, as such, an “effective amount” or synonym thereto depends on the context in which it is being applied. For example, in the context of treating cancer, it is an amount of the agent that reduces the level and/or activity of BRD9 sufficient to achieve a treatment response as compared to the response obtained without administration of the agent that reduces the level and/or activity of BRD9. The amount of a given agent that reduces the level and/or activity of BRD9 described herein that will correspond to such an amount will vary depending upon various factors, such as the given agent, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject (e.g., age, sex, and/or weight) or host being treated, and the like, but can nevertheless be routinely determined by one of skill in the art. Also, as used herein, a “therapeutically effective amount” of an agent that reduces the level and/or activity of BRD9 of the present disclosure is an amount which results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of an agent that reduces the level and/or activity of BRD9 of the present disclosure may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen may be adjusted to provide the optimum therapeutic response.

As used herein, the term “inhibitor” refers to any agent which reduces the level and/or activity of a protein (e.g., BRD9). Non-limiting examples of inhibitors include small molecule inhibitors, degraders, antibodies, enzymes, or polynucleotides (e.g., siRNA).

The term “inhibitory RNA agent” refers to an RNA, or analog thereof, having sufficient sequence complementarity to a target RNA to direct RNA interference. Examples also include a DNA that can be used to make the RNA. RNA interference (RNAi) refers to a sequence-specific or selective process by which a target molecule (e.g., a target gene, protein, or RNA) is down-regulated. Generally, an interfering RNA (“iRNA”) is a double-stranded short-interfering RNA (siRNA), short hairpin RNA (shRNA), or single-stranded micro-RNA (miRNA) that results in catalytic degradation of specific mRNAs, and also can be used to lower or inhibit gene expression.

By “level” is meant a level of a protein, or mRNA encoding the protein, as compared to a reference. The reference can be any useful reference, as defined herein. By a “decreased level” or an “increased level” of a protein is meant a decrease or increase in protein level, as compared to a reference (e.g., a decrease or an increase by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, or more; a decrease or an increase of more than about 10%, about 15%, about 20%, about 50%, about 75%, about 100%, or about 200%, as compared to a reference; a decrease or an increase by less than about 0.01-fold, about 0.02-fold, about 0.1-fold, about 0.3-fold, about 0.5-fold, about 0.8-fold, or less; or an increase by more than about 1.2-fold, about 1.4-fold, about 1.5-fold, about 1.8-fold, about 2.0-fold, about 3.0-fold, about 3.5-fold, about 4.5-fold, about 5.0-fold, about 10-fold, about 15-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 100-fold, about 1000-fold, or more). A level of a protein may be expressed in mass/vol (e.g., g/dL, mg/mL, μg/mL, ng/mL) or percentage relative to total protein or mRNA in a sample.

The terms “miRNA” and “microRNA” refer to an RNA agent, preferably a single-stranded agent, of about 10-50 nucleotides in length, preferably between about 15-25 nucleotides in length, which is capable of directing or mediating RNA interference. Naturally-occurring miRNAs are generated from stem-loop precursor RNAs (i.e., pre-miRNAs) by Dicer. The term “Dicer” as used herein, includes Dicer as well as any Dicer ortholog or homolog capable of processing dsRNA structures into siRNAs, miRNAs, siRNA-like or miRNA-like molecules. The term microRNA (“miRNA”) is used interchangeably with the term “small temporal RNA” (“stRNA”) based on the fact that naturally-occurring miRNAs have been found to be expressed in a temporal fashion (e.g., during development).

By “modulating the activity of a BAF complex,” is meant altering the level of an activity related to a BAF complex (e.g., GBAF), or a related downstream effect. The activity level of a BAF complex may be measured using any method known in the art, e.g., the methods described in Kadoch et al, Cell 153:71-85 (2013), the methods of which are herein incorporated by reference.

“Percent (%) sequence identity” with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:

100 multiplied by (the fraction X/Y)

where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program's alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.

A “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

As used herein, the term “pharmaceutically acceptable salt” means any pharmaceutically acceptable salt of the compound of any of the compounds described herein. For example, pharmaceutically acceptable salts of any of the compounds described herein include those that are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P. H. Stahl and C. G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid.

The compounds described herein may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds described herein, be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparation of the appropriate salts are well-known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.

By “reducing the activity of BRD9,” is meant decreasing the level of an activity related to an BRD9, or a related downstream effect. A non-limiting example of inhibition of an activity of BRD9 is decreasing the level of a BAF complex (e.g., GBAF) in a cell. The activity level of BRD9 may be measured using any method known in the art. In some embodiments, an agent which reduces the activity of BRD9 is a small molecule BRD9 inhibitor. In some embodiments, an agent which reduces the activity of BRD9 is a small molecule BRD9 degrader.

By “reducing the level of BRD9,” is meant decreasing the level of BRD9 in a cell or subject. The level of BRD9 may be measured using any method known in the art.

By a “reference” is meant any useful reference used to compare protein or mRNA levels. The reference can be any sample, standard, standard curve, or level that is used for comparison purposes. The reference can be a normal reference sample or a reference standard or level. A “reference sample” can be, for example, a control, e.g., a predetermined negative control value such as a “normal control” or a prior sample taken from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (e.g., a cell or tissue) from a subject not having a disease; a sample from a subject that is diagnosed with a disease, but not yet treated with a compound described herein; a sample from a subject that has been treated by a compound described herein; or a sample of a purified protein (e.g., any described herein) at a known normal concentration. By “reference standard or level” is meant a value or number derived from a reference sample. A “normal control value” is a pre-determined value indicative of non-disease state, e.g., a value expected in a healthy control subject. Typically, a normal control value is expressed as a range (“between X and Y”), a high threshold (“no higher than X”), or a low threshold (“no lower than X”). A subject having a measured value within the normal control value for a particular biomarker is typically referred to as “within normal limits” for that biomarker. A normal reference standard or level can be a value or number derived from a normal subject not having a disease or disorder (e.g., cancer); a subject that has been treated with a compound described herein. In preferred embodiments, the reference sample, standard, or level is matched to the sample subject sample by at least one of the following criteria: age, weight, sex, disease stage, and overall health. A standard curve of levels of a purified protein, e.g., any described herein, within the normal reference range can also be used as a reference.

The terms “short interfering RNA” and “siRNA” (also known as “small interfering RNAs”) refer to an RNA agent, preferably a double-stranded agent, of about 10-50 nucleotides in length, the strands optionally having overhanging ends comprising, for example 1, 2 or 3 overhanging nucleotides (or nucleotide analogs), which is capable of directing or mediating RNA interference. Naturally-occurring siRNAs are generated from longer dsRNA molecules (e.g., >25 nucleotides in length) by a cell's RNAi machinery (e.g., Dicer or a homolog thereof).

The term “shRNA”, as used herein, refers to an RNA agent having a stem-loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region.

As used herein, the term “subject” refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition.

As used herein, the term “SS18-SSX fusion protein-related disorder” refers to a disorder that is caused or affected by the level and/or activity of SS18-SSX fusion protein.

As used herein, the terms “treat,” “treated,” or “treating” mean both therapeutic treatment and prophylactic or preventative measures wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.

As used herein, the terms “variant” and “derivative” are used interchangeably and refer to naturally-occurring, synthetic, and semi-synthetic analogues of a compound, peptide, protein, or other substance described herein. A variant or derivative of a compound, peptide, protein, or other substance described herein may retain or improve upon the biological activity of the original material.

The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a series of graphs illustrating the effect of specific guide RNA (sgRNA) targeting of the BRD9 BAF complex subunit on synovial sarcoma cell growth. The Y-axis indicated the dropout ratio. The X-axis indicates the nucleotide position of the BRD9 gene. The grey box indicates the range of the negative control sgRNAs in the screen. The SYO1 cell line carries SS18-SSX2 fusion protein. The breakpoint joining the N-terminal region of SS18 to the C-terminal region of SSX2 are indicated by the black lines in their respective panel. The linear protein sequence is show with BRD9 PFAM domains annotated from the PFAM database.

FIG. 2 is an image illustrating dose dependent depletion of BRD9 levels in a synovial sarcoma cell line (SYO1) in the presence of a BRD9 degrader.

FIG. 3 is an image illustrating sustained suppression of BRD9 levels in a synovial sarcoma cell line (SYO1) in the presence of a BRD9 degrader over 72 hours.

FIG. 4 is an image illustrating sustained suppression of BRD9 levels in two cell lines (293T and SYO1) in the presence of a BRD9 degrader over 5 days.

FIG. 5 is an image illustrating sustained suppression of BRD9 levels in synovial sarcoma cell lines (SYO1 and Yamato) in the presence of a BRD9 degrader over 7 days compared to the levels in cells treated with CRISPR reagents.

FIG. 6 is an image illustrating the effect on cell growth of six cell lines (SYO1, Yamato, A549, HS-SY-II, ASKA, and 293T) in the presence of a BRD9 degrader and a BRD9 inhibitor.

FIG. 7 is an image illustrating the effect on cell growth of two cell lines (SYO1 and G401) in the presence of a BRD9 degrader.

FIG. 8 is an image illustrating the effect on cell growth of three synovial sarcoma cell lines (SYO1, HS-SY-II, and ASKA) in the presence of a BRD9 degrader, BRD9 binder and E3 ligase binder.

FIG. 9 is an image illustrating the effect on cell growth of three non-synovial sarcoma cell lines (RD, HCT116, and Calu6) in the presence of a BRD9 degrader, BRD9 binder and E3 ligase binder.

FIG. 10 is a graph illustrating the percentage of SYO1 in various cell cycle phases following treatment with DMSO, Compound 1 at 200 nM, or Compound 1 at 1 μM for 8 or 13 days.

FIG. 11 is a series of contour plots illustrating the percentage of SYO1 cells in various cell cycle phases following treatment with DMSO, Compound 1 at 200 nM, Compound 1 at 1 μM, or lenalidomide at 200 nM for 8 days. Numerical values corresponding to each contour plot are found in the table below.

FIG. 12 is a series of contour plots illustrating the percentage of SYO1 cells in various cell cycle phases following treatment with DMSO, Compound 1 at 200 nM, Compound 1 at 1 μM, or lenalidomide at 200 nM for 13 days. Numerical values corresponding to each contour plot are found in the table below.

FIG. 13 is a series of contour plots illustrating the percentage of early- and late-apoptotic SYO1 cells following treatment with DMSO, Compound 1 at 200 nM, Compound 1 at 1 μM, or lenalidomide at 200 nM for 8 days. Numerical values corresponding to each contour plot are found in the table below.

FIG. 14 is a graph illustrating the proteins present in BAF complexes including the SS18-SSX fusion protein.

DETAILED DESCRIPTION

The present disclosure features compositions and methods useful for the treatment of BAF-related disorders (e.g., cancer and infection). The disclosure further features compositions and methods useful for inhibition of the level and/or activity of BRD9, e.g., for the treatment of disorders such as cancer (e.g., sarcoma) and infection (e.g., viral infection), e.g., in a subject in need thereof.

Compounds

Compounds described herein reduce the level of an activity related to BRD9, or a related downstream effect, or reduce the level of BRD9 in a cell or subject. Exemplary compounds described herein have the structure according to Formula I or Formula II.

Formula I is:

where

R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl;

Z¹ is CR² or N;

R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N;

X² is O or S;

R^(X1) is H or optionally substituted C₁-C₆ alkyl;

R³ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl; and

G is optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl, or a pharmaceutically acceptable salt thereof.

Formula II is:

A-L-B   Formula II,

where

L is a linker;

B is a degradation moiety; and

A has the structure of Formula III:

where

R¹ is, independently, H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl;

Z¹ is CR² or N;

R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N;

X² is O or S;

R^(X1) is H or optionally substituted C₁-C₆ alkyl;

R³ is H,

cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl; and

R³′ is absent, optionally substituted C₁-C₆ alkylene, optionally substituted C₂-C₉ heteroarylene, or optionally substituted C₁-C₆ heteroalkylene;

G is

optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

G′ is optionally substituted C₃-C₁₀ carbocyclylene, C₂-C₉ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene; and

A¹ is a bond between A and the linker,

where G is

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound has the structure of any one of compounds B1-B10 in Table 1, or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound has the structure of any one of compounds D1-D15 in Table 2A, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D16-D90 in Table 2B, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of any one of compounds D91-D220 in Table 2C, or a pharmaceutically acceptable salt thereof.

Other embodiments, as well as exemplary methods for the synthesis of production of these compounds, are described herein.

Pharmaceutical Uses

The compounds described herein are useful in the methods of the invention and, while not bound by theory, are believed to exert their desirable effects through their ability to modulate the level, status, and/or activity of a BAF complex, e.g., by inhibiting the activity or level of the BRD9 protein in a cell within the BAF complex in a mammal.

An aspect of the present invention relates to methods of treating disorders related to BRD9 such as cancer in a subject in need thereof. In some embodiments, the compound is administered in an amount and for a time effective to result in one of (or more, e.g., two or more, three or more, four or more of): (a) reduced tumor size, (b) reduced rate of tumor growth, (c) increased tumor cell death (d) reduced tumor progression, (e) reduced number of metastases, (f) reduced rate of metastasis, (g) decreased tumor recurrence (h) increased survival of subject, and (i) increased progression free survival of a subject.

Treating cancer can result in a reduction in size or volume of a tumor. For example, after treatment, tumor size is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater) relative to its size prior to treatment. Size of a tumor may be measured by any reproducible means of measurement. For example, the size of a tumor may be measured as a diameter of the tumor.

Treating cancer may further result in a decrease in number of tumors. For example, after treatment, tumor number is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater) relative to number prior to treatment. Number of tumors may be measured by any reproducible means of measurement, e.g., the number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification (e.g., 2×, 3×, 4×, 5×, 10×, or 50×).

Treating cancer can result in a decrease in number of metastatic nodules in other tissues or organs distant from the primary tumor site. For example, after treatment, the number of metastatic nodules is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment. The number of metastatic nodules may be measured by any reproducible means of measurement. For example, the number of metastatic nodules may be measured by counting metastatic nodules visible to the naked eye or at a specified magnification (e.g., 2×, 10×, or 50×).

Treating cancer can result in an increase in average survival time of a population of subjects treated according to the present invention in comparison to a population of untreated subjects. For example, the average survival time is increased by more than 30 days (more than 60 days, 90 days, or 120 days). An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with the compound described herein. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with a pharmaceutically acceptable salt of a compound described herein.

Treating cancer can also result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. For example, the mortality rate is decreased by more than 2% (e.g., more than 5%, 10%, or 25%). A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with a pharmaceutically acceptable salt of a compound described herein. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with a pharmaceutically acceptable salt of a compound described herein.

Combination Therapies

A method of the invention can be used alone or in combination with an additional therapeutic agent, e.g., other agents that treat cancer or symptoms associated therewith, or in combination with other types of therapies to treat cancer. In combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone. For example, doses may be determined empirically from drug combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., Neurology 65:S3-S6 (2005)). In this case, dosages of the compounds when combined should provide a therapeutic effect.

In some embodiments, the second therapeutic agent is a chemotherapeutic agent (e.g., a cytotoxic agent or other chemical compound useful in the treatment of cancer). These include alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. Also included is 5-fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin, capecitabine, paclitaxel, and doxetaxel. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammalI and calicheamicin omegalI (see, e.g., Agnew, Chem. Intl. Ed Engl. 33:183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® (doxorubicin, including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE®, cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; GEMZAR® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail to be administered in combination with the first therapeutic agent described herein. Suitable dosing regimens of combination chemotherapies are known in the art and described in, for example, Saltz et al., Proc. Am. Soc. Clin. Oncol. 18:233a (1999), and Douillard et al., Lancet 355(9209):1041-1047 (2000).

In some embodiments, the second therapeutic agent is a therapeutic agent which is a biologic such a cytokine (e.g., interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In some embodiments the biologic is an anti-angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab (AVASTIN®). In some embodiments the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof) that agonizes a target to stimulate an anti-cancer response, or antagonizes an antigen important for cancer. Such agents include RITUXAN® (rituximab); ZENAPAX® (daclizumab); SIMULECT® (basiliximab); SYNAGIS® (palivizumab); REMICADE® (infliximab); HERCEPTIN® (trastuzumab); MYLOTARG® (gemtuzumab ozogamicin); CAM PATH® (alemtuzumab); ZEVALIN® (ibritumomab tiuxetan); HUMIRA® (adalimumab); XOLAIR® (omalizumab); BEXXAR® (tositumomab-l-131); RAPTIVA® (efalizumab); ERBITUX® (cetuximab); AVASTIN® (bevacizumab); TYSABRI® (natalizumab); ACTEMRA® (tocilizumab); VECTIBIX® (panitumumab); LUCENTIS® (ranibizumab); SOLIRIS® (eculizumab); CIMZIA® (certolizumab pegol); SIMPONI® (golimumab); ILARIS® (canakinumab); STELARA® (ustekinumab); ARZERRA® (ofatumumab); PROLIA® (denosumab); NUMAX® (motavizumab); ABTHRAX® (raxibacumab); BENLYSTA® (belimumab); YERVOY® (ipilimumab); ADCETRIS® (brentuximab vedotin); PERJETA® (pertuzumab); KADCYLA® (ado-trastuzumab emtansine); and GAZYVA® (obinutuzumab). Also included are antibody-drug conjugates.

The second agent may be a therapeutic agent which is a non-drug treatment. For example, the second therapeutic agent is radiation therapy, cryotherapy, hyperthermia, and/or surgical excision of tumor tissue.

The second agent may be a checkpoint inhibitor. In one embodiment, the inhibitor of checkpoint is an inhibitory antibody (e.g., a monospecific antibody such as a monoclonal antibody). The antibody may be, e.g., humanized or fully human. In some embodiments, the inhibitor of checkpoint is a fusion protein, e.g., an Fc-receptor fusion protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with the ligand of a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of CTLA-4 (e.g., an anti-CTLA4 antibody or fusion a protein such as ipilimumab/YERVOY® or tremelimumab). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PD-1 (e.g., nivolumab/OPDIVO®; pembrolizumab/KEYTRUDA®; pidilizumab/CT-011). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PDL1 (e.g., MPDL3280A/RG7446; MEDI4736; MSB0010718C; BMS 936559). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or Fc fusion or small molecule inhibitor) of PDL2 (e.g., a PDL2/Ig fusion protein such as AMP 224). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of B7-H3 (e.g., MGA271), B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands, or a combination thereof.

In some embodiments, the anti-cancer therapy is a T cell adoptive transfer (ACT) therapy. In some embodiments, the T cell is an activated T cell. The T cell may be modified to express a chimeric antigen receptor (CAR). CAR modified T (CAR-T) cells can be generated by any method known in the art. For example, the CAR-T cells can be generated by introducing a suitable expression vector encoding the CAR to a T cell. Prior to expansion and genetic modification of the T cells, a source of T cells is obtained from a subject. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments of the present invention, any number of T cell lines available in the art, may be used. In some embodiments, the T cell is an autologous T cell. Whether prior to or after genetic modification of the T cells to express a desirable protein (e.g., a CAR), the T cells can be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

In any of the combination embodiments described herein, the first and second therapeutic agents are administered simultaneously or sequentially, in either order. The first therapeutic agent may be administered immediately, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17 hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14, 1-21 or 1-30 days before or after the second therapeutic agent.

Pharmaceutical Compositions

The pharmaceutical compositions described herein are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo.

The compounds described herein may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the methods described herein. In accordance with the methods of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds described herein may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, intratumoral, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.

A compound described herein may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound described herein may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers. A compound described herein may also be administered parenterally. Solutions of a compound described herein can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO, and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2012, 22nd ed.) and in The United States Pharmacopeia: The National Formulary (USP 41 NF36), published in 2018. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe. Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form includes an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter. A compound described herein may be administered intratumorally, for example, as an intratumoral injection. Intratumoral injection is injection directly into the tumor vasculature and is specifically contemplated for discrete, solid, accessible tumors. Local, regional, or systemic administration also may be appropriate. A compound described herein may advantageously be contacted by administering an injection or multiple injections to the tumor, spaced for example, at approximately, 1 cm intervals. In the case of surgical intervention, the present invention may be used preoperatively, such as to render an inoperable tumor subject to resection. Continuous administration also may be applied where appropriate, for example, by implanting a catheter into a tumor or into tumor vasculature.

The compounds described herein may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.

Dosages

The dosage of the compounds described herein, and/or compositions including a compound described herein, can vary depending on many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds described herein may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, satisfactory results may be obtained when the compounds described herein are administered to a human at a daily dosage of, for example, between 0.05 mg and 3000 mg (measured as the solid form). Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered.

Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of a compound, or pharmaceutical composition thereof, administered to a patient may range from 0.1-100 mg/kg (e.g., 0.1-50 mg/kg (e.g., 0.25-25 mg/kg)). In exemplary, non-limiting embodiments, the dose may range from 0.5-5.0 mg/kg (e.g., 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg/kg) or from 5.0-20 mg/kg (e.g., 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg).

Kits

The invention also features kits including (a) a pharmaceutical composition including an agent that reduces the level and/or activity of BRD9 in a cell or subject described herein, and (b) a package insert with instructions to perform any of the methods described herein. In some embodiments, the kit includes (a) a pharmaceutical composition including an agent that reduces the level and/or activity of BRD9 in a cell or subject described herein, (b) an additional therapeutic agent (e.g., an anti-cancer agent), and (c) a package insert with instructions to perform any of the methods described herein.

EXAMPLES Example 1—High Density Tiling sgRNA Screen Against Human BAF Complex Subunits in Synovial Sarcoma Cell Line SYO1

The following example shows that BRD9 sgRNA inhibits cell growth in synovial sarcoma cells.

Procedure: To perform high density sgRNA tiling screen, an sgRNA library against BAF complex subunits was custom synthesized at Cellecta (Mountain View, Calif.). Sequences of DNA encoding the BRD9-targeting sgRNAs used in this screen are listed in Table 3. Negative and positive control sgRNA were included in the library. Negative controls consisted of 200 sgRNAs that do not target human genome. The positive controls are sgRNAs targeting essential genes (CDC16, GTF2B, HSPA5, HSPA9, PAFAH1B1, PCNA, POLR2L, RPL9, and SF3A3). DNA sequences encoding all positive and negative control sgRNAs are listed in Table 4. Procedures for virus production, cell infection, and performing the sgRNA screen were previously described (Tsherniak et al, Cell 170:564-576 (2017); Munoz et al, Cancer Discovery 6:900-913 (2016)). For each sgRNA, 50 counts were added to the sequencing counts and for each time point the resulting counts were normalized to the total number of counts. The log 2 of the ratio between the counts (defined as dropout ratio) at day 24 and day 1 post-infection was calculated. For negative control sgRNAs, the 2.5 and 97.5 percentile of the log 2 dropout ratio of all non-targeting sgRNAs was calculated and considered as background (grey box in the graph). Protein domains were obtained from PFAM regions defined for the UNIPROT identifier: Q9H8M2.

Results: As shown in FIG. 1 , targeted inhibition of the GBAF complex component BRD9 by sgRNA resulted in growth inhibition of the SYO1 synovial sarcoma cell line. sgRNAs against other components of the BAF complexes resulted in increased proliferation of cells, inhibition of cell growth, or had no effect on SYO1 cells. These data show that targeting various subunits of the GBAF complex represents a therapeutic strategy for the treatment of synovial sarcoma.

TABLE 3 BRD9 sgRNA Library SEQ ID NO Nucleic Acid Sequence 203 CAAGAAGCACAAGAAGCACA 204 CTTGTGCTTCTTGCCCATGG 205 CTTCTTGTGCTTCTTGCCCA 206 ACAAGAAGCACAAGGCCGAG 207 CTCGTAGGACGAGCGCCACT 208 CGAGTGGCGCTCGTCCTACG 209 GAGTGGCGCTCGTCCTACGA 210 AGGCTTCTCCAGGGGCTTGT 211 AGATTATGCCGACAAGCCCC 212 ACCTTCAGGACTAGCTTTAG 213 AGCTTTAGAGGCTTCTCCAG 214 CTAGCTTTAGAGGCTTCTCC 215 TAGCTTTAGAGGCTTCTCCA 216 CTAAAGCTAGTCCTGAAGGT 217 GCCTCTAAAGCTAGTCCTGA 218 CTTCACTTCCTCCGACCTTC 219 AAGCTAGTCCTGAAGGTCGG 220 AGTGAAGTGACTGAACTCTC 221 GTGACTGAACTCTCAGGATC 222 ATAGTAACTGGAGTCGTGGC 223 CATCATAGTAACTGGAGTCG 224 TGACCTGTCATCATAGTAAC 225 ACTCCAGTTACTATGATGAC 226 CTTTGTGCCTCTCTCGCTCA 227 GGTCAGACCATGAGCGAGAG 228 GAAGAAGAAGAAGTCCGAGA 229 GTCCAGATGCTTCTCCTTCT 230 GTCCGAGAAGGAGAAGCATC 231 GGAGAAGCATCTGGACGATG 232 TGAGGAAAGAAGGAAGCGAA 233 ATCTGGACGATGAGGAAAGA 234 AGAAGAAGCGGAAGCGAGAG 235 GAAGAAGCGGAAGCGAGAGA 236 CCGCCCAGGAAGAGAAGAAG 237 AGAGAGGGAGCACTGTGACA 238 AGGGAGCACTGTGACACGGA 239 GAGGGAGCACTGTGACACGG 240 GCACTGTGACACGGAGGGAG 241 GAGGCTGACGACTTTGATCC 242 AGGCTGACGACTTTGATCCT 243 TCCACCTCCACCTTCTTCCC 244 CGACTTTGATCCTGGGAAGA 245 CTTTGATCCTGGGAAGAAGG 246 TGATCCTGGGAAGAAGGTGG 247 TCCTGGGAAGAAGGTGGAGG 248 CGGACTGGCCGATCTGGGGG 249 ACGCTCGGACTGGCCGATCT 250 AGGTGGAGCCGCCCCCAGAT 251 CGCTCGGACTGGCCGATCTG 252 GCTCGGACTGGCCGATCTGG 253 CACGCTCGGACTGGCCGATC 254 TGTGTCCGGCACGCTCGGAC 255 CTGGCTGTGTCCGGCACGCT 256 ATCGGCCAGTCCGAGCGTGC 257 CACCCTTGCCTGGCTGTGTC 258 CGAGCGTGCCGGACACAGCC 259 TGTTCCAGGAGTTGCTGAAT 260 CACACCTATTCAGCAACTCC 261 GCTGGCGGAGGAAGTGTTCC 262 TTTACCTCTGAAGCTGGCGG 263 CCCCGGTTTACCTCTGAAGC 264 ACTTCCTCCGCCAGCTTCAG 265 CAGGAAAAGCAAAAAATCCA 266 GCTTTCAGAAAAGATCCCCA 267 AGGAAAAGCAAAAAATCCAT 268 GGAAAAGCAAAAAATCCATG 269 GGAGCAATTGCATCCGTGAC 270 GTCACGGATGCAATTGCTCC 271 TTTATTATCATTGAATATCC 272 AATGATAATAAAACATCCCA 273 ATAAAACATCCCATGGATTT 274 TTCATGGTGCCAAAATCCAT 275 TTTCATGGTGCCAAAATCCA 276 TAATGAATACAAGTCAGTTA 277 CAAGTCAGTTACGGAATTTA 278 ATAATGCAATGACATACAAT 279 AACTTGTAGTACACGGTATC 280 CTTCGCCAACTTGTAGTACA 281 AGATACCGTGTACTACAAGT 282 GCGAAGAAGATCCTTCACGC 283 TCATCTTAAAGCCTGCGTGA 284 TTCTCAGCAGGCAGCTCTTT 285 CAATGAAGATACAGCTGTTG 286 ACTGGTACAACTTCAGGGAC 287 CTTGTACTGGTACAACTTCA 288 ACTTGTACTGGTACAACTTC 289 TTGGCAGTTTCTACTTGTAC 290 TACCTGATAACTTCTCTACT 291 AGCCGAGTAGAGAAGTTATC 292 AGCTGCATGTTTGAGCCTGA 293 GCTGCATGTTTGAGCCTGAA 294 AAGCTGCAGGCATTCCCTTC 295 GGTACTGTCCGTCAAGCTGC 296 AGGGAATGCCTGCAGCTTGA 297 CTTGACGGACAGTACCGCAG 298 CGCCAGCACGTGCTCCTCTG 299 TACCGCAGAGGAGCACGTGC 300 AGAGGAGCACGTGCTGGCGC 301 GGAGCACGTGCTGGCGCTGG 302 AGCACGCAGCTGACGAAGCT 303 GCACGCAGCTGACGAAGCTC 304 CAGCTGACGAAGCTCGGGAC 305 AAGCTCGGGACAGGATCAAC 306 CCTTGCCGCCTGGGAGGAAC 307 AGGATCAACCGGTTCCTCCC 308 ATCAACCGGTTCCTCCCAGG 309 GCACTACCTTGCCGCCTGGG 310 AGAGCACTACCTTGCCGCCT 311 CCGGTTCCTCCCAGGCGGCA 312 TCCTCTTCAGATAGCCCATC 313 ATGGGCTATCTGAAGAGGAA 314 GGGCTATCTGAAGAGGAACG 315 TGGGCTATCTGAAGAGGAAC 316 TATCTGAAGAGGAACGGGGA 317 ATCTGAAGAGGAACGGGGAC 318 TGTTGACCACGCTGTAGAGC 319 GCTCTACAGCGTGGTCAACA 320 CGGGAGCCTGCTCTACAGCG 321 CGTGGTCAACACGGCCGAGC 322 CCCACCATCAGCGTCCGGCT 323 ACGGCCGAGCCGGACGCTGA 324 GGGCACCCACCATCAGCGTC 325 GCCGAGCCGGACGCTGATGG 326 CCATGTCCGTGTTGCAGAGG 327 CCGAGCCGGACGCTGATGGT 328 CGAGCTCAAGTCCACCGGGT 329 GCGAGCTCAAGTCCACCGGG 330 AGAGCGAGCTCAAGTCCACC 331 GAGAGCGAGCTCAAGTCCAC 332 GAAGCCTGGGAGTAGCTTAC 333 CTCTCCAGTAAGCTACTCCC 334 AGCCCAGCGTGGTGAAGCCT 335 AAGCCCAGCGTGGTGAAGCC 336 ACTCCCAGGCTTCACCACGC 337 CTCCCAGGCTTCACCACGCT 338 CTCGTCTTTGAAGCCCAGCG 339 CACTGGAGAGAAAGGTGACT 340 GCACTGGAGAGAAAGGTGAC 341 AGTAGTGGCACTGGAGAGAA 342 CGAAAGCGCAGTAGTGGCAC 343 CTGCATCGAAAGCGCAGTAG 344 ATGCAGAATAATTCAGTATT 345 AGTATTTGGCGACTTGAAGT 346 CGACTTGAAGTCGGACGAGA 347 GAGCTGCTCTACTCAGCCTA 348 CACGCCTGTCTCATCTCCGT 349 TCAGCCTACGGAGATGAGAC 350 CAGGCGTGCAGTGTGCGCTG 351 CCGCGGCCCCTCTAGCCTGC 352 CATCCTTCACAAACTCCTGC 353 TAGCCTGCAGGAGTTTGTGA 354 CAGGAGTTTGTGAAGGATGC 355 AGGAGTTTGTGAAGGATGCT 356 TGGGAGCTACAGCAAGAAAG 357 GAGCTACAGCAAGAAAGTGG 358 GAAAGTGGTGGACGACCTCC 359 CGCCTGTGATCTGGTCCAGG 360 CTCCGCCTGTGATCTGGTCC 361 GACCTCCTGGACCAGATCAC 362 CTCCTGGACCAGATCACAGG 363 GCTGGAAGAGCGTCCTAGAG 364 TGCAGCCCACCTGCTTCAGC 365 GACGCTCTTCCAGCTGAAGC 366 CTCTTCCAGCTGAAGCAGGT 367 GCTCTTCCAGCTGAAGCAGG 368 CCTCCAGATGAAGCCAAGGT 369 GCTTCATCTGGAGGCTTCAT 370 GGCTTCATCTGGAGGCTTCA 371 CTTACCTTGGCTTCATCTGG 372 AAACTTACCTTGGCTTCATC 373 GAAGCCTCCAGATGAAGCCA 374 TCCTAGGGTGTCCCCAACCT 375 CCTAGGGTGTCCCCAACCTG 376 GTGTCTGTCTCCACAGGTTG 377 TGTGTCTGTCTCCACAGGTT 378 CCACAGGTTGGGGACACCCT 379 AGAGCTGCTGCTGTCTCCTA 380 CAGAGCTGCTGCTGTCTCCT 381 AGACAGCAGCAGCTCTGTTC 382 ATCCACAGAAACGTCGGGAT 383 GAGATATCCACAGAAACGTC 384 GGAGATATCCACAGAAACGT 385 GTCCTATCCCGACGTTTCTG 386 TCTCCATGCTCAGCTCTCTG 387 CTCACCCAGAGAGCTGAGCA 388 ATCTCCATGCTCAGCTCTCT 389 TATCTCCATGCTCAGCTCTC 390 ATGTCCTGTTTACACAGGGA 391 TTACACAGGGAAGGTGAAGA 392 AGTTCAAATGGCTGTCGTCA 393 TGACGACAGCCATTTGAACT 394 AAGTTCAAATGGCTGTCGTC 395 TCGTCTCATCCAAGTTCAAA 396 TGAGACGACGAAGCTCCTGC 397 GTGCTTCGTGCAGGTCCTGC 398 GCAGGACCTGCACGAAGCAC 399 GCTCCGCCTGTGCTTCGTGC 400 GGACCTGCACGAAGCACAGG 401 CACGAAGCACAGGCGGAGCG 402 AGGCGGAGCGCGGCGGCTCT 403 AGGGAGCTGAGGTTGGACGA 404 GTTGGACAGGGAGCTGAGGT 405 AGGCGTTGGACAGGGAGCTG 406 CCCTCTCGGAGGCGTTGGAC 407 CCTCTCGGAGGCGTTGGACA 408 CTGGTCCCTCTCGGAGGCGT 409 CCCTGTCCAACGCCTCCGAG 410 CCTGTCCAACGCCTCCGAGA 411 GTGGTGCTGGTCCCTCTCGG 412 CAGGTGGTGCTGGTCCCTCT 413 GCATCTCACCCAGGTGGTGC 414 CGAGAGGGACCAGCACCACC 415 GAGAGGGACCAGCACCACCT 416 GTGGGGGCATCTCACCCAGG 417 CCCCGACACTCAGGCGAGAA 418 TCCCCGACACTCAGGCGAGA 419 AGCCCTTCTCGCCTGAGTGT 420 CTGGCTGCTCCCCGACACTC 421 CCCTTCTCGCCTGAGTGTCG 422 GCCCTTCTCGCCTGAGTGTC 423 TAGGGGTCGTGGGTGACGTC 424 AAGAAACTCATAGGGGTCGT 425 GAAGAAACTCATAGGGGTCG 426 GAGACTGAAGAAACTCATAG 427 GGAGACTGAAGAAACTCATA 428 TGGAGACTGAAGAAACTCAT 429 TCTTCAGTCTCCAGAGCCTG 430 TTGGCAGAGGCCGCAGGCTC 431 TAGGTCTTGGCAGAGGCCGC 432 CTAGAGTTAGGTCTTGGCAG 433 GGTGGTCTAGAGTTAGGTCT

TABLE 4 Control sgRNA Library SEQ ID NO. gRNA Label Gene Nucleic Acid Sequence 434 1|sg_Non_Targeting_Human_0001| Non_Targeting_Human GTAGCGAACGTGTCCGGCGT Non_Targeting_Human 435 1|sg_Non_Targeting_Human_0002| Non_Targeting_Human GACCGGAACGATCTCGCGTA Non_Targeting_Human 436 1|sg_Non_Targeting_Human_0003| Non_Targeting_Human GGCAGTCGTTCGGTTGATAT Non_Targeting_Human 437 1|sg_Non_Targeting_Human_0004| Non_Targeting_Human GCTTGAGCACATACGCGAAT Non_Targeting_Human 438 1|sg_Non_Targeting_Human_0005| Non_Targeting_Human GTGGTAGAATAACGTATTAC Non_Targeting_Human 439 1|sg_Non_Targeting_Human_0006| Non_Targeting_Human GTCATACATGGATAAGGCTA Non_Targeting_Human 440 1|sg_Non_Targeting_Human_0007| Non_Targeting_Human GATACACGAAGCATCACTAG Non_Targeting_Human 441 1|sg_Non_Targeting_Human_0008| Non_Targeting_Human GAACGTTGGCACTACTTCAC Non_Targeting_Human 442 1|sg_Non_Targeting_Human_0009| Non_Targeting_Human GATCCATGTAATGCGTTCGA Non_Targeting_Human 443 1|sg_Non_Targeting_Human_0010| Non_Targeting_Human GTCGTGAAGTGCATTCGATC Non_Targeting_Human 444 1|sg_Non_Targeting_Human_0011| Non_Targeting_Human GTTCGACTCGCGTGACCGTA Non_Targeting_Human 445 1|sg_Non_Targeting_Human_0012| Non_Targeting_Human GAATCTACCGCAGCGGTTCG Non_Targeting_Human 446 1|sg_Non_Targeting_Human_0013| Non_Targeting_Human GAAGTGACGTCGATTCGATA Non_Targeting_Human 447 1|sg_Non_Targeting_Human_0014| Non_Targeting_Human GCGGTGTATGACAACCGCCG Non_Targeting_Human 448 1|sg_Non_Targeting_Human_0015| Non_Targeting_Human GTACCGCGCCTGAAGTTCGC Non_Targeting_Human 449 1|sg_Non_Targeting_Human_0016| Non_Targeting_Human GCAGCTCGTGTGTCGTACTC Non_Targeting_Human 450 1|sg_Non_Targeting_Human_0017| Non_Targeting_Human GCGCCTTAAGAGTACTCATC Non_Targeting_Human 451 1|sg_Non_Targeting_Human_0018| Non_Targeting_Human GAGTGTCGTCGTTGCTCCTA Non_Targeting_Human 452 1|sg_Non_Targeting_Human_0019| Non_Targeting_Human GCAGCTCGACCTCAAGCCGT Non_Targeting_Human 453 1|sg_Non_Targeting_Human_0020| Non_Targeting_Human GTATCCTGACCTACGCGCTG Non_Targeting_Human 454 1|sg_Non_Targeting_Human_0021| Non_Targeting Human GTGTATCTCAGCACGCTAAC Non_Targeting_Human 455 1|sg_Non_Targeting_Human_0022| Non_Targeting_Human GTCGTCATACAACGGCAACG Non_Targeting_Human 456 1|sg_Non_Targeting_Human_0023| Non_Targeting_Human GTCGTGCGCTTCCGGCGGTA Non_Targeting_Human 457 1|sg_Non_Targeting_Human_0024| Non_Targeting_Human GCGGTCCTCAGTAAGCGCGT Non_Targeting_Human 458 1|sg_Non_Targeting_Human_0025| Non_Targeting_Human GCTCTGCTGCGGAAGGATTC Non_Targeting_Human 459 1|sg_Non_Targeting_Human_0026| Non_Targeting_Human GCATGGAGGAGCGTCGCAGA Non_Targeting_Human 460 1|sg_Non_Targeting_Human_0027| Non_Targeting_Human GTAGCGCGCGTAGGAGTGGC Non_Targeting_Human 461 1|sg_Non_Targeting_Human_0028| Non_Targeting_Human GATCACCTGCATTCGTACAC Non_Targeting_Human 462 1|sg_Non_Targeting_Human_0029| Non_Targeting_Human GCACACCTAGATATCGAATG Non_Targeting_Human 463 1|sg_Non_Targeting_Human_0030| Non_Targeting_Human GTTGATCAACGCGCTTCGCG Non_Targeting_Human 464 1|sg_Non_Targeting_Human_0031| Non_Targeting_Human GCGTCTCACTCACTCCATCG Non_Targeting_Human 465 1|sg_Non_Targeting_Human_0032| Non_Targeting_Human GCCGACCAACGTCAGCGGTA Non_Targeting_Human 466 1|sg_Non_Targeting_Human_0033| Non_Targeting_Human GGATACGGTGCGTCAATCTA Non_Targeting_Human 467 1|sg_Non_Targeting_Human_0034| Non_Targeting_Human GAATCCAGTGGCGGCGACAA Non_Targeting_Human 468 1|sg_Non_Targeting_Human_0035| Non_Targeting_Human GCACTGTCAGTGCAACGATA Non_Targeting_Human 469 1|sg_Non_Targeting_Human_0036| Non_Targeting_Human GCGATCCTCAAGTATGCTCA Non_Targeting_Human 470 1|sg_Non_Targeting_Human_0037| Non_Targeting_Human GCTAATATCGACACGGCCGC Non_Targeting_Human 471 1|sg_Non_Targeting_Human_0038| Non_Targeting_Human GGAGATGCATCGAAGTCGAT Non_Targeting_Human 472 1|sg_Non_Targeting_Human_0039| Non_Targeting_Human GGATGCACTCCATCTCGTCT Non_Targeting_Human 473 1|sg_Non_Targeting_Human_0040| Non_Targeting_Human GTGCCGAGTAATAACGCGAG Non_Targeting_Human 474 1|sg_Non_Targeting_Human_0041| Non_Targeting_Human GAGATTCCGATGTAACGTAC Non_Targeting_Human 475 1|sg_Non_Targeting_Human_0042| Non_Targeting_Human GTCGTCACGAGCAGGATTGC Non_Targeting_Human 476 1|sg_Non_Targeting_Human_0043| Non_Targeting_Human GCGTTAGTCACTTAGCTCGA Non_Targeting_Human 477 1|sg_Non_Targeting_Human_0044| Non_Targeting_Human GTTCACACGGTGTCGGATAG Non_Targeting_Human 478 1|sg_Non_Targeting_Human_0045| Non_Targeting_Human GGATAGGTGACCTTAGTACG Non_Targeting_Human 479 1|sg_Non_Targeting_Human_0046| Non_Targeting_Human GTATGAGTCAAGCTAATGCG Non_Targeting_Human 480 1|sg_Non_Targeting_Human_0047| Non_Targeting_Human GCAACTATTGGAATACGTGA Non_Targeting_Human 481 1|sg_Non_Targeting_Human_0048| Non_Targeting_Human GTTACCTTCGCTCGTCTATA Non_Targeting_Human 482 1|sg_Non_Targeting_Human_0049| Non_Targeting_Human GTACCGAGCACCACAGGCCG Non_Targeting_Human 483 1|sg_Non_Targeting_Human_0050| Non_Targeting_Human GTCAGCCATCGGATAGAGAT Non_Targeting_Human 484 1|sg_Non_Targeting_Human_0051| Non_Targeting_Human GTACGGCACTCCTAGCCGCT Non_Targeting_Human 485 1|sg_Non_Targeting_Human_0052| Non_Targeting_Human GGTCCTGTCGTATGCTTGCA Non_Targeting_Human 486 1|sg_Non_Targeting_Human_0053| Non_Targeting_Human GCCGCAATATATGCGGTAAG Non_Targeting_Human 487 1|sg_Non_Targeting_Human_0054| Non_Targeting_Human GCGCACGTATAATCCTGCGT Non_Targeting_Human 488 1|sg_Non_Targeting_Human_0055| Non_Targeting_Human GTGCACAACACGATCCACGA Non_Targeting_Human 489 1|sg_Non_Targeting_Human_0056| Non_Targeting_Human GCACAATGTTGACGTAAGTG Non_Targeting_Human 490 1|sg_Non_Targeting_Human_0057| Non_Targeting_Human GTAAGATGCTGCTCACCGTG Non_Targeting_Human 491 1|sg_Non_Targeting_Human_0058| Non_Targeting_Human GTCGGTGATCCAACGTATCG Non_Targeting_Human 492 1|sg_Non_Targeting_Human_0059| Non_Targeting_Human GAGCTAGTAGGACGCAAGAC Non_Targeting_Human 493 1|sg_Non_Targeting_Human_0060| Non_Targeting_Human GTACGTGGAAGCTTGTGGCC Non_Targeting_Human 494 1|sg_Non_Targeting_Human_0061| Non_Targeting_Human GAGAACTGCCAGTTCTCGAT Non_Targeting_Human 495 1|sg_Non_Targeting_Human_0062| Non_Targeting_Human GCCATTCGGCGCGGCACTTC Non_Targeting_Human 496 1|sg_Non_Targeting_Human_0063| Non_Targeting_Human GCACACGACCAATCCGCTTC Non_Targeting_Human 497 1|sg_Non_Targeting_Human_0064| Non_Targeting_Human GAGGTGATCGATTAAGTACA Non_Targeting_Human 498 1|sg_Non_Targeting_Human_0065| Non_Targeting_Human GTCACTCGCAGACGCCTAAC Non_Targeting_Human 499 1|sg_Non_Targeting_Human_0066| Non Targeting_Human GCGCTACGGAATCATACGTT Non_Targeting_Human 500 1|sg_Non_Targeting_Human_0067| Non_Targeting_Human GGTAGGACCTCACGGCGCGC Non_Targeting_Human 501 1|sg_Non_Targeting_Human_0068| Non_Targeting_Human GAACTGCATCTTGTTGTAGT Non_Targeting_Human 502 1|sg_Non_Targeting_Human_0069| Non_Targeting_Human GATCCTGATCCGGCGGCGCG Non_Targeting_Human 503 1|sg_Non_Targeting_Human_0070| Non_Targeting_Human GGTATGCGCGATCCTGAGTT Non_Targeting_Human 504 1|sg_Non_Targeting_Human_0071| Non_Targeting_Human GCGGAGCTAGAGAGCGGTCA Non_Targeting_Human 505 1|sg_Non_Targeting_Human_0072| Non_Targeting_Human GAATGGCAATTACGGCTGAT Non_Targeting_Human 506 1|sg_Non_Targeting_Human_0073| Non_Targeting_Human GTATGGTGAGTAGTCGCTTG Non_Targeting_Human 507 1|sg_Non_Targeting_Human_0074| Non_Targeting_Human GTGTAATTGCGTCTAGTCGG Non_Targeting_Human 508 1|sg_Non_Targeting_Human_0075| Non_Targeting_Human GGTCCTGGCGAGGAGCCTTG Non_Targeting_Human 509 1|sg_Non_Targeting_Human_0076| Non_Targeting_Human GAAGATAAGTCGCTGTCTCG Non_Targeting_Human 510 1|sg_Non_Targeting_Human_0077| Non_Targeting_Human GTCGGCGTTCTGTTGTGACT Non_Targeting_Human 511 1|sg_Non_Targeting_Human_0078| Non_Targeting_Human GAGGCAAGCCGTTAGGTGTA Non_Targeting_Human 512 1|sg_Non_Targeting_Human_0079| Non_Targeting_Human GCGGATCCAGATCTCATTCG Non_Targeting_Human 513 1|sg_Non_Targeting_Human_0080| Non_Targeting_Human GGAACATAGGAGCACGTAGT Non_Targeting_Human 514 1|sg_Non_Targeting_Human_0081| Non_Targeting_Human GTCATCATTATGGCGTAAGG Non_Targeting_Human 515 1|sg_Non_Targeting_Human_0082| Non_Targeting_Human GCGACTAGCGCCATGAGCGG Non_Targeting_Human 516 1|sg_Non_Targeting_Human_0083| Non_Targeting_Human GGCGAAGTTCGACATGACAC Non_Targeting_Human 517 1|sg_Non_Targeting_Human_0084| Non_Targeting_Human GCTGTCGTGTGGAGGCTATG Non_Targeting_Human 518 1|sg_Non_Targeting_Human_0085| Non_Targeting_Human GCGGAGAGCATTGACCTCAT Non_Targeting_Human 519 1|sg_Non_Targeting_Human_0086| Non_Targeting_Human GACTAATGGACCAAGTCAGT Non_Targeting_Human 520 1|sg_Non_Targeting_Human_0087| Non_Targeting_Human GCGGATTAGAGGTAATGCGG Non_Targeting_Human 521 1|sg_Non_Targeting_Human_0088| Non_Targeting_Human GCCGACGGCAATCAGTACGC Non_Targeting_Human 522 1|sg_Non_Targeting_Human_0089| Non_Targeting_Human GTAACCTCTCGAGCGATAGA Non_Targeting_Human 523 1|sg_Non_Targeting_Human_0090| Non_Targeting_Human GACTTGTATGTGGCTTACGG Non_Targeting_Human 524 1|sg_Non_Targeting_Human_0091| Non_Targeting_Human GTCACTGTGGTCGAACATGT Non_Targeting_Human 525 1|sg_Non_Targeting_Human_0092| Non_Targeting_Human GTACTCCAATCCGCGATGAC Non_Targeting_Human 526 1|sg_Non_Targeting_Human_0093| Non_Targeting_Human GCGTTGGCACGATGTTACGG Non_Targeting_Human 527 1|sg_Non_Targeting_Human_0094| Non_Targeting_Human GAACCAGCCGGCTAGTATGA Non_Targeting_Human 528 1|sg_Non_Targeting_Human_0095| Non_Targeting_Human GTATACTAGCTAACCACACG Non_Targeting_Human 529 1|sg_Non_Targeting_Human_0096| Non_Targeting_Human GAATCGGAATAGTTGATTCG Non_Targeting_Human 530 1|sg_Non_Targeting_Human_0097| Non_Targeting_Human GAGCACTTGCATGAGGCGGT Non_Targeting_Human 531 1|sg_Non_Targeting_Human_0098| Non Targeting_Human GAACGGCGATGAAGCCAGCC Non_Targeting_Human 532 1|sg_Non_Targeting_Human_0099| Non_Targeting_Human GCAACCGAGATGAGAGGTTC Non_Targeting_Human 533 1|sg_Non_Targeting_Human_0100| Non_Targeting_Human GCAAGATCAATATGCGTGAT Non_Targeting_Human 534 1|sg_Non_Targeting_Human_GA_0101| Non_Targeting_Human ACGGAGGCTAAGCGTCGCAA Non_Targeting_Human 535 1|sg_Non_Targeting_Human_GA_0102| Non_Targeting_Human CGCTTCCGCGGCCCGTTCAA Non_Targeting_Human 536 1|sg_Non_Targeting_Human_GA_0103| Non_Targeting_Human ATCGTTTCCGCTTAACGGCG Non_Targeting_Human 537 1|sg_Non_Targeting_Human_GA_0104| Non_Targeting_Human GTAGGCGCGCCGCTCTCTAC Non_Targeting_Human 538 1|sg_Non_Targeting_Human_GA_0105| Non_Targeting_Human CCATATCGGGGCGAGACATG Non_Targeting_Human 539 1|sg_Non_Targeting_Human_GA_0106| Non_Targeting_Human TACTAACGCCGCTCCTACAG Non_Targeting_Human 540 1|sg_Non_Targeting_Human_GA_0107| Non_Targeting Human TGAGGATCATGTCGAGCGCC Non_Targeting_Human 541 1|sg_Non_Targeting_Human_GA_0108| Non_Targeting Human GGGCCCGCATAGGATATCGC Non_Targeting_Human 542 1|sg_Non_Targeting_Human_GA_0109| Non_Targeting_Human TAGACAACCGCGGAGAATGC Non_Targeting_Human 543 1|sg_Non Targeting_Human_GA_0110| Non_Targeting_Human ACGGGCGGCTATCGCTGACT Non_Targeting_Human 544 1|sg_Non_Targeting_Human_GA_0111| Non_Targeting_Human CGCGGAAATTTTACCGACGA Non_Targeting_Human 545 1|sg_Non_Targeting_Human_GA_0112| Non_Targeting_Human CTTACAATCGTCGGTCCAAT Non_Targeting_Human 546 1|sg_Non_Targeting_Human_GA_0113| Non_Targeting_Human GCGTGCGTCCCGGGTTACCC Non_Targeting_Human 547 1|sg_Non_Targeting_Human_GA_0114| Non_Targeting_Human CGGAGTAACAAGCGGACGGA Non_Targeting_Human 548 1|sg_Non_Targeting_Human_GA_0115| Non_Targeting_Human CGAGTGTTATACGCACCGTT Non_Targeting_Human 549 1|sg_Non_Targeting_Human_GA_0116| Non_Targeting_Human CGACTAACCGGAAACTTTTT Non_Targeting_Human 550 1|sg_Non_Targeting_Human_GA_0117| Non_Targeting_Human CAACGGGTTCTCCCGGCTAC Non_Targeting_Human 551 1|sg_Non_Targeting_Human_GA_0118| Non_Targeting_Human CAGGAGTCGCCGATACGCGT Non_Targeting_Human 552 1|sg_Non_Targeting_Human_GA_0119| Non_Targeting_Human TTCACGTCGTCTCGCGACCA Non_Targeting_Human 553 1|sg_Non_Targeting_Human_GA_0120| Non_Targeting_Human GTGTCGGATTCCGCCGCTTA Non_Targeting_Human 554 1|sg_Non_Targeting_Human_GA_0121| Non_Targeting_Human CACGAACTCACACCGCGCGA Non_Targeting_Human 555 1|sg_Non_Targeting_Human_GA_0122| Non_Targeting_Human CGCTAGTACGCTCCTCTATA Non_Targeting_Human 556 1|sg_Non_Targeting_Human_GA_0123| Non_Targeting_Human TCGCGCTTGGGTTATACGCT Non_Targeting_Human 557 1|sg_Non_Targeting_Human_GA_0124| Non_Targeting_Human CTATCTCGAGTGGTAATGCG Non_Targeting_Human 558 1|sg_Non_Targeting_Human_GA_0125| Non_Targeting_Human AATCGACTCGAACTTCGTGT Non_Targeting_Human 559 1|sg_Non_Targeting_Human_GA_0126| Non Targeting_Human CCCGATGGACTATACCGAAC Non_Targeting_Human 560 1|sg_Non Targeting_Human_GA_0127| Non_Targeting_Human ACGTTCGAGTACGACCAGCT Non_Targeting_Human 561 1|sg_Non_Targeting_Human_GA_0128| Non_Targeting Human CGCGACGACTCAACCTAGTC Non_Targeting_Human 562 1|sg_Non_Targeting_Human GA_0129| Non_Targeting Human GGTCACCGATCGAGAGCTAG Non_Targeting_Human 563 1|sg_Non_Targeting_Human_GA_0130| Non_Targeting_Human CTCAACCGACCGTATGGTCA Non_Targeting_Human 564 1|sg_Non_Targeting_Human_GA_0131| Non_Targeting_Human CGTATTCGACTCTCAACGCG Non_Targeting_Human 565 1|sg_Non_Targeting_Human_GA_0132| Non_Targeting_Human CTAGCCGCCCAGATCGAGCC Non_Targeting_Human 566 1|sg_Non_Targeting_Human_GA_0133| Non_Targeting_Human GAATCGACCGACACTAATGT Non_Targeting_Human 567 1|sg_Non_Targeting_Human_GA_0134| Non Targeting_Human ACTTCAGTTCGGCGTAGTCA Non_Targeting_Human 568 1|sg_Non_Targeting_Human_GA_0135| Non_Targeting_Human GTGCGATGTCGCTTCAACGT Non_Targeting_Human 569 1|sg_Non_Targeting_Human_GA_0136| Non_Targeting_Human CGCCTAATTTCCGGATCAAT Non_Targeting Human 570 1|sg_Non_Targeting_Human_GA_0137| Non_Targeting_Human CGTGGCCGGAACCGTCATAG Non_Targeting_Human 571 1|sg_Non_Targeting_Human_GA_0138| Non_Targeting_Human ACCCTCCGAATCGTAACGGA Non_Targeting_Human 572 1|sg_Non_Targeting_Human_GA_0139| Non_Targeting_Human AAACGGTACGACAGCGTGTG Non_Targeting_Human 573 1|sg_Non_Targeting_Human_GA_0140| Non_Targeting_Human ACATAGTCGACGGCTCGATT Non_Targeting_Human 574 1|sg_Non_Targeting_Human_GA_0141| Non_Targeting_Human GATGGCGCTTCAGTCGTCGG Non_Targeting_Human 575 1|sg_Non_Targeting_Human_GA_0142| Non_Targeting_Human ATAATCCGGAAACGCTCGAC Non_Targeting_Human 576 1|sg_Non_Targeting_Human_GA_0143| Non Targeting_Human CGCCGGGCTGACAATTAACG Non_Targeting_Human 577 1|sg_Non_Targeting_Human_GA_0144| Non_Targeting_Human CGTCGCCATATGCCGGTGGC Non_Targeting_Human 578 1|sg_Non_Targeting_Human_GA_0145| Non_Targeting_Human CGGGCCTATAACACCATCGA Non_Targeting_Human 579 1|sg_Non_Targeting_Human_GA_0146| Non_Targeting_Human CGCCGTTCCGAGATACTTGA Non_Targeting_Human 580 1|sg_Non_Targeting_Human_GA_0147| Non_Targeting_Human CGGGACGTCGCGAAAATGTA Non_Targeting_Human 581 1|sg_Non_Targeting_Human_GA_0148| Non_Targeting_Human TCGGCATACGGGACACACGC Non_Targeting_Human 582 1|sg Non_Targeting_Human_GA_0149| Non_Targeting_Human AGCTCCATCGCCGCGATAAT Non_Targeting_Human 583 1|sg_Non_Targeting_Human_GA_0150| Non_Targeting_Human ATCGTATCATCAGCTAGCGC Non_Targeting_Human 584 1|sg_Non_Targeting_Human_GA_0151| Non_Targeting_Human TCGATCGAGGTTGCATTCGG Non_Targeting_Human 585 1|sg_Non_Targeting_Human_GA_0152| Non_Targeting Human CTCGACAGTTCGTCCCGAGC Non_Targeting_Human 586 1|sg_Non_Targeting_Human_GA_0153| Non_Targeting_Human CGGTAGTATTAATCGCTGAC Non_Targeting_Human 587 1|sg_Non_Targeting_Human_GA_0154| Non_Targeting_Human TGAACGCGTGTTTCCTTGCA Non_Targeting_Human 588 1|sg_Non_Targeting_Human_GA_0155| Non_Targeting_Human CGACGCTAGGTAACGTAGAG Non_Targeting_Human 589 1|sg_Non_Targeting_Human_GA_0156| Non_Targeting_Human CATTGTTGAGCGGGCGCGCT Non_Targeting_Human 590 1|sg_Non_Targeting_Human_GA_0157| Non_Targeting_Human CCGCTATTGAAACCGCCCAC Non_Targeting_Human 591 1|sg_Non_Targeting_Human_GA_0158| Non_Targeting_Human AGACACGTCACCGGTCAAAA Non_Targeting_Human 592 1|sg_Non_Targeting_Human_GA_0159| Non Targeting Human TTTACGATCTAGCGGCGTAG Non_Targeting_Human 593 1|sg_Non_Targeting_Human_GA_0160| Non_Targeting_Human TTCGCACGATTGCACCTTGG Non_Targeting_Human 594 1|sg_Non_Targeting_Human_GA_0161| Non_Targeting_Human GGTTAGAGACTAGGCGCGCG Non_Targeting_Human 595 1|sg_Non_Targeting_Human_GA_0162| Non_Targeting_Human CCTCCGTGCTAACGCGGACG Non_Targeting_Human 596 1|sg_Non_Targeting_Human_GA_0163| Non_Targeting_Human TTATCGCGTAGTGCTGACGT Non_Targeting_Human 597 1|sg_Non_Targeting_Human_GA_0164| Non_Targeting_Human TACGCTTGCGTTTAGCGTCC Non_Targeting_Human 598 1|sg_Non_Targeting_Human_GA_0165| Non_Targeting_Human CGCGGCCCACGCGTCATCGC Non_Targeting_Human 599 1|sg_Non_Targeting_Human_GA_0166| Non_Targeting_Human AGCTCGCCATGTCGGTTCTC Non_Targeting_Human 600 1|sg_Non_Targeting_Human_GA_0167| Non_Targeting_Human AACTAGCCCGAGCAGCTTCG Non_Targeting_Human 601 1|sg_Non_Targeting_Human_GA_0168| Non_Targeting_Human CGCAAGGTGTCGGTAACCCT Non_Targeting_Human 602 1|sg_Non_Targeting_Human_GA_0169| Non_Targeting_Human CTTCGACGCCATCGTGCTCA Non_Targeting_Human 603 1|sg_Non_Targeting_Human_GA_0170| Non_Targeting_Human TCCTGGATACCGCGTGGTTA Non_Targeting_Human 604 1|sg_Non_Targeting_Human_GA_0171| Non_Targeting_Human ATAGCCGCCGCTCATTACTT Non_Targeting_Human 605 1|sg_Non_Targeting_Human_GA_0172| Non_Targeting_Human GTCGTCCGGGATTACAAAAT Non_Targeting_Human 606 1|sg Non_Targeting_Human_GA_0173| Non_Targeting_Human TAATGCTGCACACGCCGAAT Non_Targeting_Human 607 1|sg_Non_Targeting_Human_GA_0174| Non_Targeting_Human TATCGCTTCCGATTAGTCCG Non_Targeting_Human 608 1|sg_Non_Targeting_Human_GA_0175| Non_Targeting_Human GTACCATACCGCGTACCCTT Non_Targeting_Human 609 1|sg_Non_Targeting_Human_GA_0176| Non_Targeting_Human TAAGATCCGCGGGTGGCAAC Non_Targeting_Human 610 1|sg_Non_Targeting_Human_GA_0177| Non_Targeting_Human GTAGACGTCGTGAGCTTCAC Non_Targeting_Human 611 1|sg_Non_Targeting_Human_GA_0178| Non_Targeting_Human TCGCGGACATAGGGCTCTAA Non_Targeting_Human 612 1|sg_Non_Targeting_Human_GA_0179| Non_Targeting_Human AGCGCAGATAGCGCGTATCA Non_Targeting_Human 613 1|sg_Non_Targeting_Human_GA_0180| Non_Targeting_Human GTTCGCTTCGTAACGAGGAA Non_Targeting_Human 614 1|sg_Non_Targeting_Human_GA_0181| Non_Targeting_Human GACCCCCGATAACTTTTGAC Non_Targeting_Human 615 1|sg_Non_Targeting_Human_GA_0182| Non_Targeting_Human ACGTCCATACTGTCGGCTAC Non_Targeting_Human 616 1|sg_Non_Targeting_Human_GA_0183| Non_Targeting_Human GTACCATTGCCGGCTCCCTA Non_Targeting_Human 617 1|sg_Non_Targeting_Human_GA_0184| Non_Targeting_Human TGGTTCCGTAGGTCGGTATA Non_Targeting_Human 618 1|sg_Non_Targeting_Human_GA_0185| Non_Targeting_Human TCTGGCTTGACACGACCGTT Non_Targeting_Human 619 1|sg_Non_Targeting_Human_GA_0186| Non_Targeting_Human CGCTAGGTCCGGTAAGTGCG Non_Targeting_Human 620 1|sg_Non_Targeting_Human_GA_0187| Non_Targeting_Human AGCACGTAATGTCCGTGGAT Non_Targeting_Human 621 1|sg_Non_Targeting_Human_GA_0188| Non_Targeting_Human AAGGCGCGCGAATGTGGCAG Non_Targeting_Human 622 1|sg_Non_Targeting_Human_GA_0189| Non_Targeting_Human ACTGCGGAGCGCCCAATATC Non_Targeting_Human 623 1|sg_Non_Targeting_Human_GA_0190| Non_Targeting_Human CGTCGAGTGCTCGAACTCCA Non_Targeting_Human 624 1|sg_Non_Targeting_Human_GA_0191| Non_Targeting_Human TCGCAGCGGCGTGGGATCGG Non_Targeting_Human 625 1|sg_Non_Targeting_Human_GA_0192| Non_Targeting_Human ATCTGTCCTAATTCGGATCG Non_Targeting_Human 626 1|sg_Non_Targeting_Human_GA_0193| Non_Targeting_Human TGCGGCGTAATGCTTGAAAG Non_Targeting_Human 627 1|sg_Non_Targeting_Human_GA_0194| Non_Targeting_Human CGAACTTAATCCCGTGGCAA Non_Targeting_Human 628 1|sg_Non_Targeting_Human_GA_0195| Non_Targeting Human GCCGTGTTGCTGGATACGCC Non_Targeting_Human 629 1|sg_Non_Targeting_Human_GA_0196| Non_Targeting_Human TACCCTCCGGATACGGACTG Non_Targeting_Human 630 1|sg_Non_Targeting_Human_GA_0197| Non_Targeting_Human CCGTTGGACTATGGCGGGTC Non_Targeting_Human 631 1|sg_Non_Targeting_Human_GA_0198| Non_Targeting_Human GTACGGGGCGATCATCCACA Non_Targeting_Human 632 1|sg_Non_Targeting_Human_GA_0199| Non_Targeting_Human AAGAGTAGTAGACGCCCGGG Non_Targeting_Human 633 1|sg_Non_Targeting_Human_GA_0200| Non_Targeting_Human AAGAGCGAATCGATTTCGTG Non_Targeting_Human 634 3|sg_hCDC16_CC_1|CDC16 CDC16 TCAACACCAGTGCCTGACGG 635 3|sg_hCDC16_CC_2|CDC16 CDC16 AAAGTAGCTTCACTCTCTCG 636 3|sg_hCDC16_CC_3|CDC16 CDC16 GAGCCAACCAATAGATGTCC 637 3|sg_hCDC16_CC_4|CDC16 CDC16 GCGCCGCCATGAACCTAGAG 638 3|sg_hGTF2B_CC_1|GTF2B GTF2B ACAAAGGTTGGAACAGAACC 639 3|sg_hGTF2B_CC 2|GTF2B GTF2B GGTGACCGGGTTATTGATGT 640 3|sg_hGTF2B_CC_3|GTF2B GTF2B TTAGTGGAGGACTACAGAGC 641 3|sg_hGTF2B_CC_4|GTF2B GTF2B ACATATAGCCCGTAAAGCTG 642 3|sg_hHSPA5_CC_1|HSPA5 HSPA5 CGTTGGCGATGATCTCCACG 643 3|sg_hHSPA5_CC_2|HSPA5 HSPA5 TGGCCTTTTCTACCTCGCGC 644 3|sg_hHSPA5_CC_3|HSPA5 HSPA5 AATGGAGATACTCATCTGGG 645 3|sg_hHSPA5_CC_4|HSPA5 HSPA5 GAAGCCCGTCCAGAAAGTGT 646 3|sg_hHSPA9_CC_1|HSPA9 HSPA9 CAATCTGAGGAACTCCACGA 647 3|sg_hHSPA9_CC_2|HSPA9 HSPA9 AGGCTGCGGCGCCCACGAGA 648 3|sg_hHSPA9_CC_3|HSPA9 HSPA9 ACTTTGACCAGGCCTTGCTA 649 3|sg_hHSPA9_CC_4|HSPA9 HSPA9 ACCTTCCATAACTGCCACGC 650 3|sg_hPAFAH1B1_CC_1|PAFAH1B1 PAFAH1B1 CGAGGCGTACATACCCAAGG 651 3|sg hPAFAH1B1_CC_2|PAFAH1B1 PAFAH1B1 ATGGTACGGCCAAATCAAGA 652 3|sg hPAFAH1B1_CC_3|PAFAH1B1 PAFAH1B1 TCTTGTAATCCCATACGCGT 653 3|sg_hPAFAH1B1_CC_4|PAFAH1B1 PAFAH1B1 ATTCACAGGACACAGAGAAT 654 3|sg_hPCNA_CC_1|PCNA PCNA CCAGGGCTCCATCCTCAAGA 655 3|sg_hPCNA_CC_2|PCNA PCNA TGAGCTGCACCAAAGAGACG 656 3|sg_hPCNA_CC_3|PCNA PCNA ATGTCTGCAGATGTACCCCT 657 3|sg_hPCNA_CC_4|PCNA PCNA CGAAGATAACGCGGATACCT 658 3|sg_hPOLR2L_CC_1|POLR2L POLR2L GCTGCAGGCCGAGTACACCG 659 3|sg_hPOLR2L_CC_2|POLR2L POLR2L ACAAGTGGGAGGCTTACCTG 660 3|sg_hPOLR2L_CC_3|POLR2L POLR2L GCAGCGTACAGGGATGATCA 661 3|sg_hPOLR2L_CC_4|POLR2L POLR2L GCAGTAGCGCTTCAGGCCCA 662 3|sg_hRPL9_CC_1|RPL9 RPL9 CAAATGGTGGGGTAACAGAA 663 3|sg_hRPL9_CC_2|RPL9 RPL9 GAAAGGAACTGGCTACCGTT 664 3|sg_hRPL9_CC_3|RPL9 RPL9 AGGGCTTCCGTTACAAGATG 665 3|sg_hRPL9_CC_4|RPL9 RPL9 GAACAAGCAACACCTAAAAG 666 3|sg_hSF3A3_CC_1|SF3A3 SF3A3 TGAGGAGAAGGAACGGCTCA 667 3|sg_hSF3A3_CC_2|SF3A3 SF3A3 GGAAGAATGCAGAGTATAAG 668 3|sg_hSF3A3_CC_3|SF3A3 SF3A3 GGAATTTGAGGAACTCCTGA 669 3|sg_hSF3A3_CC_4|SF3A3 SF3A3 GCTCACCGGCCATCCAGGAA 670 3|sg_hSF3B3_CC_1|SF3B3 SF3B3 ACTGGCCAGGAACGATGCGA 671 3|sg_hSF3B3_CC_2|SF3B3 SF3B3 GCAGCTCCAAGATCTTCCCA 672 3|sg_hSF3B3_CC_3|SF3B3 SF3B3 GAATGAGTACACAGAACGGA 673 3|sg_hSF3B3_CC_4|SF3B3 SF3B3 GGAGCAGGACAAGGTCGGGG

Example 2—BRD9 Degrader Depletes BRD9 Protein

The following example demonstrates the depletion of the BRD9 protein in synovial sarcoma cells treated with a BRD9 degrader.

Procedure: Cells were treated with DMSO or the BRD9 degrader, Compound 1 (also known as dBRD9, see Remillard et al, Angew. Chem. Int. Ed. Engl. 56(21):5738-5743 (2017); see structure of compound 1 below), for indicated doses and timepoints.

Whole cell extracts were fractionated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane using a transfer apparatus according to the manufacturer's protocols (Bio-Rad). After incubation with 5% nonfat milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 60 min, the membrane was incubated with antibodies against BRD9 (1:1,000, Bethyl laboratory A303-781A), GAPDH (1:5,000, Cell Signaling Technology), and/or MBP (1:1,000, BioRad) overnight at 4° C. Membranes were washed three times for 10 minutes and incubated with anti-mouse or anti-rabbit antibodies conjugated with either horseradish peroxidase (HRP, FIGS. 2-3 ) or IRDye (FIG. 4 , 1:20,000, LI-COR) for at least 1 h. Blots were washed with TBST three times and developed with either the ECL system according to the manufacturer's protocols (FIGS. 2-3 ) or scanned on an Odyssey CLx Imaging system (FIG. 4 ).

Results: Treatment of SYO1 synovial sarcoma cells with the BRD9 degrader Compound 1 results in dose dependent (FIG. 2 ) and time dependent (FIG. 3 ) depletion of BRD9 in the cells. Further, as shown in FIG. 4 , the depletion of BRD9 by Compound 1 is replicated in a non-synovial sarcoma cell line (293T) and may be sustained for at least 5 days.

Example 3—Inhibition of Growth of Synovial Cell Lines by BRD9 Inhibitors and BRD9 Degraders

The following example demonstrates that BRD9 degraders and inhibitors selectively inhibit growth of synovial sarcoma cells.

Procedures:

Cells were treated with DMSO or the BRD9 degrader, Compound 1, at indicated concentrations, and proliferation was monitored from day 7 to day 14 by measuring confluency over time using an IncuCyte live cell analysis system (FIG. 5 ). Growth medium and compounds were refreshed every 3-4 days.

Cells were seeded into 12-well plates and treated with DMSO, 1 μM BRD9 inhibitor, Compound 2 (also known as BI-7273, see Martin et al, J Med Chem. 59(10):4462-4475 (2016); see structure of compound 2 below), or 1 μM BRD9 degrader, Compound 1.

The number of cells was optimized for each cell line. Growth medium and compounds were refreshed every 3-5 days. SYO1, Yamato, A549, 293T and HS-SY-II cells were fixed and stained at day 11. ASKA cells were fixed and stained at day 23. Staining was done by incubation with crystal violet solution (0.5 g Crystal Violet, 27 ml 37% Formaldehyde, 100 mL 10×PBS, 10 mL Methanol, 863 dH2O to 1 L) for 30 minutes followed by 3× washes with water and drying the plates for at least 24h at room temperature. Subsequently plates were scanned on an Odyssey CLx Imaging system (FIG. 6 ).

Cells were seeded into 96-well ultra low cluster plate (Costar, #7007) in 200 μL complete media and treated at day 2 with DMSO, Staurosporin, or BRD9 degrader, Compound 1, at indicated doses (FIG. 7 ). Media and compounds were changed every 5 d and cell colonies were imaged at day 14.

Results: As shown in FIGS. 5, 6, and 7 , treatment of synovial sarcoma cell lines (SYO1, Yamato, HS-SY-II, and ASKA) with a BRD9 inhibitor, Compound 2, or a BRD9 degrader, Compound 1, results in inhibition of the growth of the cells, but does not result in inhibition of the growth of non-synovial control cancer cell lines (293T, A549, G401).

Example 4—Selective Inhibition of Growth of Synovial Cell Lines by BRD9 Degraders and BRD9 Binders

The following example demonstrates that BRD9 degraders and binders selectively inhibit growth of synovial sarcoma cells.

Procedure: Cells were seeded into 6-well or 12-well plates and were treated daily with a BRD9 degrader (Compound 1), a bromo-domain BRD9 binder (Compound 2), E3 ligase binder (lenalidomide), DMSO, or staurosporin (positive control for cell killing), at indicated concentrations. The number of cells was optimized for each cell line. Growth media was refreshed every 5 days. By day 14, medium was removed, cells were washed with PBS, and stained using 500 μL of 0.005% (w/v) crystal violet solution in 25% (v/v) methanol for at least 1 hour at room temperature. Subsequently plates were scanned on an Odyssey CLx Imaging system.

Results: As shown in FIGS. 8 and 9 , treatment of synovial sarcoma cell lines (SYO1, HS-SY-II, and ASKA) with Compound 1 or Compound 2 resulted in inhibition of the growth of the cells, but did not result in inhibition of the growth of non-synovial control cancer cell lines (RD, HCT116, and Calu6). Overall, Compound 1 showed most significant growth inhibition in all synovial cell lines.

Example 5—Inhibition of Cell Growth in Synovial Sarcoma Cells

The following example shows that BRD9 degraders inhibit cell growth and induce apoptosis in synovial sarcoma cells.

Procedure: SYO1 cells were treated for 8 or 13 days with DMSO, a BRD9 degrader (Compound 1) at 200 nM or 1 μM, or an E3 ligase binder (lenalidomide) at 200 nM. Compounds were refreshed every 5 days. Cell cycle analysis was performed using the Click-iT™ Plus EdU Flow Cytometry Assay (Invitrogen). The apoptosis assay was performed using the Annexin V-FITC Apoptosis Detection Kit (Sigma A9210). Assays were performed according to the manufacturer's protocol.

Results: As shown in FIGS. 10-13 , treatment with Compound 1 for 8 or 13 days resulted in reduced numbers of cells in the S-phase of the cell cycle as compared to DMSO and lenalidomide. Treatment with Compound 1 for 8 days also resulted in increased numbers of early- and late-apoptotic cells as compared to DMSO controls.

Example 6—Composition for SS18-SSX1-BAF

The following example shows the identification of BRD9 as a component of SS18-SSX containing BAF complexes.

Procedure: A stable 293T cell line expressing HA-SS18SSX1 was generated using lentiviral integration. SS18-SSX1 containing BAF complexes were subject to affinity purification and subsequent mass spectrometry analysis revealed SS18-SSX1 interacting proteins.

Results: As shown in FIG. 14 , BAF complexes including the SS18-SSX fusion protein also included BRD9. More than 5 unique peptides were identified for ARID1A (95 peptides), ARID1B (77 peptides), SMARCC1 (69 peptides), SMARCD1 (41 peptides), SMARCD2 (37 peptides), DPF2 (32 peptides), SMARCD3 (26 peptides), ACTL6A (25 peptides), BRD9 (22 peptides), DPF1 Isoform 2 (18 peptides), DPF3 (13 peptides), and ACTL6B (6 peptides).

Example 7—Preparation of N-(1,1-dioxo-1λ6,2-thiazinan-4-yl)-5-methyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide (Compound B1)

Step 1: Preparation of 4-amino-1λ6,2-thiazinane-1,1-dione (i-1)

4-(benzylamino)-1λ6,2-thiazinane-1,1-dione (200.00 mg, 0.832 mmol, 1.00 equiv) and Pd/C (199.27 mg, 1.873 mmol, 2.25 equiv) in MeOH (10.00 mL) were stirred under an atmosphere of hydrogen at balloon and room temperature for 3 hours. The solid was filtered out, and the filtrate was concentrated under reduced pressure to afford 4-amino-1λ6,2-thiazinane-1,1-dione (120 mg, 96%) as a brown solid. This material was used directly in the next step without further purification. LCMS (ESI) m/z: [M+H]+=151.

Step 2: Preparation of 4-amino-1λ6,2-thiazinane-1,1-dione Hydrochloride (i-2)

4-amino-1λ6,2-thiazinane-1,1-dione (110.00 mg, 0.732 mmol, 1.00 equiv) was added a solution of HCl in 1,4-dioxane (4 mL, 4 M), and the resulting mixture was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure to afford 4-amino-1λ6,2-thiazinane-1,1-dione hydrochloride (131 mg, 96%) as a brown solid. This material was used directly in the next step without further purification. LCMS (ESI) m/z: [M+H]+=151.

Step 3: Preparation of N-(1,1-dioxo-1λ6,2-thiazinan-4-yl)-5-methyl-4-oxo-7-[3-(trifluoromethyl)phen yl]thieno[3,2-c]pyridine-2-carboximidamide (Compound B1)

To a solution of 5-methyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carbonitrile (50.00 mg, 0.150 mmol, 1.00 equiv) in MeOH (1.00 mL) was added NaOMe (8.08 mg, 0.150 mmol, 1 equiv), and the resulting mixture was stirred at 75° C. for 3 hours. Then 4-amino-1λ6,2-thiazinane-1,1-dione hydrochloride (33.50 mg, 0.179 mmol, 1.2 equiv) was added to the reaction mixture. After stirring at 75° C. for 16 hours, the crude product was purified by flash C18-flash chromatography, elution gradient 0 to 50% MeCN in water (containing 0.1% NH₄HCO₃). Pure fractions were evaporated to dryness to afford crude product. The crude product was purified by preparative HPLC (conditions: XBridge Prep OBD 018 Column, 19*250 mm, 5 μm; Mobile Phase A: Water (10 mmol/L NH₄HCO₃), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 35 B to 50 B in 12 minutes; 254/220 nm; R_(T) (retention time): 8.62 minutes). Fractions containing the desired compound were evaporated to dryness to afford N-(1,1-dioxo-1λ6,2-thiazinan-4-yl)-5-methyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide (5.8 mg, 7.9%) as a white solid. LCMS (ESI) m/z: [M+H]+=485.20.

Example 8—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (Compound B2)

Step 1: Preparation of 5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (i-6)

To a solution of 2-bromo-5-methylthieno[3,2-c]pyridin-4-one (2.00 g, 8.193 mmol, 1.00 equiv) in THF (20.00 mL) was added n-BuLi (1.05 g, 16.386 mmol, 2.00 equiv) in dropwise at −78° C. under nitrogen atmosphere, the resulting mixture was stirred at −78° C. for 30 minutes, then DMF (5.99 g, 81.930 mmol, 10.00 equiv) was added to the reaction mixture. The reaction was warmed to room temperature naturally. The reaction was quenched by the addition of sat. NH₄Cl (aq.) (30 mL) at 0° C., and extracted with EtOAc (ethyl acetate) (50 mL×4). The organic layer was washed with water (50 mL) and brine (50 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product that was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in petroleum ether (PE). Pure fractions were evaporated to dryness to afford 5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (658 mg, 42%) as a brown solid. LCMS (ESI) m/z: [M+H]⁺=194.

Step 2: Preparation of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (i-7)

To a solution of 5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (600.00 mg, 3.105 mmol, 1.00 equiv) in THF (10.00 mL) was added NBS (663.23 mg, 3.726 mmol, 1.20 equiv), the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with EtOAc (50 mL), and washed with water (3×30 mL) and saturated brine (1×30 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (510 mg, 60%) as a brown solid. LCMS (ESI) m/z: [M+H]⁺=272.

Step 3: Preparation of 7-bromo-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (i-9)

To a solution of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carbaldehyde (300.00 mg, 1.102 mmol, 1.00 equiv) and 3,4-diaminopyridine (120.31 mg, 1.102 mmol, 1 equiv) in DMF (5.00 mL) was added Na₂S₂O₅ (628.75 mg, 3.307 mmol, 3 equiv), the resulting mixture was stirred at 120° C. for 16 hours. The solvent was removed under reduced pressure. The residue was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 7-bromo-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (165 mg, 41%) as a brown solid. LCMS (ESI) m/z: [M+H]⁺=361.

Step 4: Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (Compound 82)

To a solution of 7-bromo-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (60.00 mg, 0.166 mmol, 1.00 equiv), 4-[(dimethylamino)methyl]-3,5-dimethoxyphenylboronic acid (47.65 mg, 0.199 mmol, 1.20 equiv) and 052003 (108.24 mg, 0.332 mmol, 2.00 equiv) in DMF (1.00 mL) and H₂O (0.25 mL) was added Pd(dppf)Cl₂ (12.15 mg, 0.017 mmol, 0.10 equiv), the resulting mixture was stirred at 100° C. for 1 hour under a nitrogen atmosphere. The mixture was concentrated, the crude product was purified by reverse phase flash with the following conditions to afford crude product: column, 018 silica gel; mobile phase, MeCN in water, 5% to 50% gradient in 10 min; detector, UV 254 nm. The crude product was purified by Prep-HPLC (conditions: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (0.05% TFA, trifluoroacetic acid); Mobile Phase B: ACN (acetonitrile); Flow rate: 25 mL/minute; Gradient: 8% B to 8% B in 2 minutes; 254/220 nm; R_(T) (retention time): 13.87 minutes) to afford 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-[3H-imidazo[4,5-c]pyridin-2-yl]-5-methylthieno[3,2-c]pyridin-4-one (3 mg, 3.8%) as a yellow solid. ¹H NMR (400 MHz, Methanol-d4) δ 9.19 (s, 1H), 8.55 (d, J=6.5 Hz, 1H), 8.46 (s, 1H), 8.10 (d, J=6.5 Hz, 1H), 7.93 (s, 1H), 7.11 (s, 2H), 4.44 (s, 2H), 4.05 (s, 6H), 3.75 (s, 3H), 2.94 (s, 6H). LCMS (ESI) m/z: [M+H]⁺=476.30.

Example 9—Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-1-methylpiperidine-4-carboxamide (Compound B3)

Step 1: Preparation of 2-bromo-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (i-11)

To a solution of 2-bromo-5-methylthieno[3,2-c]pyridin-4-one (1.50 g, 6.145 mmol, 1.00 equiv) in DMF (5.00 mL) was added NCS (0.90 mg, 0.007 mmol, 1.1 equiv) at 25° C. The resulting solution was stirred at 70° C. for 3 hours. The resulting mixture was concentrated. The residue was purified by chromatography on silica gel eluted with petroleum ether/EtOAc (2/1) to afford 2-bromo-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (1.6 g, 94%) as a brown solid. LCMS (ESI) m/z: [M+H]+=278

Step 2: Preparation of 7-chloro-2-[(diphenylmethylidene)amino]-5-methylthieno[3,2-c]pyridin-4-one (i-12)

To a solution of 2-bromo-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (1.6 g, 5.744 mmol, 1.00 equiv) and benzophenone imine (1093.09 mg, 6.032 mmol, 1.05 equiv) in dioxane (15 mL) was added Xantphos (332.37 mg, 0.574 mmol, 0.1 equiv), sodium tert-butoxide (1656.09 mg, 17.232 mmol, 3 equiv), and Pd₂(dba)₃ (262.99 mg, 0.288 mmol, 0.05 equiv) at 25° C. The resulting solution was stirred for 2 hours at 80° C. The resulting mixture was concentrated. The residue was purified by chromatography on silica gel eluted with petroleum ether/EtOAc (5:1) to afford 7-chloro-2-[(diphenylmethylidene)amino]-5-methylthieno[3,2-c]pyridin-4-one (1.6 g, 74%) as a dark yellow solid. LCMS (ESI) m/z: [M+H]+=379.

Step 3: Preparation of 2-amino-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (i-13)

To a solution of 7-chloro-2-[(diphenylmethylidene)amino]-5-methylthieno[3,2-c]pyridin-4-one (1.60 g, 4.223 mmol, 1.00 equiv) in THF (10.00 mL) was added HCl (5.00 mL) at 25° C. The resulting solution was stirred at 25° C. for 2 hours. The solvent was removed under reduced pressure. This resulted in 1.5 g (crude) of 2-amino-7-chloro-5-methylthieno [3,2-c]pyridin-4-one as a dark brown solid. The product was used in the next step directly without further purification. LCMS (ESI) m/z: [M+H]+=215.

Step 4: Preparation of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide (i-14)

To a solution of 1-methylpiperidine-4-carboxylic acid (80.04 mg, 0.559 mmol, 1.20 equiv) and HATU (354.25 mg, 0.932 mmol, 2.00 equiv) in DMF (1.00 mL) was added 2-amino-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (100.00 mg, 0.466 mmol, 1.00 equiv) and DIEA (180.62 mg, 1.397 mmol, 3.00 equiv), the resulting solution was stirred at 25 degree for 2 hours. The resulting mixture was concentrated. The residue was applied onto a silica gel column with CH₂Cl₂/MeOH (20:1). This resulted in (80 mg, 51%) of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide as a yellow solid. LCMS (ESI) m/z: [M+H]+=340.10

Step 5: Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-1-methylpiperidine-4-carboxamide (Compound 83

To a solution of N-[7-chloro-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide (60.00 mg, 0.177 mmol, 1.00 equiv) and [4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]boronic acid (50.65 mg, 0.212 mmol, 1.20 equiv) in H₂O (1.00 mL) and dioxane (3.00 mL) was added 052003 (172.57 mg, 0.530 mmol, 3.00 equiv) and Pd(dppf)Cl₂.CH₂Cl₂ (12.92 mg, 0.018 mmol, 0.10 equiv). The resulting solution was stirred at 80° C. for 2 hours (under N₂ atmosphere). The crude product was purified by preparative HPLC (conditions: XSelect CSH Prep C18 OBD Column, 19*150 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 20% B to 55% B in 8 minutes; 254 nm; R_(T): 7.12 minutes). Fractions containing the desired compound were evaporated to dryness to afford N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-1-methylpiperidine-4-carboxamide (32 mg, 36%) as a white solid. ¹H NMR (400 MHz, Methanol-d4) δ 7.68 (s, 1H), 7.23 (s, 1H), 7.06 (s, 2H), 4.42 (s, 2H), 4.02 (s, 6H), 3.75 (s, 3H), 3.64 (d, J=12.6 Hz, 2H), 3.16-3.06 (m, 2H), 2.92 (d, J=1.0 Hz, 9H), 2.82-2.71 (m, 1H), 2.21 (d, J=14.5 Hz, 2H), 2.10-1.94 (m, 2H). LCMS (ESI) m/z: [M+H]+=499.30.

Example 10—Preparation of N-(7-[4-[(Dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-4-methylmorpholine-2-carboxamide Formic Acid (Compound B4 Formic Acid)

Step 1: Preparation of tert-butyl 2-([7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]carbamoyl l)morpholine-4-carboxylate (i-15)

To a solution of 2-amino-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (507.00 mg, 2.362 mmol, 1.00 equiv) and 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (710.00 mg, 3.070 mmol, 1.3 equiv)) in DMF (6 mL) was added HATU (1796.03 mg, 4.724 mmol, 2 equiv) and DIEA (1220.97 mg, 9.447 mmol, 4 equiv) at 25° C. The resulting solution was stirred at 25° C. for 2 hours. The resulting mixture was concentrated. The residue was purified by chromatography on silica gel eluted with petroleum ether/EtOAc (2:1) to afford tert-butyl2-([7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]carbamoyl)morpholine-4-carboxylate (820 mg, 81%) as a brown solid. LCMS (ESI) m/z: [M+H]+=428.

Step 2: Preparation of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]morpholine-2-carboxamide (i-16)

To a solution of tert-butyl 2-([7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]carbamoyl)morpholine-4-carboxylate (800.00 mg, 1.870 mmol, 1.00 equiv) in DCM (6.00 mL) was added TFA (2.00 mL) at 25° C. The resulting solution was stirred at 25° C. for 2 hours. The solvent was removed under reduced pressure. This resulted in 1 g (crude) of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]morpholine-2-carboxamide as a dark brown solid. The product was used in the next step directly without further purification. LCMS (ESI) m/z: [M+H]+=328.

Step 3: Preparation of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-4-methylmorpholine-2-carboxamide (i-17)

To a solution of N-[7-chloro-5-methyl-4-oxothie[3,2-c]pyridin-2-yl]morpholine-2-carboxamide (1.00 g, 3.051 mmol, 1.00 equiv) in HCHO (4.00 mL) and MeOH (10.00 mL) was added NaBH₃CN (0.38 g, 0.006 mmol, 2 equiv) and CH₃COOH (0.50 mL, 8.726 mmol, 2.86 equiv) at 25° C. The resulting solution was stirred at 25° C. for 4 hours. The resulting mixture was concentrated. The residue was purified by chromatography on silica gel eluted with petroleum ether/EtOAc (1:1) to afford N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-4-methylmorpholine-2-carboxamide (284 mg, 27%) as a brown solid. LCMS (ESI) m/z: [M+H]+=342.

Step 4: Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-4-methylmorpholine-2-carboxamide Formic Acid (Compound 84 Formic Acid)

To a solution of N-[7-chloro-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl]-4-methylmorpholine-2-carboxamide (100 mg, 0.293 mmol, 1.00 equiv) and [4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]boronic acid (104.92 mg, 0.439 mmol, 1.5 equiv) in H₂O (1 mL) and dioxane (4 mL) was added 052003 (190.64 mg, 0.585 mmol, 2 equiv) and XPhos palladium(II) biphenyl-2-amine chloride (23.02 mg, 0.029 mmol, 0.10 equiv) at 25° C. The resulting solution was stirred at 90° C. for 12 hours. The crude product was purified by Prep-HPLC (conditions: Sun Fire Prep 018 OBD Column 19×150 mm 10 nm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 3% B to 3% B in 2 minutes; 254/220 nm; R_(T): 7.5 minutes) to afford N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-2-yl)-4-methylmorpholine-2-carboxamide; formic acid (31.7 mg, 20%) as a light brown solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.46 (s, 1H), 7.67 (s, 1H), 7.39 (d, J=0.9 Hz, 1H), 7.06 (d, J=1.1 Hz, 2H), 4.41 (s, 2H), 4.27 (dd, J=10.3, 2.8 Hz, 1H), 4.14-4.01 (m, 1H), 4.02 (s, 6H), 3.79 (td, J=11.4, 2.5 Hz, 1H), 3.74 (s, 3H), 3.12 (d, J=11.7 Hz, 1H), 2.91 (s, 6H), 2.77 (d, J=11.9 Hz, 1H), 2.38 (s, 3H), 2.28 (t, J=11.6 Hz, 1H), 2.17 (t, J=10.9 Hz, 1H). LCMS (ESI) m/z: [M+H]+=501.35.

Example 11—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (Compound B5)

Step 1: Preparation of Methyl 5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylate (i-18)

To a mixture of 2-bromo-5-methylthieno[3,2-c]pyridin-4-one (2.44 g, 9.996 mmol, 1.00 equiv) and Pd(dppf)Cl₂.CH₂Cl₂ (0.82 g, 1.00 mmol, 0.100 equiv) in MeOH (20.00 mL) was added TEA (2.78 mL, 27.460 mmol, 2.00 equiv). The resulting mixture was stirred at 100° C. for 16 hours under CO atmosphere (50 atm). Then the mixture was concentrated under reduced pressure, and the resulting residue was purified by flash silica chromatography, elution gradient 0 to 70% EtOAc in petroleum ether to give methyl 5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylate (1.81 g, 81%) as a yellow solid. LCMS (ESI) m/z: [M+H]⁺=224.

Step 2: Preparation of Methyl 7-bromo-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylate (i-19)

To a stirred mixture of methyl 5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylate (1.80 g, 8.063 mmol, 1.00 equiv) in) DMF (30 mL) was added NBS (1.58 g, 8.869 mmol, 1.10 equiv). The resulting mixture was stirred at room temperature for 1 hour under nitrogen atmosphere. The mixture was then diluted with water (100 mL) and extracted with EtOAc (300 mL×3). The organic layers were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give methyl 7-bromo-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylate (2.43 g, crude) as a yellow solid. This material was used directly in the next step without further purification. LCMS (ESI) m/z: [M+H]⁺=302.

Step 3: Preparation of 7-bromo-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylic Acid (i-20)

Into a sealed tube was added methyl 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylate (2.43 g, 8.05 mmol, 1.00 equiv) and concentrated hydrochloric acid (40 mL). The mixture was stirred for 4 hours at 90° C. The resulting mixture was concentrated to give 7-bromo-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxylic acid (2.20 g, 95%) as a brown solid. This material was used directly in the next step without further purification. LCMS (ESI) m/z: [M+H]⁺=288.

Step 4: Preparation of 7-bromo-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)thieno[3,2-c]pyridine-2-carboxamide (i-21)

To a solution of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylic acid (50.00 mg, 0.174 mmol, 1.00 equiv) and HATU (131.97 mg, 0.347 mmol, 2.00 equiv) in DMF (1.00 mL) was added 5-aminopiperidin-2-one (21.79 mg, 0.191 mmol, 1.10 equiv) and DIEA (67.29 mg, 0.521 mmol, 3.00 equiv). The resulting solution was stirred at 25° C. for 2 hours. The resulting mixture was concentrated. The residue was applied onto a silica gel column with CH₂Cl₂/MeOH (20:1) to afford 7-bromo-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)thieno[3,2-c]pyridine-2-carboxamide (42 mg, 63%) as a yellow solid. LCMS (ESI) m/z: [M+H]+=386.01.

Step 5: Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (Compound 85)

To a solution of 7-bromo-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (30.00 mg, 0.078 mmol, 1.00 equiv) and [4-[(dimethylamino)methyl]-3,5-dimethoxy phenyl]boronic acid (22.40 mg, 0.094 mmol, 1.20 equiv) in H₂O (1.00 mL) and dioxane (3.00 mL) was added Cs₂CO₃ (76.31 mg, 0.234 mmol, 3.00 equiv) and Pd(dppf)Cl₂.CH₂Cl₂ (6.38 mg, 0.008 mmol, 0.10 equiv). The resulting solution was stirred at 80° C. for 2 hours (under N₂ atmosphere). The crude product was purified by preparative HPLC (conditions: XSelect CSH Prep 018 OBD Column, 5 μm, 19150 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 20% B to 55% B in 8 minutes; 254 nm; R_(T): 7.12 minutes). Fractions containing the desired compound were evaporated to dryness to afford 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-N-(6-oxopiperidin-3-yl)-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (28 mg, 72%) as a white solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H, FA), 8.28 (s, 1H), 7.86 (s, 1H), 7.06 (s, 2H), 4.37 (s, 2H), 4.37-4.30 (m, 1H), 4.02 (s, 6H), 3.75 (s, 3H), 3.58 (dd, J=12.0, 4.9 Hz, 1H), 3.30-3.26 (m, 1H), 2.88 (s, 6H), 2.55-2.47 (m, 2H), 2.19-2.01 (m, 2H). LCMS (ESI) m/z: [M+H]+=499.35.

Example 12—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (Compound B6)

Step 1: Preparation of 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide (i-22)

To a solution of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylic acid (50.00 mg, 0.174 mmol, 1.00 equiv) and HATU (131.97 mg, 0.347 mmol, 2.00 equiv) in DMF (1.00 mL) was added 1-methylpiperidin-4-amine (21.80 mg, 0.191 mmol, 1.10 equiv) and DIEA (67.29 mg, 0.521 mmol, 3.00 equiv). The resulting solution was stirred at 25° C. for 2 hours. The resulting mixture was concentrated. The residue was applied onto a silica gel column with CH₂Cl₂/MeOH (20:1). This resulted in (45 mg, 68%) of 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide as a yellow solid. LCMS (ESI) m/z: [M+H]+=384.01.

Step 2: Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (Compound 86)

To a solution of 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (30.00 mg, 0.078 mmol, 1.00 equiv) and [4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]boronic acid (22.40 mg, 0.094 mmol, 1.20 equiv) in H₂O (1.00 mL) and dioxane (3.00 mL) was added Cs₂CO₃ (76.31 mg, 0.234 mmol, 3.00 equiv) and Pd(dppf)Cl₂.CH₂Cl₂ (6.38 mg, 0.008 mmol, 0.10 equiv). The resulting solution was stirred at 80° C. for 2 hours (under N2 atmosphere). The crude product was purified by preparative HPLC (conditions: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 20% B to 55% B in 8 minutes; 254 nm; R_(T): 7.12 minutes). Fractions containing the desired compound were evaporated to dryness to afford 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboxamide (21 mg, 54%) as a white solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H, FA), 8.26 (s, 1H), 7.86 (s, 1H), 7.07 (s, 2H), 4.40 (s, 2H), 4.02 (s, 7H), 3.75 (s, 3H), 3.27 (d, J=11.2 Hz, 2H), 2.90 (s, 6H), 2.79-2.67 (m, 2H), 2.62 (s, 3H), 2.12 (d, J=13.4 Hz, 2H), 1.94-1.79 (m, 2H). LCMS (ESI) m/z: [M+H]+=499.25.

Example 13—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-2-(4-methylpiperazine-1-carbonyl)-4H,5H-thieno[3,2-c]pyridin-4-one (Compound B7)

Step 1: Preparation of 7-bromo-5-methyl-2-(4-methylpiperazine-1-carbonyl)thieno[3,2-c]pyridin-4-one (i-23)

To a solution of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylic acid (150.00 mg, 0.521 mmol, 1.00 equiv), HATU (296.93 mg, 0.781 mmol, 1.50 equiv) and DIEA (134.57 mg, 1.041 mmol, 2.00 equiv) in DMF (10.00 mL). The resulting mixture was stirred for 10 minutes at 25° C. Then 1-methylpiperazine (62.58 mg, 0.625 mmol, 1.20 equiv) was added to the reaction mixture. The resulting solution was stirred for 2 hours at 25° C. The resulting mixture was concentrated. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:1). This resulted in 80 mg (42%) of 7-bromo-5-methyl-2-(4-methylpiperazine-1-carbonyl)thieno[3,2-c]pyridin-4-one as a yellow solid.

Step 2: Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-2-(4-methylpiperazine-1-carbonyl)-4H,5H-thieno[3,2-c]pyridin-4-one (Compound 87)

To a solution of 7-bromo-5-methyl-2-(4-methylpiperazine-1-carbonyl)-4H,5H-thieno[3,2-c]pyridin-4-one (100.00 mg, 0.270 mmol, 1.00 equiv) and 052003 (263.99 mg, 0.810 mmol, 3.00 equiv) in 1,4-dioxane (5.00 mL) was added [4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]boronic acid (64.57 mg, 0.270 mmol, 1.00 equiv), Pd(dppf)Cl₂.CH₂Cl₂ (22.06 mg, 0.027 mmol, 0.10 equiv), and H₂O (1.00 mL). The resulting solution was stirred for 2 hours at 80° C. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with ethyl acetate (3×10 mL) and the organic layers combined and dried over anhydrous sodium sulfate and concentrated. The crude product was purified by Prep-HPLC (conditions: 2 #SHIMADZU (HPLC-01); SunFire 018 OBD Prep Column, 19 mm×250 mm; mobile phase: Water (0.1% FA, formic acid) and ACN (hold 5% Phase B in 2 minutes, up to 12% in 10 minutes); UV Detector). This resulted in 5.3 mg (4.1%) of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-2-(4-methylpiperazine-1-carbonyl)-4H,5H-thieno[3,2-c]pyridin-4-one as a brown semi-solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.45 (s, 2H, FA), 7.93 (s, 1H), 7.87 (s, 1H), 7.06 (s, 2H), 4.41 (s, 2H), 4.01 (s, 6H), 3.97-3.85 (m, 4H), 3.75 (s, 3H), 2.91 (s, 6H), 2.75-2.64 (m, 4H), 2.45 (s, 3H); LCMS (ESI) m/z: [M+H]+=485.20.

Example 14—Preparation of 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetic Acid Trifluoroacetic Acid (Compound B8 Trifluoroacetic Acid)

Step 1 Preparation of 5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (i-24)

To a solution of 2-bromo-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (500.00 mg, 2.048 mmol, 1.00 equiv) and Zn(CN)₂ (529.22 mg, 4.506 mmol, 2.20 equiv) in DMF (20.00 mL) was added Pd(dppf)Cl₂ (149.87 mg, 0.205 mmol, 0.10 equiv). The resulting mixture was stirred at 120° C. for 16 hours under N₂ atmosphere. Fifteen identical reactions were set up in 15 sealed tubes in parallel. The reaction mixtures were combined and diluted with EA (500 mL). The resulting mixture was washed with water (3×300 mL) and saturated brine (300 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (4.4 g, 75%) as a black solid.

Step 2: Preparation of 7-bromo-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (i-25)

To a solution of 5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (4.40 g, 23.131 mmol, 1.00 equiv) in THF (50.00 mL) was added NBS (6.18 g, 34.697 mmol, 1.50 equiv). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with EA (400 mL). The resulting mixture was washed with water (3×200 mL) and saturated brine (300 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 7-bromo-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (3.5 g, 56%) as a brown solid.

Step 3: Preparation of 7-bromo-N-(1,1-dioxo-1λ6-thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboximidamide (i-26)

To a solution of 7-bromo-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (3 g, 11.147 mmol, 1.00 equiv) in MeOH (45.00 mL, 11.451 mmol, 99.70 equiv) was added MeONa (2.00 g, 11.147 mmol, 1 equiv) solution in MeOH (30% by weight). The reaction mixture was heated to 75° C. for 3 hours. Then 4-amino-1λ6-thiane-1,1-dione hydrochloride (2.48 g, 0.013 mmol, 1.2 equiv) was added at 75° C., and the reaction mixture was stirred for a further 16 hours. The volatile components were removed in vacuo, and the resulting solid was suspended in MeOH (50 mL), filtered under reduced pressure, and washed with MeOH (20 mL) to afford 7-bromo-N-(1,1-dioxo-1λ6-thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboximidamide (3.0 g, 64%) as a brown solid.

Step 4: Preparation of Ethyl 2-(4-bromo-2-methoxyphenoxy)acetate (i-27)

To a solution of 4-bromo-2-methoxyphenol (5 g, 24.626 mmol, 1 equiv) and K2003 (6.81 g, 49.253 mmol, 2 equiv) in acetone (50 mL) was added ethyl 2-bromoacetate (4.94 g, 29.580 mmol, 1.20 equiv). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with EA (500 mL), The resulting mixture was washed with water (3×300 mL) and saturated brine (300 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 8% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford ethyl 2-(4-bromo-2-methoxyphenoxy)acetate (4 g, 56%) as a yellow oil.

Step 5: Preparation of Ethyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate (i-28)

To a solution of ethyl 2-(4-bromo-2-methoxyphenoxy)acetate (6 g, 20.752 mmol, 1 equiv) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (6.32 g, 24.903 mmol, 1.2 equiv) in solvent dioxane (120 mL) was added KOAc (4.07 g, 41.505 mmol, 2 equiv) and Pd(dppf)Cl₂ (1.52 g, 2.075 mmol, 0.1 equiv). The resulting solution was stirred at 90° C. for 1 hour (under N2 atmosphere). The resulting mixture was washed with water (3×300 mL). The organic phase was concentrated under reduced pressure. The residue was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford ethyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate (6.9 g, 98%) as a yellow oil.

Step 6: Preparation of ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetate (i-29)

To a solution of 7-bromo-N-(1,1-dioxo-1λ6-thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboximidamide (1.00 g, 2.391 mmol, 1.00 equiv), ethyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate (0.88 g, 2.630 mmol, 1.10 equiv), and K3PO4 (1.01 g, 4.781 mmol, 2.00 equiv) in water (2.00 mL) and DMF (20.00 mL) was added Pd(dppf)Cl₂ (0.17 g, 0.239 mmol, 0.10 equiv). The resulting mixture was stirred at 75° C. for 1 hour. The reaction mixture was diluted with EA (500 mL). The resulting mixture was washed with water (3×300 mL) and saturated brine (300 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 15% MeOH in DCM. Pure fractions were evaporated to dryness to afford ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetate (860 mg, 66%) as a brown solid.

Step 7: Preparation of 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetic Acid Trifluoroacetic Acid (Compound B8 Trifluoroacetic Acid)

To a solution of ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetate (560 mg, 1.023 mmol, 1.00 equiv) in MeOH (25.00 mL) and H₂O (2.50 mL) was added LiOH.H₂O (429.48 mg, 10.226 mmol, 10.00 equiv). The resulting mixture was stirred at room temperature for 5 hours. The mixture was acidified to pH 2 with 1 N HCl (aq.). The crude product was purified by HPLC (conditions: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 5% B to 22% B in 8 minutes; 254 nm; R_(T): 5.68 minutes). Fractions containing the desired compound were evaporated to dryness to afford 2-(4-[2-[N-(1,1-dioxo-11A6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)acetic acid trifluoroacetic acid (330 mg, 49%) as a yellow solid. LCMS (ES, m/z): 520.20. ¹H NMR (400 MHz, DMSO-d6) δ9.73 (d, J=8.1 Hz, 1H), 9.65 (s, 1H), 9.34 (s, 1H), 8.55 (s, 1H), 7.99 (s, 1H), 7.25-7.12 (m, 2H), 7.02 (d, J=8.4 Hz, 1H), 4.76 (s, 2H), 4.01 (d, J=8.9 Hz, 1H), 3.87 (s, 3H), 3.63 (s, 3H), 3.30-3.15 (m, 4H). 2.28-2.15 (m, 4H).

Example 15—Preparation of 7-(3,4-dimethoxyphenyl)-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridine-4-one (Compound B9)

Step 1: Preparation of 7-bromo-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (i-30)

To a solution of 7-bromo-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carbonitrile (50.00 mg, 0.186 mmol, 1.00 equiv) and NaOMe (100.37 mg, 1.858 mmol, 10.00 equiv) in MeOH (1.00 mL) was stirred for 3 hours at room temperature. To the above mixture was added AcOH (446.28 mg, 7.432 mmol, 40.00 equiv) and HCl (1.50 mL, 49.368 mmol, 265.72 equiv) at room temperature. The resulting mixture was stirred for additional 16 hours at 75° C. The residue was dissolved in EtOAc (100 mL). The resulting mixture was washed with water (3×30 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (PE/EtOAc 5:1) to afford 7-bromo-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (30 mg, 52%) as a white solid. LCMS (ES, m/z): 310.0.

Step 2: Preparation of 7-(3,4-dimethoxyphenyl)-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridine-4-one (Compound 89)

To a solution of 7-bromo-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (30.00 mg, 0.097 mmol, 1.00 equiv) and (3,4-dimethoxyphenyl)boronic acid (17.60 mg, 0.097 mmol, 1 equiv) in dioxane (1.50 mL) and H₂O (0.50 mL) was added Cs₂CO₃ (63.03 mg, 0.193 mmol, 2.00 equiv) and XPhos-Pd-G3 (16.37 mg, 0.019 mmol, 0.2 equiv). The resulting solution was stirred at 80° C. for 1 hour (under N₂ atmosphere). The crude product was purified by preparative HPLC (conditions: XBridge Shield RP18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (10 mmol/L NH₄HCO₃), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 25% B to 33% B in 8 minutes; 254 nm; R_(T): 6.77 minutes). Fractions containing the desired compound were evaporated to dryness to afford 7-(3,4-dimethoxyphenyl)-2-(1H-imidazol-2-yl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (10.8 mg, 30%) as a white solid. LCMS (ES, m/z): 368.1. ¹H-NMR (400 MHz, CD₃OD) δ 7.96 (s, 1H), 7.62 (s, 1H), 7.26 (m, J=2.1 Hz, 1H), 7.24 (m, J=8.1, 2.2 Hz, 1H), 7.17 (s, 2H), 7.11 (m, J=8.1 Hz, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.74 (s, 3H).

Example 16—Preparation of 7-(3,4-dimethoxyphenyl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (Compound B10)

Step 1: Preparation of 7-bromothieno[3,2-c]pyridin-4(5H)-one (i-32)

A solution of 4H,5H-thieno[3,2-c]pyridin-4-one (1 g, 6.615 mmol, 1 equiv) and NBS (1.41 g, 7.938 mmol, 1.2 equiv) in DMF (10 mL) was stirred for 16 hours at room temperature. The resulting solution was diluted with of EtOAc. The resulting mixture was washed with water (3×50 mL). The resulting mixture was concentrated. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (30/70). Fractions containing the desired compound were evaporated to dryness to afford 7-bromo-4H,5H-thieno[3,2-c]pyridin-4-one (440.0 mg, 29%) as a purple solid. LCMS (ES, m/z): 230.0.

Step 2: Preparation of 7-bromo-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (i-33)

To a solution of 7-bromo-4H,5H-thieno[3,2-c]pyridin-4-one (200.00 mg, 0.869 mmol, 1.00 equiv) and Cs₂CO₃ (849.67 mg, 2.608 mmol, 3 equiv) in THF (10.00 mL) was added MeI (246.76 mg, 1.739 mmol, 2 equiv) at room temperature. The resulting mixture was stirred for 2 hours at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (hexane/EtOAc 5:1) to afford 7-bromo-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (200 mg, 94%) as a brown solid. LCMS (ES, m/z): 244.0.

Step 3: Preparation of 7-(3,4-dimethoxyphenyl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (Compound B10)

To a solution of 7-bromo-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (100.00 mg, 0.410 mmol, 1.00 equiv) and (3,4-dimethoxyphenyl)boronic acid (74.55 mg, 0.410 mmol, 1 equiv) in solvent H₂O (1.00 mL) and dioxane (3.00 mL) was added 052003 (266.95 mg, 0.819 mmol, 2 equiv) and XPhos-Pd-G3 (69.35 mg, 0.082 mmol, 0.2 equiv). The resulting solution was stirred at 80° C. for 1 hour (under N₂ atmosphere). The crude product was purified by preparative HPLC (conditions: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 20% B to 55% B in 8 minutes; 254 nm; R_(T): 7.12 minutes). Fractions containing the desired compound were evaporated to dryness to afford 7-(3,4-dimethoxyphenyl)-5-methyl-4H,5H-thieno[3,2-c]pyridin-4-one (60.1 mg, 48%) as a white solid. LCMS (ES, m/z): 302. ¹H NMR (400 MHz, DMSO) δ 7.72 (s, 1H), 7.66 (d, J=5.4 Hz, 1H), 7.58 (d, J=5.4 Hz, 1H), 7.22-7.15 (m, 2H), 7.09 (d, J=8.1 Hz, 1H), 3.83 (d, J=6.4 Hz, 6H), 3.60 (s, 3H).

Example 17—Preparation of Intermediates Preparation of Ethyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy]-acetate (i-35)

Step 1: Preparation of Ethyl 2-[4-bromo-2-(trifluoromethyl)phenoxy]acetate (i-34)

To a solution of 4-bromo-2-(trifluoromethyl)phenol (5 g, 20.746 mmol, 1 equiv) and K₂CO₃ (5.73 g, 41.493 mmol, 2 equiv) in acetone (50 mL) was added ethyl 2-bromoacetate (5.20 g, 31.119 mmol, 1.5 equiv) at room temperature. The resulting mixture was stirred for 1 hour at room temperature. The solid was then filtered off, the filtrate was concentrated, and the residue was purified by silica gel column chromatography, eluted with PE/EtOAc (5:1) to afford ethyl 2-[4-bromo-2-(trifluoromethyl)phenoxy] acetate (6.5 g, 96%) as a white solid. LCMS (ESI) m/z: [M+H]+=327.

Step 2: Preparation of Ethyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy]-acetate (i-35)

To a solution of ethyl 2-[4-bromo-2-(trifluoromethyl)phenoxy]acetate (1 g, 3.057 mmol, 1 equiv) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (931.6 mg, 3.669 mmol, 1.2 equiv) in dioxane (10 mL) was added KOAc (0.60 g, 6.114 mmol, 2.00 equiv) and Pd(dppf)Cl₂ (223.7 mg, 0.306 mmol, 0.1 equiv). The resulting mixture was stirred for 1 h at 90° C. under a nitrogen atmosphere. The mixture was concentrated and the residue was purified by silica gel column chromatography, eluted with PE/EtOAc (5:1) to afford ethyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy]acetate (800 mg, 70%) as a yellow oil. LCMS (ESI) m/z: [M+H]+=375.

Preparation of Tert-Butyl N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)carbamate (i-37)

Step 1: Preparation of Tert-Butyl (8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4yl)amino)octyl)carbamate (i-36)

To a solution of 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (200 mg, 0.773 mmol, 1 equiv) and tert-butyl N-(8-oxooctyl)carbamate (225.31 mg, 0.927 mmol, 1.2 equiv) in MeOH (10 mL) was added NaBH₃CN (145.41 mg, 2.319 mmol, 3 equiv) and AcOH (0.5 mL). The resulting solution was stirred at 25° C. for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (5:1) to afford tert-butyl N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-ihydro-1H-isoindol-4-yl]amino]octyl)carbamate (202 mg, 62%) as an off-white solid. LCMS (ESI) m/z: [M+H]+=487.

Step 2: Preparation of tert-butyl N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)carbamate (i-37)

To a solution of tert-butyl N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)carbamate (100 mg, 0.310 mmol, 1 equiv) in DCM (5.0 ml) was added TFA (2.0 ml). The resulting solution was stirred at 25° C. for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (conditions: column, 018 silica gel; mobile phase, MeCN in water, 10% to 50% gradient in 10 minutes; detector, UV 254 nm). This resulted in 3-[4-[(8-aminooctyl)amino]-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (103 mg, 87%) as a yellow solid. LCMS (ESI) m/z: [M+H]+=387.

Preparation of 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentanal (i-39)

Step 1: Preparation of 4-(4-(1,3-dioxolan-2-yl)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (i-38)

To a stirred mixture of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione (400 mg, 1.459 mmol, 1.00 equiv) and 2-(4-bromobutyl)-1,3-dioxolane (274.5 mg, 1.313 mmol, 0.90 equiv) in DMF (4.00 mL) was added Cs₂CO₃ (950.5 mg, 2.917 mmol, 2.00 equiv) at 60° C. under nitrogen atmosphere. The resulting mixture was stirred for 5 hours. The resulting mixture was filtered with acetonitrile (200 mL), concentrated, and purified by Prep-TLC (PE/EtOAc (1:1)) to afford 4-[4-(1,3-dioxolan-2-yl)butoxy]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (81 mg, 13%) as a colorless oil. LCMS (ESI) m/z: [M+H]⁺=403.

Step 2: Preparation of 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentanal (i-39)

To a stirred mixture of 4-[4-(1,3-dioxolan-2-yl)butoxy]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (46.0 mg, 0.114 mmol, 1.00 equiv) in H₂O (3.0 mL) was added 4 M HCl in dioxane (3 mL) dropwise at room temperature under nitrogen atmosphere. After 3 hours, saturated NaHCO₃ solution (50 mL) was added to the mixture. The mixture was then extracted with EtOAc (100 mL×3), and the combined organic layers were concentrated to give 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanal (35 mg, 70%) as a light yellow semi-solid. LCMS (ESI) m/z: [M+H]₊=359.

Preparation of tert-butyl 4-([7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]carbamoyl)piperidine-1-carboxylate (i-40)

To a solution of 2-amino-7-chloro-5-methylthieno[3,2-c]pyridin-4-one (300.0 mg, 1.397 mmol, 1.00 equiv)v) and 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (416.5 mg, 1.817 mmol, 1.3 equiv) in solvent DMF (4 mL) was added DIEA (722.5 mg, 5.590 mmol, 4 equiv) and HATU (1062.7 mg, 2.795 mmol, 2 equiv). The resulting solution was stirred at 25° C. for 2 hours. The mixture was diluted with EtOAc (30 mL) and washed with water (30 mL×3). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by chromatography on silica gel eluted with DCM/MeOH (from 20:1 to 10:1) to give tert-butyl 4-([7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]carbamoyl)piperidine-1-carboxylate (360 mg, 61%) as a brown solid. LCMS (ESI) m/z: [M+H]+=426.

The following compounds (intermediates i-41, i-42, and i-43) were prepared in a similar manner as described in the preparation of intermediate i-40.

Compound (Intermediate No.) Structure Analytical Data tert-butyl 3-([7-chloro-5-methyl-4-oxothieno[3,2- c]pyridin-2-yl]carbamoyl)piperidine-1- carboxylate (i-41)

340 mg (57%) as a yellow oil; LCMS (ESI) m/z: [M + H]⁺ = 426.12 7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2- yl]-1-methylpiperidine-4-carboxamide (i-42)

80 mg (51%) as a yellow solid; LCMS (ESI) m/z: [M + H]+ = 340 tert-butyl 4-(7-bromo-5-methyl-4-oxo-4,5- dihydrothieno[3,2-c]pyridine-2- carboxamido)piperidine-1-carboxylate (i-42)

154 mg (31%) as a yellow solid; LCMS (ESI) m/z: [M + H]⁺ = 470

Preparation of tert-butyl 2-[([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetate (i-44)

To a solution of N-[7-chloro-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide (50.0 mg, 0.147 mmol, 1.00 equiv) and 4-([[2-(tert-butoxy)-2-oxoethyl](methyl)amino]methyl)-3,5-dimethoxyphenylboronic acid (59.9 mg, 0.177 mmol, 1.20 equiv) in solvent dioxane (1.50 mL) and H₂O (0.50 mL) was added Pd(dppf)Cl₂*CH₂Cl₂ (8.5 mg, 0.015 mmol, 0.10 equiv) and 052003 (95.9 mg, 0.294 mmol, 2.00 equiv), and the resulting solution was stirred at 90° C. for 3 hours. The reaction mixture was then diluted with 10 mL of water and extracted ethyl acetate (2×20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was applied onto a silica gel column with CH₂Cl₂/MeOH (20:1). This resulted in tert-butyl 2-[([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetate (40 mg, 45%) as a yellow solid. LCMS (ESI) m/z: [M+H]+=599.

The following compounds (intermediates i-45, i-46, and i-47) were prepared in a similar manner as described in the preparation of intermediate i-44.

Compound (Intermediate No.) Structure Analytical Data tert-butyl 4-[(7-[4-[(dimethylamino)methyl]-3,5- dimethoxyphenyl]-5-methyl-4-oxothieno[3,2- c]pyridin-2-yl)carbamoyl]piperidine-1- carboxylate (i-45)

168 mg (34%) as a brown solid; LCMS (ESI) m/z: [M + H]+ = 585 tert-butyl 3-[(7-[4-[(dimethylamino)methyl]-3,5- dimethoxyphenyl]-5-methyl-4-oxothieno[3,2- c]pyridin-2-yl)carbamoyl]piperidine-1- carboxylate (i-46)

260 mg (63%) as a red oil; LCMS (ESI) m/z: [M + H]+ = 585.27 tert-butyl 4-(7-(4-((dimethylamino)methyl)-3,5- dimethoxyphenyl)-5-methyl-4-oxo-4,5- dihydrothieno[3,2-c]pyridine-2- carboxamido)piperidine-1-carboxylate (i-47)

122 mg (62%) as a brown solid; LCMS (ESI) m/z: [M + H]⁺ = 585

Preparation of ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)acetate (i-48)

To a solution of ethyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl) phenoxy]acetate (100 mg, 0.267 mmol, 1 equiv) and 7-bromo-N-(1,1-dioxo-1λ6-thian-4-yl)-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridine-2-carboximidamide (111.8 mg, 0.267 mmol, 1 equiv) in DMF (3 mL) and H₂O (0.3 mL) was added K3PO4 (113.46 mg, 0.535 mmol, 2 equiv) and Pd(dppf)Cl₂ (39.1 mg, 0.053 mmol, 0.2 equiv) at room temperature. The resulting mixture was stirred for 1 hour at 75° C. under nitrogen atmosphere. The mixture was concentrated and the residue was purified by silica gel column chromatography, eluted with CH₂Cl₂/MeOH (5:1) to afford ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy) acetate (97 mg, 62%) as an off-white solid. LCMS (ESI) m/z: [M+H]+=586.

Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-4-carboxamide (i-49)

To a solution of tert-butyl 4-[(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)carbamoyl]piperidine-1-carboxylate (168.0 mg, 0.287 mmol, 1.00 equiv) in

DCM (9.00 mL) was added TFA (3.00 mL, 13.463 mmol, 262.41 equiv), and the resulting solution was stirred at 25° C. for 2 hours. The solvent was removed to afford N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-4-carboxamide (180 mg, crude) as a brown solid that was used directly without further purification. LCMS (ESI) m/z: [M+H]+=485.

The following compounds (intermediates i-50 and i-51) were prepared in a similar manner as described in the preparation of intermediate i-49.

Compound (Intermediate No.) Structure Analytical Data N-(7-[4-[(dimethylamino)methyl]-3,5- dimethoxyphenyl]-5-methyl-4- oxothieno[3,2-c]pyridin-2-yl)piperidine-3- carboxamide (i-50)

160 mg (88%) as a red oil; LCMS (ESI) m/z: [M + H]⁺ = 485.21 N-(7-[4-[(dimethylamino)methyl]-3,5- dimethoxyphenyl]-5-methyl-4- oxothieno[3,2-c]pyridin-2-yl)piperidine-4- carboxamide (i-51)

180 mg (crude) as a brown solid (used directly without further purification); LCMS (ESI) m/z: [M + H]+ = 485

Preparation of [([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetic Acid (i-52)

To a solution of tert-butyl 2-[([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetate (40.0 mg, 0.067 mmol, 1.00 equiv) in DCM (2.00 mL) was added TFA (2.00 mL), and the resulting solution was stirred at 25° C. for 1 hour. The resulting mixture was concentrated to afford [([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetic acid (50 mg, crude) as a yellow solid that was used directly without further purification.

Preparation of 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)acetic Acid (i-53)

A solution of ethyl 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)acetate (90 mg, 0.154 mmol, 1 equiv) and LiOH.H₂O (64.49 mg, 1.537 mmol, 10 equiv) in MeOH (2 mL) and H₂O (0.5 mL) was stirred for 1 hour at room temperature. The resulting mixture was concentrated under vacuum and afforded 2-(4-[2-[N-(1,1-dioxo-1A6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)acetic acid (80 mg, 93%) as a yellow solid. LCMS (ESI) m/z: [M+H]+=558.

Preparation of tert-butyl 4-[7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido]-3,3-difluoro piperidine-1-carboxylate (i-55)

To a solution of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylic acid (200.0 mg, 0.694 mmol, 1.00 equiv) and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (213.2 mg, 0.902 mmol, 1.3 equiv) in DMF (4 mL) was added DIEA (448.57 mg, 3.471 mmol, 5 equiv) and HATU (527.8 mg, 1.388 mmol, 2 equiv), and the resulting solution was stirred at room temperature for 4 hours. The mixture was diluted with EtOAc (20 mL) and washed with water (30 mL×3). The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by chromatography on silica gel eluted with DCM/MeOH (from 30:1 to 20:1) to give tert-butyl 4-[7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido]-3,3-difluoropiperidine-1-carboxylate (100 mg, 28.45%) as a brown yellow solid. LCMS (ESI) m/z: [M+H]+=506.

Preparation of Tert-Butyl 4-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido)-3,3-difluoropiperidine-1-carboxylate (i-57)

To a solution of tert-butyl 4-[7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido]-3,3-difluoropiperidine-1-carboxylate (90.0 mg, 0.178 mmol, 1.00 equiv) and 4-[(dimethylamino)methyl]-3,5-dimethoxyphenylboronic acid (63.7 mg, 0.267 mmol, 1.5 equiv) in dioxane (4 mL) and H₂O (0.4 mL) was added 052003 (115.8 mg, 0.355 mmol, 2 equiv) and RuPhos Palladacycle Gen.4 (15.1 mg, 0.018 mmol, 0.1 equiv). The resulting solution was stirred at room temperature for 2 hours (under N₂ atmosphere). The mixture was diluted with EtOAc (20 mL) and washed with water (30 mL×3). The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by chromatography on silica gel eluted with DCM/MeOH (from 20:1 to 10:1) to give tert-butyl 4-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido)-3,3-difluoropiperidine-1-carboxylate (66 mg, 59.82%) as an off-white solid. LCMS (ESI) m/z: [M+H]+=621.

Preparation of N-(3,3-difluoropiperidin-4-yl)-7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide (i-58)

To a solution of tert-butyl 4-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-amido)-3,3-difluoropiperidine-1-carboxylate (66.0 mg, 0.106 mmol, 1.00 equiv) in DCM (9.00 mL) was added TFA (3 mL, 40.389 mmol, 379.85 equiv). The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to afford N-(3,3-difluoropiperidin-4-yl)-7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide (66 mg, crude) as a yellow solid that was used directly without further purification. LCMS (ESI) m/z: [M+H]+=521.

Preparation of 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide (i-59)

To a stirred mixture of 7-bromo-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxylic acid (200.00 mg, 0.694 mmol, 1.00 equiv) and 1-methylpiperidin-4-amine (118.90 mg, 1.041 mmol, 1.50 equiv) in DMF (2.00 mL) was added HATU (527.88 mg, 1.388 mmol, 2 equiv) at 0° C. After 10 minutes, DIEA (358.86 mg, 2.777 mmol, 4.00 equiv) was added, and the reaction mixture was stirred for 10 minutes at 0° C. The mixture was allowed to stirred one hour at room temperature. The resulting mixture was extracted with the mixture of DCM and isopropanol (3:1; 3×100 mL), concentrated, and purified by silica gel column chromatography, eluted with DCM/MeOH (10:1) to afford 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide (232 mg, 82.10%) as a yellow solid. LCMS (ESI) m/z: [M+H]⁺=384.

Preparation of 7-(4-formyl-3,5-dimethoxyphenyl)-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide (i-60)

To a stirred mixture of 7-bromo-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide (232.00 mg, 0.604 mmol, 1.00 equiv) and 4-formyl-3,5-dimethoxyphenylboronic acid (190.16 mg, 0.906 mmol, 1.50 equiv) in dioxane (4.00 mL) and H₂O (0.80 mL) was added Pd(dppf)Cl₂.CH₂Cl₂ (49.30 mg, 0.060 mmol, 0.10 equiv) and Cs₂CO₃ (590.10 mg, 1.811 mmol, 3.00 equiv). The mixture was allowed to stir at 80° C. under nitrogen atmosphere for 3 hours. The resulting mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH (10:1) to afford 7-(4-formyl-3,5-dimethoxyphenyl)-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide (131 mg, 43.67%) as a yellow solid. LCMS (ESI) m/z: [M+H]⁺=470.

Preparation of tert-butyl 2-[[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7-yl]phenyl)methyl]methyl)amino]acetate (i-61)

To a stirred mixture of 7-(4-formyl-3,5-dimethoxyphenyl)-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide (131.00 mg, 0.279 mmol, 1.00 equiv) and tert-butyl 2-(methylamino)acetate hydrochloride (60.82 mg, 0.335 mmol, 1.20 equiv) in MeOH (1.50 mL) was added TEA (84.69 mg, 0.837 mmol, 3.00 equiv) at room temperature. After 30 minutes, NaBH₃CN (52.60 mg, 0.837 mmol, 3.00 equiv) was added at room temperature. After 3 hours, the reaction mixture was purified by silica gel column chromatography, eluted with DCM/MeOH (20:1) to afford tert-butyl 2-[[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7-yl]phenyl)methyl] (methyl)amino]acetate (84 mg, 50.28%) as a yellow solid. LCMS (ESI) m/z: [M+H]⁺=599.

Preparation of [[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7-yl]phenyl)methyl]methyl)amino] trifluoroacetic Acid (i-62)

To a stirred mixture of tert-butyl 2-[[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7-yl]phenyl)methyl](methyl)amino]acetate (84.00 mg, 0.140 mmol, 1.00 equiv) in DCM (4.00 mL) was added TFA (1.00 mL) dropwise at room temperature and stirred for one hour at room temperature. The resulting mixture was concentrated under vacuum. This resulted in [[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7yl]phenyl) methyl](methyl) amino] trifluoroacetic acid (101 mg, 96.48%) as a yellow crude solid. LCMS (ESI) m/z: [M+H]⁺=543.

Example 18—Preparation of N-[7-(4-[[([[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]ethoxy)ethyl]carbamoyl]methyl)(methyl)amino]methyl]-3,5-dimethoxyphenyl)-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide Formic Acid (Compound D1 Formic Acid)

To a solution of [([2,6-dimethoxy-4-[5-methyl-2-(1-methylpiperidine-4-amido)-4-oxothieno[3,2-c]pyridin-7-yl]phenyl]methyl)(methyl)amino]acetic acid (50.0 mg, 0.092 mmol, 1.00 equiv) and HATU (70.1 mg, 0.184 mmol, 2.00 equiv) in DMF (2.00 mL) was added 4-[2-(2-aminoethoxy)ethoxy]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (33.3 mg, 0.092 mmol, 1.00 equiv) and DIEA (35.7 mg, 0.276 mmol, 3.00 equiv). The resulting solution was stirred at 25° C. for 2 hours. The crude product was purified by preparative HPLC (conditions: XSelect CSH Prep C18 OBD Column, 5 μm, 19*150 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 20% B to 55% B in 8 minutes; 254 nm; R_(T): 7.12 minutes) to afford N-[7-(4-[[([[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]ethoxy)ethyl]carbamoyl]methyl)(methyl)amino]methyl]-3,5-dimethoxyphenyl)-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl]-1-methylpiperidine-4-carboxamide formic acid (7 mg, 8.6%) of as a yellow solid. ¹H NMR (300 MHz, Methanol-d4) δ 8.40 (br s, 0.4H, FA), 7.64-7.53 (m, 2H), 7.25 (d, J=7.2 Hz, 1H), 7.20-7.09 (m, 2H), 6.97 (s, 2H), 5.07 (dd, J=12.9, 5.3 Hz, 1H), 4.29 (s, 2H), 4.07-3.90 (m, 8H), 3.73 (s, 4H), 3.63-3.48 (m, 7H), 3.46-3.38 (m, 2H), 3.18-3.02 (m, 2H), 2.91-2.72 (m, 9H), 2.64-2.47 (m, 1H), 2.25-1.98 (m, 5H). LCMS (ESI) m/z: [M+H]+=886.80.

The following compound (compound D2) was prepared in a similar manner as described for compound D1.

2-(4-[2-[N-(1,1-dioxo-A6-thian-4-yl) carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-methoxyphenoxy)-N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)acetamide (14 mg, 16%) as a yellow solid. ¹H NMR (300 MHz, Methanol-d4) δ 8.54 (s, 0.4H, FA), 8.21 (s, 1H), 7.74 (s, 1H), 7.34-7.16 (m, 3H), 7.13 (d, J=8.3 Hz, 1H), 7.02 (d, J=7.5 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 5.16 (dd, J=13.3, 5.1 Hz, 1H), 4.59 (d, J=5.2 Hz, 3H), 4.28 (d, J=3.0 Hz, 2H), 3.96 (s, 3H), 3.73 (s, 3H), 3.29-3.10 (m, 4H), 3.03-2.79 (m, 3H), 2.51 (td, J=13.2, 5.0 Hz, 1H), 2.32-2.15 (m, 5H), 1.61 (dd, J=15.5, 7.3 Hz, 4H), 1.36 (s, 8H). LCMS (ESI) m/z: [M+H]+=888.30.

Example 19—Preparation of 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)-N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)acetamide (Compound D3)

To a solution of 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)acetic acid (69 mg, 0.124 mmol, 1 equiv) and DIEA (N,N-diisopropylamine) (48 mg, 0.371 mmol, 3 equiv) in DMF (1 mL) was added PyBOP (96.6 mg, 0.186 mmol, 1.5 equiv) and 4-[(8-aminooctyl)amino]-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione (49.6 mg, 0.124 mmol, 1 equiv). The resulting solution was stirred at room temperature for overnight. Without workup, the crude product (69 mg) was purified by Prep-HPLC (conditions: SunFire Prep 018 OBD Column 19×150 mm 5 μm 10 nm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 25% B to 55% B in 8 minutes; 254 nm; R_(T): 7.35 minutes) to afford 2-(4-[2-[N-(1,1-dioxo-1λ6-thian-4-yl)carbamimidoyl]-5-methyl-4-oxo-4H,5H-thieno[3,2-c]pyridin-7-yl]-2-(trifluoromethyl)phenoxy)-N-(8-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino]octyl)acetamide (30 mg, 25%) as a yellow solid. ¹H NMR (300 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.23 (s, 1H), 8.14 (s, 0.26H, FA), 7.94-7.78 (m, 4H), 7.62-7.50 (m, 1H), 7.30 (d, J=8.8 Hz, 1H), 7.03 (dd, J=13.8, 7.8 Hz, 2H), 6.51 (t, J=5.9 Hz, 1H), 5.05 (dd, J=12.8, 5.3 Hz, 1H), 4.74 (s, 2H), 3.69 (s, 1H), 3.58 (s, 3H), 3.26 (d, J=6.6 Hz, 2H), 3.20-3.09 (m, 5H), 3.12-2.96 (m, 1H), 2.98-2.79 (m, 1H), 2.61 (s, 1H), 2.03 (s, 4H), 1.79-1.68 (m, 1H), 1.55-1.45 (m, 4H), 1.30 (s, 8H). LCMS (ESI) m/z: [M+H]+=940.50.

Example 20—Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-[3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy]propanoyl]piperidine-4-carboxamide Formic Acid (Compound D4)

To a solution of 3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy]propanoic acid (39.4 mg, 0.091 mmol, 1.1 equiv), HOBt (22.3 mg, 0.165 mmol, 2 equiv), and EDCI (31.7 mg, 0.165 mmol, 2 equiv) in DMF (1 mL) was added N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-4-carboxamide (40.0 mg, 0.083 mmol, 1.00 equiv) and DIEA (53.4 mg, 0.413 mmol, 5 equiv), and the resulting solution was stirred at 25° C. for 2 hours. Without any additional work-up, the mixture was purified by Prep-HPLC (conditions: SunFire 018 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate:25 mL/minute; Gradient:11 B to 26 B in 13 minutes; 254 nm) to give N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-[3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy]propanoyl]piperidine-4-carboxamide formic acid (22.3 mg, 29%). ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (br s, 0.8H, FA), 7.64 (s, 1H), 7.47-7.41 (m, 1H), 7.15 (d, J=2.2 Hz, 1H), 7.03-6.98 (m, 3H), 6.95 (d, J=7.2 Hz, 1H), 5.02 (dd, J=12.7, 5.4 Hz, 1H), 4.59 (d, J=13.3 Hz, 1H), 4.28 (s, 2H), 4.13 (d, J=13.9 Hz, 1H), 3.99 (s, 6H), 3.81-3.66 (m, 9H), 3.65-3.61 (m, 2H), 3.52-3.44 (m, 2H), 3.23-3.14 (m, 1H), 2.88-2.79 (m, 8H), 2.77-2.60 (m, 4H), 2.55-2.46 (m, 1H), 2.11-2.01 (m, 1H), 1.95-1.74 (m, 3H), 1.73-1.60 (m, 1H). LCMS (ESI) m/z: [M+H]+=900.50.

Example 21—Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-[3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy]propanoyl]piperidine-3-carboxamide (Compound D5)

To a stirred solution of 3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy] propanoic acid (53.66 mg, 0.124 mmol, 1.20 equiv) in DMF (1.00 mL) was added HOBT (27.88 mg, 0.206 mmol, 2.00 equiv) and EDCI (39.56 mg, 0.206 mmol, 2.00 equiv) at 25° C. The resulting mixture was stirred for 20 minutes at 25° C. Then N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-3-carboxamide (50.00 mg, 0.103 mmol, 1.00 equiv) and DIEA (40.00 mg, 0.310 mmol, 3.00 equiv) was added to the reaction mixture. The resulting mixture was stirred for 2 hours at room temperature. The crude product was purified by Prep-HPLC (conditions: SunFire 018 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; mobile phase, Water (0.1% FA) and ACN (11% Phase B up to 23% in 18 minutes); Detector, UV) to afford N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-[3-[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy)ethoxy]propanoyl]piperidin e-3-carboxamide (12 mg, 13%) as a green solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (brs, 0.8H, FA), 7.66-7.58 (m, 1H), 7.57-7.25 (m, 1H), 7.19-7.06 (m, 1H), 7.05-6.95 (m, 3H), 6.86-6.76 (m, 1H), 5.04 (dd, J=12.5, 5.4 Hz, 1H), 4.53-4.40 (m, 1H), 4.37-4.24 (m, 0.5H), 4.20 (d, J=7.0 Hz, 2H), 4.03-3.98 (m, 6H), 3.95-3.88 (m, 0.5H), 3.81-3.62 (m, 11H), 3.52-3.48 (m, 1H), 3.45-3.36 (m, 1.5H), 3.21-3.12 (m, 0.5H), 3.06-2.92 (m, 1H), 2.87-2.63 (m, 11H), 2.61-2.53 (m, 1H), 2.25-1.98 (m, 2H), 1.86-1.73 (m, 2H), 1.69-1.46 (m, 1H). LCMS (ESI) m/z: [M+H]+=900.50.

Example 22—Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl)piperidine-4-carboxamide Formic Acid (Compound D6 Formic Acid)

To a solution of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-4-carboxamide (30.0 mg, 0.062 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanal (24.4 mg, 0.068 mmol, 1.10 equiv) in DMF (1.00 mL) was added sodium triacetoxyborohydride (26.2 mg, 0.124 mmol, 2.00 equiv), and the resulting solution was stirred at room temperature for 2 hours. Without any additional work-up, the mixture was purified by Prep-HPLC (conditions: Xselect CSH F-Phenyl OBD column, 19*250, 5 μm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient:7 B to 19 B in 12 minutes; 254/220 nm) to give N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl)piperidine-4-carboxamide; formic acid (4.7 mg, 8.7%). ¹H NMR (400 MHz, Methanol-d4) δ 8.55 (br s, 1.1H, FA), 7.67 (s, 1H), 7.63-7.57 (m, 1H), 7.29 (d, J=7.1 Hz, 1H), 7.21 (s, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.05 (s, 2H), 5.13 (dd, J=12.9, 5.5 Hz, 1H), 4.38 (s, 2H), 4.02 (s, 6H), 3.85 (t, J=7.0 Hz, 2H), 3.74 (s, 3H), 3.39-3.35 (m, 2H), 2.93-2.87 (m, 8H), 2.78 (s, 2H), 2.71-2.56 (m, 4H), 2.15-2.08 (m, 1H), 2.05-1.92 (m, 4H), 1.77-1.60 (m, 4H), 1.44-1.34 (m, 2H). LCMS (ESI) m/z: [M+H]+=827.50.

Compound D11 was prepared in a similar manner as described for compound D6.

7-(4-((dimethylamino)methyl)-3,5-dimethoxyphenyl)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-4-yl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide trifluoroacetic acid (12.8 mg, 26%) as a white solid. ¹H NMR (300 MHz, Methanol-d4) δ 8.25 (s, 1H), 7.87 (s, 1H), 7.67 (t, J=7.8 Hz, 1H), 7.39 (d, J=7.2 Hz, 1H), 7.23 (d, J=8.4 Hz, 1H), 7.06 (s, 2H), 5.16 (dd, J=12.8, 5.4 Hz, 1H), 4.42 (s, 2H), 4.24-4.10 (m, 1H), 4.02 (s, 6H), 3.88 (t, J=6.8 Hz, 2H), 3.75 (s, 3H), 3.69 (s, 2H), 3.25-3.06 (m, 4H), 2.96-2.87 (m, 8H), 2.77-2.60 (m, 1H), 2.31-2.14 (m, 3H), 2.01-1.88 (m, 2H), 1.86-1.62 (m, 4H), 1.51-1.39 (m, 2H). LCMS (ESI) m/z: [M+H]⁺=827.40.

Example 23—Preparation of (3R) and (3S) N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo thieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoyl)piperidine-3-carboxamide (Compounds D7 and D8)

To a stirred solution of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-3-carboxamide (50.00 mg, 0.103 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoic acid (46.35 mg, 0.124 mmol, 1.20 equiv) in DMF (1 mL) was added DIEA (26.67 mg, 0.206 mmol, 2.00 equiv) dropwise at room temperature. The resulting mixture was stirred for 15 minutes at room temperature. Then HATU (58.84 mg, 0.155 mmol, 1.50 equiv) was added to the reaction mixture. The resulting mixture was stirred for 1 hour at room temperature. The crude products were purified by Prep-HPLC (conditions: SunFire C18 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; mobile phase, Water (0.1% FA) and ACN (7% Phase B up to 21% in 12 minutes); Detector, UV).

(3R)—N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoyl)piperidine-3-carboxamide (9.7 mg, 11%) as a white semi-solid. ¹H NMR (400 MHz, Methanol-d4) δ 7.78-7.61 (m, 2H), 7.42 (dd, J=8.0, 2.5 Hz, 1H), 7.34 (d, J=8.5 Hz, 0.5H), 7.23 (d, J=7.2 Hz, 0.5H), 7.18 (s, 0.5H), 7.06 (s, 0.5H), 7.04 (d, J=2.3 Hz, 2H), 5.10-4.92 (m, 1H), 4.41 (d, J=5.1 Hz, 2H), 4.31-4.18 (m, 3H), 4.14 (d, J=12.6 Hz, 0.5H), 4.03 (d, J=2.8 Hz, 6H), 3.89 (d, J=14.1 Hz, 0.5H), 3.73 (d, J=5.0 Hz, 3H), 3.52-3.43 (m, 1H), 3.26-3.14 (m, 1H), 2.92 (d, J=4.2 Hz, 6H), 2.78-2.55 (m, 6H), 2.13-1.99 (m, 2H), 1.97-1.84 (m, 6H), 1.68-1.47 (m, 1H). LCMS (ESI) m/z: [M+H]+=841.32.

(3S)—N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoyl)piperidine-3-carboxamide (11.3 mg, 13%) as a white semi-solid. ¹H NMR (300 MHz, Methanol-d4) δ 7.79-7.71 (m, 0.5H), 7.64 (s, 1H), 7.60 (d, J=7.9 Hz, 0.5H), 7.43 (d, J=7.8 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.19 (s, 0.5H), 7.05 (s, 2H), 7.04 (s, 0.5H), 6.92 (s, 0.5H), 5.12-5.08 (m, 0.5H), 4.96-4.92 (m, 0.5H), 4.42 (d, J=4.5 Hz, 2H), 4.35-4.22 (m, 3H), 4.21-4.14 (m, 0.5H), 4.03 (s, 6H), 3.96-3.88 (m, 0.5H), 3.74 (d, J=5.8 Hz, 3H), 3.43-3.40 (m, 1H), 3.24-3.09 (m, 1H), 2.92 (s, 6H), 2.88-2.49 (m, 6H), 2.16-2.00 (m, 2H), 1.99-1.76 (m, 6H), 1.69-1.42 (m, 1H). LCMS (ESI) m/z: [M+H]+=841.32.

Example 24—Preparation of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl)piperidine-3-carboxamide (Compound D9)

A solution of N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)piperidine-3-carboxamide (30.00 mg, 0.062 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanal (26.62 mg, 0.074 mmol, 1.20 equiv) in DMF (1.5 mL) was stirred for 20 minutes at room temperature. Then NaBH₃CN (7.78 mg, 0.124 mmol, 2.00 equiv) was added to the reaction mixture. The resulting mixture was stirred for 2 hours at room temperature. The crude product was purified by Prep-HPLC (conditions: SunFire 018 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; mobile phase, Water (0.1% FA) and ACN (7% Phase B up to 21% in 12 minutes); Detector, UV). This resulted in N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl) piperidine-3-carboxamide (5.2 mg, 10%) as a red semi-solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.45 (brs, 0.2H, FA), 7.66 (d, J=5.8 Hz, 1H), 7.62-7.55 (m, 1H), 7.33-7.12 (m, 3H), 7.04 (d, J=2.0 Hz, 2H), 5.14-5.04 (m, 1H), 4.41 (s, 2H), 4.01 (d, J=5.8 Hz, 6H), 3.86 (d, J=7.5 Hz, 2H), 3.74 (s, 3H), 3.31-3.12 (m, 3H), 3.04-2.95 (m, 3H), 2.91 (s, 6H), 2.89-2.82 (m, 2H), 2.73-2.60 (m, 1H), 2.10-1.93 (m, 3H), 1.90-1.73 (m, 4H), 1.66 (t, J=7.1 Hz, 2H), 1.48-1.38 (m, 2H). LCMS (ESI) m/z: [M+H]⁺=827.80.

Example 25—Preparation of 7-(4-((dimethylamino)methyl)-3,5-dimethoxyphenyl)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentanoyl)piperidin-4-yl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide Formic Acid (Compound D10 Formic Acid)

Into a stirred mixture of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxo-N-(piperidin-4-yl)thieno[3,2-c]pyridine-2-carboxamide (25.0 mg, 0.052 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoic acid (19.3 mg, 0.052 mmol, 1.00 equiv) in DMF (0.50 mL) was added HATU (49.0 mg, 0.129 mmol, 2.50 equiv) at 0° C. under nitrogen atmosphere. After 10 minutes, to the above mixture was added DIEA (33.3 mg, 0.258 mmol, 5.00 equiv) at 0° C. under nitrogen atmosphere and stirred for 10 minutes. Then the mixture was allowed to stir at room temperature for 2 hours. The crude product was purified by Prep-HPLC (conditions: Sunfire C18 OBD Prep Column, 100A, 5 μm, 19 mm*250 mm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 12% B to 35% B in 15 minutes; 254/220 nm; R_(T): 11.34 minutes). This resulted in 7-(4-((dimethylamino)methyl)-3,5-dimethoxyphenyl)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentanoyl)piperidin-4-yl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide; formic acid (7.8 mg, 17%) as a white solid. ¹H NMR (300 MHz, Methanol-d4) δ 8.56 (br s, 0.9H, FA), 8.23 (s, 1H), 7.84 (s, 1H), 7.83-7.76 (m, 1H), 7.47 (d, J=8.8 Hz, 2H), 7.06 (s, 2H), 5.14-5.05 (m, 1H), 4.61-4.52 (m, 1H), 4.36-4.27 (m, 4H), 4.16-4.05 (m, 2H), 4.01 (s, 6H), 3.74 (s, 3H), 2.85 (s, 7H), 2.81-2.73 (m, 3H), 2.69-2.59 (m, 3H), 2.14-2.06 (m, 1H), 2.04-1.87 (m, 6H), 1.66-1.47 (m, 2H). LCMS (ESI) m/z: [M+H]⁺=841.50.

Compound D12 was prepared in a similar manner as described in compound D10.

N-(7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridin-2-yl)-1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanoyl)piperidine-4 carboxamide formic acid (8.2 mg, 15%) as a light yellow solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (brs, 0.7H, FA), 7.79 (dd, J=8.6, 7.3 Hz, 1H), 7.64 (s, 1H), 7.45 (dd, J=7.6, 3.3 Hz, 2H), 7.20 (d, J=3.1 Hz, 1H), 7.03 (s, 2H), 5.10-5.04 (m, 1H), 4.62-4.56 (m, 1H), 4.32-4.23 (m, 4H), 4.16-4.08 (m, 1H), 4.00 (s, 6H), 3.74 (s, 3H), 3.23-3.15 (m, 1H), 2.79 (s, 6H), 2.76-2.59 (m, 6H), 2.15-2.07 (m, 1H), 1.99-1.84 (m, 7H), 1.81-1.58 (m, 2H). LCMS (ESI) m/z: [M+H]+=841.35.

Example 26—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-N-[1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl)-3,3-difluoropiperidin-4-yl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide Formic Acid (Compound D13 Formic Acid)

To a solution of N-(3,3-difluoropiperidin-4-yl)-7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide (40.0 mg, 0.077 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentanal (30.29 mg, 0.085 mmol, 1.1 equiv) in DMF (1 mL) was added NaBH(AcO)₃ (32.6 mg, 0.154 mmol, 2 equiv). The resulting solution was stirred at room temperature for 2 hours. Without any additional work-up, the mixture was purified by Prep-HPLC (conditions: SunFire 018 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; Mobile Phase A: Water (0.05% FA), Mobile Phase B: ACN; Flow rate:25 mL/minute; Gradient:13 B to 25 B in 10 minutes; 254 nm) to afford 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-N-[1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]pentyl)-3,3-difluoropiperidin-4-yl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide formic acid (20.9 mg, 29.78%) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.87 (d, J=8.8 Hz, 1H), 8.59 (s, 1H), 8.15 (s, 0.3H, FA), 7.97 (s, 1H), 7.82 (t, J=7.9 Hz, 1H), 7.54 (d, J=8.6 Hz, 1H), 7.45 (d, J=7.3 Hz, 1H), 6.96 (s, 2H), 5.09 (dd, J=12.9, 5.4 Hz, 1H), 4.38-4.20 (m, 3H), 3.88 (s, 6H), 3.79 (s, 2H), 3.63 (s, 3H), 3.15 (s, 1H), 2.96-2.83 (m, 2H), 2.70-2.56 (m, 3H), 2.41 (s, 8H), 2.19 (t, J=11.4 Hz, 1H), 2.08-2.00 (m, 1H), 1.92-1.73 (m, 4H), 1.58-1.43 (m, 4H). LCMS (ESI) m/z: [M+H]+=863.35.

Example 27—Preparation of 7-(4-[[([[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4 yl]oxy]ethoxy)ethyl] carbamoyl]methyl)(methyl)amino]methyl]-3,5-dimethoxyphenyl)-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno[3,2-c]pyridine-2-carboxamide Formic Acid (Compound D14 Formic Acid)

To a stirred mixture of [[(2,6-dimethoxy-4-[5-methyl-2-[(1-methylpiperidin-4-yl)carbamoyl]-4-oxothieno[3,2-c]pyridin-7-yl]phenyl)methyl](methyl)amino]acetic acid (50.00 mg, 0.076 mmol, 1.00 equiv) and 4-[2-(2-aminoethoxy)ethoxy]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione trifluoroacetic acid (36.20 mg, 0.076 mmol, 1.00 equiv) in DMF (1.00 mL) was added HATU (72.38 mg, 0.190 mmol, 2.50 equiv) at 0° C. under atmosphere. After 10 minutes, DIEA (49.20 mg, 0.381 mmol, 5.00 equiv) was added at 0° C. under nitrogen atmosphere, and the reaction mixture was then stirred for 10 minutes. Then the mixture was allowed to stir at room temperature for 3 hours. The crude product (0.1% TA) was concentrated, purified by Prep-TLC (DCM/MeOH=10:1) to afford crude product. Then the crude product was purified by Prep-HPLC (conditions: Sunfire C18 OBD Prep Column, 100 Å, 5 μm, 19 mm*250 mm; Mobile Phase A: Water (0.05% FA), Mobile Phase B: ACN; Flow rate: 25 mL/minute; Gradient: 12 B to 35 B in 12 minutes; 254 nm; R_(T): 11.68 minutes). This resulted in 7-(4-[[([[2-(2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxy]ethoxy)ethyl]carbamoyl]methyl)(methyl)amino]methyl]-3,5-dimethoxyphenyl)-5-methyl-N-(1-methylpiperidin-4-yl)-4-oxothieno [3,2-c]pyridine-2-carboxamide formic acid (3.0 mg, 7.96%) as a white solid. ¹H NMR (400 MHz, Methanol-d4) δ 8.45 (s, 1.0H, FA), 8.21 (s, 1H), 7.78 (s, 1H), 7.64 (dd, J=8.6, 7.2 Hz, 1H), 7.33 (dd, J=7.8, 2.1 Hz, 2H), 6.88 (s, 2H), 5.07 (dd, J=12.7, 5.5 Hz, 1H), 4.32-4.26 (m, 2H), 4.17-4.08 (m, 1H), 4.02 (s, 2H), 3.92 (s, 6H), 3.90-3.86 (m, 2H), 3.73 (s, 3H), 3.69 (t, J=5.2 Hz, 2H), 3.54-3.43 (m, 6H), 3.09 (t, J=12.2 Hz, 2H), 2.91-2.80 (m, 4H), 2.78-2.61 (m, 2H), 2.56 (s, 3H), 2.27-2.18 (m, 2H), 2.14-2.06 (m, 1H), 2.02-1.89 (m, 2H). LCMS (ESI) m/z: [M+H]⁺=886.20.

Example 28—Preparation of 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-N-[1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy]pentyl)-3,3-difluoropiperidin-4-yl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide Formic Acid (Compound D15 Formic Acid)

To a solution of N-(3,3-difluoropiperidin-4-yl)-7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide (40.0 mg, 0.077 mmol, 1.00 equiv) and 5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy]pentanal (30.3 mg, 0.085 mmol, 1.1 equiv) in DMF (1 mL) was added NaBH(AcO)₃ (32.6 mg, 0.154 mmol, 2 equiv). The resulting solution was stirred at room temperature for 2 hours. Without any additional work-up, the mixture was purified by Prep-HPLC (conditions: SunFire 018 OBD Prep Column, 100 Å, 5 μm, 19 mm×250 mm; Mobile Phase A: Water (0.05% FA), Mobile Phase B:ACN; Flow rate:25 mL/minute; Gradient:15 B to 25 B in 12 minutes; 254 nm) to afford 7-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-N-[1-(5-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxy]pentyl)-3,3-difluoropiperidin-4-yl]-5-methyl-4-oxothieno[3,2-c]pyridine-2-carboxamide formic acid (14 mg, 19.81%) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 8.88 (d, J=8.8 Hz, 1H), 8.60 (s, 1H), 8.15 (s, 0.3H, FA), 7.98 (s, 1H), 7.84 (d, J=8.3 Hz, 1H), 7.44 (d, J=2.3 Hz, 1H), 7.36 (dd, J=8.3, 2.3 Hz, 1H), 6.97 (s, 2H), 6.53 (s, 0.3H, FA salt), 5.13 (dd, J=12.9, 5.3 Hz, 1H), 4.35 (s, 1H), 4.20 (t, J=6.5 Hz, 2H), 3.88 (s, 6H), 3.82 (s, 2H), 3.63 (s, 3H), 3.15 (s, 1H), 2.95-2.84 (m, 2H), 2.65-2.55 (m, 3H), 2.44 (s, 8H), 2.18 (t, J=11.3 Hz, 1H), 2.10-2.01 (m, 1H), 1.91-1.74 (m, 4H), 1.57-1.41 (m, 4H). LCMS (ESI) m/z: [M+H]+=863.35.

Example 29—Preparation of Compounds D16-D90

In analogy to the procedures described in the examples above, compounds D16-D90 were prepared using the appropriate starting materials

Compound No. LCMS ¹H NMR D16 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.87 (d, J = 8.8 Hz, [M + H]+ = 863.35 1H), 8.59 (s, 1H), 8.15 (s, 0.3H, FA), 7.97 (s, 1H), 7.82 (t, J = 7.9 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.45 (d, J = 7.3 Hz, 1H), 6.96 (s, 2H), 5.09 (dd, J = 12.9, 5.4 Hz, 1H), 4.38-4.20 (m, 3H), 3.88 (s, 6H), 3.79 (s, 2H), 3.63 (s, 3H), 3.15 (s, 1H), 2.96-2.83 (m, 2H), 2.70-2.56 (m, 3H), 2.41 (s, 8H), 2.19 (t, J = 11.4 Hz, 1H), 2.08- 2.00 (m, 1H), 1.92-1.73 (m, 4H), 1.58-1.43 (m, 4H). D17 879.15 ¹H NMR (300 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.89 (d, J = 8.8 Hz, 1H), 8.60 (s, 1H), 8.17 (s, 2H, FA), 8.01 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 7.25 (d, J = 1.7 Hz, 1H), 7.07 (d, J = 7.6 Hz, 2H), 5.15-4.95 (m, 1H), 4.47-4.14 (m, 3H), 3.89 (s, 3H), 3.62 (s, 3H), 3.59-3.52 (m, 2H), 3.33-3.14 (m, 4H), 3.03- 2.79 (m, 3H), 2.69-2.54 (m, 8H), 2.46-2.26 (m, 3H), 2.25-2.16 (m, 7H), 2.05-1.90 (m, 1H), 1.90-1.69 (m, 2H). D18 929.25 ¹H NMR (300 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.95 (d, J = 9.0 Hz, 1H), 8.62 (d, J = 13.0 Hz, 1H), 8.14 (s, 0.47H, FA), 8.00 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.00 (s, 2H), 6.56-6.45 (m, 2H), 5.04 (dd, J = 13.2, 5.1 Hz, 1H), 4.62 (s, 2H), 4.31 (d, J = 16.9 Hz, 1H), 4.18 (d, J = 17.0 Hz, 2H), 4.00 (s, 2H), 3.90 (s, 6H), 3.65 (d, J = 9.8 Hz, 7H), 3.22 (dd, J = 15.8, 3.3 Hz, 2H), 3.01-2.84 (m, 3H), 2.64-2.53 (m, 6H), 2.44-2.31 (m, 5H), 2.02-1.88 (m, 3H), 1.88- 1.66 (m, 4H). D19 915.25 ¹H NMR (300 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.98 (s, 1H, TFA salt), 8.92 (d, J = 8.8 Hz, 1H), 8.61 (s, 1H), 8.02 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.03 (s, 2H), 6.56-6.48 (m, 2H), 5.05 (dd, J = 13.1, 5.0 Hz, 1H), 4.50-4.10 (m, 7H), 3.93 (s, 6H), 3.74 (s, 4H), 3.64 (s, 3H), 3.04-2.84 (m, 4H), 2.81-2.76 (m, 8H), 2.69-2.55 (m, 5H), 2.40-2.30 (m, 2H), 2.12-1.94 (m, 5H), 1.91-1.75 (m, 2H). D20 752.2  ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.63 (s, 1H), 8.23 (s, 2H, FA), 8.14 (s, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.14 (s, 2H), 6.72-6.64 (m, 2H), 5.13-5.04 (m, 1H), 4.31 (d, J = 16.6 Hz, 1H), 4.18 (d, J = 16.6 Hz, 1H), 3.86 (s, 6H), 3.81 (s, 2H), 3.68 (s, 3H), 3.56 (s, 6H), 3.17 (s, 2H), 2.91 (m, J = 17.7, 13.4, 5.4 Hz, 1H), 2.59 (d, J = 17.0 Hz, 2H), 2.45 (d, J = 6.9 Hz, 2H), 2.40-2.22 (m, 5H), 2.04-1.93 (m, 1H), 1.72 (t, J = 5.4 Hz, 4H). D21 734.34 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.87 (d, J = 53.7 Hz, 2H, TFA), 8.26 (d, J = 2.0 Hz, 1H), 7.90 (s, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 2.1 Hz, 1H), 6.91 (d, J = 2.2 Hz, 2H), 6.70 (dd, J = 4.8, 2.4 Hz, 2H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.50- 4.28 (m, 3H), 4.20 (d, J = 17.0 Hz, 2H), 3.95 (s, 6H), 3.73 (s, 2H), 3.65 (s, 5H), 2.96 (s, 3H), 2.78 (d, J = 4.7 Hz, 2H), 2.63 (s, 2H), 2.43-2.31 (m, 1H), 2.12 (d, J = 13.6 Hz, 2H), 2.03-1.79 (m, 3H). D22 818.15 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.51 (s, 1H, TFA), 9.05 (s, 1H, TFA), 8.61 (s, 1H), 8.03 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.19-7.10 (m, 2H), 7.06 (s, 2H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.64 (s, 1H), 4.44-4.30 (m, 3H), 4.24 (d, J = 17.0 Hz, 1H), 3.99 (d, J = 12.7 Hz, 2H), 3.96 (s, 6H), 3.76 (s, 1H), 3.65 (s, 3H), 3.50 (m, 1H), 3.40 (m, 1H), 3.25 (m, 1H), 3.21 (m, 2H), 3.00- 2.70 (m, 5H), 2.69-2.55 (m, 2H), 2.45-2.29 (m, 2H), 2.09 (s, 2H), 2.03-1.93 (m, 1H). D23 854.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.36 (s, 1H), 8.30 (s, 0.3H, FA), 7.85 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 2.3 Hz, 1H), 7.33 (dd, J = 8.6, 2.3 Hz, 1H), 7.05 (s, 2H), 5.11 (dd, J = 12.5, 5.5 Hz, 1H), 4.50-4.37 (m, 1H), 4.31 (s, 2H), 4.02 (s, 6H), 3.75 (s, 3H), 3.69 (s, 4H), 3.40-3.35 (m, 2H), 3.31-3.21 (m, 2H), 3.19 (t, J = 9.9 Hz, 1H), 2.97 (d, J = 12.0 Hz, 1H), 2.89 (ddd, J = 18.3, 14.2, 5.1 Hz, 1H), 2.78 (d, J = 3.2 Hz, 1H), 2.73 (d, J = 9.9 Hz, 1H), 2.47 (dd, J = 28.7, 12.4 Hz, 1H), 2.40 (s, 3H), 2.31 (t, J = 11.7 Hz, 1H), 2.19-2.04 (m, 1H), 2.01 (dd, J = 11.9, 4.4 Hz, 1H), 1.96 (d, J = 7.4 Hz, 1H). D24 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.37 (d, J = 1.8 Hz, 1H), 7.89 [M + H]+ = 846.25 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 11.8 Hz, 2H), 7.08 (s, 2H), 5.16 (dd, J = 13.3, 5.0 Hz, 1H), 4.74 (m, 1H) 4.43 (d, J = 6.3 Hz, 4H), 4.10 (d, J = 12.5 Hz, 1H), 4.02 (s, 6H), 3.95 (d, J = 12.6 Hz, 2H), 3.87 (s, 1H), 3.76 (s, 3H), 3.53 (d, 2H), 3.22 (s, 1H), 2.92 (s, 8H), 2.89-2.74 (m, 2H), 2.60-2.42 (m, 1H), 2.21 (s, 5H), 1.90 (t, J = 11.8 Hz, 2H). D25 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.36 (s, 1H), 7.88 (s, 1H), 7.67 [M + H]⁺ = 846.25. (d, J = 9.2 Hz, 1H), 7.13-7.03 (t, 4H), 5.12 (dd, J = 13.2, 5.1 Hz, 1H), 4.75 (s, 1H), 4.52-4.33 (m, 4H), 4.12 (d, J = 12.9 Hz, 2H), 4.02 (s, 6H), 3.93 (s, 1H), 3.75 (s, 3H), 3.65-3.46 (m, 3H), 3.25 (s, 1H), 2.99 (d, J = 12.6 Hz, 2H), 2.92-2.73 (m, 7H), 2.57-2.40 (m, 1H), 2.27 (s, 1H), 2.21 (s, 5H), 1.90 (q, J = 12.2, 11.6 Hz, 2H). D26 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6, D₂O) δ 8.45 (s, 1H), 7.90 (s, 1H), [M + H]⁺ = 943.45. 7.75 (d, J = 8.5 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.31 (dd, J = 8.6, 2.3 Hz, 1H), 6.99-6.95 (m, 2H), 5.02 (dd, J = 12.8, 5.6 Hz, 1H), 4.76-4.58 (m, 1H), 4.35-4.12 (m, 4H), 3.96-3.83 (m, 7H), 3.72- 3.48 (m, 7H), 3.39 (d, J = 11.5 Hz, 2H), 3.31-3.07 (m, 7H), 2.97 (t, J = 12.3 Hz, 2H), 2.86 (s, 3H), 2.83-2.72 (m, 1H), 2.69-2.55 (m, 2H), 2.19-2.00 (m, 3H), 1.87-1.56 (m, 5H), 1.49-1.32 (m, 2H). D27 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6, D₂O) δ 8.45 (s, 1H), 7.90 (s, 1H), [M + H]⁺ = 935.55. 7.75 (d, J = 8.5 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.31 (dd, J = 8.6, 2.3 Hz, 1H), 6.99-6.95 (m, 2H), 5.02 (dd, J = 12.8, 5.6 Hz, 1H), 4.76-4.58 (m, 1H), 4.35-4.12 (m, 4H), 3.96-3.83 (m, 7H), 3.72- 3.48 (m, 7H), 3.39 (d, J = 11.5 Hz, 2H), 3.31-3.07 (m, 7H), 2.97 (t, J = 12.3 Hz, 2H), 2.86 (s, 3H), 2.83-2.72 (m, 1H), 2.69-2.55 (m, 2H), 2.19-2.00 (m, 3H), 1.87-1.56 (m, 5H), 1.49-1.32 (m, 2H). D28 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.58 (s, 1H, FA), 8.35 (s, 1H), [M + H]⁺ = 875.50. 7.85-7.78 (m, 2H), 7.42 (d, J = 2.2 Hz, 1H), 7.33 (dd, J = 8.3, 2.3 Hz, 1H), 7.02 (s, 2H), 5.12 (dd, J = 12.2, 5.4 Hz, 1H), 4.52-4.39 (m, 1H), 4.36 (s, 2H), 4.20 (t, J = 6.3 Hz, 2H), 4.06 (t, J = 8.0 Hz, 4H), 4.00 (s, 6H), 3.74 (s, 3H), 3.26-3.18 (m, 1H), 3.07-2.97 (m, 1H), 2.89-2.69 (m, 3H), 2.59-2.36 (m, 5H), 2.34-2.23 (m, 1H), 2.20-2.07 (m, 1H), 2.02-1.85 (m, 4H), 1.69-1.54 (m, 4H). D29 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.52 (s, 2H, FA), 8.22 (s, 1H), [M + H]⁺ = 853.45. 7.86-7.76 (m, 2H), 7.46 (dd, J = 8.3, 2.4 Hz, 2H), 7.05 (s, 2H), 5.09 (dd, J = 12.5, 5.2 Hz, 1H), 4.55 (d, J = 13.7 Hz, 1H), 4.48 (s, 2H), 4.34-4.26 (m, 2H), 4.20 (t, J = 8.2 Hz, 4H), 4.14-4.05 (m, 2H), 4.02 (s, 6H), 3.74 (s, 3H), 3.29-3.18 (m, 1H), 2.86-2.60 (m, 6H), 2.58-2.46 (m, 2H), 2.14-1.87 (m, 7H), 1.69-1.44 (m, 2H). D30 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6 with a drop of D2O) δ 9.07 (d, J = [M + H]⁺ = 922.35 8.5 Hz, 1H, FA salt), 8.49 (s, 1H), 7.91 (s, 1H), 7.76 (dd, J = 8.5, 7.3 Hz, 1H), 7.42 (dd, J = 11.9, 7.9 Hz, 2H), 6.92 (s, 2H), 5.01 (dd, J = 12.8, 5.5 Hz, 1H), 4.53 (br s, 1H), 4.28 (s, 4H), 3.85-3.31 (m, 6H), 3.78 (s, 4H), 3.60 (s, 3H), 3.55 (d, J = 5.6 Hz, 2H), 3.35- 3.21 (m, 3H), 2.87-2.55 (m, 10H), 2.48-2.40 (m, 2H), 2.09- 1.93 (m, 3H). D31 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.27 (s, 1H), 8.14 [M + H]⁺ = 925.15. (s, 0.4H, FA), 7.98 (dd, J = 5.3, 3.5 Hz, 2H), 7.96-7.86 (m, 2H), 7.79 (d, J = 7.0 Hz, 2H), 7.56 (dd, J = 8.6, 7.1 Hz, 1H), 7.03 (dd, J = 13.0, 7.8 Hz, 2H), 6.86 (s, 1H), 6.48 (t, J = 5.9 Hz, 1H), 5.05 (dd, J = 12.7, 5.4 Hz, 1H), 3.85 (s, 2H), 3.71 (d, J = 16.7 Hz, 1H), 3.60 (s, 3H), 3.52-3.37 (m, 2H), 3.23 (q, J = 6.5 Hz, 3H), 2.99 (d, J = 6.6 Hz, 2H), 2.88 (ddd, J = 16.7, 13.7, 5.2 Hz, 1H), 2.59 (d, J = 18.0 Hz, 2H), 2.49-2.41 (m, 1H), 2.22 (s, 1H), 2.06-1.94 (m, 1H), 1.66-1.45 (m, 2H), 1.42-1.00 (m, 11H). D32 LCMS (ESI) m/z: ¹H NMR (400 MHz, Methanol-d4) δ 8.45 (s, 1.0H, FA), 8.21 (s, [M + H]⁺ = 886.20 1H), 7.78 (s, 1H), 7.64 (dd, J = 8.6, 7.2 Hz, 1H), 7.33 (dd, J = 7.8, 2.1 Hz, 2H), 6.88 (s, 2H), 5.07 (dd, J = 12.7, 5.5 Hz, 1H), 4.32- 4.26 (m, 2H), 4.17-4.08 (m, 1H), 4.02 (s, 2H), 3.92 (s, 6H), 3.90- 3.86 (m, 2H), 3.73 (s, 3H), 3.69 (t, J = 5.2 Hz, 2H), 3.54-3.43 (m, 6H), 3.09 (t, J = 12.2 Hz, 2H), 2.91-2.80 (m, 4H), 2.78-2.61 (m, 2H), 2.56 (s, 3H), 2.27-2.18 (m, 2H), 2.14-2.06 (m, 1H), 2.02-1.89 (m, 2H). D33 LCMS (ESI) m/z: [M + H]+ = 921.65 D34 LCMS (ESI) m/z: [M + H]+ = 921.45 D35 LCMS (ESI) m/z: [M + H]+ = 935.6 D36 LCMS (ESI) m/z: [M + H]+ = 907.4 D37 LCMS (ESI) m/z: [M + H]+ = 893.45 D38 LCMS (ESI) m/z: [M + H]+ = 879.25 D39 LCMS (ESI) m/z: [M + H]+ = 893.5 D40 LCMS (ESI) m/z: [M + H]+ = 921.75 D41 LCMS (ESI) m/z: [M + H]+ = 893.15 D42 LCMS (ESI) m/z: [M + H]+ = 907.65 D43 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.82-8.73 (m, [M + H]+ = 893.3 1H), 8.36 (d, J = 4.1 Hz, 1H), 8.22 (s, 2H, FA), 7.92 (d, J = 4.3 Hz, 1H), 7.65 (dd, J = 8.5, 6.6 Hz, 1H), 7.32 (d, J = 2.3 Hz, 1H), 7.26- 7.18 (m, 1H), 6.91 (s, 2H), 5.11-5.00 (m, 1H), 3.85 (d, J = 2.3 Hz, 6H), 3.61 (d, J = 3.9 Hz, 6H), 3.45-3.38 (m, 4H), 3.25 (t, J = 5.8 Hz, 1H), 3.19 (t, J = 6.5 Hz, 1H), 2.93-2.83 (m, 1H), 2.72-2.66 (m, 1H), 2.65-2.60 (m, 2H), 2.59-2.53 (m, 7H), 2.48-2.44 (m, 3H), 2.26 (d, J = 2.3 Hz, 8H), 2.05-1.94 (m, 3H), 1.55 (dd, J = 12.5, 6.1 Hz, 1H), 1.46-1.36 (m, 1H), 1.08-0.97 (m, 1H). D44 LCMS (ESI) m/z: [M + H]+ = 893.3 D45 929.45 D46 943.45 ¹H NMR (300 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.92 (d, J = 8.6 Hz, 1H), 8.59 (d, J = 8.7 Hz, 1H), 8.22 (s, 1H, FA), 7.96 (s, 1H), 7.66 (d, J = 8.4 Hz, 1H), 6.92 (s, 2H), 6.81 (s, 1H), 6.73-6.63 (m, 1H), 5.06 (dd, J = 12.6, 5.4 Hz, 1H), 4.75-4.07 (m, 4H), 4.04-3.93 (m, 4H), 3.85 (s, 6H), 3.63 (s, 4H), 3.54-3.51 (m, 4H), 2.93- 2.55 (m, 8H), 2.20 (s, 7H), 2.12-2.00 (m, 3H), 1.93-1.82 (m, 2H). D47 LCMS (ESI) m/z: [M + H]+ = 461.45 D48 LCMS (ESI) m/z: [M + H]+ = 951.4 D49 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.97 (t, J = 5.8 Hz, [M + H]+ = 937.4 1H), 8.40 (s, 1H), 8.16 (s, 1H FA), 7.99 (s, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.27 (dd, J = 8.6, 2.2 Hz, 1H), 6.99 (s, 2H), 5.08 (dd, J = 12.7, 5.4 Hz, 1H), 4.09 (t, J = 6.5 Hz, 1H), 4.00 (s, 2H), 3.90 (s, 6H), 3.62 (s, 3H), 3.60-3.49 (m, 4H), 3.46- 3.42 (m, 6H), 3.02-2.60 (m, 9H), 2.59-2.55 (m, 7H), 2.37 (t, J = 7.0 Hz, 2H), 2.07-1.87 (m, 3H), 1.78-1.68 (m, 2H), 1.67-1.57 (m, 4H), 1.49-1.39 (m, 1H). D50 LCMS (ESI) m/z: [M + H]+ = 923.4 D51 LCMS (ESI) m/z: [M + H]+ = 907.4 D52 LCMS (ESI) m/z: [M + H]+ = 893.4 D53 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.80 (t, J = 5.7 Hz, [M + H]⁺ = 879. 1H), 8.36 (s, 1H), 7.92 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.32 (d, J = 2.2 Hz, 1H), 7.23 (dd, J = 8.7, 2.3 Hz, 1H), 6.90 (s, 2H), 5.07 (dd, J = 12.8, 5.4 Hz, 1H), 3.58 (d, J = 12.5 Hz, 5H), 3.37 (d, J = 13.7 Hz, 8H), 3.24 (t, J = 6.2 Hz, 2H), 2.89 (td, J = 17.8, 15.7, 5.3 Hz, 1H), 2.69 (s, 3H), 2.55 (s, 3H), 2.34 (d, J = 6.2 Hz, 3H), 2.22 (s, 6H), 2.17 (d, J = 8.5 Hz, 1H), 2.01 (s, 1H), 1.89 (dd, J = 12.1, 6.6 Hz, 2H). D54 LCMS (ESI) m/z: [M + H]+ = 921.25 D55 LCMS (ESI) m/z: [M + H]+ = 907.35 D56 LCMS (ESI) m/z: [M + H]+ = 454.5 D57 LCMS (ESI) m/z: [M + H]+ = 893.35 D58 LCMS (ESI) m/z: [M + H]+ = 907.35 D59 LCMS (ESI) m/z: ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H, FA), 7.83-7.74 [M + H]⁺ = 863.50. (m, 1H), 7.67 (s, 1H), 7.45 (d, J = 7.8 Hz, 2H), 7.25 (d, J = 1.9 Hz, 1H), 7.06 (s, 2H), 5.10 (dd, J = 12.2, 5.4 Hz, 1H), 4.36 (s, 2H), 4.27 (t, J = 6.1 Hz, 2H), 4.02 (s, 6H), 3.74 (s, 3H), 3.24-3.17 (m, 1H), 3.03-2.93 (m, 2H), 2.88 (s, 6H), 2.83-2.67 (m, 3H), 2.57- 2.42 (m, 3H), 2.27 (t, J = 11.1 Hz, 1H), 2.19-2.09 (m, 2H), 1.99- 1.88 (m, 3H), 1.71-1.57 (m, 4H). D60 D61 LCMS (ESI) m/z: [M + H]+ = 469.3 D62 LCMS (ESI) m/z: [M + H]+ = 909.2 D63 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.10 (d, J = 3.2 Hz, 1H), 8.86 [M + H]+ = 893.25 (dd, J = 26.1, 5.8 Hz, 1H), 8.55 (d, J = 38.1 Hz, 1H), 8.15 (s, 1H, FA), 8.04-7.87 (m, 1H), 7.66 (dd, J = 25.8, 8.5 Hz, 1H), 7.38- 7.24 (m, 1H), 7.20-7.07 (m, 1H), 7.03-6.90 (m, 2H), 5.08 (dd, J = 12.7, 6.4 Hz, 1H), 4.37-4.25 (m, 1H), 4.04 (s, 2H), 3.89 (d, J = 15.0 Hz, 6H), 3.77-3.53 (m, 7H), 3.45-3.41 (m, 3H), 3.24 (s, 3H), 3.16-3.04 (m, 2H), 3.03-2.73 (m, 4H), 2.64-2.55 (m, 10H), 2.41-2.36 (m, 2H), 2.05-1.85 (m, 2H). D64 LCMS (ESI) m/z: [M + H]+ = 865.25 D65 LCMS (ESI) m/z: [M + H]+ = 879.35 D66 LCMS (ESI) m/z: [M + H]+ = 879.3 D67 921.5  D68 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.80 (dd, J = 11.0, [M + H]+ = 893.5 5.8 Hz, 1H), 8.54 (s, 1H), 8.14 (s, 1H FA), 8.01-7.92 (m, 1H), 7.65 (dd, J = 18.7, 8.5 Hz, 1H), 7.37-7.15 (m, 2H), 6.99 (d, J = 11.3 Hz, 2H), 5.11-5.01 (m, 1H), 4.48-4.20 (m, 2H), 4.13 (s, 2H), 3.92 (s, 6H), 3.62 (d, J = 9.3 Hz, 3H), 3.48-3.36 (m, 10H), 2.98-2.72 (m, 4H), 2.70-2.59 (m, 9H), 2.42-2.34 (m, 1H), 2.14- 1.92 (m, 2H), 1.78-1.56 (m, 3H). D69 LCMS (ESI) m/z: [M + H]+ = 879.4 D70 LCMS (ESI) m/z: [M + H]+ = 865.25 D71 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 7.81 (d, J = 8.3 Hz, 1H), 7.46 [M + H]⁺ = 813.25. (s, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.33 (dd, J = 8.4, 2.3 Hz, 1H), 6.95 (s, 2H), 6.41 (s, 1H), 5.11 (dd, J = 12.4, 5.4 Hz, 1H), 4.37 (d, J = 13.5 Hz, 1H), 4.22 (t, J = 5.8 Hz, 2H), 4.06 (s, 2H), 3.99-3.92 (m, 7H), 3.71 (s, 3H), 3.59-3.51 (m, 1H), 3.06-2.93 (m, 1H), 2.91-2.68 (m, 4H), 2.66-2.51 (m, 8H), 2.23-2.05 (m, 3H), 1.96- 1.82 (m, 4H), 1.54-1.35 (m, 2H). D72 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.04-8.96 (m, [M + H]+ = 907.45 1H), 8.39 (s, 1H), 8.29 (s, 2H, FA), 7.94 (s, 1H), 7.68 (dd, J = 8.5, 3.4 Hz, 1H), 7.35 (d, J = 2.7 Hz, 1H), 7.27 (d, J = 7.3 Hz, 1H), 6.91- 6.86 (m, 2H), 5.07 (dd, J = 12.7, 5.3 Hz, 1H), 4.44-4.34 (m, 1H), 3.84 (s, 6H), 3.62 (s, 4H), 3.53-3.48 (m, 10H), 2.93-2.82 (m, 2H), 2.63-2.55 (m, 6H), 2.33-2.23 (m, 3H), 2.21-2.07 (m, 9H), 2.00-1.80 (m, 3H). D73 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.01-8.92 (m, [M + H]+ = 893.3 1H), 8.39 (s, 1H), 8.23 (s, 3H, FA), 7.95 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 6.91 (s, 2H), 5.08 (dd, J = 12.7, 5.3 Hz, 1H), 4.33-4.24 (m, 1H), 3.85 (s, 6H), 3.62 (s, 5H), 3.44 (s, 5H), 2.97-2.81 (m, 2H), 2.77-2.69 (m, 3H), 2.64-2.53 (m, 5H), 2.39-2.33 (m, 3H), 2.27 (s, 6H), 2.17-2.09 (m, 2H), 2.04-1.84 (m, 4H), 1.68 (s, 2H). D74 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.00-8.93 (m, [M + H]+ = 893.3 1H), 8.37 (s, 1H), 8.20 (s, 1H, FA), 7.95 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.30-7.23 (m, 1H), 6.91 (s, 2H), 5.08 (dd, J = 12.8, 5.3 Hz, 1H), 4.31-4.19 (m, 2H), 4.12 (s, 1H), 3.92 (s, 1H), 3.87-3.80 (m, 7H), 3.63-3.56 (m, 6H), 3.45-3.40 (m, 8H), 2.91-2.83 (m, 1H), 2.64-2.55 (m, 5H), 2.32-2.20 (m, 10H), 2.08-1.96 (m, 1H). D75 LCMS (ESI) m/z: [M + H]+ = 879.45 D76 LCMS (ESI) m/z: [M + H]+ = 907.35 D77 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.24 (s, 1H), 7.87 (s, 1H), 7.80 [M + H]⁺ = 867.50. (d, J = 8.4 Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.39 (dd, J = 8.6, 2.3 Hz, 1H), 7.07 (s, 2H), 5.12 (dd, J = 12.3, 5.4 Hz, 1H), 4.60 (d, J = 14.2 Hz, 1H), 4.42 (s, 2H), 4.40-4.29 (m, 2H), 4.20-4.12 (m, 1H), 4.02 (s, 7H), 3.87-3.78 (m, 2H), 3.75 (s, 4H), 3.66-3.45 (m, 4H), 3.21-3.12 (m, 1H), 2.99-2.89 (m, 8H), 2.86-2.70 (m, 3H), 2.19-2.07 (m, 3H), 1.72-1.57 (m, 2H). D78 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d₆) δ 11.09 (s, 1H), 8.66 (d, J = 7.6 Hz, [M + H]⁺ = 881.50. 1H), 8.41 (s, 1H), 8.23 (s, 1H, FA), 7.95 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 2.3 Hz, 1H), 7.27 (dd, J = 8.7, 2.3 Hz, 1H), 6.91 (s, 2H), 5.08 (dd, J = 12.9, 5.4 Hz, 1H), 4.35 (d, J = 13.1 Hz, 1H), 4.05-3.92 (m, 3H), 3.85 (s, 6H), 3.62 (s, 3H), 3.57 (s, 2H), 3.47-3.41 (m, 6H), 3.17-3.11 (m, 1H), 2.94-2.83 (m, 1H), 2.76- 2.66 (m, 1H), 2.61-2.55 (m, 7H), 2.22 (s, 6H), 2.06-1.98 (m, 1H), 1.92-1.79 (m, 2H), 1.55-1.32 (m, 2H). D79 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.35 (d, J = 1.6 Hz, 1H), 7.88 [M + H]⁺ = 889.25 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 2.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.08 (s, 2H), 5.13 (dd, J = 12.1, 5.3 Hz, 1H), 4.58- 4.45 (m, 1H), 4.42 (s, 2H), 4.02 (s, 6H), 3.87-3.77 (m, 4H), 3.76 (s, 3H), 3.69-3.57 (m, 4H), 3.49-3.38 (m, 3H), 3.16 (d, J = 11.8 Hz, 1H), 3.03-2.97 (m, 2H), 2.92 (s, 6H), 2.90-2.70 (m, 3H), 2.70-2.41 (m, 2H), 2.19-1.94 (m, 3H). D80 LCMS (ESI) m/z: ¹H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 2H, FA), 8.32 (s, 1H), [M + H]⁺ = 841.35 7.87 (s, 1H), 7.80 (dd, J = 8.6, 7.3 Hz, 1H), 7.47 (dd, J = 7.9, 4.8 Hz, 2H), 7.06 (s, 2H), 5.09 (dd, J = 12.7, 5.5 Hz, 1H), 4.41-4.31 (m, 4H), 4.23-4.17 (m, 1H), 4.02 (s, 6H), 3.99-3.82 (m, 1H), 3.75 (s, 3H), 3.49-3.38 (m, 2H), 2.89 (s, 6H), 2.88-2.82 (m, 4H), 2.78-2.65 (m, 2H), 2.23-2.12 (m, 3H), 2.06-1.93 (m, 8H), 1.86-1.75 (m, 2H). D81 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.79 (s, 1H), 8.37 [M + H]⁺ = 828.30. (s, 1H), 8.23 (s, 2H FA), 7.94 (s, 1H), 7.81 (dd, J = 8.5, 7.2 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 7.2 Hz, 1H), 6.91 (s, 2H), 5.08 (dd, J = 12.8, 5.4 Hz, 1H), 4.23 (t, J = 6.1 Hz, 2H), 3.84 (s, 6H), 3.62 (s, 3H), 3.53 (s, 2H), 3.17-3.11 (m, 3H), 2.93-2.88 (m, 2H), 2.64-2.59 (m, 2H), 2.42-2.31 (m, 3H), 2.19 (s, 6H), 2.07-1.98 (m, 1H), 1.95-1.84 (m, 2H), 1.81-1.74 (m, 2H), 1.71- 1.54 (m, 5H), 1.30-1.08 (m, 3H). D82 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.56 (s, 2H, FA), 8.27 (s, 1H), [M + H]+ = 838.98. 7.87-7.77 (m, 2H), 7.47 (dd, J = 7.7, 2.6 Hz, 2H), 7.03 (s, 2H), 5.21-5.10 (m, 1H), 4.30 (t, J = 5.7 Hz, 2H), 4.24 (s, 2H), 4.17- 4.08 (m, 1H), 4.00 (s, 7H), 3.75 (s, 3H), 3.29-3.14 (m, 2H), 3.10- 2.98 (m, 2H), 2.95-2.86 (m, 1H), 2.81-2.69 (m, 9H), 2.50 (dd, J = 15.0, 8.0 Hz, 1H), 2.21-2.11 (m, 1H), 2.04-1.80 (m, 7H), 1.74-1.63 (m, 2H). D83 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d₆) δ 11.11 (s, 1H), 9.40 (s, 1H, TFA), [M + H]⁺ = 863. 8.63 (s, 1H), 8.45 (s, 1H), 8.01 (s, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.38 (dd, J = 8.3, 2.3 Hz, 1H), 7.02 (s, 2H), 5.13 (dd, J = 12.8, 5.4 Hz, 1H), 4.26 (dd, J = 9.4, 5.4 Hz, 4H), 3.93 (s, 7H), 3.63 (s, 4H), 3.40 (d, J = 1.3 Hz, 1H), 3.02-2.82 (m, 3H), 2.76 (d, J = 4.7 Hz, 7H), 2.66-2.53 (m, 2H), 2.53-2.52 (m, 1H), 2.26-1.90 (m, 7H), 1.77 (s, 1H), 1.60 (s, 1H). D84 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.82 (t, J = 8.0 Hz, [M + H]+ = 845.40. 1H), 8.48 (d, J = 67.2 Hz, 1H), 8.19 (s, 1H, FA), 7.96 (d, J = 2.3 Hz, 1H), 7.82 (t, J = 7.8 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 7.2 Hz, 1H), 6.93 (s, 2H), 6.57 (s, 1H), 5.09 (dd, J = 12.9, 5.5 Hz, 1H), 4.81-4.45 (m, 1H), 4.23 (t, J = 6.4 Hz, 2H), 3.86 (s, 6H), 3.65-3.61 (m, 4H), 3.15-3.08 (m, 1H), 2.95-2.78 (m, 3H), 2.62- 2.57 (m, 2H), 2.34-2.25 (m, 7H), 2.20-1.92 (m, 4H), 1.90- 1.73 (m, 3H), 1.66-1.36 (m, 6H). D85 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 8.85 (d, J = 8.0 Hz, [M + H]⁺ = 845.35 1H), 8.50 (d, J = 66.8 Hz, 1H), 8.14 (s, 1H, FA), 8.00 (d, J = 1.1 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 8.3, 2.2 Hz, 1H), 7.03 (s, 2H), 6.53 (s, 1H), 5.13 (dd, J = 13.0, 5.3 Hz, 1H), 4.27-4.17 (m, 4H), 3.93 (s, 7H), 3.64 (d, J = 1.5 Hz, 3H), 2.96-2.84 (m, 2H), 2.76 (s, 6H), 2.63-2.58 (m, 2H), 2.47-2.34 (m, 2H), 2.12-1.95 (m, 3H), 1.89-1.68 (m, 3H), 1.66- 1.40 (m, 5H), 1.30-1.21 (m, 1H). D86 LCMS (ESI) m/z: ¹H NMR (300 MHz, Methanol-d4) δ 8.31 (br s, 1H, FA), 8.27 (s, [M + H]+ = 881.45. 1H), 7.88 (s, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.42 (s, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.06 (s, 2H), 5.10 (dd, J = 12.4, 5.3 Hz, 1H), 4.42 (s, 2H), 4.22-4.12 (m, 1H), 4.02 (s, 6H), 3.75 (s, 3H), 3.69-3.53 (m, 7H), 3.22-3.08 (m, 4H), 2.92 (s, 9H), 2.82-2.69 (m, 5H), 2.26 (d, J = 14.0 Hz, 2H), 2.16-1.95 (m, 3H), 1.93-1.81 (m, 2H), 1.81-1.67 (m, 2H). D87 LCMS (ESI) m/z: ¹H NMR (300 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.61 (d, J = 7.9 Hz, [M + H]+ = 841.35. 1H), 8.39 (s, 1H), 8.18 (s, 1H, FA), 7.93 (s, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 6.91 (s, 2H), 5.11 (dd, J = 13.0, 5.3 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 4.03 (s, 1H), 3.85 (s, 6H), 3.64-3.56 (m, 5H), 2.75-2.72 (m, 1H), 2.69-2.60 (m, 3H), 2.60-2.53 (m, 4H), 2.30-2.22 (m, 7H), 1.97- 1.66 (m, 8H), 1.60-1.43 (m, 5H). D88 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.60 (d, J = 7.9 Hz, [M + H]⁺ = 841.35. 1H), 8.36 (d, J = 2.4 Hz, 1H), 8.19 (s, 2H, FA), 7.92 (s, 1H), 7.87- 7.74 (m, 1H), 7.51 (d, J = 9.0 Hz, 1H), 7.42 (dd, J = 7.2, 2.6 Hz, 1H), 6.90 (s, 2H), 5.11-5.04 (m, 1H), 4.23 (t, J = 6.3 Hz, 2H), 4.03 (s, 1H), 3.85 (s, 6H), 3.61 (s, 3H), 3.55 (s, 2H), 2.93-2.84 (m, 1H), 2.78-2.70 (m, 1H), 2.69-2.54 (m, 7H), 2.21 (s, 6H), 2.08-1.99 (m, 1H), 1.93-1.70 (m, 7H), 1.59-1.47 (m, 5H). D89 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 8.61 (d, J = 7.7 Hz, [M + H]+ = 827.35. 1H), 8.42 (s, 1H), 8.21 (s, 1H, FA), 7.94 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 6.91 (s, 2H), 5.12 (dd, J = 13.0, 5.4 Hz, 1H), 4.19 (t, J = 6.5 Hz, 2H), 3.84 (s, 6H), 3.74-3.67 (m, 1H), 3.62 (s, 3H), 3.55 (s, 2H), 2.95-2.84 (m, 3H), 2.64-2.54 (m, 2H), 2.35-2.29 (m, 2H), 2.21 (s, 6H), 2.07-1.94 (m, 3H), 1.83-1.73 (m, 4H), 1.62-1.42 (m, 6H). D90 LCMS (ESI) m/z: ¹H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 8.88 (d, J = 8.8 Hz, [M + H]+ = 863.35.. 1H), 8.60 (s, 1H), 8.15 (s, 0.3H, FA), 7.98 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 6.97 (s, 2H), 6.53 (s, 0.3H, FA salt), 5.13 (dd, J = 12.9, 5.3 Hz, 1H), 4.35 (s, 1H), 4.20 (t, J = 6.5 Hz, 2H), 3.88 (s, 6H), 3.82 (s, 2H), 3.63 (s, 3H), 3.15 (s, 1H), 2.95-2.84 (m, 2H), 2.65-2.55 (m, 3H), 2.44 (s, 8H), 2.18 (t, J = 11.3 Hz, 1H), 2.10-2.01 (m, 1H), 1.91-1.74 (m, 4H), 1.57-1.41 (m, 4H).

Example 30—Preparation of Compounds D91-D220, DD1, and DD2

In analogy to the procedures described in the examples above, compounds D91-D220, DD1, and DD2 were prepared using the appropriate starting materials

Compound No. LCMS ¹H NMR D91 662.30 ¹H NMR (400 MHz, Methanol-d4) δ 8.27-8.21 (m, 1H), 7.92 (s, 1H), 7.74-7.70 (m, 1H), 7.65-7.60 (m, 1H), 7.56-7.50 (m, 1H), 6.99 (s, 2H), 5.13 (dd, J = 13.3, 5.2 Hz, 1H), 4.53-4.38 (m, 2H), 4.18-4.10 (m, 2H), 4.10-4.01 (m, 2H), 3.97 (s, 6H), 3.83-3.74 (m, 2H), 3.71 (s, 3H), 3.67-3.57 (m, 1H), 2.99-2.85 (m, 1H), 2.84-2.75 (m, 1H), 2.56-2.40 (m, 1H), 2.26-2.15 (m, 1H). D92 637.35 ¹H NMR (300 MHz, Methanol-d4) δ 7.82-7.78 (m, 1H), 7.73 (s, 1H), 7.70-7.64 (m, 2H), 7.60-7.52 (m, 2H), 7.05 (s, 2H), 5.16 (dd, J = 13.3, 5.2 Hz, 1H), 4.58-4.42 (m, 2H), 4.27 (s, 2H), 4.24- 4.15 (m, 2H), 4.00 (s, 6H), 3.97-3.89 (m, 2H), 3.80-3.70 (m, 4H), 3.03-2.75 (m, 2H), 2.60-2.41 (m, 1H), 2.29-2.16 (m, 1H). D93 674.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.68 (d, J = 7.7 Hz, 1H), 8.40 (s, 1H), 7.97 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.38- 7.22 (m, 3H), 7.19 (t, J = 1.9 Hz, 1H), 7.15-7.06 (m, 1H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.41-4.18 (m, 2H), 4.06-3.92 (m, 3H), 3.80-3.76 (m, 3H), 3.60 (s, 3H), 3.02-2.83 (m, 3H), 2.60 (d, J = 16.5 Hz, 1H), 2.48-2.31 (m, 1H), 1.96 (dd, J = 27.3, 11.8 Hz, 3H), 1.70 (d, J = 12.2 Hz, 2H). D94 808.55 ¹H NMR (300 MHz, Methanol-d4) δ 7.53-7.48 (m, 2H), 7.40- 7.33 (m, 2H), 7.01-6.98 (m, 2H), 6.28 (s, 1H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.51-4.42 (m, 2H), 4.41-4.35 (m, 2H), 4.06-3.96 (m, 10H), 3.71 (s, 3H), 3.49-3.40 (m, 4H), 3.25-3.07 (m, 6H), 3.02-2.85 (m, 3H), 2.84-2.76 (m, 1H), 2.60-2.51 (m, 1H), 2.50- 2.40 (m, 2H), 2.25-2.14 (m, 1H), 2.11-1.97 (m, 2H), 1.83- 1.48 (m, 5H). D95 605.36 ¹H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 10.49 (s, 1H), 8.67 (s, 1H), 8.23-8.16 (m, 1H), 8.00 (s, 1H), 7.52 (t, J = 2.2 Hz, 1H), 7.38 (dd, J = 7.8, 1.9 Hz, 1H), 7.27 (t, J = 8.2 Hz, 1H), 6.94 (s, 2H), 6.80 (dd, J = 8.0, 2.5 Hz, 1H), 5.17 (dd, J = 10.7, 5.2 Hz, 1H), 3.86 (s, 6H), 3.64 (s, 3H), 3.63-3.55 (m, 2H), 2.81-2.70 (m, 1H), 2.68- 2.56 (m, 1H), 2.32-2.10 (m, 8H). D96 631.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.72 (d, J = 7.7 Hz, 1H), 8.46 (s, 1H), 7.96 (s, 1H), 7.18 (t, J = 8.4 Hz, 1H), 6.86 (d, J = 2.2 Hz, 2H), 6.70-6.61 (m, 3H), 6.51 (d, J = 8.0 Hz, 1H), 5.26 (dd, J = 10.4, 5.2 Hz, 1H), 4.01 (s, 1H), 3.89 (s, 6H), 3.82 (d, J = 12.1 Hz, 2H), 3.67 (s, 3H), 2.88 (q, J = 10.2, 8.1 Hz, 2H), 2.81- 2.62 (m, 2H), 2.31-2.12 (m, 2H), 1.94 (d, J = 12.2 Hz, 2H), 1.81- 1.64 (m, 2H). D97 711.20 ¹H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H, FA), 7.43 (s, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.01-6.91 (m, 3H), 6.85 (s, 1H), 6.77 (d, J = 8.3 Hz, 1H), 6.29 (s, 1H), 5.16-5.08 (m, 1H), 4.44-4.30 (m, 2H), 4.18-3.99 (m, 2H), 3.98-3.92 (m, 6H), 3.75-3.67 (m, 7H), 3.62 (s, 1H), 3.08-2.95 (m, 2H), 2.88 (s, 3H), 2.82-2.70 (m, 1H), 2.50-2.39 (m, 1H), 2.22-2.11 (m, 1H), 2.05-2.00 (m, 4H). D98 789.2 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.86 (s, 1H), 8.57 (s, 1H, FA), 7.92 (s, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.23-7.05 (m, 2H), 6.79 (d, J = 2.3 Hz, 2H), 6.60-6.50 (m, 1H), 5.10 (dd, J = 13.2, 5.1 Hz, 1H), 4.42-4.12 (m, 3H), 3.90- 3.73 (m, 8H), 3.60 (s, 3H), 3.24-3.09 (m, 1H), 3.00-2.84 (m, 2H), 2.82-2.69 (m, 2H), 2.64-2.54 (m, 2H), 2.46-2.32 (m, 2H), 2.27-2.07 (m, 1H), 2.03-1.95 (m, 1H), 1.93-1.72 (m, 4H), 1.66- 1.49 (m, 2H). D99 779.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.16 (s, FA, 1H), 7.88 (s, 1H), 7.70 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 5.3 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 6.97 (s, 2H), 6.73-6.61 (m, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.36-4.14 (m, 2H), 3.88 (s, 6H), 3.81 (s, 2H), 3.62 (s, 3H), 3.58 (s, 4H), 3.13-3.02 (m, 2H), 2.99-2.78 (m, 2H), 2.64-2.55 (m, 1H), 2.47-2.38 (m, 2H), 2.38-2.20 (m, 4H), 2.19-2.06 (m, 2H), 2.03-1.92 (m, 1H), 1.87-1.53 (m, 7H), 1.32- 1.06 (m, 2H). D100 809.55 ¹H NMR (300 MHz, Methanol-d4) δ 7.66 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.01 (s, 2H), 6.88 (s, 1H), 6.83-6.78 (m, 1H), 6.76 (s, 1H), 5.14 (dd, J = 13.2, 5.2 Hz, 1H), 4.56-4.30 (m, 4H), 4.04- 3.97 (m, 9H), 3.86-3.76 (m, 3H), 3.75-3.71 (m, 4H), 3.69-3.53 (m, 4H), 3.36-3.34 (m, 1H), 3.23-3.07 (m, 5H), 2.99-2.78 (m, 2H), 2.62-2.43 (m, 1H), 2.37-1.99 (m, 9H), 1.72-1.61 (m, 1H). D101 804.55 ¹H NMR (300 MHz, Methanol-d4) δ 8.61 (s, 1H) FA, 8.36 (s, 1H), 8.04 (s, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.10 (s, 2H), 6.94-6.88 (m, 1H), 6.87-6.81 (m, 1H), 5.20 (dd, J = 13.2, 5.1 Hz, 1H), 4.54- 4.39 (m, 4H), 4.08 (s, 6H), 3.81 (s, 3H), 3.76-3.72 (m, 4H), 3.65- 3.55 (m, 2H), 3.26-3.11 (m, 2H), 3.02-2.81 (m, 2H), 2.77- 2.40 (m, 7H), 2.31-2.18 (m, 1H), 2.16-2.07 (m, 2H), 2.00 (s, 5H), 1.72-1.49 (m, 2H). D102 874.5 ¹H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.88 (d, J = 8.9 Hz, 1H), 8.59 (s, 1H), 8.17 (s, 2H, FA), 7.96 (s, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 7.9 Hz, 2H), 6.93 (s, 2H), 5.05 (dd, J = 13.3, 5.1 Hz, 1H), 4.38-4.16 (m, 3H), 3.85 (s, 8H), 3.63 (s, 5H), 3.19-3.14 (m, 2H), 2.95-2.76 (m, 5H), 2.64-2.58 (m, 1H), 2.41-2.36 (m, 2H), 2.26 (d, J = 4.0 Hz, 6H), 2.21-2.15 (m, 1H), 2.00-1.86 (m, 2H), 1.82-1.73 (m, 3H), 1.54-1.50 (m, 1H), 1.46-1.38 (m, 2H), 1.30-1.19 (m, 2H). D103 650.2 ¹H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.42 (d, 1H), 8.46 (s, 1H), 8.06-7.94 (m, 3H), 7.86-7.73 (m, 2H), 7.42 (d, 1H), 6.82- 6.72 (m, 2H), 5.11 (dd, 1H), 4.91-4.78 (m, 1H), 4.42-4.15 (m, 4H), 3.89-3.79 (m, 2H), 3.61 (s, 3H), 3.01-2.83 (m, 1H), 2.66- 2.53 (m, 1H), 2.45-2.28 (m, 1H), 2.05-1.95 (m, 1H). D104 927.45 ¹H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 10.14-9.84 (m, 2H, TFA), 9.07 (s, 1H), 8.61 (s, 1H), 8.02 (s, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.03 (d, J = 2.9 Hz, 2H), 6.54-6.45 (m, 2H), 5.05 (dd, J = 13.2, 5.2 z, 1H), 4.71-4.57 (m, 1H), 4.43-4.33 (m, 2H), 4.31- 4.16 (m, 4H), 4.08-4.00 (m, 2H), 3.93 (s, 6H), 3.78 (s, 2H), 3.69 (s, 3H), 3.51 (s, 5H), 3.45 (s, 2H), 3.39 (s, 2H), 3.19 (s, 2H), 3.01- 2.89 (m, 3H), 2.80 (s, 3H), 2.70-2.54 (m, 1H), 2.38-2.32 (m, 1H), 2.10 (s, 4H), 1.94 (d, J = 14.0 Hz, 3H). D105 688.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.95 (s, 1H), 9.07 (s, 1H, TFA), 8.84-8.76 (m, 1H), 8.48 (s, 1H), 8.01 (s, 1H), 7.40-7.18 (m, 2H), 7.09-7.02 (m, 4H), 5.21-5.13 (m, 1H), 4.26 (d, J = 5.0 Hz, 2H), 4.15-4.01 (m, 2H), 3.93 (s, 6H), 3.64 (s, 3H), 3.30-3.14 (m, 2H), 2.78 (d, J = 4.5 Hz, 6H), 2.75-2.71 (m, 1H), 2.70-2.61 (m, 2H), 2.23-2.13 (m, 2H), 2.06-1.97 (m, 2H), 1.93-1.82 (m, 2H). D106 696.3 ¹H NMR (300 MHz, Methanol-d4) δ 7.78-7.67 (m, 2H), 7.60 (d, J = 5.4 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.37-7.28 (m, 2H), 7.04 (s, 2H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.49-4.32 (m, 2H), 4.20 (s, 2H), 3.98 (s, 6H), 3.76 (s, 3H), 3.60 (s, 1H), 3.47 (d, J = 10.6 Hz, 2H), 3.25-3.12 (m, 3H), 3.00-2.80 (m, 4H), 2.51 (dd, J = 12.9, 4.8 Hz, 1H), 2.24-2.03 (m, 5H), 1.84 (s, 2H). D107 825.4 ¹H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H, FA), 7.86 (s, 1H), 7.68 (d, J = 5.4 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 6.93 (s, 2H), 6.78 (s, 1H), 6.65 (dd, J = 8.4, 2.2 Hz, 1H), 5.78-5.68 (m, 1H), 5.63 (dd, J = 9.5, 4.0 Hz, 1H), 5.28-5.19 (m, 1H), 3.85 (s, 6H), 3.74 (s, 4H), 3.61 (s, 3H), 3.56 (s, 2H), 3.51 (s, 1H), 3.22-3.16 (m, 2H), 3.12-2.98 (m, 2H), 2.87-2.78 (m, 1H), 2.65-2.54 (m, 2H), 2.47-2.38 (m, 2H), 2.11-2.03 (m, 1H), 1.87- 1.80 (m, 1H), 1.76-1.72 (m, 4H), 0.89-0.83 (m, 3H), 0.83- 0.77 (m, 3H). D108 688.35 ¹H NMR (300 MHz, Methanol-d4) δ 8.56 (s, 1H, FA salt), 8.24 (s, 1H), 7.84 (s, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.05 (s, 2H), 6.74-6.64 (m, 2H), 6.57 (d, J = 8.2 Hz, 1H), 5.09 (dd, J = 9.6, 4.8 Hz, 1H), 4.34 (s, 2H), 4.01 (s, 7H), 3.74 (s, 5H), 2.94-2.88 (m, 1H), 2.85 (s, 6H), 2.81-2.71 (m, 3H), 2.43-2.13 (m, 2H), 2.10-2.00 (m, 2H), 1.85-1.75 (m, 2H). D109 670.2 ¹H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.86 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.38-7.32 (m, 1H), 7.29 (s, 1H), 6.77 (d, J = 2.2 Hz, 2H), 6.56 (t, J = 2.2 Hz, 1H), 5.07 (dd, J = 13.2, 5.1 Hz, 1H), 4.42-4.17 (m, 2H), 3.98 (s, 1H), 3.82-3.71 (m, 8H), 3.58 (s, 3H), 3.04-2.80 (m, 3H), 2.61 (d, J = 17.7 Hz, 1H), 2.41-2.30 (m, 1H), 2.05-1.87 (m, 3H), 1.71 (dd, J = 22.0, 10.0 Hz, 2H). D110 724.3 ¹H NMR (300 MHz, Methanol-d4) δ 8.57 (s, 1H, FA salt), 7.68 (s, 1H), 7.44-7.35 (m, 2H), 7.00 (s, 2H), 6.87 (d, J = 2.1 Hz, 1H), 6.79 (dd, J = 8.2, 2.3 Hz, 1H), 5.14 (dd, J = 13.1, 5.1 Hz, 1H), 4.48- 4.30 (m, 2H), 4.14 (s, 2H), 3.98 (s, 6H), 3.73 (s, 7H), 3.33-3.20 (m, 1H), 3.08 (s, 4H), 2.99-2.73 (m, 2H), 2.58-2.41 (m, 1H), 2.17 (d, J = 12.6 Hz, 1H), 2.07 (s, 4H), 1.41 (d, J = 6.8 Hz, 6H). D111 718.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.89 (s, 1H), 7.74- 7.55 (m, 2H), 7.39 (d, J = 8.8 Hz, 1H), 6.95 (s, 2H), 6.77-6.67 (m, 2H), 5.17-5.00 (m, 1H), 4.42-4.11 (m, 2H), 3.87 (s, 8H), 3.72- 3.55 (m, 7H), 3.02-2.81 (m, 1H), 2.75-2.54 (m, 4H), 2.46-2.28 (m, 2H), 2.00 (s, 3H). D112 875.45 ¹H NMR (300 MHz, Methanol-d4) δ 8.42 (d, J = 15.6 Hz, 1H), 7.87 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 2H), 7.08 (s, 2H), 5.27-5.10 (m, 1H), 4.44 (d, J = 14.5 Hz, 5H), 4.02 (s, 6H), 3.75 (s, 3H), 3.63 (s, 8H), 3.46 (s, 3H), 3.14 (d, J = 12.3 Hz, 1H), 3.01-2.89 (m, 9H), 2.90-2.77 (m, 1H), 2.78-2.38 (m, 3H), 2.26- 2.16 (m, 1H), 2.10-1.91 (m, 2H). D113 696.3 ¹H NMR (300 MHz, DMSO-d6) δ 8.32 (s, 1H, FA), 7.80 (s, 1H), 7.69-7.56 (m, 2H), 7.43 (d, J = 8.2 Hz, 1H), 7.28-7.13 (m, 2H), 7.01-6.88 (m, 2H), 5.04-4.89 (m, 1H), 4.31 (d, 2H), 4.19 (d, J = 16.2 Hz, 2H), 3.91-3.72 (m, 6H), 3.60 (s, 5H), 3.48 (s, 1H), 3.33- 2.91 (m, 4H), 2.90-2.71 (m, 2H), 2.71-2.56 (m, 1H), 2.43- 2.31 (m, 1H), 2.29-2.12 (m, 1H), 2.11-1.80 (m, 4H), 1.70 (d, J = 13.8 Hz, 1H), 1.48 (s, 1H). D114 713.35 ¹H NMR (300 MHz, DMSO-d6 + a drop of D2O) δ 8.45 (s, 1H), 7.97 (s, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.01 (s, 2H), 6.91-6.83 (m, 1H), 6.80 (d, J = 2.3 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.58 (t, J = 5.7 Hz, 1H), 4.38-4.10 (m, 4H), 3.92 (s, 6H), 3.53-3.45 (m, 1H), 3.42-3.36 (m, 3H), 3.39-3.25 (m, 3H), 2.92-2.75 (m, 1H), 2.77 (s, 6H), 2.66-2.54 (m, 1H), 2.43-2.24 (m, 2H), 2.17-2.07 (m, 1H), 2.05-1.95 (m, 1H). D115 642.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.39 (d, J = 7.1 Hz, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.42 (d, J = 8.8 Hz, 1H), 6.78 (dd, J = 6.6, 2.3 Hz, 4H), 6.58 (t, J = 2.2 Hz, 1H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.84 (d, J = 6.8 Hz, 1H), 4.40-4.15 (m, 4H), 3.82 (s, 8H), 3.60 (s, 3H), 2.95-2.83 (m, 1H), 2.62 (s, 1H), 2.45-2.34 (m, 1H), 2.05-1.94 (m, 1H). D116 669.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.41 (d, J = 7.1 Hz, 1H), 8.45 (s, 1H), 8.16 (s, 0.2H, FA), 7.98 (s, 1H), 7.43 (d, J = 8.8 Hz, 1H), 6.95 (s, 2H), 6.82-6.72 (m, 2H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.89-4.79 (m, 1H), 4.40-4.15 (m, 4H), 3.87 (s, 6H), 3.84- 3.74 (m, 4H), 3.62 (s, 3H), 2.95-2.83 (m, 1H), 2.63 (s, 1H), 2.39 (s, 7H), 2.05-1.95 (m, 1H). D117 718.3 ¹H NMR (300 MHz, DMSO) δ 10.98 (s, 1H), 8.99 (d, J = 7.6 Hz, 1H), 8.43 (s, 1H), 8.05-7.94 (m, 3H), 7.86-7.73 (m, 2H), 7.44 (d, J = 8.3 Hz, 1H), 7.38-7.17 (m, 2H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.48-4.40 (m, 1H), 4.39-4.18 (m, 2H), 3.62 (s, 3H), 3.31- 3.12 (m, 5H), 3.01-2.83 (m, 1H), 2.65-2.55 (m, 2H), 2.45-2.34 (m, 1H), 2.33-2.19 (m, 2H), 2.05-1.85 (m, 3H), 1.76-1.70 (m, 4H). D118 751.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.98-8.89 (m, 1H), 8.59 (d, J = 2.3 Hz, 1H), 8.15 (s, 0.2H, FA salt), 8.02 (s, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.36 (dt, J = 8.6, 2.2 Hz, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.20-7.10 (m, 2H), 5.12 (dd, J = 13.2, 5.2, 1H), 4.70- 4.49 (m, 1H), 4.36 (d, J = 16.9 Hz, 1H), 4.29-4.08 (m, 2H), 3.91 (s, 3H), 3.87 (s, 1H), 3.62 (s, 5H), 3.51-3.42 (m, 1H), 3.21-3.08 (m, 1H), 3.01-2.83, (m, 1H), 2.66-2.55 (m, 1H), 2.45-2.37 (m, 1H), 2.27 (s, 6H), 2.08-1.92 (m, 3H). D119 726.35 ¹H NMR (300 MHz, Methanol-d4) δ 8.56 (s, 1H, FA salt), 7.75 (s, 1H), 7.59 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.04 (s, 2H), 6.88 (s, 1H), 6.80 (d, J = 8.3 Hz, 1H), 5.19-5.08 (m, 1H), 4.72 (s, 2H), 4.40 (d, J = 5.2 Hz, 2H), 4.27 (s, 2H), 4.00 (s, 6H), 3.82-3.62 (m, 8H), 3.42 (s, 3H), 3.24-3.18 (m, 3H), 3.00-2.71 (m, 2H), 2.56- 2.45 (m, 1H), 2.15-2.09 (m, 5H). D120 712.3 ¹H NMR (300 MHz, Methanol-d4) δ 8.57 (s, 1H), 7.63 (s, 1H), 7.39 (d, J = 8.2 Hz, 1H), 6.93 (s, 2H), 6.85 (d, J = 2.2 Hz, 1H), 6.80- 6.73 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.47-4.27 (m, 2H), 4.02 (s, 5H), 3.95 (s, 6H), 3.72 (s, 3H), 3.70 (s, 4H), 3.06-2.72 (m, 6H), 2.60-2.37 (m, 1H), 2.23-2.11 (m, 1H), 2.01 (t, J = 5.6 Hz, 4H). D121 696.35 ¹H NMR (300 MHz, DMSO-d6) δ 8.26 (s, 1H, FA), 7.83 (s, 1H), 7.67 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 9.3 Hz, 2H), 6.91 (d, J = 1.9 Hz, 2H), 5.01 (dd, J = 13.3, 5.1 Hz, 1H), 4.31 (d, J = 16.9 Hz, 1H), 4.21 (d, 1H), 3.80 (d, J = 1.6 Hz, 7H), 3.71-3.60 (m, 6H), 3.50 (s, 1H), 3.28- 3.01 (m, 2H), 2.98-2.77 (m, 1H), 2.59 (d, J = 17.1 Hz, 4H), 2.39- 2.24 (m, 1H), 2.05-1.90 (m, 2H), 1.89-1.78 (m, 1H), 1.77-1.58 (m, 3H), 1.57-1.42 (m, 1H). D122 613.25 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.86 (s, 1H), 7.69 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 6.96 (s, 2H), 6.86 (dd, J = 8.4, 2.4 Hz, 1H), 6.79 (d, J = 2.3 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.33 (d, J = 16.4 Hz, 1H), 4.25-4.07 (m, 2H), 3.85 (s, 6H), 3.62 (s, 4H), 3.55-3.40 (m, 3H), 2.99-2.83 (m, 1H), 2.71-2.55 (m, 2H), 2.46-2.34 (m, 1H), 2.18-2.08 (m, 1H), 2.08-1.97 (m, 1H). D123 627.2 ¹H NMR (400 MHz, DMSO-d6 with a drop of D2O) δ 8.30 (s, 0.1H, FA), 7.82 (s, 1H), 7.67 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.35-7.28 (m, 1H), 7.23-7.18 (m, 1H), 6.90 (s, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.40-4.18 (m, 2H), 3.88-3.78 (m, 8H), 3.60 (s, 3H), 3.42-3.32 (m, 1H), 2.97-2.83 (m, 1H), 2.82-2.70 (m, 2H), 2.68-2.55 (m, 1H), 2.49-2.31 (m, 3H), 2.05-1.97 (m, 1H), 1.55 (d, J = 12.4 Hz, 2H). D124 687.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 8.67 (d, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.22 (s, 1H, FA), 7.94 (s, 1H), 7.23-7.14 (m, 1H), 6.89 (d, J = 14.8 Hz, 4H), 6.67 (d, J = 7.4 Hz, 1H), 4.46 (s, 2H), 4.00-3.87 (m, 1H), 3.84 (s, 6H), 3.75 (s, 1H), 3.72 (s, 1H), 3.61 (s, 3H), 3.56 (s, 2H), 3.28 (t, J = 6.8 Hz, 2H), 2.81 (t, J = 11.9 Hz, 2H), 2.54 (d, J = 6.8 Hz, 2H), 2.22 (s, 6H), 1.93-1.85 (m, 2H), 1.72-1.59 (m, 2H). D125 552.1 ¹H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.14-7.99 (m, 3H), 7.76-7.70 (m, 2H), 7.70-7.59 (m, 4H), 5.16 (dd, J = 13.3, 5.1 Hz, 1H), 4.57 (d, J = 17.5 Hz, 1H), 4.43 (d, J = 17.5 Hz, 1H), 3.63 (s, 3H), 3.00-2.87 (m, 1H), 2.70-2.58 (m, 1H), 2.45-2.32 (m, 1H), 2.11-2.01 (m, 1H). D126 846.4 ¹H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.26 (s, 1H, FA), 7.94 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.21 (s, 1H), 6.90 (s, 2H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.39-4.16 (m, 2H), 4.01-3.97 (m, 1H), 3.90 (d, J = 12.3 Hz, 1H), 3.84 (s, 6H), 3.72 (d, J = 10.4 Hz, 1H), 3.78-3.56 (m, 3H), 3.52 (s, 2H), 3.07-3.02 (m, 1H), 2.98-2.82 (m, 5H), 2.64-2.55 (m, 3H), 2.52-2.28 (m, 1H), 2.19 (s, 6H), 2.03-1.87 (m, 3H), 1.82-1.77 (m, 2H), 1.58-1.51 (m, 2H). D127 846.35 ¹H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 7.6 Hz, 1H), 8.41 (s, 1H), 8.20 (s, 1H, FA), 7.94 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.17- 7.08 (m, 2H), 6.93 (s, 2H), 5.05 (dd, J = 13.2, 5.1 Hz, 1H), 4.45- 4.16 (m, 2H), 4.12 (s, 1H), 4.01 (d, J = 12.4 Hz, 1H), 3.86 (s, 6H), 3.78-3.65 (m, 3H), 3.62 (s, 3H), 3.15 (d, J = 12.9 Hz, 1H), 3.05- 2.82 (m, 5H), 2.64-2.55 (m, 3H), 2.42-2.34 (m, 1H), 2.32 (s, 6H), 2.01-1.87 (m, 3H), 1.81-1.77 (m, 2H), 1.58-1.50 (m, 2H). D128 678.1 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.70 (d, J = 7.7 Hz, 1H), 8.43 (s, 1H), 8.08-7.91 (m, 3H), 7.80 (d, J = 6.7 Hz, 2H), 7.47 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 25.7 Hz, 2H), 5.12 (dd, J = 13.2, 5.1 Hz, 1H), 4.44-4.15 (m, 2H), 4.11-3.90 (m, 1H), 3.82 (d, J = 12.5 Hz, 2H), 3.61 (s, 3H), 3.01-2.91 (m, 2H), 2.90 (s, 1H), 2.74 (s, 1H), 2.73-2.70 (m, 1H), 2.68-2.55 (m, 1H), 2.43- 231 (m, 1H), 2.07-1.85 (m, 3H), 1.80-1.61 (m, 2H). D129 704.3 ¹H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.92 (dd, J = 9.0, 2.9 Hz, 1H), 8.57 (d, J = 2.9 Hz, 1H), 7.89 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.5, 2.6 Hz, 1H), 7.26 (s, 1H), 7.09 (s, 1H), 7.01 (s, 1H), 6.87 (s, 1H), 5.17-5.07 (m, 1H), 4.62-4.57 (m, 1H), 4.36 (d, J = 16.8 Hz, 1H), 4.28-4.10 (m, 2H), 3.92-3.80 (m, 4H), 3.61 (s, 3H), 3.48-3.40 (m, 1H), 3.20-3.09 (m, 1H), 2.99- 2.86 (m, 1H), 2.72-2.56 (m, 3H), 2.44-2.36 (m, 1H), 2.13-1.92 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H). D130 839.4 ¹H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.26-8.96 TFA (m, 1H), 8.83 (s, 1H), 8.47 (s, 1H), 8.02 (s, 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.38-7.22 (m, 2H), 7.02 (s, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.45-4.11 (m, 5H), 4.09-3.76 (m, 9H), 3.67-3.61 (m, 5H), 3.28-3.06 (m, 6H), 3.04-2.85 (m, 3H), 2.84-2.71 (m, 6H), 2.69-2.56 (m, 2H), 2.46-2.26 (m, 2H), 2.23-1.92 (m, 4H), 1.92- 1.72 (m, 2H). D131 706.25 ¹H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.94-8.87 (m, 1H), 8.56 (d, J = 2.8 Hz, 1H), 7.92 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.40-7.32 (m, 1H), 7.26 (d, J = 1.5 Hz, 1H), 6.79 (d, J = 2.2 Hz, 2H), 6.57 (t, J = 2.2 Hz, 1H), 5.15-5.07 (m, 1H), 4.70-4.51 (m, 1H), 4.35 (d, J = 16.8 Hz, 1H), 4.27-4.18 (m, 1H), 4.14 (s, 1H), 3.88 (d, J = 13.0 Hz, 1H), 3.82 (s, 6H), 3.60 (s, 3H), 3.47-3.40 (m, 1H), 3.15-3.11 (m, 1H), 2.94-2.86 (m, 1H), 2.64-2.56 m, 1H), 2.42-2.38 (m, 1H), 2.04-1.89 (m, 3H). D132 696.35 ¹H NMR (400 MHz, DMSO-d6) δ 7.76 (s, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 1.3 Hz, 1H), 6.89 (s, 2H), 6.73-6.66 (m, 2H), 5.02 (dd, J = 13.3, 5.1 Hz, 1H), 4.36-4.12 (m, 2H), 3.84 (s, 6H), 3.72-3.62 (m, 4H), 3.60-3.55 (m, 7H), 2.93-2.80 (m, 1H), 2.70- 2.52 (m, 6H), 2.52-2.25 (m, 1H), 2.43-2.27 (m, 1H), 2.03- 1.95 (m, 1H), 1.80-1.76 (m, 4H). D133 753.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.20 (s, 1H, FA), 7.96 (s, 1H), 7.87 (s, 1H), 7.47 (d, J = 8.2 Hz, 1H), 6.91 (s, 2H), 6.54-6.43 (m, 2H), 5.04 (dd, J = 13.3, 5.1 Hz, 1H), 4.36-4.11 (m, 2H), 3.85 (s, 6H), 3.62 (s, 8H), 3.57-3.51 (m, 3H), 3.30- 3.25 (m, 2H), 3.08-3.02 (m, 2H), 2.99-2.78 (m, 1H), 2.64-2.58 (m, 2H), 2.45-2.24 (m, 4H), 2.00-1.92 (m, 1H), 1.76-1.70 (m, 4H). D134 846.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.38 (s, 1H), 7.89 (s, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.41-7.34 (m, 2H), 7.07 (s, 2H), 5.16 (dd, J = 13.3, 5.1 Hz, 1H), 4.43 (d, J = 10.6 Hz, 4H), 4.02 (s, 6H), 4.00- 3.93 (m, 3H), 3.76 (s, 3H), 3.69-3.57 (m, 2H), 3.39 (s, 2H), 3.24 (d, J = 13.0 Hz, 1H), 2.92 (s, 9H), 2.85-2.81 (m, 1H), 2.55-2.46 (m, 1H), 2.30-2.15 (m, 5H), 1.99-1.87 (m, 2H). D135 846.5 ¹H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 1H, FA), 8.37 (s, 1H), 7.86 (s, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.40-7.33 (m, 2H), 7.05 (s, 2H), 5.15 (d, J = 8.1 Hz, 1H), 4.49-4.41 (m, 3H), 4.35 (d, J = 13.8 Hz, 2H), 4.01 (s, 6H), 3.86 (d, J = 12.1 Hz, 2H), 3.76 (s, 3H), 3.37 (s, 1H), 3.16-3.10 (m, 1H), 2.98-2.91 (m, 1H), 2.89-2.79 (m, 9H), 2.71-2.61 (m, 2H), 2.57-2.49 (m, 2H), 2.25-2.17 (m, 1H), 2.07-1.97 (m, 4H), 1.81-1.68 (m, 2H). D136 670.3 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.68 (s, TFA, 1H), 7.93 (s, 1H), 7.72 (d, J = 5.3 Hz, 1H), 7.66-7.57 (m, 2H), 7.20- 7.12 (m, 2H), 7.08 (s, 2H), 5.07 (dd, J = 13.2, 5.1 Hz, 1H), 4.50 (d, J = 13.9, 4.3 Hz, 1H), 4.43-4.19 (m, 3H), 3.97 (s, 6H), 3.95- 3.74 (m, 4H), 3.73-3.62 (m, 4H), 3.61-3.53 (m, 1H), 2.99-2.85 (m, 1H), 2.64-2.57 (m, 1H), 2.45-2.36 (m, 1H), 2.04-1.93 (m, 1H), 1.50 (dd, J = 6.5, 3.3 Hz, 6H). D137 858.6 ¹H NMR (300 MHz, Methanol-d4) δ 8.36 (s, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.08 (d, J = 1.3 Hz, 2H), 6.79 (d, J = 7.2 Hz, 2H), 5.11 (dd, J = 13.4, 5.1 Hz, 1H), 4.45-4.31 (m, 6H), 4.12-3.90 (m, 9H), 3.88-3.81 (m, 1H), 3.79-3.66 (m, 4H), 3.62-3.54 (m, 2H), 3.03-2.85 (m, 8H), 2.84-2.74 (m, 1H), 2.55- 2.10 (m, 9H). D138 739.45 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.97 (s, 1H, TFA), 8.81 (d, J = 4.9 Hz, 1H), 8.29 (s, 1H), 8.00 (s, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.04 (s, 2H), 6.71 (dd, J = 5.7, 2.4 Hz, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.39-4.13 (m, 4H), 3.95 (s, 6H), 3.76 (s, 2H), 3.64 (s, 4H), 3.38 (d, J = 12.2 Hz, 2H), 3.19-3.09 (m, 2H), 2.94- 2.82 (m, 1H), 2.79 (d, J = 4.2 Hz, 3H), 2.60 (d, J = 16.2 Hz, 1H), 2.43-2.25 (m, 1H), 2.14 (d, J = 13.7 Hz, 2H), 2.06-1.96 (m, 3H). D139 707.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.49 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.8 Hz, 2H), 7.39 (d, J = 8.0 Hz, 1H), 6.97 (s, 2H), 6.70 (d, J = 7.5 Hz, 2H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.36-4.15 (m, 2H), 3.90 (s, 8H), 3.63 (d, J = 4.3 Hz, 8H), 2.96-2.85 (m, 2H), 2.77 (s, 2H), 2.63-2.60 (m, 1H), 2.38 (dd, J = 13.2, 4.6 Hz, 1H), 2.06-1.95 (m, 2H), 1.87 (s, 3H) D140 846.25 ¹H NMR (300 MHz, Acetonitrile-d3) δ 8.29 (s, 1H), 7.74 (s, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.39-7.27 (m, 2H), 6.98 (s, 2H), 5.07 (dd, J = 13.3, 5.2 Hz, 1H), 4.87-4.65 (m, 1H), 4.42-4.23 (m, 3H), 3.94 (s, 7H), 3.83 (s, 1H), 3.64 (d, J = 20.7 Hz, 4H), 3.55- 3.37 (m, 2H), 3.30-2.99 (m, 3H), 2.81-2.80 (m, 6H), 2.52-2.30 (m, 3H), 2.27-2.10 (m, 4H), 1.87 (s, 2H), 1.73 (s, 1H), 1.32 (d, J = 21.7 Hz, 2H). D141 846.2 ¹H NMR (300 MHz, Acetonitrile-d3) δ 8.29 (s, 1H), 7.75 (s, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.41-7.30 (m, 2H), 6.97 (s, 2H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.79 (d, J = 22.1 Hz, 1H), 4.32 (q, J = 10.1, 9.0 Hz, 3H), 3.93 (s, 7H), 3.67 (s, 4H), 3.62-3.48 (m, 3H), 2.95-2.90 (m, 4H), 2.80 (s, 6H), 2.43 (dd, J = 13.1, 5.0 Hz, 1H), 2.22 (q, J = 22.0, 16.5 Hz, 5H), 1.94-1.82 (m, 2H), 1.74 (s, 1H), 1.31 (d, J = 21.7 Hz, 2H). D142 860.5 ¹H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 1.2 Hz, 1H), 8.28 (s, 1H, FA), 7.95 (s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 8.5, 2.4 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 6.92 (s, 2H), 5.16 (dd, J = 13.4, 5.1 Hz, 1H), 4.42-4.13 (m, 3H), 3.84 (s, 6H), 3.80 (s, 2H), 3.62 (s, 3H), 3.57 (s, 2H), 3.17 (s, 1H), 3.00 (s, 3H), 2.96 (dd, J = 12.8, 5.2 Hz, 2H), 2.80-2.69 (m, 3H), 2.62-2.58 (m, 2H), 2.43- 2.35 (m, 2H), 2.22 (s, 6H), 2.04-1.97 (m, 1H), 1.84-1.80 (m, 4H), 1.71-1.46 (m, 2H). D143 777.55 ¹H NMR (400 MHz, DMSO-d6 with a drop of D2O) δ 8.5-8.50 (m, 1H), 8.28 (s, 1H), 7.95 (s, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.38-7.31 (m, 1H), 7.26 (s, 1H), 6.97 (s, 2H), 5.12 (dd, J = 13.3, 4.9 Hz, 1H), 4.58-4.53 (m, 1H), 4.36 (d, J = 16.9 Hz, 1H), 4.22 (dd, J = 17.0, 3.6 Hz, 1H), 4.13 (s, 1H), 4.04 (s, 2H), 3.88 (s, 7H), 3.61 (s, 3H), 3.41-3.28 (m, 1H), 3.11 (t, J = 12.3 Hz, 1H), 2.99 (s, 3H), 2.97- 2.88 (m, 1H), 2.81-2.72 (m, 1H), 2.59 (s, 6H), 2.42-2.34 (m, 1H), 2.06-2.01 (m, 2H), 1.96-1.91 (m, 1H). D144 670.2 ¹H NMR (400 MHz, Methanol-d4) δ 7.77 (s, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.62 (d, J = 5.4 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 10.2 Hz, 2H), 7.09 (s, 2H), 5.24-5.12 (m, 1H), 4.69-4.53 (m, 2H), 4.52-4.37 (m, 3H), 4.04 (s, 6H), 3.88 (s, 2H), 3.76 (s, 3H), 3.74-3.51 (m, 3H), 3.00-2.86 (m, 1H), 2.85-2.76 (m, 1H), 2.61- 2.42 (m, 1H), 2.25-2.15 (m, 1H), 1.62 (d, J = 6.4 Hz, 6H). D145 858.6 ¹H NMR (300 MHz, Methanol-d4) δ 8.57 (br s, 2H, FA), 8.36 (d, J = 1.5 Hz, 1H), 7.88 (s, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 11.0 Hz, 4H), 5.15 (dd, J = 13.7, 6.0 Hz, 1H), 4.67-4.62 (m, 3H), 4.45-4.36 (m, 3H), 4.18 (s, 2H), 3.99 (s, 6H), 3.91-3.81 (m, 2H), 3.76 (s, 3H), 3.67 (s, 1H), 3.53 (s, 2H), 2.94-2.81 (m, 2H), 2.72 (s, 6H), 2.58-2.13 (m, 9H). D146 727.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.68 (m, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.18 (d, J = 2.2 Hz, 1H), 7.44 (m, J = 8.5 Hz, 1H), 7.21 (m, J = 2.3 Hz, 1H), 6.95 (s, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.45-4.26 (m, 1H), 4.25-4.12 (m, 1H), 4.05-3.95 (m, 2H), 3.92 (s, 6H), 3.83-3.81 (m, 1H), 3.80-3.76 (m, 2H), 3.62 (s, 3H), 3.00-2.81 (m, 3H), 2.55 (s, 2H), 2.39 (s, 6H), 2.06-1.96 (m, 1H), 1.95-1.81 (m, 2H), 1.78-1.55 (m, 2H). D147 645.3 ¹H NMR (300 MHz, Methanol-d4) δ 8.52 (s, 0.2H, FA), 7.75 (s, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.38-7.32 (m, 2H), 7.04 (s, 2H), 5.16 (dd, J = 13.3, 5.2 Hz, 1H), 4.49-4.35 (m, 2H), 4.16 (s, 2H), 3.99 (s, 6H), 3.42 (s, 4H), 3.17 (m, 4H), 2.94-2.85 (m, 1H), 2.85-2.75 (m, 1H), 2.56-2.45 (m, 1H), 2.24-2.13 (m, 1H). D148 860.5 ¹H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.41 (d, J = 8.9 Hz, 1H), 7.95 (d, J = 1.3 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.27 (dd, J = 8.5, 2.4 Hz, 1H), 7.17 (d, J = 2.4 Hz, 1H), 6.99 (d, J = 4.5 Hz, 2H), 5.10 (dd, J = 13.2, 5.1 Hz, 1H), 4.43-4.03 (m, 5H), 3.91 (d, J = 3.2 Hz, 6H), 3.82 (d, J = 11.9 Hz, 2H), 3.59 (s, 3H), 3.16 (s, 1H), 2.92 (s, 2H), 2.77 (s, 3H), 2.75-2.56 (m, 11H), 2.46-2.30 (m, 2H), 1.99 (d, J = 12.0 Hz, 1H), 1.80 (s, 4H), 1.56 (d, J = 12.7 Hz, 2H). D149 767.4 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H, FA), 8.27 (s, 1H), 7.85 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.39-7.30 (m, 2H), 7.05 (s, 2H), 5.15 (dd, J = 13.3, 5.2 Hz, 1H), 4.53 (t, J = 8.3 Hz, 1H), 4.52- 4.34 (m, 2H), 4.31 (s, 2H), 4.01 (s, 6H), 3.75 (s, 3H), 3.31-3.17 (m, 4H), 2.99-2.72 (m, 8H), 2.59-2.43 (m, 1H), 2.46-2.36 (m, 2H), 2.23-2.13 (m, 1H), 2.01-1.97 (m, 2H), 1.88 (t, J = 5.6 Hz, 2H), 1.82 (t, J = 5.6 Hz, 2H). D150 810.55 ¹H NMR (300 MHz, Methanol-d4) δ 8.54 (s, FA 2H), 8.27 (s, 1H), 7.87 (s, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.35 (d, J = 10.4 Hz, 2H), 7.07 (s, 2H), 5.16 (dd, J = 13.3, 5.2 Hz, 1H), 4.53-4.33 (m, 4H), 4.11-3.97 (m, 7H), 3.96-3.86 (m, 2H), 3.75 (s, 3H), 3.02-2.87 (m, 8H), 2.87-2.65 (m, 6H), 2.58-2.43 (m, 1H), 2.30-2.01 (m, 6H), 1.94-1.69 (m, 4H). D151 763.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.17 (s, 1H), 9.01- 8.91 (m, 1H), 8.59 (d, J = 1.8 Hz, 1H), 8.02 (s, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.23-7.12 (m, 2H), 7.04 (s, 2H), 5.13-5.01 (m, 1H), 4.62 (s, 1H), 4.41-4.16 (m, 6H), 4.01 (s, 1H), 3.93 (s, 6H), 3.63 (s, 3H), 3.49 (dd, J = 30.5, 13.7 Hz, 1H), 3.22 (t, J = 12.3 Hz, 1H), 2.92 (s, 1H), 2.78 (d, J = 4.6 Hz, 6H), 2.60 (d, J = 17.0 Hz, 1H), 2.40 (d, J = 13.6 Hz, 1H), 2.00 (dd, J = 20.3, 10.8 Hz, 3H). D152 763.35 ¹H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.08 (s, 1H), 9.00- 8.90 (m, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.02 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.42-7.32 (m, 1H), 7.28 (d, J = 9.0 Hz, 1H), 7.04 (s, 2H), 5.18-5.05 (m, 1H), 4.60 (s, 1H), 4.36 (d, J = 16.9 Hz, 1H), 4.25 (d, J = 4.4 Hz, 3H), 4.23-4.08 (m, 1H), 3.93 (s, 6H), 3.63 (s, 3H), 3.54-3.07 (m, 3H), 3.02-2.84 (m, 1H), 2.82-2.80 (m, 1H), 2.78 (d, J = 4.6 Hz, 6H), 2.61 (d, J = 16.5 Hz, 1H), 2.46-2.35 (m, 1H), 1.98 (d, J = 25.6 Hz, 3H). D153 794.2 ¹H NMR (400 MHz, Methanol-d4) δ 8.35 (s, 3H, FA), 7.62 (d, J = 5.4 Hz, 1H), 7.47-7.37 (m, 2H), 6.90-6.82 (m, 3H), 6.79 (d, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.47-4.32 (m, 4H), 3.95 (s, 6H), 3.75 (s, 3H), 3.72 (s, 4H), 3.59 (d, J = 12.0 Hz, 2H), 3.23-3.19 (m, 1H), 3.01-3.75 (m, 6H), 2.68 (s, 3H), 2.57-2.44 (m, 1H), 2.41 (s, 3H), 2.23-2.15 (m, 1H), 2.13-2.01 (m, 7H), 1.63 (s, 2H). D154 683.3 ¹H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.50-9.43 (m, 1H, TFA), 7.94 (s, 1H), 7.72 (d, J = 5.4 Hz, 1H), 7.67-7.60 (m, 2H), 7.34-7.24 (m, 2H), 7.09 (s, 2H), 5.09 (dd, J = 13.3, 5.1 Hz, 1H), 4.97-4.62 (m, 1H), 4.59-4.49 (m, 1H), 4.40 (d, J = 17.0 Hz, 1H), 4.28 (d, J = 16.9 Hz, 1H), 4.09 (d, J = 13.1 Hz, 1H), 3.98 (s, 6H), 3.83 (d, J = 13.9 Hz, 1H), 3.64 (s, 3H), 3.58 (d, J = 13.5 Hz, 2H), 3.29 (t, J = 11.8 Hz, 1H), 3.07 (d, J = 12.9 Hz, 1H), 2.93 (ddd, J = 17.9, 13.5, 5.4 Hz, 1H), 2.77-2.54 (m, 3H), 2.40 (td, J = 13.1, 4.5 Hz, 1H), 2.14 (s, 3H), 2.03-1.88 (m, 2H). D155 763.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 1H, FA), 8.36 (d, J = 0.7 Hz, 1H), 7.87 (s, 1H), 7.68 (d, J = 9.3 Hz, 1H), 7.20-7.14 (m, 2H), 7.07 (s, 2H), 5.17-5.08 (m, 1H), 4.73-4.63 (m, 1H), 4.50- 4.42 (m, 2H), 4.38 (s, 2H), 4.34-4.22 (m, 1H), 4.09 (d, J = 13.7 Hz, 1H), 4.02 (s, 6H), 3.75 (s, 3H), 3.44-3.38 (m, 1H), 3.23- 3.14 (m, 1H), 2.98-2.92 (m, 1H), 2.89 (s, 6H), 2.83-2.76 (m, 1H), 2.55-2.44 (m, 1H), 2.23-2.13 (m, 2H), 2.13-2.02 (m, 1H). D156 763.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H, FA), 8.38 (s, 1H), 7.87 (s, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.43-7.35 (m, 2H), 7.07 (s, 2H), 5.20-5.13 (m, 1H), 4.71-4.59 (m, 2H), 4.51-4.41 (m, 2H), 4.37 (s, 2H), 4.10 (s, 1H), 4.02 (s, 6H), 3.93 (d, J = 12.9 Hz, 1H), 3.75 (s, 3H), 3.16-3.08 (m, 1H), 2.98-2.91 (m, 1H), 2.87 (s, 6H), 2.84-2.78 (m, 1H), 2.58-2.47 (m, 1H), 2.26-2.15 (m, 2H), 2.13-2.04 (m, 1H). D157 844.35 ¹H NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 7.90 (s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.17 (s, 2H), 7.11 (s, 1H), 5.05 (dd, J = 13.4, 4.8 Hz, 1H), 4.40-4.15 (m, 3H), 3.86 (s, 4H), 3.82-3.80 (m, 3H), 3.61 (s, 3H), 3.16 (s, 1H), 2.95-2.80 (m, 2H), 2.80-2.65 (m, 4H), 2.64-2.54 (m, 3H), 2.51 (s, 6H), 2.45- 2.35 (m, 2H), 2.04-1.96 (m, 1H), 1.87-1.75 (m, 4H), 1.64-1.47 (m, 2H), 1.17 (t, J = 7.6 Hz, 3H). D158 696.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.92 (s, 1H, TFA salt), 7.53 (s, 2H), 7.42 (d, J = 8.9 Hz, 1H), 6.84 (s, 2H), 6.72 (s, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.39-4.17 (m, 4H), 3.88 (s, 6H), 3.77 (s, 2H), 3.65 (s, 2H), 3.62 (s, 3H), 3.21-3.12 (m, 2H), 2.98-2.85 (m, 1H), 2.64-2.60 (m, 2H), 2.57 (s, 1H), 2.42-2.37 (m, 1H), 2.35 (s, 3H), 2.14 (d, J = 14.0 Hz, 2H), 2.00 (t, J = 11.7 Hz, 3H). D159 849.4 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H, FA), 8.39 (d, J = 5.2 Hz, 1H), 7.86 (s, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.34 (s, 1H), 7.23 (d, J = 8.3, 2.4 Hz, 1H), 7.05 (s, 2H), 5.17 (dd, J = 13.3, 6.9, 5.1 Hz, 1H), 4.49-4.39 (m, 3H), 4.35 (s, 2H), 4.11 (t, 2H), 4.01 (s, 6H), 3.75 (s, 3H), 3.29-3.14 (m, 1H), 3.07-2.98 (m, 1H), 2.97- 2.88 (m, 1H), 2.86 (s, 6H), 2.83-2.76 (m, 1H), 2.59-2.47 (m, 3H), 2.45-2.33 (m, 1H), 2.32-2.25 (m, 1H), 2.24-2.15 (m, 1H), 2.08-1.98 (m, 1H), 1.98-1.92 (m, 1H), 1.92-1.83 (m, 2H), 1.69- 1.52 (m, 4H). D160 822.4 ¹H NMR (400 MHz, Methanol-d4) δ 7.82 (d, J = 8.2 Hz, 1H), 7.67 (s, 1H), 7.30 (d, J = 2.3 Hz, 1H), 7.25 (dd, J = 8.3, 2.3 Hz, 1H), 7.14 (d, J = 1.3 Hz, 1H), 7.04 (d, J = 3.1 Hz, 2H), 5.12 (dd, J = 12.5, 5.4 Hz, 1H), 4.98 (d, J = 6.5 Hz, 1H), 4.40 (s, 2H), 4.00-3.99 (s, 6H), 3.69-3.63 (s, 3H), 3.60-3.49 (m, 4H), 3.37 (s, 1H), 3.23- 3.12 (m, 2H), 3.12-3.07 (m, 2H), 3.07-2.93 (m, 1H), 2.92- 2.74 (m, 4H), 2.66 (d, J = 1.2 Hz, 3H), 2.65 (s, 1H), 2.05 (m, 1H), 2.16-2.05 (m, 6H), 2.03-1.97 (m, 3H), 1.64 (q, J = 12.1 Hz, 2H). D161 807.43 D162 846.35 ¹H NMR (400 MHz, Methanol-d4 with a drop of D2O) δ 8.37 (s, 1H), 8.36 (br s, 1H, FA), 7.87 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.39- 7.31 (m, 2H), 7.08 (s, 2H), 5.15 (dd, J = 13.3, 5.2 Hz, 1H), 4.49- 4.34 (m, 5H), 4.02 (s, 6H), 3.86 (d, J = 12.3 Hz, 2H), 3.75 (s, 3H), 3.30-3.26 (m, 1H), 3.16-3.09 (m, 1H), 2.92 (s, 7H), 2.86-2.74 (m, 3H), 2.71-2.60 (m, 2H), 2.56-2.48 (m, 2H), 2.24-2.15 (m, 1H), 2.05-1.92 (m, 4H), 1.71 (q, J = 12.6 Hz, 2H). D163 849.4 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.88 (d, J = 8.8 Hz, 1H), 8.59 (s, 1H), 8.24 (s, 1H, FA), 7.97 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.05 (d, J = 8.4, 2.2 Hz, 1H), 6.93 (s, 2H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.33 (q, J = 22.5 Hz, 3H), 4.07 (t, J = 6.3 Hz, 2H), 3.85 (s, 6H), 3.62 (s, 5H), 3.20-3.08 (m, 1H), 2.97-2.83 (m, 2H), 2.66-2.56 (m, 1H), 2.46-2.31 (m, 4H), 2.26 (s, 6H), 2.20-2.08 (m, 1H), 2.05-1.92 (m, 1H), 1.91- 1.82 (m, 1H), 1.83-1.71 (m, 3H), 1.57-1.38 (m, 4H). D164 763.2 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.97-8.90 (m, 1H), 8.57 (d, J = 2.5 Hz, 1H), 8.27 (s, 1H, FA), 7.96 (s, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.23-7.14 (m, 2H), 6.91 (s, 2H), 5.10-5.02 (m, 1H), 4.75-4.56 (m, 1H), 4.41-4.16 (m, 3H), 4.04-3.92 (m, 1H), 3.84 (s, 6H), 3.51 (s, 3H), 3.57-3.46 (m, 2H), 3.22 (t, J = 12.3 Hz, 1H), 2.97-2.85 (m, 1H), 2.69-2.56 (m, 1H), 2.45-2.32 (m, 1H), 2.17 (s, 6H), 2.06-1.89 (m, 3H). D165 763.35 ¹H NMR (300 MHz, Methanol-d4) δ 8.55 (s, FA, 1H), 8.37 (s, 1H), 7.86 (s, 1H), 7.54-7.45 (m, 1H), 7.43-7.32 (m, 2H), 7.07 (s, 2H), 5.23-5.11 (m, 1H), 4.74-4.56 (m, 1H), 4.48-4.35 (m, 4H), 4.12- 4.02 (m, 7H), 3.97-3.87 (m, 1H), 3.78-3.72 (s, 3H), 3.27-3.05 (m, 2H), 2.88-2.78 (m, 8H), 2.56-2.47 (m, 1H), 2.28-2.14 (m, 2H), 2.13-2.05 (m, 1H). D166 875.5 ¹H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.06 (s, 1H, TFA salt), 8.91 (dd, J = 9.0, 2.8 Hz, 1H), 8.61 (s, 1H), 8.01 (s, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.38-7.27 (m, 2H), 7.03 (s, 2H), 5.10 (dd, J = 13.2, 5.1 Hz, 1H), 4.38 (d, J = 17.0 Hz, 2H), 4.28-4.19 (m, 3H), 3.92 (s, 6H), 3.63 (s, 3H), 3.57-3.45 (m, 7H), 3.37-3.35 (m, 4H), 3.05-2.99 (m, 1H), 2.93-2.89 (m, 1H), 2.88-2.83 (m, 2H), 2.80- 2.74 (m, 6H), 2.65-2.58 (m, 2H), 2.43-2.36 (m, 2H), 2.05- 1.96 (m, 1H), 1.94-1.76 (m, 2H). D167 846.4 ¹H NMR (300 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.88 (d, J = 8.7 Hz, 1H), 8.60 (s, 1H), 8.23 (s, 2H, FA salt), 7.97 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.28 (dd, J = 8.5, 2.3 Hz, 1H), 7.17 (d, J = 2.3 Hz, 1H), 6.93 (s, 2H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.53-4.09 (m, 4H), 3.86 (s, 6H), 3.80 (s, 2H), 3.64 (d, J = 8.8 Hz, 5H), 3.20- 3.14 (m, 1H), 2.99-2.83 (m, 2H), 2.74 (t, J = 11.9 Hz, 2H), 2.65- 2.54 (m, 3H), 2.44-2.34 (m, 1H), 2.29 (s, 6H), 2.04-1.94 (m, 1H), 1.85-1.79 (m, 4H), 1.62-1.52 (m, 2H). D168 629.15 ¹H NMR (400 MHz, Methanol-d4) δ 7.77 (s, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.64-7.56 (m, 2H), 7.26 (d, J = 8.5 Hz, 1H), 7.21 (s, 1H), 7.08 (s, 2H), 5.38-5.06 (m, 2H), 4.76 (s, 2H), 4.65 (d, J = 16.6 Hz, 2H), 4.55-4.40 (m, 2H), 4.37-4.32 (m, 2H), 4.08-3.95 (m, 6H), 3.75 (s, 3H), 2.98-2.86 (m, 1H), 2.85-2.76 (m, 1H), 2.58- 2.45 (m, 1H), 2.22-2.18 (m, 1H). D169 643.1 ¹H NMR (400 MHz, Methanol-d4) δ 7.90 (d, J = 8.3 Hz, 1H), 7.77 (s, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 5.4 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.32 (dd, J = 8.3, 2.3 Hz, 1H), 7.08 (s, 2H), 5.34 (s, 1H), 5.15 (dd, J = 12.5, 5.4 Hz, 1H), 4.78 (dd, J = 12.0, 6.3 Hz, 2H), 4.64 (s, 2H), 4.38 (d, J = 10.8 Hz, 2H), 4.00 (s, 6H), 3.75 (s, 3H), 2.96-2.83 (m, 1H), 2.83-2.66 (m, 2H), 2.20-2.10 (m, 1H). D170 629.1 ¹H NMR (400 MHz, Methanol-d4) δ 7.83-7.74 (m, 2H), 7.71 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 5.4 Hz, 1H), 7.13-7.05 (m, 4H), 5.38- 5.08 (m, 2H), 4.77 (s, 2H), 4.66 (s, 2H), 4.55-4.40 (m, 2H), 4.35 (s, 2H), 4.07-3.92 (m, 6H), 3.75 (s, 3H), 3.00-2.86 (m, 1H), 2.85-2.75 (m, 1H), 2.57-2.42 (m, 1H), 2.27-2.10 (m, 1H). D171 889.45 ¹H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.08 (s, 1H, TFA salt), 8.83 (d, J = 8.7 Hz, 1H), 8.53 (s, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.40-7.28 (m, 2H), 6.82 (d, J = 2.2 Hz, 2H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.42-4.22 (m, 5H), 3.86 (s, 6H), 3.62 (s, 3H), 3.50-3.45 (m, 8H), 3.07-2.95 (m, 2H), 2.95-2.90 (m, 1H), 2.89- 2.74 (m, 9H), 2.68-2.54 (m, 2H), 2.45-2.30 (m, 6H), 2.01- 1.79 (m, 3H). D172 941.40 ¹H NMR (300 MHz, MeOD) δ 8.27 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 6.92-6.76 (m, 4H), 5.14 (dd, J = 13.2, 5.1 Hz, 1H), 4.85-4.68 (m, 1H), 4.67-4.51 (m, 2H), 4.48-4.31 (m, 4H), 4.23-4.18 (m, 2H), 3.96 (s, 7H), 3.81-3.70 (m, 7H), 3.69-3.39 (m, 8H), 3.26-3.05 (m, 2H), 3.02-2.72 (m, 5H), 2.60-2.40 (m, 4H), 2.36-2.08 (m, 7H). D173 822.35 ¹H NMR (300 MHz, Methanol-d4) δ 8.39 (s, 1H, FA), 7.82 (d, J = 8.3 Hz, 1H), 7.71 (s, 1H), 7.36 (d, J = 1.4 Hz, 1H), 7.33-7.22 (m, 2H), 7.04 (s, 2H), 5.13 (dd, J = 12.4, 5.4 Hz, 1H), 5.03-4.96 (m, 1H), 4.69-4.59 (m, 1H), 4.40 (s, 2H), 4.01 (s, 6H), 3.74 (s, 3H), 3.63-3.52 (m, 2H), 3.22-3.13 (m, 2H), 3.11-2.96 (m, 3H), 2.93- 2.70 (m, 5H), 2.64-2.56 (m, 5H), 2.23-2.04 (m, 6H), 2.02- 1.87 (m, 4H), 1.91-1.53 (m, 2H). D174 794.25 ¹H NMR (400 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.69-7.59 (m, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.16-7.07 (m, 2H), 6.99 (s, 2H), 4.99 (dd, J = 13.3, 5.1 Hz, 1H), 4.86-4.78 (m, 1H), 4.42-4.24 (m, 2H), 4.21 (d, J = 6.4 Hz, 2H), 3.88 (s, 6H), 3.60 (s, 3H), 3.37 (dd, J = 28.0, 12.1 Hz, 4H), 3.16 (s, 1H), 3.01 (t, J = 12.7 Hz, 2H), 2.92 (d, J = 6.9 Hz, 2H), 2.90-2.78 (m, 2H), 2.70-2.64 (m, 1H), 2.39 (s, 2H), 2.08-1.73 (m, 11H), 1.44 (q, J = 12.1 Hz, 2H). D175 915.35 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.07 (s, 1H, TFA salt), 8.93 (d, J = 8.8 Hz, 1H), 8.62 (s, 1H), 8.02 (s, 1H), 7.42 (d, J = 8.9 Hz, 1H), 7.03 (s, 2H), 6.77-6.65 (m, 2H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.49-4.38 (m, 1H), 4.39-4.14 (m, 5H), 3.93 (s, 6H), 3.70 (s, 2H), 3.64 (s, 3H), 3.29 (s, 6H), 3.07-2.95 (m, 2H), 2.95- 2.89 (m, 1H), 2.91-2.69 (m, 9H), 2.68-2.56 (m, 2H), 2.45-2.28 (m, 2H), 2.17-1.78 (m, 7H). D176 682.45 ¹H NMR (400 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.32 (d, J = 7.7 Hz, 1H, TFA), 7.94 (s, 1H), 7.72 (d, J = 5.4 Hz, 1H), 7.63 (d, J = 5.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.49-7.39 (m, 2H), 7.09 (s, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.53 (dd, J = 13.2, 7.9 Hz, 1H), 4.40 (d, J = 16.9 Hz, 1H), 4.27 (dd, J = 17.3, 1.8 Hz, 1H), 4.09 (d, J = 13.1 Hz, 1H), 3.98 (s, 6H), 3.88 (d, J = 13.7 Hz, 1H), 3.73 (s, 2H), 3.64 (s, 2H), 3.51 (s, 1H), 3.47 (d, J = 7.4 Hz, 1H), 3.31 (s, 1H), 3.08 (d, J = 12.8 Hz, 1H), 3.00-2.87 (m, 1H), 2.61 (d, J = 19.7 Hz, 3H), 2.40 (dt, J = 13.3, 6.7 Hz, 1H), 2.22 (d, J = 10.8 Hz, 2H), 2.12 (q, J = 8.9, 8.5 Hz, 1H), 2.06-1.98 (m, 1H), 1.92 (d, J = 11.0 Hz, 1H). D177 749.25 ¹H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H, FA), 8.39 (s, 1H), 7.86 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.05 (s, 3H), 7.03-6.97 (m, 1H), 5.24-5.12 (m, 2H), 4.48-4.35 (m, 2H), 4.21 (s, 2H), 4.06- 3.97 (m, 7H), 3.96-3.83 (m, 2H), 3.75 (s, 3H), 3.57 (t, J = 8.4 Hz, 1H), 2.99-2.87 (m, 1H), 2.85-2.80 (m, 1H), 2.74 (s, 6H), 2.56- 2.46 (m, 1H), 2.24-2.15 (m, 1H). D178 682.2 ¹H NMR (400 MHz, DMSO-d6) δ 10.94 (s, 1H), 8.28 (s, 1H), 7.87 (s, 1H), 7.69 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.3 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 6.92 (s, 2H), 6.54-6.44 (m, 2H), 5.03 (dd, J = 13.3, 5.1 Hz, 1H), 4.30 (d, J = 16.9 Hz, 1H), 4.17 (d, J = 16.8 Hz, 1H), 3.85 (s, 6H), 3.61 (s, 6H), 3.52 (s, 2H), 2.98-2.83 (m, 1H), 2.58 (d, J = 17.1 Hz, 1H), 2.46-2.28 (m, 6H), 2.02-1.88 (m, 1H), 1.72 (t, J = 5.3 Hz, 4H). D179 848.25 ¹H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.01 (s, 1H), 8.95 (s, 1H, TFA), 8.61 (s, 1H), 8.02 (s, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.03 (s, 2H), 6.71 (d, J = 7.9 Hz, 1H), 6.17 (s, 1H), 5.24 (dd, J = 12.4, 5.2 Hz, 1H), 4.25 (d, J = 5.0 Hz, 2H), 3.93 (s, 9H), 3.64 (s, 3H), 2.92-2.83 (m, 4H), 2.81-2.75 (m, 7H), 2.68-2.59 (m, 2H), 2.51-2.41 (m, 2H), 2.17-2.04 (m, 2H), 1.98-1.82 (m, 4H), 1.64- 1.47 (m, 2H). D180 749.3 ¹H NMR (300 MHz, Methanol-d4) δ 8.38 (s, 1H), 7.88 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.08 (s, 2H), 6.88-6.68 (m, 2H), 5.32-5.07 (m, 2H), 4.54-4.3 (m, 4H), 4.03 (s, 6H), 3.99-3.88 (m, 2H), 3.75 (s, 3H), 3.67-3.54 (m, 1H), 2.92 (s, 7H), 2.83-2.72 (m, 2H), 2.58- 2.38 (m, 1H), 2.23-2.09 (m, 1H). D181 832.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H, FA), 8.32 (s, 1H), 7.86 (s, 1H), 7.65 (d, 1H), 7.11 (d, J = 7.6 Hz, 2H), 7.05 (s, 2H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.83-4.77 (m, 1H), 4.48-4.35 (d, J = 16.8 Hz, 2H), 4.32 (s, 2H), 4.01 (s, 6H), 3.93 (d, J = 13.0 Hz, 2H), 3.75 (s, 3H), 3.45-3.38 (m, 2H), 3.08-2.95 (m, 3H), 2.95- 2.89 (m, 1H), 2.84 (s, 6H), 2.81-2.70 (m, 2H), 2.57-2.42 (m, 2H), 2.21-2.13 (m, 1H), 2.04 (t, J = 12.7 Hz, 2H), 1.74-1.56 (m, 2H). D182 832.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.65 (br s, FA, 1H), 8.33 (s, 1H), 7.86 (s, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.39-7.30 (m, 2H), 7.06 (s, 2H), 5.15 (dd, J = 13.4, 5.1 Hz, 1H), 4.83-4.78(m, 1H), 4.51-4.39 (m, 2H), 4.33 (s, 2H), 4.01 (s, 6H), 3.87-3.68 (m, 5H), 3.48-3.39 (m, 2H), 3.08-2.96 (m, 1H), 2.97-2.88 (m, 3H), 2.85 (s, 6H), 2.83-2.71 (m, 2H), 2.58-2.39 (m, 2H), 2.23-2.15 (m, 1H), 2.13-1.98 (m, 2H), 1.79-1.59(m, 2H). D183 696.15 ¹H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.21 (s, 1H, FA), 7.87 (s, 1H), 7.69 (d, J = 5.4 Hz, 1H), 7.66-7.55 (m, 2H), 6.93 (s, 2H), 6.78 (d, J = 2.1 Hz, 1H), 6.69-6.60 (m, 1H), 5.12-4.97 (m, 1H), 3.85 (s, 6H), 3.73 (s, 4H), 3.62 (s, 3H), 3.53 (s, 2H), 2.97- 2.81 (m, 1H), 2.70-2.53 (m, 2H), 2.46-2.31 (m, 4H), 2.07-1.95 (m, 1H), 1.80-1.67 (m, 4H). D184 807.35 ¹H NMR (300 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.45 (s, 1H, TFA salt), 9.23 (s, 1H, TFA salt), 7.85 (s, 1H), 7.69 (dd, J = 8.3, 2.6 Hz, 1H), 7.33 (d, J = 1.4 Hz, 1H), 7.03 (s, 2H), 6.78 (d, J = 2.2 Hz, 1H), 6.66 (dd, J = 8.3, 2.1 Hz, 1H), 5.06 (dd, J = 12.9, 5.4 Hz, 1H), 4.35- 4.19 (m, 2H), 3.99-3.79 (m, 10H), 3.61 (s, 3H), 3.54-3.50 (m, 2H), 3.48-3.46 (m, 2H), 3.25-3.16 (m, 2H), 3.10-2.83 (m, 7H), 2.66-2.60 (m, 1H), 2.56-2.53 (m, 3H), 2.20-2.10 (m, 2H), 2.06- 1.88 (m, 5H), 1.58-1.39 (m, 2H). D185 793.25 ¹H NMR (300 MHz, Methanol-d4) δ 8.49 (s, 1H, FA), 7.80-7.57 (m, 4H), 7.07 (s, 2H), 6.83 (d, J = 2.0 Hz, 1H), 6.67 (dd, J = 8.4, 2.1 Hz, 1H), 5.07 (dd, J = 12.4, 5.4 Hz, 1H), 4.39 (s, 2H), 4.01 (s, 6H), 3.79 (d, J = 16.3 Hz, 7H), 3.55 (d, J = 11.6 Hz, 2H), 3.23- 3.07 (m, 2H), 2.96-2.81 (m, 1H), 2.81-2.67 (m, 2H), 2.58 (s, 4H), 2.39 (s, 2H), 2.16-2.00 (m, 3H), 1.99-1.89 (m, 5H), 1.55 (s, 2H). D186 682.2 ¹H NMR (400 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.73-7.55 (m, 2H), 7.40 (d, J = 8.9 Hz, 1H), 6.98 (s, 2H), 6.83-6.67 (m, 2H), 5.09- 4.91 (m, 1H), 4.44-4.12 (m, 4H), 3.89 (s, 6H), 3.73 (s, 2H), 3.61 (s, 5H), 3.34 (d, J = 12.2 Hz, 2H), 3.09 (t, J = 11.9 Hz, 2H), 2.90- 2.75 (m, 1H), 2.70-2.57 (m, 1H), 2.44-2.28 (m, 1H), 2.17-1.88 (m, 5H). D187 846.1 ¹H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.97 (d, J = 8.4 Hz, 1H), 8.53 (s, 1H), 8.18 (s, 1H, FA), 7.98 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.36 (s, 1H), 7.28 (dd, J = 8.7, 2.3 Hz, 1H), 6.92 (s, 2H), 5.08 (dd, J = 12.9, 5.4 Hz, 1H), 4.71-4.58 (m, 1H), 4.01 (d, J = 12.9 Hz, 2H), 3.85 (s, 6H), 3.62 (s, 3H), 3.56 (s, 2H), 3.08 (t, J = 11.7 Hz, 3H), 2.96-2.76(m, 3H), 2.73-2.53 (m, 4H), 2.22 (s, 6H), 2.08-1.86 (m, 3H), 1.53-1.46 (m, 2H). D188 927.58 ¹H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 2H, FA), 8.36 (s, 1H), 7.85 (s, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.06 (s, 2H), 6.85 (d, J = 2.1 Hz, 1H), 6.77 (dd, J = 8.2, 2.2 Hz, 1H), 5.14 (dd, J = 13.2, 5.1 Hz, 1H), 4.62 (s, 1H), 4.47 (s, 2H), 4.46-4.32 (m, 2H), 4.22 (t, J = 9.6 Hz, 2H), 4.02 (s, 6H), 3.95 (t, J = 9.3 Hz, 2H), 3.75 (s, 3H), 3.67 (s, 4H), 3.23-3.04 (m, 2H), 2.99-2.89 (m, 2H), 2.85-2.74(m, 1H), 2.69 (d, J = 6.9 Hz, 2H), 2.55-2.45 (m, 5H), 2.39 (s, 3H), 2.29 (t, J = 11.7 Hz, 1H), 2.21-2.13 (m, 1H), 2.08-1.99 (m, 1H), 1.98- 1.86 (m, 4H), 1.31 (s, 2H). D189 808.35 ¹H NMR (300 MHz, DMSO-d6) δ 11.14 (s, 1H), 9.22 (s, 2H, TFA), 7.94-7.83 (m, 2H), 7.75-7.60 (m, 2H), 7.37-7.26 (m, 2H), 7.06 (d, J = 1.7 Hz, 2H), 5.17-4.97 (m, 2H), 4.27 (d, J = 27.8 Hz, 2H), 3.94 (s, 6H), 3.63 (s, 3H), 3.55-3.49 (m, 1H), 3.46 (s, 3H), 3.26- 3.17 (m, 2H), 3.06-2.83 (m, 6H), 2.68-2.53 (m, 3H), 2.10-1.79 (m, 10H), 1.58-1.39 (m, 2H). D190 763.15 ¹H NMR (300 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.25 (d, J = 8.5 Hz, 1H), 8.55 (s, 1H), 8.17 (s, 1H, FA), 7.99 (s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 2.2 Hz, 1H), 6.97 (dd, J = 8.5, 2.2 Hz, 1H), 6.93 (s, 2H), 5.16-5.04 (m, 2H), 4.14-4.01 (m, 3H), 3.86 (s, 6H), 3.66-3.57 (m, 6H), 3.00-2.81 (m, 1H), 2.65-2.54 (m, 2H), 2.25 (s, 6H), 2.07-2.01 (m, 1H). D191 832.4 ¹H NMR (300 MHz, Methanol-d4) δ 8.56 (s, FA, 1H), 8.34 (s, 1H), 7.84 (s, 1H), 7.62 (d, J = 8.3 Hz, 1H), 7.02 (s, 2H), 6.82 (d, J = 2.1 Hz, 1H), 6.65 (dd, J = 8.3, 2.1 Hz, 1H), 5.07 (dd, J = 12.4, 5.4 Hz, 1H), 4.60-4.39 (m, 1H), 4.27 (s, 2H), 4.15 (t, J = 7.8 Hz, 2H), 4.00 (s, 6H), 3.96-3.83 (m, 2H), 3.72 (s, 3H), 3.63-3.51 (m, 1H), 3.28- 3.21 (m, 1H), 3.09-3.00 (m, 1H), 2.95-2.60 (m, 9H), 2.58- 2.39 (m, 1H), 2.36-2.23 (m, 1H), 2.18-1.93 (m, 3H). D192 777.25 ¹H NMR (300 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.05 (s, 1H, TFA), 8.94 (d, J = 8.8 Hz, 1H), 8.57 (s, 1H), 8.02 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.51 (s, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.04 (s, 2H), 5.10 (dd, J = 12.8, 5.3 Hz, 1H), 4.76-4.63 (m, 1H), 4.58-4.52 (m, 1H), 4.25 (d, J = 4.8 Hz, 2H), 4.18 (d, J = 13.6 Hz, 1H), 3.93 (s, 6H), 3.76-3.51 (m, 5H), 2.93-2.83 (m, 1H), 2.82-2.75 (m, 6H), 2.66-2.54 (m, 2H), 2.09-1.92 (m, 3H). D193 794.2 ¹H NMR (300 MHz, DMSO-d6) δ 8.28 (s, 3H), 8.08 (d, J = 5.4 Hz, 1H), 7.76 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 5.1 Hz, 1H), 7.03 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.82 (s, 2H), 5.02 (dd, J = 13.2, 5.1 Hz, 1H), 4.85-4.74 (m, 1H), 4.38 (d, J = 17.1 Hz, 1H), 4.24 (d, J = 17.1 Hz, 1H), 3.96 (s, 2H), 3.86 (s, 6H), 3.62 (s, 3H), 3.16 (d, J = 9 Hz, 2H), 2.96-2.80 (m, 1H), 2.74-2.52 (m, 3H), 2.48-2.12 (m, 9H), 2.05-1.90 (m, 1H), 1.85-1.50 (m, 9H), 1.40- 1.20 (m, 2H). D194 642.15 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.69 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.3 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.25 (dd, J = 8.5, 2.4 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 6.94 (s, 2H), 5.09 (dd, J = 13.3, 5.1 Hz, 1H), 4.37-4.14 (m, 2H), 3.87 (s, 6H), 3.62 (d, J = 3.5 Hz, 5H), 3.17 (t, J = 4.9 Hz, 4H), 2.91 (ddd, J = 17.2, 13.6, 5.4 Hz, 1H), 2.61 (d, J = 5.0 Hz, 5H), 2.45-2.33 (m, 1H), 2.03-1.95 (m, 1H). D195 874.2 ¹H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.89 (d, J = 9.0 Hz, 1H), 8.59 (s, 1H), 8.26 (s, 3H, FA), 7.96 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.50 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 6.92 (s, 2H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.43-4.29 (m, 2H), 3.84 (s, 6H), 3.65- 3.59 (m, 5H), 3.24-3.00 (m, 3H), 2.98-2.79 (m, 3H), 2.66-2.55 (m, 7H), 2.21 (s, 6H), 2.22-2.04 (m, 3H), 2.04-1.88 (m, 2H), 1.79-1.76 (m, 6H). D196 875.35 ¹H NMR (400 MHz, Methanol-d4) δ 8.91 (dd, J = 8.8 Hz, 0.16H, TFA salt), 8.34 (s, 1H), 7.88 (s, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.20 (d, J = 7.7 Hz, 2H), 7.07 (s, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.51 (s, 3H), 4.43 (d, J = 15.7 Hz, 2H), 4.02 (s, 6H), 3.75 (s, 3H), 3.68 (d, J = 11.2 Hz, 4H), 3.62 (s, 4H), 3.49-3.43 (m, 2H), 3.38 (s, 2H), 3.17 (d, J = 11.5 Hz, 1H), 2.99 (t, J = 5.3 Hz, 2H), 2.92 (s, 6H), 2.80 (d, J = 17.3 Hz, 1H), 2.65 (dd, J = 28.9, 12.3 Hz, 1H), 2.57-2.41 (m, 2H), 2.22-2.14 (m, 1H), 2.12-2.04 (m, 1H), 2.02- 1.97 (m, 1H). D197 735.34 ¹H NMR (400 MHz, Methanol-d4) δ 8.00 (s, 1H), 7.86 (d, J = 2.1 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.16 (s, 2H), 7.09 (d, J = 2.1 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 6.79 (dd, J = 8.2, 2.1 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 (d, J = 31.5 Hz, 2H), 4.37 (dd, J = 16.3, 9.0 Hz, 4H), 4.17 (d, J = 23.2 Hz, 2H), 4.02 (s, 6H), 3.76 (s, 7H), 3.54 (d, J = 12.4 Hz, 4H), 3.18-2.98 (m, 2H), 2.91 (s, 4H), 2.79 (ddd, J = 17.6, 4.7, 2.4 Hz, 1H), 2.50 (qd, J = 13.2, 4.7 Hz, 1H), 2.34-2.02 (m, 4H). D198 736.2 ¹H NMR (300 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.35 (s, 1H), 7.40 (s, 1H), 7.14 (s, 2H), 6.70 (s, 2H), 5.06 (dd, J = 13.1, 5.1 Hz, 1H), 4.45-4.27 (m, 3H), 4.19 (d, J = 16.7 Hz, 3H), 4.02 (d, J = 10.1 Hz, 2H), 3.95 (s, 6H), 3.88 (s, 1H), 3.72 (s, 2H), 3.67 (s, 3H), 3.65 (s, 2H), 3.43 (s, 2H), 3.16 (s, 1H), 3.05-2.81 (m, 3H), 2.76-2.54 (m, 1H), 2.28 (s, 2H), 2.12 (d, J = 13.6 Hz, 2H), 2.02-1.80 (m, 3H). D199 794.2 ¹H NMR (300 MHz, DMSO-d6) δ 8.28 (s, 3H), 8.08 (d, J = 5.4 Hz, 1H), 7.76 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 5.1 Hz, 1H), 7.03 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.82 (s, 2H), 5.02 (dd, J = 13.2, 5.1 Hz, 1H), 4.85-4.74 (m, 1H), 4.38 (d, J = 17.1 Hz, 1H), 4.24 (d, J = 17.1 Hz, 1H), 3.96 (s, 2H), 3.86 (s, 6H), 3.62 (s, 3H), 3.16 (d, J = 9 Hz, 2H), 2.96-2.80 (m, 1H), 2.74-2.52 (m, 3H), 2.48-2.12 (m, 9H), 2.05-1.90 (m, 1H), 1.85-1.50 (m, 9H), 1.40- 1.20 (m, 2H). D200 875.45 ¹H NMR (400 MHz, Methanol-d4) δ 8.48-8.35 (m, 1H), 7.87 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.46-7.34 (m, 2H), 7.07 (s, 2H), 5.18 (ddd, J = 20.4, 13.3, 5.1 Hz, 1H), 4.55-4.44 (m, 5H), 4.47- 4.36 (m, 6H), 4.02 (s, 3H), 3.70-3.54 (m, 6H), 3.65-3.60 (m, 2H), 3.49-3.42 (m, 1H), 3.15-3.08 (m, 2H), 3.01-2.94 (m, 2H), 2.92 (s, 6H), 2.88-2.86 (m, 3H), 2.85-2.82 (m, 1H), 2.83-2.73 (m, 1H), 2.59-2.52 (m, 1H), 2.51-2.37 (m, 1H), 2.24-2.15 (m, 1H), 2.00-1.95 (m, 1H). D201 752.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.18 (s, 1H), 7.93 (s, 1H), 7.42-7.36 (m, 1H), 6.95 (s, 2H), 6.68 (d, J = 7.2 Hz, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.29 (s, 1H), 4.17 (d, J = 24.7 Hz, 3H), 3.93 (s, 8H), 3.68 (s, 3H), 3.58 (s, 6H), 2.98-2.76 (m, 2H), 2.61 (s, 1H), 2.56 (d, J = 7.4 Hz, 2H), 2.45-2.29 (m, 5H), 2.05- 1.93 (m, 1H), 1.79-1.71 (m, 4H). D202 697.3 . ¹H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.24 (s, 1H), 8.21 (s, 1H, FA), 8.06 (s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 6.91 (s, 2H), 6.78 (s, 1H), 6.65 (d, J = 8.4, 2.1 Hz, 1H), 5.05 (dd, J = 12.9, 5.4 Hz, 1H), 3.85 (s, 7H), 3.73 (s, 4H), 3.66 (s, 4H), 3.52 (s, 2H), 2.95- 2.81 (m, 1H), 2.60 (s, 1H), 2.40 (s, 3H), 2.05-1.95 (m, 1H), 1.73 (s, 4H). D203 683.5 ¹H NMR (300 MHz, Methanol-d4) δ 9.04 (s, 1H), 7.79 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.10-6.94 (m, 2H), 6.89 (d, J = 2.2 Hz, 1H), 6.85-6.75 (m, 1H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.57-4.26 (m, 4H), 4.11-3.92 (m, 7H), 3.78 (s, 7H), 3.56 (s, 2H), 3.09 (s, 1H), 3.05-2.72 (m, 2H), 2.68-2.38 (m, 1H), 2.37-1.94 (m, 5H). D204 683.2 ¹H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.28 (s, 1H), 8.47 (s, 1H, FA), 8.10 (s, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.02 (s, 2H), 6.96-6.87 (m, 2H), 6.20 (s, 1H, FA salt), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.51 (s, 2H), 4.38-4.09 (m, 2H), 3.86 (s, 6H), 3.68 (s, 3H), 3.63 (s, 3H), 3.51 (s, 2H), 3.21-3.13 (m, 2H), 2.98-2.87 (m, 1H), 2.65-2.56 (m, 2H), 2.47-2.35 (m, 1H), 2.14 (s, 2H), 2.01-1.91 (m, 1H), 1.79 (s, 2H). D205 666.45 ¹H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 1.2 Hz, 1H), 7.25 (dd, J = 8.5, 2.4 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 6.59-6.52 (m, 2H), 5.09 (dd, J = 13.3, 5.1 Hz, 1H), 4.39-4.16 (m, 2H), 3.81 (s, 6H), 3.62 (s, 2H), 3.54 (s, 3H), 3.22-3.11 (m, 4H), 2.98-2.84 (m, 1H), 2.72-2.56 (m, 5H), 2.46- 2.36 (m, 1H), 2.33 (s, 3H), 2.04 (s, 3H), 2.02-1.94 (m, 1H). D206 630.2 ¹H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.25 (s, 1H), 8.14 (s, 0.1H, FA), 8.09 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.09 (s, 1H), 7.05-6.97 (m, 3H), 6.54 (s, 0.2H, FA salt), 5.09 (dd, J = 13.2, 5.1 Hz, 2H), 4.47-4.15 (m, 6H), 3.90 (s, 8H), 3.67 (s, 3H), 3.03- 2.77 (m, 1H), 2.71-2.60 (m, 1H), 2.43-2.30 (m, 1H), 2.10-1.93 (m, 1H). D207 682.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.22 (s, 1H, FA), 8.09 (d, J = 5.3 Hz, 1H), 7.78 (s, 1H), 7.52 (d, J = 5.3 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 6.78 (s, 2H), 6.69 (d, J = 7.9 Hz, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.37-4.11 (m, 2H), 3.84 (s, 6H), 3.63 (s, 3H), 3.55 (d, J = 10.1 Hz, 6H), 2.98-2.82 (m, 1H), 2.62 (s, 1H), 2.45-2.21 (s, 5H), 2.06-1.90 (m, 1H), 1.72 (t, J = 5.5 Hz, 4H). D208 696.25 ¹H NMR (300 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.55 (d, J = 3.1 Hz, 1H), 8.16 (FA, s, 1H), 7.89 (d, J = 3.2 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.32 (s, 1H), 6.81 (d, J = 16.7 Hz, 3H), 6.72-6.57 (m, 1H), 5.17-4.96 (m, 1H), 3.85 (s, 6H), 3.81-3.68 (m, 5H), 3.57 (s, 3H), 3.49 (s, 4H), 2.98-2.79 (m, 2H), 2.76-2.63 (m, 1H), 2.63- 2.55 (m, 1H), 2.07-1.90 (m, 1H), 1.82-1.65 (m, 4H). D209 697.3 ¹H NMR (300 MHz, Methanol-d4) δ 9.10 (s, 1H), 8.01 (s, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.03 (s, 2H), 6.86 (d, J = 2.1 Hz, 1H), 6.70 (dd, J = 8.3, 2.1 Hz, 1H), 5.08 (dd, J = 12.4, 5.4 Hz, 1H), 4.21 (s, 2H), 4.01 (s, 6H), 3.88 (s, 4H), 3.77 (s, 3H), 3.28-3.00 (m, 4H), 2.97- 2.58 (m, 3H), 2.22-1.99 (m, 5H). D210 667.35 ¹H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.74 (s, 1H), 8.30 (s, 1H), 8.14 (s, 1H, FA), 7.37 (d, J = 8.0 Hz, 1H), 7.06 (s, 2H), 6.70-6.69 (m, 2H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.33-4.16 (m, 2H), 3.88 (s, 6H), 3.72-3.65 (m, 5H), 3.58 (s, 4H), 2.98-2.82 (m, 1H), 2.66-2.56 (m, 4H), 2.45-2.24 (m, 2H), 2.05-1.96 (m, 1H), 1.78 (s, 4H). D211 662.3 ¹H NMR (300 MHz, MeOD) δ 8.17-8.06 (m, 3H), 7.77-7.68 (m, 3H), 7.57 (d, J = 7.1 Hz, 2H), 7.51 (d, J = 8.6 Hz, 1H), 5.17 (dd, J = 13.3, 5.2 Hz, 1H), 4.56-4.37 (m, 2H), 4.25-4.12 (m, 1H), 3.85 (d, J = 12.7 Hz, 2H), 3.75 (s, 3H), 3.26-3.19 (m, 2H), 3.03-2.74 (m, 2H), 2.62-2.41 (m, 1H), 2.25-2.13 (m, 3H), 2.03-1.85 (m, 2H). D212 630.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.23 (s, 1H), 8.24 (s, 1H, FA), 8.06 (s, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.12 (dd, J = 8.2, 2.5 Hz, 1H), 7.02 (d, J = 2.4 Hz, 1H), 6.91 (s, 2H), 5.09 (dd, J = 13.1, 5.0 Hz, 1H), 4.85-4.75 (m, 1H), 4.45-4.16 (m, 2H), 3.85 (s, 6H), 3.72-3.63 (m, 7H), 3.13-3.07 (m, 2H), 2.94-2.83 (m, 1H), 2.65-2.59 (m, 1H), 2.42-2.35 (m, 1H), 2.04-1.98 (m, 1H). D213 630.15 ¹H NMR (300 MHz, Methanol-d4) δ 9.10 (s, 1H), 8.01 (s, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.27-7.16 (m, 2H), 7.02 (s, 2H), 5.23-5.04 (m, 2H), 4.54-4.43 (m, 4H), 4.43-4.39 (m, 2H), 4.12-3.93 (m, 8H), 3.77 (s, 3H), 3.00-2.86 (m, 1H), 2.85-2.75 (m, 1H), 2.60- 2.42 (m, 1H), 2.25-2.13 (m, 1H). D214 697.15 ¹H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 7.99 (s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 6.88 (s, 2H), 6.68 (d, J = 8.1 Hz, 2H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.38-4.13 (m, 2H), 3.85 (s, 6H), 3.63 (s, 3H), 3.57 (d, J = 4.5 Hz, 6H), 2.97-2.83 (m, 1H), 2.77 (s, 3H), 2.63-2.54 (m, 2H), 2.37 (dd, J = 13.2, 4.6 Hz, 2H), 2.02-1.94 (m, 1H), 1.73 (t, J = 5.5 Hz, 4H). D215 683.2 ¹H NMR (400 MHz, Methanol-d4) δ 9.47 (s, 1H), 7.99 (s, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.19 (s, 2H), 6.86 (d, J = 2.2 Hz, 1H), 6.77 (m, J = 8.2, 2.3 Hz, 1H), 5.16-5.07 (m, 1H), 4.37 (d, J = 7.8 Hz, 2H), 4.30 (s, 2H), 3.98 (s, 6H), 3.78 (s, 3H), 3.74 (s, 4H), 3.24 (s, 4H), 2.96-2.83 (m, 1H), 2.83-2.73 (m, 1H), 2.56-2.40 (m, 1H), 2.21- 2.09 (m, 5H). D216 682.3 ¹H NMR (300 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.55 (d, J = 3.2 Hz, 1H), 7.89 (d, J = 3.2 Hz, 1H), 7.44-7.27 (m, 2H), 6.84 (s, 2H), 6.76-6.62 (m, 2H), 5.08 (dd, J = 13.1, 5.1 Hz, 1H), 4.38-4.12 (m, 2H), 3.86 (s, 6H), 3.67-3.53 (m, 6H), 3.50 (s, 3H), 3.02- 2.80 (m, 1H), 2.66-2.52 (m, 4H), 2.43-2.26 (m, 2H), 2.06-1.91 (m, 1H), 1.75 (s, 4H). D217 667.45 ¹H NMR (300 MHz, Methanol-d4) δ 8.74 (s, 1H), 8.16 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.38 (s, 2H), 6.89 (d, J = 2.1 Hz, 1H), 6.81 (dd, J = 8.2, 2.3 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.45-4.36 (m, 4H), 4.05 (s, 6H), 3.91-3.68 (m, 7H), 3.62-3.40 (m, 2H), 3.29-3.12 (m, 2H), 3.01-2.74 (m, 2H), 2.50 (qd, J = 13.0, 4.7 Hz, 1H), 2.39-1.98 (m, 5H). D218 747.45 ¹H NMR (300 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.24 (s, 1H, FA), 7.86 (s, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.48-7.37 (m, 2H), 7.30 (s, 2H), 5.23 (ddd, J = 13.2, 5.2, 2.2 Hz, 1H), 4.71 (dd, J = 15.5, 7.7 Hz, 1H), 4.53-4.41 (m, 4H), 4.10 (d, J = 1.1 Hz, 7H), 3.98 (d, J = 13.1 Hz, 1H), 3.84 (s, 3H), 3.32 (d, J = 13.3 Hz, 1H), 3.20 (d, J = 6.3 Hz, 1H), 3.05-2.96 (m, 7H), 2.92-2.82 (m, 1H), 2.58 (qd, J = 13.1, 4.7 Hz, 1H), 2.33-2.09 (m, 3H). D219 654.4 ¹H NMR (300 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.68 (s, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.36 (d, J = 14.9 Hz, 2H), 6.93 (d, J = 2.2 Hz, 2H), 6.51 (s, 1H), 5.03 (dd, J = 13.4, 5.1 Hz, 1H), 4.43-4.20 (m, 2H), 4.06-3.93 (m, 3H), 3.78 (s, 6H), 3.59 (s, 3H), 3.01 (t, J = 12.1 Hz, 2H), 2.88-2.72 (m, 1H), 2.70-2.62 (m, 1H), 2.43-2.24 (m, 1H), 1.97 (dd, J = 22.7, 10.4 Hz, 3H), 1.73 (t, J = 10.8 Hz, 2H). D220 794.7 ¹H NMR (400 MHz, Methanol-d4) δ 7.78-7.69 (m, 3H), 7.61 (d, J = 5.4 Hz, 1H), 7.08 (s, 2H), 7.06-6.97 (m, 2H), 5.14 (dd, J = 13.4, 5.2 Hz, 1H), 4.55-4.37 (m, 4H), 4.02 (s, 6H), 3.76 (s, 3H), 3.65 (d, J = 12.5 Hz, 2H), 3.59-3.53 (m, 1H), 3.40-3.33 (m, 1H), 3.28- 3.16 (m, 2H), 3.10 (d, J = 6.7 Hz, 2H), 3.04-2.87 (m, 3H), 2.84- 2.75 (m, 1H), 2.74-2.64 (m, 1H), 2.57-2.41 (m, 2H), 2.36- 2.21 (m, 2H), 2.21-1.93 (m, 9H), 1.71-1.57 (m, 2H). DD1 775.10 ¹H NMR (300 MHz, DMSO-d6) δ 12.39 (s, 1H), 9.05-8.89 (m, 2H), 8.61 (d, J = 8.4 Hz, 2H), 8.32 (dd, J = 6.4, 2.9 Hz, 1H), 7.96 (s, 1H), 7.57 (s, 1H), 7.36-7.24 (m, 2H), 6.90 (s, 2H), 4.87 (d, J = 47.4 Hz, 2H), 4.55 (s, 1H), 3.83 (s, 7H), 3.62 (s, 4H), 3.46 (s, 2H), 2.13 (s, 8H). DD2 654.20 ¹H NMR (300 MHz, Methanol-d4) δ 9.05 (s, 1H), 8.44-8.36 (m, 2H), 7.74-7.67 (m, 2H), 7.61-7.50 (m, 2H), 7.36-7.27 (m, 2H), 7.00 (s, 2H), 4.12-3.86 (m, 12H), 3.75 (s, 3H), 3.11-2.98 (m, 4H).

Example 31—BRD9 Bromodomain TR-FRET Competition Binding Assay

This example demonstrates the ability of the compounds of the disclosure to biochemically inhibit BRD9 bromodomain in a competition binding assay.

Procedure: His-Flag-BRD9 (P133-K239; Swiss Prot Q9H8M2; SEQ ID NO:1 mgsshhhhhhenlyfq/gdykddddkgslevlfqg/PAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMII KHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSK) was cloned, expressed, purified, and then treated with TEV protease. Cleaved His tag was removed by purification. The binding of a biotinylated small molecule ligand of BRD9 was assessed via the LANCE® TR-FRET platform (PerkinElmer), and the compounds were assayed for inhibitory activity against this interaction.

Results: A mixture of biotinylated-ligand and SureLight™ Allophycocyanin-Streptavidin (APC-SA, PerkinElmer AD0201) in 50 mM HEPES (pH 7.4), 50 mM NaCl, 1 mM TCEP (pH 7), 0.01% (v/v) Tween-20, 0.01% (w/v) bovine serum albumin was added to a white 384-well PerkinElmer Proxiplate Plus plate. DMSO or 3-fold serially diluted compounds were then added to the Proxiplate followed by addition of Flag-BRD9. After a 10-minute incubation at room temperature, Eu-W1024 anti-FLAG (PerkinElmer, AD0273) was added. The final reaction mixture that contained 3.75 nM biotinylated ligand, 3 nM Flag-BRD9, 7.5 nM SureLight™ Allophycocyanin-Streptavidin, and 0.2 nM Eu-W1024 anti-FLAG was incubated at room temperature for 90 minutes.

The plates were then read on a PerkinElmer Envision plate reader to determine the ratio of emission at 665 nm over 615 nm. Data was normalized to a DMSO control (100%) and a no protein control (0%) and then fit to a four parameter, non-linear curve fit to calculate an IC₅₀ (μM) as shown in Table 5. As shown by the results in Table 5, a number of compounds of the present disclosure exhibit an IC₅₀ value of <1 μM for BRD9 binding, indicating their affinity for targeting BRD9.

TABLE 5 Bromodomain TR-FRET Binding Compound No. Bromodomain TR-FRET BRD9 IC₅₀ (nM) B1 +++ B2 ++++ B3 +++ B4 +++ B5 ++++ B6 ++++ B7 ++ B8 +++ B9 +++ B10 +++ B11 ++ D1 ++ D2 ++++ D3 +++ D4 +++ D5 ++ D6 ++++ D7 ++ D8 ++ D9 +++ D10 ++++ D11 ++++ D12 ++++ D13 ++++ D14 +++ D15 ++++ “+” indicates inhibitory effect of ≥1000 nM; “++” indicates inhibitory effect of ≥100 nM; “+++” indicates inhibitory effect of ≥10 nM; “++++” indicates inhibitory effect of <10 nM; “NT” indicates not tested

Example 32—SYO1 BRD9 NanoLuc Degradation Assay

This example demonstrates the ability of the compounds of the disclosure to degrade a Nanoluciferase-BRD9 fusion protein in a cell-based degradation assay.

Procedure: A stable SYO-1 cell line expressing 3×FLAG-NLuc-BRD9 was generated. On day 0 cells were seeded in 30 μL media into each well of 384-well cell culture plates. The seeding density was 8000 cells/well. On day 1, cells were treated with 30 nL DMSO or 30 nL of 3-fold serially DMSO-diluted compounds (10 points in duplicates with 1 μM as final top dose). Subsequently plates were incubated for 6 hours in a standard tissue culture incubator and equilibrated at room temperature for 15 minutes. Nanoluciferase activity was measured by adding 15 μL of freshly prepared Nano-Glo Luciferase Assay Reagent (Promega N1130), shaking the plates for 10 minutes and reading the bioluminescence using an EnVision reader.

Results: The Inhibition % was calculated using the following formula: % Inhibition=100×(Lum_(HC)−Lum_(Sample))/(Lum_(HC)−Lum_(LC)). DMSO treated cells are employed as High Control (HC) and 1 μM of a known BRD9 degrader standard treated cells are employed as Low Control (LC). The data was fit to a four parameter, non-linear curve fit to calculate IC₅₀ (μM) values as shown in Table 6A and Table 6B. As shown by the results in Table 6A and Table 6B, a number of compounds of the present disclosure exhibit an IC₅₀ value of <1 μM for the degradation of BRD9, indicating their use as compounds for reducing the levels and/or activity of BRD9 and their potential for treating BRD9-related disorders.

TABLE 6A SYO1 BRD9-NanoLuc Degradation Compound No. SYO1 BRD9-NanoLuc degradation IC₅₀ (nM) D1 + D2 +++ D3 ++++ D4 +++ D5 + D6 + D7 ++ D8 ++ D9 + D10 ++++ D11 + D12 ++++ D13 ++++ D14 ++ D15 ++++ “+” indicates inhibitory effect of ≥1000 nM; “++” indicates inhibitory effect of ≥100 nM; “+++” indicates inhibitory effect of ≥10 nM; “++++” indicates inhibitory effect of <10 nM; “NT” indicates not tested

TABLE 6B SYO1 BRD9-NanoLuc Degradation Compound No. SYO1 BRD9-NanoLuc degradation IC₅₀ (nM) D16 ++++ D17 ++++ D18 ++++ D19 ++++ D20 ++++ D21 ++++ D22 ++++ D23 ++++ D24 ++++ D25 ++++ D26 ++++ D27 ++++ D28 ++++ D29 ++++ D30 +++ D31 +++ D32 ++ D33 ++++ D34 ++ D35 ++++ D36 ++++ D37 ++++ D38 ++++ D39 ++++ D40 ++++ D41 ++++ D42 ++++ D43 ++++ D44 +++ D45 + D46 ++++ D47 +++ D48 +++ D49 ++++ D50 ++++ D51 +++ D52 +++ D53 +++ D54 ++ D55 ++ D56 +++ D57 ++++ D58 +++ D59 +++ D60 ++++ D61 ++ D62 +++ D63 ++ D64 ++ D65 ++++ D66 ++++ D67 +++ D68 +++ D69 +++ D70 ++++ D71 +++ D72 ++++ D73 ++++ D74 ++++ D75 ++++ D76 +++ D77 ++++ D78 ++++ D79 ++++ D80 ++ D81 ++ D82 ++ D83 ++++ D84 ++++ D85 ++++ D86 ++++ D87 ++++ D88 +++ D89 ++++ D90 ++++ “+” indicates inhibitory effect of ≥1000 nM; “++” indicates inhibitory effect of ≥100 nM; “+++” indicates inhibitory effect of ≥10 nM; “++++” indicates inhibitory effect of <10 nM; “NT” indicates not tested

TABLE 6C SYO1 BRD9-NanoLuc Degradation Compound No. SYO1 BRD9-NanoLuc degradation IC₅₀ (nM) D91 ++++ D92 ++++ D93 ++++ D94 ++++ D95 ++ D96 ++++ D97 ++++ D98 ++++ D99 ++++ D100 ++++ D101 ++++ D102 ++++ D103 ++++ D104 ++++ D105 ++++ D106 ++++ D107 ++++ D108 ++++ D109 ++++ D110 ++++ D111 ++++ D112 ++++ D113 ++++ D114 ++++ D115 ++++ D116 ++++ D117 ++++ D118 ++++ D119 ++++ D120 ++++ D121 ++++ D122 ++++ D123 ++++ D124 ++++ D125 ++++ D126 ++++ D127 ++++ D128 ++++ D129 ++++ D130 ++++ D131 ++++ D132 ++++ D133 ++++ D134 ++++ D135 ++++ D136 ++++ D137 ++ D138 ++++ D139 ++++ D140 ++++ D141 ++++ D142 + D143 + D144 ++++ D145 ++ D146 ++++ D147 ++++ D148 + D149 ++++ D150 ++++ D151 ++++ D152 ++++ D153 ++++ D154 ++++ D155 ++++ D156 ++++ D157 ++++ D158 ++++ D159 ++++ D160 ++++ D161 ++++ D162 ++++ D163 ++++ D164 ++++ D165 ++++ D166 ++++ D167 ++++ D168 ++++ D169 ++++ D170 ++++ D171 +++ D172 + D173 ++++ D174 ++++ D175 ++++ D176 ++++ D177 ++++ D178 ++++ D179 ++++ D180 ++++ D181 ++++ D182 ++++ D183 ++++ D184 ++++ D185 ++++ D186 ++++ D187 ++++ D188 ++++ D189 ++++ D190 ++++ D191 ++++ D192 ++++ D193 ++++ D194 ++++ D195 ++++ D196 ++++ D197 ++++ D198 +++ D199 ++++ D200 ++++ D201 ++++ D202 ++++ D203 ++++ D204 ++ D205 ++++ D206 ++++ D207 ++++ D208 ++++ D209 ++++ D210 ++++ D211 +++ D212 ++++ D213 ++++ D214 ++++ D215 ++++ D216 ++++ D217 ++++ D218 +++ D219 ++++ D220 ++++ DD1 + DD2 + “+” indicates inhibitory effect of ≥1000 nM; “++” indicates inhibitory effect of ≥100 nM; “+++” indicates inhibitory effect of ≥10 nM; “++++” indicates inhibitory effect of <10 nM; “NT” indicates not tested

Other Embodiments

All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

While the invention has been described in connection with specific embodiments thereof, it will be understood that invention is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.

Other embodiments are in the claims. 

1. A compound having the structure Formula I:

wherein R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl; Z¹ is CR² or N; R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N; X² is O or S; R^(X1) is H or optionally substituted C₁-C₆ alkyl; R³ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl; and G is optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl, or a pharmaceutically acceptable salt thereof.
 2. A compound having the structure of Formula II: A-L-B   Formula II, wherein L is a linker; B is a degradation moiety; and A has the structure of Formula III:

wherein R¹ is, independently, H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ carbocyclyl; Z¹ is CR² or N; R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl;

X¹ is CR^(X1) or N; X² is O or S; R^(X1) is H or optionally substituted C₁-C₆ alkyl; R³″ is H,

cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl; R³′ is absent, optionally substituted C₁-C₆ alkylene, optionally substituted C₂-C₉ heteroarylene, or optionally substituted C₁-C₆ heteroalkylene; G″ is

optionally substituted C₃-C₁₀ carbocyclyl, C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl; G′ is optionally substituted C₃-C₁₀ carbocyclylene, C₂-C₉ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene; and A¹ is a bond between A and the linker, wherein G″ is

or R³″ is

or a pharmaceutically acceptable salt thereof.
 3. The compound of claim 1 or 2, wherein R¹ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, or optionally substituted C₃-C₁₀ carbocyclyl.
 4. The compound of claim 3, wherein R¹ is H.
 5. The compound of claim 3, wherein R¹ is optionally substituted C₁-C₆ alkyl.
 6. The compound of claim 5, wherein R¹ is


7. The compound of claim 6, wherein R¹ is optionally substituted C₂-C₆ alkenyl.
 8. The compound of claim 7, wherein R¹ is


9. The compound of claim 8, wherein R¹ is optionally substituted C₃-C₁₀ carbocyclyl.
 10. The compound of claim 9, wherein R¹ is


11. The compound of claim 3, wherein R¹ is H or


12. The compound of claim 11, wherein R¹ is H.
 13. The compound of claim 11, wherein R¹ is


14. The compound of any one of claims 1 to 13, wherein Z¹ is N.
 15. The compound of any one of claims 1 to 13, wherein Z¹ is CR².
 16. The compound of claim 15, wherein R² is H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₆-C₁₀ aryl.
 17. The compound of claim 16, wherein R² is H, halogen, or optionally substituted C₁-C₆ alkyl.
 18. The compound of claim 17, wherein R² is H, F, or


19. The compound of claims 2 to 18, wherein the compound of Formula III has the structure of Formula IIIA:

or a pharmaceutically acceptable salt thereof.
 20. The compound of claims 2 to 18, wherein the compound of Formula III has the structure of Formula IIIB:

or a pharmaceutically acceptable salt thereof.
 21. The compound of claims 2 to 18, wherein the compound of Formula IIIC:

or a pharmaceutically acceptable salt thereof.
 22. The compound of claims 2 to 18, wherein the compound of Formula IIID:

or a pharmaceutically acceptable salt thereof.
 23. The compound of claims 2 to 18, wherein the compound of Formula IIIE:

or a pharmaceutically acceptable salt thereof.
 24. The compound of claims 2 to 18, wherein the compound of Formula IIIF:

or a pharmaceutically acceptable salt thereof.
 25. The compound of any one of claims 2 to 24, wherein X¹ is CH or N.
 26. The compound of any one of claims 2 to 24, wherein X¹ is CH.
 27. The compound of any one of claims 2 to 26, wherein X² is O.
 28. The compound of any one of claims 2 to 26, wherein X² is S.
 29. The compound of any one of claims 2 to 28, wherein R³″ is H, cyano, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkoxy, optionally substituted amino, optionally substituted C₃-C₁₀ heterocyclyl, or optionally substituted C₂-C₉ heteroaryl.
 30. The compound of any one of claims 2 to 29, wherein R³″ is H.
 31. The compound of any one of claims 2 to 29, wherein R³″ is cyano.
 32. The compound of any one of claims 2 to 29, wherein R³″ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₁₀ heterocyclyl.
 33. The compound of any one of claims 2 to 32, wherein R³″ is


34. The compound of any one of claims 2 to 32, wherein R³″ is


35. The compound of any one of claims 2 to 32, wherein R³″ is


36. The compound of claim 32, wherein R³″ is optionally substituted C₁-C₆ heteroalkyl.
 37. The compound of claim 36, wherein R³″ is

wherein W¹ is NR⁴ or O; W² is NH, O, or S; W³ is NR⁷ or O; R⁴ is H or optionally substituted C₁-C₆ alkyl; R⁵ is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl; R⁶ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl; R⁷ is H or optionally substituted C₁-C₆ alkyl; and R⁸ is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.
 38. The compound of claim 37, wherein W¹ is NR⁴.
 39. The compound of claim 38, wherein R⁴ is H,


40. The compound of claim 39, wherein R⁶ is H,


41. The compound of claim 40, wherein R³″ is


42. The compound of claim 41, wherein R³″ is


43. The compound of any one of claims 2 to 42, wherein G″ is


44. The compound of claim 43, wherein G′ is optionally substituted C₆-C₁₀ arylene or optionally substituted C₂-C₉ heteroarylene.
 45. The compound of claim 44, wherein G′ is optionally substituted C₆-C₁₀ arylene.
 46. The compound of claim 45, wherein G′ is

wherein each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G6)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G6)′, together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, wherein one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.
 47. The compound of claim 46, wherein each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, wherein one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or

is substituted with A¹.
 48. The compound of claim 47, wherein each of RG1, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.
 49. The compound of claim 48, wherein each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F, Cl,


50. The compound of claim 49, wherein each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F,


51. The compound of claim 50, wherein each of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is, independently, H, A¹, F, Cl,


52. The compound of claim 51, wherein R^(G3)′ is A¹.
 53. The compound of claim 51, wherein R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is

and R^(G5)′ is H.
 54. The compound of claim 51, wherein R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is H; and R^(G5)′ is


55. The compound of claim 51, wherein R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is Cl or F; and R^(G5)′ is H.
 56. The compound of claim 51, wherein R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is H; and R^(G5)′ is H.
 57. The compound of claim 51, wherein R^(G1)′ is H; R^(G2)′ is

R^(G3)′ is A¹; R^(G4)′ is

and R^(G5)′ is H.
 58. The compound of claim 47, wherein R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A¹,

wherein one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G5)′ is A¹, or is substituted with A¹.
 59. The compound of claim 47, wherein R^(G1)′ and R^(G2)′, R^(G2)′ and R^(G3)′, R^(G3)′ and R^(G4)′, and/or

R^(G4)′ and R^(G5)′, together with the carbon atoms to which each is attached, combine to form and

is optionally substituted C₂-C₉ heteroaryl, which is optionally substituted with A¹, wherein one of R^(G1)′, R^(G2)′, R^(G3)′, R^(G4)′, and R^(G6)′ is A¹, or

is substituted with A¹.
 60. The compound of claim 58, wherein G′ is

wherein R^(G6)′ is H, A¹, or optionally substituted C₁-C₆ alkyl.
 61. The compound of claim 59, wherein G′ is

wherein R^(G6)′ is H, A¹, or optionally substituted C₁-C₆ alkyl
 62. The compound of claim 60 or 61, wherein R^(G6)′ is H, A¹, or


63. The compound of claim 62, wherein R^(G6)′ is H.
 64. The compound of claim 44, wherein G′ is optionally substituted C₂-C₉ heteroarylene.
 65. The compound of claim 64, wherein G′ is

wherein each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7)′ and R^(G9)′, R^(G9)′ and R^(G9)′, R^(G9)′ and R^(G19)′, and/or R^(G10)′ and R^(G11)′, together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, wherein one of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is A¹; or

is substituted with A¹.
 66. The compound of claim 65, wherein each of R^(G7)′, R^(G8)′, R^(G9)′, R^(G10)′, and R^(G11)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.
 67. The compound of claim 65 or 66, wherein G′ is


68. The compound of any one of claims 65 to 67, wherein R^(G7)′ is H; R^(G8)′ is

R^(G9)′ is A¹; and R^(G11)′ is H.
 69. The compound of claim 64, wherein G′ is

wherein each of R^(G12)′, R^(G13)′, and R^(G14)′ is, independently, H, A¹, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12)′ and R^(G14)′, together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl, any of which is optionally substituted with A¹, wherein one of R^(G12)′, R^(G13)′, and R^(G14)′ is A¹; or

is substituted with A¹.
 70. The compound of any one of claims 2 to 28, wherein R³″ is

and R³′ is absent.
 71. The compound of claim 70, wherein G″ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl.
 72. The compound of claim 71, wherein G″ is optionally substituted C₆-C₁₀ aryl.
 73. The compound of claim 72, wherein G″ is

wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.
 74. The compound of claim 73, wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl; or R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocyclyl.
 75. The compound of claim 74, wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.
 76. The compound of claim 75, wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl,


77. The compound of claim 76, wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F,


78. The compound of claim 77, wherein each of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is, independently, H, F, Cl,


79. The compound of claim 78, wherein two or more of R^(G1), R^(G2), R^(G3), R^(G4), and R^(G5) is H.
 80. The compound of claim 79, wherein R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is

and R^(G5) is H.
 81. The compound of claim 79, wherein R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is


82. The compound of claim 79, wherein R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is Cl or F; and R^(G5) is H.
 83. The compound of claim 79, wherein R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is H; and R^(G5) is H.
 84. The compound of claim 79, wherein R^(G1) is H; R^(G2) is

R^(G3) is

R^(G4) is

and R^(G5) is H.
 85. The compound of claim 74, wherein R^(G1) and R^(G2), R^(G2) and R^(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heterocyclyl.
 86. The compound of claim 74, wherein R^(G1) and R^(G2), R^(G2) and R_(G3), R^(G3) and R^(G4), and/or R^(G4) and R^(G5), together with the carbon atoms to which each is attached, combine to form optionally substituted C₂-C₉ heteroaryl.
 87. The compound of claim 85, wherein G″ is

wherein R^(G6) is H or optionally substituted C₁-C₆ alkyl.
 88. The compound of claim 86, wherein G″ is

wherein R^(G6) is H or optionally substituted C₁-C₆ alkyl.
 89. The compound of claim 87 or 88, wherein R^(G6) is H or


90. The compound of claim 89, wherein R^(G6) is H.
 91. The compound of claim 71, wherein G″ is optionally substituted C₂-C₉ heteroaryl.
 92. The compound of claim 91, wherein G″ is

wherein each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G7) and R^(G8), R^(G8) and R^(G9), R^(G9) and R^(G10), and/or R^(G10) and R^(G11), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl.
 93. The compound of claim 92, wherein each of R^(G7), R^(G8), R^(G9), R^(G10), and R^(G11) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, or optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl.
 94. The compound of claim 92 or 93, wherein G″ is


95. The compound of claim 94, wherein R^(G7) is H; R^(G8) is

R^(G9) is H; and R^(G11) is H.
 96. The compound of claim 91, wherein G″ is

wherein each of R^(G12), R^(G13), and R^(G14) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₃-C₆ carbocyclyl, optionally substituted —C₁-C₃ alkyl-C₂-C₅ heterocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(G12) and R^(G14), together with the carbon atoms to which each is attached, combine to form optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl.
 97. The compound of any one of claims 70 to 96, wherein R⁷′ is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.
 98. The compound of claim 97, wherein R⁷′ is H or optionally substituted C₁-C₆ alkyl.
 99. The compound of claim 98, wherein R⁷′ is H,


100. The compound of claim 99, wherein R⁷′ is H or


101. The compound of claim 100, wherein R⁷′ is H.
 102. The compound of claim 100, wherein R⁷′ is


103. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIAa:

or a pharmaceutically acceptable salt thereof.
 104. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIc:

or a pharmaceutically acceptable salt thereof.
 105. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIe:

or a pharmaceutically acceptable salt thereof.
 106. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIf:

or a pharmaceutically acceptable salt thereof.
 107. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIg:

or a pharmaceutically acceptable salt thereof.
 108. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIh:

or a pharmaceutically acceptable salt thereof.
 109. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIj:

or a pharmaceutically acceptable salt thereof.
 110. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIn:

or a pharmaceutically acceptable salt thereof.
 111. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIo:

or a pharmaceutically acceptable salt thereof.
 112. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIs:

or a pharmaceutically acceptable salt thereof.
 113. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIu:

or a pharmaceutically acceptable salt thereof.
 114. The compound of any one of claims 2 to 102, wherein A has the structure of Formula IIIv:

or a pharmaceutically acceptable salt thereof.
 115. The compound of any one of claims 2 to 114, wherein the degradation moiety is a ubiquitin ligase binding moiety.
 116. The compound of claim 115, wherein the ubiquitin ligase binding moiety comprises Cereblon ligands, IAP (Inhibitors of Apoptosis) ligands, mouse double minute 2 homolog (MDM2), or von Hippel-Lindau (VHL) ligands, or derivatives or analogs thereof.
 117. The compound of claim 115 or 116, wherein the degradation moiety comprises the structure of Formula Y:

wherein A² is a bond between the degradation moiety and the linker; v1 is 0, 1, 2, 3, 4, or 5; u1 is 1, 2, or 3; T¹ is a bond or

T² is

R^(5A) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; each R^(J1) is, independently, halogen, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; J^(A) is absent, O, optionally substituted amino, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; and J is absent, optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₆-C₁₀ arylene, optionally substituted C₂-C₉ heterocyclylene, or optionally substituted C₂-C₉ heteroarylene, or a pharmaceutically acceptable salt thereof.
 118. The compound of claim 117, wherein T² is


119. The compound of claim 118, wherein T² is


120. The compound of claim 118, wherein T² is


121. The compound of any one of claims 117 to 120, wherein the structure of Formula Y has the structure of Formula Y1:

or a pharmaceutically acceptable salt thereof.
 122. The compound of claim 121, wherein T¹ is a bond.
 123. The compound of claim 121, wherein T¹ is


124. The compound of any one of claims 117 to 123, wherein the structure of Formula Y has the structure of Formula Y2:

or a pharmaceutically acceptable salt thereof.
 125. The compound of any one of claims 117 to 123, wherein the structure of Formula Y has the structure of Formula Z:

or a pharmaceutically acceptable salt thereof.
 126. The compound of any one of claims 117 to 125, wherein u1 is
 2. 127. The compound of claim 126, wherein the structure of Formula Z has the structure of Formula AA0:

or a pharmaceutically acceptable salt thereof.
 128. The compound of any one of claims 117 to 125, wherein u1 is
 1. 129. The compound of claim 128, wherein the structure of Formula Z has the structure of Formula AB:

or a pharmaceutically acceptable salt thereof.
 130. The compound of any one of claims 117 to 125, wherein u1 is
 3. 131. The compound of claim 130, wherein the structure of Formula Z has the structure of Formula AC:

or a pharmaceutically acceptable salt thereof.
 132. The compound of any one of claims 117 to 131, wherein J^(A) is absent.
 133. The compound of any one of claims 117 to 131, wherein J^(A) is optionally substituted C₁-C₆ alkyl.
 134. The compound of claim 133, wherein J^(A) is


135. The compound of claim 132, wherein the structure of Formula AA0 has the structure of Formula AA0:

or a pharmaceutically acceptable salt thereof.
 136. The compound of any one of claims 117 to 135, wherein v1 is 0, 1, 2, or
 3. 137. The compound of claim 136, wherein v1 is
 0. 138. The compound of claim 137, wherein the structure of Formula AA has the structure of Formula AA1:

or a pharmaceutically acceptable salt thereof.
 139. The compound of any one of claims 117 to 138, wherein R^(A5) is H or optionally substituted C₁-C₆ alkyl.
 140. The compound of claim 139, wherein R^(A5) is H.
 141. The compound of claim 139, wherein R^(A5) is methyl.
 142. The compound of any one of claims 117 to 138, wherein R^(A5) is optionally substituted C₁-C₆ heteroalkyl.
 143. The compound of claim 142, wherein R^(A5) is


144. The compound of claim 135, wherein the structure of Formula AA has the structure of Formula AA1:

or a pharmaceutically acceptable salt thereof.
 145. The compound of claim 129, wherein the structure of Formula AB has the structure of Formula AB1:

or a pharmaceutically acceptable salt thereof.
 146. The compound of claim 131, wherein the structure of Formula AC has the structure of Formula AC1:

or a pharmaceutically acceptable salt thereof.
 147. The compound of any one of claims 117 to 146, wherein J is absent.
 148. The compound of claim 147, wherein the structure of Formula AA1 has the structure of Formula AA2:

or a pharmaceutically acceptable salt thereof.
 149. The compound of any one of claims 117 to 146, wherein J is optionally substituted C₃-C₁₀ carbocyclylene or optionally substituted C₆-C₁₀ arylene.
 150. The compound of claim 149, wherein the structure of Formula AA has the structure of Formula AA4:

or a pharmaceutically acceptable salt thereof.
 151. The compound of any one of claims 117 to 146, wherein J is optionally substituted C₂-C₉ heterocyclylene or optionally substituted C₂-C₉ heteroarylene.
 152. The compound of claim 151, wherein the structure of Formula AA has the structure of Formula AA3:

or a pharmaceutically acceptable salt thereof.
 153. The compound of claim 151, wherein the structure of Formula AA has the structure of Formula A:

wherein in Y¹ is

R^(A5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; R^(A6) is H or optionally substituted C₁-C₆ alkyl; and R^(A7) is H or optionally substituted C₁-C₆ alkyl; or R^(A6) and R^(A7), together with the carbon atom to which each is bound, combine to form optionally substituted C₃-C₆carbocyclyl or optionally substituted C₂-C₅ heterocyclyl; or R^(A6) and R^(A7), together with the carbon atom to which each is bound, combine to form optionally substituted C₃-C₆carbocyclyl or optionally substituted C₂-C₅ heterocyclyl; R^(A8) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.
 154. The compound of claim 153, each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.
 155. The compound of claim 154, wherein each of R^(A1), R^(A2), R^(A3), and R^(A4) is, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².
 156. The compound of claim 155, wherein each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H,

or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².
 157. The compound of any one of claims 153 to 156, wherein Y¹ is


158. The compound of claim 157, wherein Y¹ is


159. The compound of claim 157, wherein Y¹ is


160. The compound of claim 159, wherein Y¹ is


161. The compound of claim 160, wherein Y¹ is


162. The compound of any one of claims 153 to 161, wherein the structure of Formula A has the structure of Formula A1:

or a pharmaceutically acceptable salt thereof.
 163. The compound of any one of claims 153 to 160, wherein the structure of Formula A has the structure of Formula A2:

or a pharmaceutically acceptable salt thereof.
 164. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A3:

or a pharmaceutically acceptable salt thereof.
 165. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A4:

or a pharmaceutically acceptable salt thereof.
 166. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A5:

or a pharmaceutically acceptable salt thereof.
 167. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A6:

or a pharmaceutically acceptable salt thereof.
 168. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A7:

or a pharmaceutically acceptable salt thereof.
 169. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A8:

or a pharmaceutically acceptable salt thereof.
 170. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A9:

or a pharmaceutically acceptable salt thereof.
 171. The compound of any one of claims 153 to 163, wherein the structure of Formula A has the structure of Formula A10:

or a pharmaceutically acceptable salt thereof.
 172. The compound of any one of claims 152 to 171, wherein the structure of Formula A is

or derivative or analog thereof.
 173. The compound of claim 172, wherein the structure of Formula A is


174. The compound of claim 173, wherein the structure of Formula A is

or derivative or analog thereof.
 175. The compound of any one of claims 153 to 171, wherein

is

wherein R^(A9) is H, A², optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl.
 176. The compound of claim 175, wherein the structure of Formula A is


177. The compound of claim 176, wherein R^(A9) is H.
 178. The compound of claim 176, wherein R^(A9) is A².
 179. The compound of claim 178, wherein the structure of Formula A is


180. The compound of claim 151, wherein the structure of Formula AA has the structure of Formula B:

wherein R^(A5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, thiol, or optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), and/or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or C₂-C₉ heterocyclyl, any of which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A², or a pharmaceutically acceptable salt thereof.
 181. The compound of claim 180, wherein each of R^(A1), R^(A2), R^(A3), and R^(A4) is, H, A², halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted —O—C₃-C₆ carbocyclyl, hydroxyl, optionally substituted amino; or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².
 182. The compound of claim 181, wherein each of R^(A1), R^(A2), R^(A3), and R^(A4) is, independently, H, A², F,

or R^(A1) and R^(A2), R^(A2) and R^(A3), or R^(A3) and R^(A4), together with the carbon atoms to which each is attached, combine to form

and

is optionally substituted C₂-C₉ heterocyclyl, which is optionally substituted with A², wherein one of R^(A1), R^(A2), R^(A3), and R^(A4) is A², or

is substituted with A².
 183. The compound of any one of claims 180 to 182, wherein the structure of Formula B has the structure of Formula B1:

or a pharmaceutically acceptable salt thereof.
 184. The compound of any one of claims 180 to 182, wherein the structure of Formula B has the structure of Formula B2:

or a pharmaceutically acceptable salt thereof.
 185. The compound of any one of claims 180 to 182, wherein the structure of Formula B has the structure of Formula B3:

or a pharmaceutically acceptable salt thereof.
 186. The compound of any one of claims 180 to 182, wherein the structure of Formula B has the structure of Formula B4:

or a pharmaceutically acceptable salt thereof.
 187. The compound of any one of claims 180 to 182, wherein the structure of Formula B is


188. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula C:

wherein R^(B1) is H, A², optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; R^(B2) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; R^(B3) is A², optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl; R^(B4) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl; R^(B5) is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; v2 is 0, 1, 2, 3, or 4; each R^(B6) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino; and each of R^(B7) and R^(B8) is, independently, H, halogen, optionally substituted C₁-C₆ alkyl, or optionally substituted C₆-C₁₀ aryl, wherein one of R^(B1) and R^(B3) is A², or a pharmaceutically acceptable salt thereof.
 189. The compound of claim 188, wherein the structure of Formula C is

or derivative or analog thereof.
 190. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula D:

wherein A² is a bond between B and the linker; each of R^(C1), R^(C2), and R^(C7) is, independently, H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; R^(C3) is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl; R^(C5) is optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl; v3 is 0, 1, 2, 3, or 4; each R^(C8) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino; v4 is 0, 1, 2, 3, or 4; and each R^(C9) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.
 191. The compound of claim 190, wherein the structure of Formula D is

or derivative or analog thereof.
 192. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula E:

wherein A² is a bond between B and the linker; each of R^(C10) and R^(C11) is, independently, H, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₁-C₆ alkyl C₃-C₁₀ carbocyclyl, or optionally substituted C₁-C₆ alkyl C₆-C₁₀ aryl; v5 is 0, 1, 2, 3, or 4; each R^(C12) is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino; v6 is 0, 1, 2, 3, or 4; and each R²¹ is, independently, halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or a pharmaceutically acceptable salt thereof.
 193. The compound of claim 192, wherein the structure of Formula E is

or derivative or analog thereof.
 194. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula FA:

wherein

or a bicyclic moiety which is substituted with A² and substituted with one or more groups independently selected from H, R^(FF1), and oxo;

is a single bond or a double bond; u2 is 0, 1, 2, or 3; A² is a bond between the degrader and the linker; Y^(Fa) is CR^(Fb)R^(Fc), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂; Y^(Fb) is NH, NR^(FF1), CH₂, CHR^(FF1), C(R^(FF1))₂, O, or S; Y^(Fc) is CR^(Fd)R^(Fe), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH2; each of R^(Fb), R^(Fc), R^(Fd), and R^(Fe) is, independently, H, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclyl, hydroxyl, alkoxy, amino, —NHalkyl, or —Nalkyl₂; or R^(Fb) and R^(Fc), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; or R^(Fd) and R^(Fe), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; and or R^(Fd) and R^(Fb), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring; each of Y^(Fd) and Y^(Ff) is, independently, CH₂, CHR^(FF2), C(R^(FF2))₂, C(O), N, NH, NR^(FF3), O, S, or S(O); Y^(Fe) is a bond or a divalent moiety attached to Y^(Fd) and Y^(Ff) that contains 1 to 5 contiguous carbon atoms that form a 3 to 3-membered ring, wherein 1; 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen, or sulfur atom; wherein one of the ring atoms is substituted with A² and the others are substituted with one or more groups independently selected from H and R^(FF1); and wherein the contiguous atoms of Y^(Fe) can be attached through a single or double bond; each R^(FF1) is, independently, H, alkyl, alkenyl, alkynyl, aliphatic, heteroaliphatic, carbocyclyl, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocyclyl, alkylamino, alkylhydroxyl, or haloalkyl; each R^(FF2) is, independently, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(aliphatic, including alkyl), —C(O)O(aliphatic, including alkyl), —NH(aliphatic, including alkyl), —N(aliphatic including alkyl)(aliphatic including alkyl), —NHSO₂alkyl, —N(alkyl)SO₂alkyl, —NHSO₂aryl, —N(alkyl)SO₂aryl, —NHSO₂alkenyl, —N(alkyl)SO₂alkenyl, —NHSO₂alkynyl, —N(alkyl)SO₂alkynyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heterocyclic, carbocyclic, cyano, nitro, nitroso, —SH, —Salkyl, or haloalkyl; and R^(FF3) is alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)alkyl, or —C(O)Oalkyl, wherein if Y^(Fd) or Y^(Ff) is substituted with A², then Y^(Fe) is a bond, or a pharmaceutically acceptable salt thereof.
 195. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula FB:

wherein

or a bicyclic moiety which is substituted with A² and substituted with one or more groups independently selected from H, R^(FF1), and oxo; A² is a bond between the degrader and the linker; Y^(Fa) is CR^(Fb)R^(Fc), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂; each of Y^(Fb) and Y^(Fg) is, independently, NH, NR^(FF1), CH₂, CHR^(FF1), C(R^(FF1))₂, O, or S; Y^(Fc) is CR^(Fd)R^(Fe), C═O, C═S, C═CH₂, SO₂, S(O), P(O)Oalkyl, P(O)NHalkyl, P(O)N(alkyl)₂, P(O)alkyl, P(O)OH, P(O)NH₂; each of R^(Fb), R^(Fc), R^(Fd), R^(Fe), R^(Ff), and R^(Fg) is, independently, H, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclyl, hydroxyl, alkoxy, amino, —NHalkyl, or —Nalkyl₂; or R^(Fb) and R_(Fc), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; or R^(Fd) and R^(Fe), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; or R^(Ff) and R^(Fg), together with the carbon atom to which each is attached, combine to form a 3-, 4-, 5-, or 6-membered spirocarbocyclylene, or a 4-, 5-, or 6-membered spiroheterocyclylene comprising 1 or 2 heteroatoms selected from N and O; or R^(Fd) and R^(Fb), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring; or R^(Fd) and R^(Ff), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring; or R^(Fb) and R^(Fg), together with the carbon atoms to which each is attached, combine to form a 1, 2, 3, or 4 carbon bridged ring; each of Y^(Fd) and Y^(Ff) is, independently, CH₂, CHR^(FF2), C(R^(FF2))₂, C(O), N, NH, NR^(FF3), O, S, or S(O); Y^(Fe) is a bond or a divalent moiety attached to Y^(Fd) and Y^(Ff) that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring, wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen, or sulfur atom; wherein one of the ring atoms is substituted with A² and the others are substituted with one or more groups independently selected from H and R^(FF1); and wherein the contiguous atoms of Y^(Fe) can be attached through a single or double bond; each R^(FF1) is, independently, H, alkyl, alkenyl, alkynyl, aliphatic, heteroaliphatic, carbocyclyl, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocyclyl, alkylamino, alkylhydroxyl, or haloalkyl; each R^(FF2) is, independently, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(aliphatic, including alkyl), —C(O)O(aliphatic, including alkyl), —NH(aliphatic, including alkyl), —N(aliphatic including alkyl)(aliphatic including alkyl), —NHSO₂alkyl, —N(alkyl)SO₂alkyl, —NHSO₂aryl, —N(alkyl)SO₂aryl, —NHSO₂alkenyl, —N(alkyl)SO₂alkenyl, —NHSO₂alkynyl, —N(alkyl)SO₂alkynyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heterocyclic, carbocyclic, cyano, nitro, nitroso, —SH, —Salkyl, or haloalkyl; and R^(FF3) is alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)alkyl, or —C(O)Oalkyl, wherein if Y^(Fd) or Y^(Ff) is substituted with A², then Y^(Fe) is a bond, or a pharmaceutically acceptable salt thereof.
 196. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula F1:

wherein A² is a bond between the degrader and the linker; and R^(F1) is absent or O, or a pharmaceutically acceptable salt thereof.
 197. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula F2:

wherein A² is a bond between the degrader and the linker; and R^(F1) is absent or O, or a pharmaceutically acceptable salt thereof.
 198. The compound of any one of claims 2 to 114, wherein the degradation moiety comprises the structure of Formula G:

wherein A² is a bond between the degrader and the linker; and R^(F1) is absent or O, or a pharmaceutically acceptable salt thereof.
 199. The compound of any one of claims 2 to 198, wherein the linker has the structure of Formula IV: A¹-(B¹)_(f)—(C¹)_(g)—(B²)_(h)-(D)-(B³)_(i)—(C²)_(j)—(B⁴)_(k)-A²   Formula IV wherein A¹ is a bond between the linker and A; A² is a bond between B and the linker; each of B¹, B², B³, and B⁴ is, independently, optionally substituted C₁-C₂ alkyl, optionally substituted C₁-C₃ heteroalkyl, O, S, S(O)₂, or NR^(N); each R^(N) is, independently, H, optionally substituted C₁₋₄ alkyl, optionally substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl, optionally substituted C₂₋₆ heterocyclyl, optionally substituted C₆₋₁₂ aryl, or optionally substituted C₁₋₇ heteroalkyl; each of C¹ and C² is, independently, carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; each of f, g, h, i, j, and k is, independently, 0 or 1; and D is optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, optionally substituted C₂₋₆ heterocyclyl, optionally substituted C₆₋₁₂ aryl, optionally substituted C₂-C₁₀ polyethylene glycol, or optionally substituted C₁₋₁₀ heteroalkyl, or a chemical bond linking A¹-(B¹)_(f)—(C¹)_(g)—(B²)_(h)— to —(B³)_(i)—(C²)_(j)—(B⁴)_(k)-A².
 200. The method of claim 199, wherein each of B¹, B², B³, and B⁴ is, independently, optionally substituted C₁-C₄ alkyl, optionally substituted C₁-C₄ heteroalkyl, or NR^(N).
 201. The method of claim 198 or 199, wherein each R_(N) is, independently, H or optionally substituted C₁-C₄ alkyl.
 202. The method of any one of claims 198 to 201, wherein each R^(N) is, independently, H or methyl.
 203. The compound of any one of claims 199 to 202, wherein each of B¹ and B⁴ is, independently,


204. The compound of claim 203 wherein B¹ is


205. The compound of any one of claims 199 to 204, wherein each of C¹ and C² is, independently,


206. The compound of claim 205, wherein C¹ is


207. The compound of any one of claims 199 to 204, wherein B² is NR^(N).
 208. The compound of any one of claims 199 to 204, wherein B² is optionally substituted C₁-C₄ alkyl.
 209. The compound of any one of claims 199 to 208, wherein f is
 0. 210. The compound of any one of claims 199 to 208, wherein f is
 1. 211. The compound of any one of claims 199 to 210, wherein g is
 1. 212. The compound of any one of claims 199 to 211, wherein h is
 0. 213. The compound of any one of claims 199 to 211, wherein h is
 1. 214. The compound of any one of claims 199 to 213, wherein i is
 0. 215. The compound of any one of claims 199 to 214, wherein j is
 0. 216. The compound of any one of claims 199 to 215, wherein k is
 0. 217. The compound of any one of claims 199 to 216, wherein the linker has the structure of

wherein x is 1, 2, 3, 4, 5, 6, 7, or 8; y is 1, 2, 3, or 4; R^(x) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; R^(y) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and W is O or NR^(w), wherein R^(w) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl.
 218. The compound of any one of claims 199 to 217, wherein the linker has the structure of:


219. The compound of any one of claims 199 to 218, wherein the linker has the structure of


220. The compound of any one of claims 2 to 198, wherein the linker has the structure of Formula V: A¹-(E¹)-(F¹)—(C³)_(m)-(E³)_(n)-(F²)_(o1)—(F³)_(o2)-(E²)_(p)-A²,   Formula V wherein A¹ is a bond between the linker and A; A² is a bond between B and the linker; each of m, n, o1, o2, and p is, independently, 0 or 1; each of E¹ and E² is, independently, O, S, NR^(N), optionally substituted C₁₋₁₀ alkylene, optionally substituted C₂₋₁₀ alkenylene, optionally substituted C₂₋₁₀ alkynylene, optionally substituted C₂-C₁₀ polyethylene glycol, or optionally substituted C₁₋₁₀ heteroalkylene; E³ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, O, S, or NR^(N); each R^(N) is, independently, H, optionally substituted C₁₋₄ alkyl, optionally substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl, optionally substituted C₂₋₆ heterocyclyl, optionally substituted C₆₋₁₂ aryl, or optionally substituted C₁₋₇ heteroalkyl; C³ is carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; and each of F¹, F², and F³ is, independently, optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₂₋₁₀ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene.
 221. The compound of claim 220, wherein the linker has the structure of Formula Va: A¹-(E¹)-(F¹)—(C³)_(m)-(E²)_(p)-A².   Formula Va
 222. The compound of claim 220, wherein the linker has the structure of Formula Vb: A¹-(E¹)-(F¹)-(E²)_(p)-A².   Formula Vb
 223. The compound of claim 220, wherein the linker has the structure of Formula Vc: A¹-(E¹)-(F¹)-A².   Formula Vc
 224. The compound of claim 220, wherein the linker has the structure of Formula Vd: A¹-(E¹)-(F¹)—(C³)_(m)—(F²)_(o1)-A².   Formula Vd
 225. The compound of claim 220, wherein the linker has the structure of Formula Ve: A¹-(E¹)-(F¹)-(E³)_(n)-(F²)_(o1)-(E²)_(p)-A².   Formula Ve
 226. The compound of claim 220, wherein the linker has the structure of Formula Vf: A¹-(E¹)-(F¹)—(C³)_(m)-(E³)_(n)-(F²)_(o1)-(E²)_(p)-A².   Formula Vf
 227. The compound of claim 220, wherein the linker has the structure of Formula Vg: A¹-(E¹)-(F¹)-(E³)_(n)-(F²)_(o1)-A²,   Formula Vg
 228. The compound of any one of claims 220 to 27, wherein each of E¹ and E² is, independently, NR^(N), optionally substituted C₁₋₁₀ alkylene, optionally substituted C₂-C₁₀ polyethylene glycolene, or optionally substituted C₁₋₁₀ heteroalkylene.
 229. The compound of any one of claims 220 to 228, wherein E³ is optionally substituted C₁-C₆ alkylene, O, S, or NR^(N).
 230. The compound of claim 229, wherein E³ is optionally substituted C₁-C₆ alkylene.
 231. The compound of claim 229, wherein E³ is optionally substituted C₁-C₃ alkylene.
 232. The compound of claim 229, wherein E³ is

wherein a is 0, 1, 2, 3, 4, or
 5. 233. The compound of claim 229, wherein E³ is


234. The compound of claim 229, wherein E³ is O.
 235. The compound of any one of claims 220 to 234, wherein each R^(N) is, independently, H or optionally substituted C₁₋₄ alkyl.
 236. The compound of claim 235, wherein each R^(N) is, independently, H or methyl.
 237. The compound of any one of claims 220 to 236, wherein E¹ is

wherein a is 0, 1, 2, 3, 4, or
 5. 238. The compound of claim 237, wherein E¹ is


239. The compound of claim 238, wherein E¹ is


240. The compound of any one of claims 220 to 239, wherein E¹ is

wherein b is 0, 1, 2, 3, 4, 5, or 6; R^(a) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; R^(b) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and R^(c) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl.
 241. The compound of claim 240, wherein E¹ is


242. The compound of claim 241, wherein E¹ is


243. The compound of claim 240, wherein E¹ is


244. The compound of claim 243, wherein E¹ is


245. The compound of any one of claims 240 to 244, wherein R^(a) is H or methyl.
 246. The compound of claim 245, wherein R^(a) is H.
 247. The compound of claim 245, wherein R^(a) is methyl.
 248. The compound of any one of claims 220 to 247, wherein E² is O, NR^(w),

wherein c is 0, 1, 2, 3, 4, 5, 6, 7, or 8; d is 0, 1, 2, or 3; e is 0, 1, 2, 3, 4, 5, or 6; f is 0, 1, 2, 3, or 4; R^(d) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; R^(e) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; R^(f) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; R^(g) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl; and W is O or NR^(w), wherein R^(w) is H or optionally substituted C₁-C₆ alkyl.
 249. The compound of claim 248, wherein E² is O,


250. The compound of any one of claims 220 to 249, wherein each of F¹, F², or F³ is, independently, optionally substituted C₃-C₁₀ carbocyclylene.
 251. The compound of claim 250, wherein the C₃-C₁₀ carbocyclylene is monocyclic.
 252. The compound of claim 250, wherein the C₃-C₁₀ carbocyclylene is polycyclic.
 253. The compound of claim 252, wherein the C₃-C₁₀ carbocyclylene is fused.
 254. The compound of claim 252, wherein the C₃-C₁₀ carbocyclylene is spirocyclic.
 255. The compound of claim 252, wherein the C₃-C₁₀ carbocyclylene is bridged.
 256. The compound of claim 255, wherein the C₃-C₁₀ carbocyclylene is


257. The compound of claim 256, wherein the C₃-C₁₀ carbocyclylene is


258. The compound of any one of claims 220 to 249, wherein each of F¹, F², or F³ is, independently, optionally substituted C₂-C₆ heterocyclylene.
 259. The compound of claim 258, wherein the C₂-C₆ heterocyclylene is monocyclic.
 260. The compound of claim 259, wherein the C₂-C₆ heterocyclylene is

wherein q1 is 0, 1, 2, 3, or 4; q2 is 0, 1, 2, 3, 4, 5, or 6; q3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8; each R^(h) is, independently, ²H, halogen, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4); or two R^(h) groups, together with the carbon atom to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl; or two R^(h) groups, together with the carbon atoms to which each is attached, combine to form optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl; R^(i1) is H or optionally substituted C₁-C₆ alkyl; R^(i2) is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₃-C₆ carbocyclyl;
 261. The compound of claim 260, wherein the C₂-C₉ heterocyclylene is


262. The compound of claim 260 or 261, wherein each R^(h) is, independently, ²H, halogen, cyano, optionally substituted C₁-C₆ alkyl, OR^(i2), or NR^(i3)R^(i4).
 263. The compound of claim 262, wherein each R^(h) is, independently, ²H, F, methyl,


264. The compound of claim 263, wherein each R^(h) is, independently, F, methyl, or NR^(i3)R^(i4).
 265. The compound of any one of claims 260 to 264, wherein q1 is 0, 1, or
 2. 266. The compound of any one of claims 260 to 265, wherein q2 is 0, 1, or
 2. 267. The compound of any one of claims 260 to 264, wherein q3 is 0, 1, or
 2. 268. The compound of any one of claims 260 to 267, wherein the C₂-C₉ heterocyclylene is


269. The compound of claim 268, wherein the C₂-C₉ heterocyclylene is


270. The compound of claim 269, wherein the C₂-C₉ heterocyclylene is


271. The compound of any one of claims 260 to 270, wherein F¹ is


272. The compound of any one of claims 260 to 271, wherein F² is


273. The compound of any one of claims 260 to 271, wherein F³ is


274. The compound of claim 258, wherein the C₂-C₆ heterocyclylene is polycyclic.
 275. The compound of claim 274, wherein the C₂-C₆ heterocyclylene is bicyclic.
 276. The compound of claim 274 or 275, wherein the C₂-C₆ heterocyclylene is bridged.
 277. The compound of claim 276, wherein the C₂-C₆ heterocyclylene is


278. The compound of claim 274 or 275, wherein the C₂-C₆ heterocyclylene is fused.
 279. The compound of claim 278, wherein the C₂-C₉ heterocyclylene is


280. The compound of claim 279, wherein F¹ is


281. The compound of claim 279 or 280, wherein F² is


282. The compound of claim 274 or 275, wherein the C₂-C₆ heterocyclylene is spirocyclic.
 283. The compound of claim 282, wherein the C₂-C₆ heterocyclylene is


284. The compound of claim 283, wherein F¹ is


285. The compound of claim 283 or 284, wherein F² is


286. The compound of any one of claims 283 to 288, wherein F³ is


287. The compound of any one of claims 258 to 286 wherein the C₂-C₉ heterocyclylene comprises a quaternary amine.
 288. The compound of any one of claims 220 to 249, wherein each of F¹, F², or F³ is, independently, optionally substituted C₆-C₁₀ arylene.
 289. The compound of claim 288, wherein the C₆-C₁₀ arylene is


290. The compound of any one of claims 220 to 249, wherein each of F¹, F², or F³ is, independently, optionally substituted C₂-C₉ heteroarylene.
 291. The compound of claim 290, wherein the C₂-C₉ heteroarylene is


292. The compound of claim 291, wherein F² is


293. The compound of claim 292, wherein F² is


294. The compound of any one of claims 220 to 293, C³ is


295. The compound of claim 294, wherein C³ is


296. The compound of any one of claims 220 to 295, wherein m is
 1. 297. The compound of any one of claims 220 to 295, wherein m is
 0. 298. The compound of any one of claims 220 to 297, wherein p is
 1. 299. The compound of any one of claims 220 to 297, wherein p is
 0. 300. The compound of any one of claims 220 to 299, wherein o1 is
 1. 301. The compound of any one of claims 220 to 299, wherein o1 is
 0. 302. The compound of any one of claims 220 to 301, wherein o2 is
 1. 303. The compound of any one of claims 220 to 301, wherein o2 is
 0. 304. The compound of any one of claims 220 to 303, wherein n is
 1. 305. The compound of any one of claims 220 to 303, wherein n is
 0. 306. The compound of any one of claims 220 to 305, wherein the linker has the structure of


307. The compound of any one of claims 220 to 305, wherein the linker has the structure of


308. The compound of any one of claims 220 to 305, wherein the linker has the structure of:


309. The compound of any one of claims 2 to 198, wherein the linker is optionally substituted C₃-C₁₀ carbocyclylene, optionally substituted C₂₋₁₀ heterocyclylene, optionally substituted C₆-C₁₀ arylene, or optionally substituted C₂-C₉ heteroarylene.
 310. The compound of claim 309, wherein the linker is optionally substituted C₂₋₁₀ heterocyclylene
 311. The compound of claim 310, wherein the linker has the structure of


312. The compound of claim 311, wherein the linker has the structure of


313. The compound of any one of claims 2 to 198, wherein the linker is absent.
 314. The compound of claim 1, wherein the compound has the structure of any one of compounds B1-B6 in Table 1, or a pharmaceutically acceptable salt thereof.
 315. The compound of any one of claims 2 to 313, wherein the compound has the structure of any one of compounds D1-D15 in Table 2A, or a pharmaceutically acceptable salt thereof.
 316. The compound of any one of claims 2 to 313, wherein the compound has the structure of any one of compounds D16-D90 in Table 2B, or a pharmaceutically acceptable salt thereof.
 317. The compound of any one of claims 2 to 313, wherein the compound has the structure of any one of compounds D91-D220 in Table 2C, or a pharmaceutically acceptable salt thereof.
 318. A pharmaceutical composition comprising the compound of any one of claims 1 to 317 and a pharmaceutically acceptable excipient.
 319. A method of inhibiting the level of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 320. A method of inhibiting the activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 321. The method of claim 319 or 320, wherein the cell is a cancer cell.
 322. The method of claim 321, wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.
 323. The method of claim 322, wherein the cancer is a sarcoma.
 324. The method of claim 323, wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.
 325. The method of claim 324, wherein the sarcoma is synovial sarcoma.
 326. A method of treating a BAF complex-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 327. A method of treating an SS18-SSX fusion protein-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 328. A method of treating a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of any one of claims 1 to 315, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 329. The method of any one of claims 326 to 328, wherein the disorder is cancer.
 330. A method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 331. The method of claim 329 or 330, wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.
 332. The method of claim 331, wherein the cancer is a sarcoma.
 333. The method of claim 332, wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.
 334. The method of claim 333, wherein the sarcoma is synovial sarcoma.
 335. The method of any one of claims 326 to 328, wherein the disorder is infection.
 336. A method of treating infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of any one of claims 1 to 317, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim
 318. 337. The method of claim 335 or 336, wherein the infection is a viral infection.
 338. The method of claim 337, wherein the viral infection is an infection with a virus of the Retroviridae family, Hepadnaviridae family, Flaviviridae family, Adenoviridae family, Herpesviridae family, Papillomaviridae family, Parvoviridae family, Polyomaviridae family, Paramyxoviridae family, or Togaviridae family.
 339. The method of claim 337 or 338, wherein the viral infection is Coffin Siris, Neurofibromatosis, or Multiple Meningioma. 